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Orientation to thesis
This thesis examines the use of buprenorphine in the management of heroin withdrawal. 
Chapter 1 begins with an overview of treatment services for heroin withdrawal, including the 
role and objectives of services, and develops a framework for the evaluation of withdrawal 
services, prior to considering non-pharmacological approaches in the management of heroin 
withdrawal. The use of other medications for heroin withdrawal is initially reviewed, including 
methadone, clonidine and lofexidine, and antagonist-accelerated withdrawal. The rationale and 
evidence regarding the efficacy of buprenorphine for heroin withdrawal is then systematically 
reviewed, with identification of the key outstanding clinical research questions regarding 
buprenorphine in withdrawal.
Three clinical research trials were conducted in order to address some of these outstanding 
research questions. The Inpatient Dose Titration Study (Chapter 2) and Outpatient Dose 
Titration Study (Chapter 3) aimed to establish suitable dosing regimes for those settings using 
sublingual buprenorphine tablets (Subutex®), the preparation becoming commercially available 
internationally. The largest trial (N=114) was an open label, multisite randomised controlled 
trial of buprenorphine compared to conventional symptomatic medication (including clonidine 
and benzodiazepines) for the management of outpatient heroin withdrawal, with a 4-week post 
withdrawal follow up phase. This study examined a range of outcomes including heroin i 
during and after withdrawal episode, retention in withdrawal and post withdrawal treatment, 
psychosocial outcomes, adverse events and cost effectiveness (Chapter 4).
The final chapter (Chapter 5) examines some key issues in the implementation and uptake of 
buprenorphine in the management of heroin withdrawal, including the application of principles 
of evidence-based medicine in clinical-decision making for individual patients; and an 
examination of broader systemic issues likely to impact upon the uptake of this new approach to 
withdrawal within the drug treatment system in Australia.
Status of buprenorphine during the research period
Buprenorphine has been registered as an analgesic (Temgesic®) in low dose preparations in 
Australia since the early 1980’s, but had not been registered for the management of opioid 
dependence at the outset of this research. This PhD commenced in August 1997. One multi­
centre trial of buprenorphine for maintenance treatment was underway in Australia at that time. 
Recruitment and service delivery for the trials in this thesis commenced in June 1998, and was 
completed in February 2000.
Buprenorphine (Subutex®) was registered in Australia for the treatment of opioid dependence 
in October 2000, although it was not widely available until February 2001. The Australian 
clinical guidelines and national policy for the use of buprenorphine were published in June 
2001, and buprenorphine (Subutex®) has been subsidised by the Commonwealth PBS 
(Pharmaceutical Benefits Scheme) since August 2001. Cost-effectiveness data from the 
outpatient withdrawal Randomised Controlled Trial (albeit unpublished data at the time) was 
the submitted for consideration by the Pharmaceutical Benefits Accreditation Committee in 
considering the subsidisation of buprenorphine by government Pharmaceutical Benefits 
Scheme.
Terminology
This thesis uses various terms that warrant clarification:
‘Patient’ refers to individuals attending treatment services, and can be used interchangeably 
with the term ‘client’.
‘Subject’ refers to patients enrolled in research trials. The term ‘participant’ was not used as it 
may be confused with other individuals involved (or participating) in the research 
process such as clinicians and researchers.
The term ‘withdrawal’ is used to describe both a syndrome (e.g. heroin withdrawal), and the 
process by which individuals undergo this syndrome (also known as ‘detoxification’).
Abstract
This thesis examines the role of buprenorphine in the management of heroin withdrawal. Prior 
research suggests that buprenorphine has a number of pharmacological properties well suited to 
this purpose. A systematic review of randomised controlled trials of buprenorphine for heroin 
withdrawal indicated that buprenorphine is more effective in reducing withdrawal severity than 
clonidine. However, research has not adequately addressed buprenorphine’s efficacy with 
regards to other key objectives of withdrawal treatment: retention in withdrawal services, 
reduction in heroin use during outpatient withdrawal, cost effectiveness, and post-withdrawal 
outcomes such as retention in treatment and heroin use. There is also uncertainty regarding the 
optimal dosing regimens for inpatient and outpatient withdrawal, with considerable variation in 
the range of doses and types of preparations used in earlier research. Three studies were 
conducted to examine these outstanding issues.
The first study examined dosing regimes of the sublingual tablet preparation, Subutex®, in 
inpatient settings, using a single-blind dose titration design. 63 dependent injecting heroin users 
with no significant co-morbidity were recruited, and doses of buprenorphine (2 or 4 mg) or 
placebo administered 4 times a day over the first 5 days, titrated against withdrawal severity 
using the Subjective Opiate Withdrawal Scale. 32 subjects completed the withdrawal regime, 
and generally described mild withdrawal severity. The mean (± SD) daily doses (in mg) were 
3.8 ± 2.8 on day 1, 5.8 ± 3.2 on day 2, 4.8 ± 3.3 on day 3, 2.3 ± 2.6 on day 4 and 0.8 ± 1.3 on 
day 5; with a total mean dose of 17.4 ± 9.7 mg. Multiple regression analysis identified that 
higher buprenorphine doses were significantly associated with poor baseline psychosocial 
functioning (p < 0.01), female sex (p < 0.01), higher frequency of heroin use at baseline (p < 
0.05) and severity of dependence to heroin at baseline (p < 0.05).
The remaining research examined outpatient withdrawal. The first outpatient study aimed to 
establish a dosing regime suitable for short withdrawal episodes using Subutex®. The open 
label, single group study recruited 18 dependent injecting heroin users with no significant co­
morbidity to an 8-day outpatient withdrawal episode in which buprenorphine was titrated over 
the first five days. 15 subjects (83%) completed the 5-day dosing regime, and 14 (78%) 
completed the 8-day withdrawal episode. Withdrawal severity was generally mild, with minimal 
rebound withdrawal upon the cessation of dosing. The following outpatient dosing regime was 
recommended: day 1: 6 mg; day 2: 8 to 10 mg; day 3: 8 to 12 mg; day 4: 6 to 10 mg; and 4 mg 
on day 5.
Finally, the safety and efficacy of buprenorphine in outpatient heroin withdrawal was examined 
in an open label, randomised controlled trial conducted at sites in Melbourne and Sydney. 114 
dependent heroin users with no significant co-morbidity underwent an 8 day withdrawal episode 
using one of two randomly allocated conditions: the Control group (n=56) using symptomatic
medications, including clonidine and benzodiazepines; and the Experimental group (n=58) 
using the buprenorphine regime identified in the previous study. At the completion of the 
withdrawal episode, subjects could self-select a range of post-withdrawal treatment options and 
were followed up for 4 weeks. Analysis was conducted on an intention-to-treat basis, with 89% 
of subjects completing the day 8 research interviews, and 80% completing the day 35 
interviews.
The key findings indicate that the Experimental group had significantly better outcomes than the 
Control group during the withdrawal episode: higher rates of treatment retention (86% 
compared to 57%, p < 0.01, 95% CI NNT = 3 to 8); used heroin on fewer days during the 8 day 
withdrawal episode (2.6 ± 2.5 compared to 4.5 ± 2.3, p< 0.001, 95% CI = 1 to 2.5 days); had 
more subjects completing withdrawal with opiate negative urines on days 5 and 8 (21% 
compared to 4%, p < 0.01; 95% Cl NNT = 4 to 18); experienced less severe withdrawal 
symptoms and reported greater improvements in various measures of psychosocial functioning. 
Examination of incremental cost effectiveness of the two withdrawal regimes demonstrated 
considerable advantages in favour of the Experimental group. Post-withdrawal outcomes were 
also significantly enhanced for the Experimental group on most measures, most notably higher 
treatment retention at day 35 (62% compared to 39%, p< 0.05, 95% Cl NNT = 3 to 25); and 
heroin use on fewer days in the 4 week post-withdrawal period (9.0 ± 8.2 compared to 14.6 ± 
10, p < 0.01, 95% Cl = 1.8 to 9.4).
In conclusion, buprenorphine is a significant advance in the pharmacological interventions for 
heroin withdrawal. This research has established suitable inpatient and outpatient dosing 
regimes using the commercially available sublingual tablet preparation, and has demonstrated 
that short buprenorphine dosing regimes have superior outcomes compared to clonidine and 
other symptomatic medications in outpatient withdrawal settings. Buprenorphine has 
considerable potential as a ‘gateway’ medication for heroin users entering treatment, facilitating 
the transition into a range of post-withdrawal treatment modalities, most notably naltrexone and 
substitution maintenance treatment. Buprenorphine’s safety and efficacy in improving 
withdrawal outcomes and enhancing the transition to post-withdrawal treatment should 
considerably enhance the future role of withdrawal services. The thesis concludes with an 
examination of key issues in the uptake of buprenorphine in treatment systems, including the 
development of clinical guidelines and training programs for service providers.
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Chapter  1: Introduction  and  Literature  review
1.1. Overview of heroin withdrawal services
1.1.1 The heroin withdrawal syndrome
Heroin withdrawal is a specific syndrome following the cessation or reduction in heavy and 
prolonged heroin use. The syndrome is associated with clinically significant distress or 
impairment in social, occupational, or other important areas of functioning (Diagnostic and 
Statistical Manual of Mental Disorders 1994). The characteristic features of the heroin 
withdrawal syndrome are shown in Table 1.1. Physical symptoms generally commence eight to 
twelve hours after last heroin use, peak in severity at about 36 to 72 hours, and generally 
subside by day seven, while the psychological features of dysphoria, anxiety, sleep 
disturbances and increased cravings may be protracted for weeks to months (Himmelsbach 
1941; Martin and Jasinski 1969). Heroin withdrawal is rarely (if ever) life threatening on its 
own, although it can complicate concomitant medical or psychiatric conditions.
Table 1.1 Features of the heroin withdrawal syndrome
increased sweating, lacrimation, rhinorrhoea, urinary frequency
diarrhoea, abdominal cramps, nausea, vomiting
muscle spasm leading to headaches, back aches, leg cramps, arthralgia
piloerection, pupillary dilatation, elevated blood pressure, tachycardia
anxiety, irritability, dysphoria, disturbed sleep
increased cravings for opiates
There is debate regarding the phenomenology of protracted withdrawal: symptoms of persistent 
cravings, sleep and mood disturbances lasting for weeks or months are common following the 
cessation of various drug classes (alcohol, opiates, stimulants, benzodiazepines) and as such, 
may not be part of a drug specific withdrawal syndrome, but rather may represent difficulties in 
adjusting to life without drugs (West and Gossop 1994). This review will focus upon the acute 
aspects of the heroin withdrawal.
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1.1.2 Treatment pathways for dependent heroin users
Many heroin users undergo withdrawal without seeking assistance from structured services 
(Gossop, Battersby et al. 1991). There is nevertheless, considerable demand among heroin 
users for elective withdrawal services from specialist alcohol and drug treatment and primary 
health care providers (such as general practitioners). Withdrawal services are also required to 
assist individuals undergoing non-elective withdrawal, such as following incarceration or 
admission to hospital. The place of withdrawal services can be better understood by 
considering the treatment options available for dependent heroin users in most comprehensive 
service systems. These can be broadly categorised into two treatment pathways (Figure 1.1).
Substitution maintenance treatment involves the use of (usually) long acting opioid 
medications (such as methadone, buprenorphine or LAAM), with the rationale that regular 
administration of prescribed opioids will diminish the need and desire for continued heroin use, 
resulting in a corresponding reduction in heroin related morbidity and mortality. The basis of 
substitution treatment is that it is a long-term approach, generally years, thereby providing 
patients sufficient time and stability to distance themselves from heroin using lifestyles. 
Withdrawal from long-term maintenance substitution treatment is not the focus of this review.
Figure. 1.1: Treatment pathways for dependent heroin users
Dependent Heroin User
r  t
Withdrawal
Withdrawal from 
substitution treatment
Substitution maintenance 
treatment
(e.g. methadone, 
buprenorphine. LAAM)
Psychosocial interventions +/- naltrexone
Post-withdrawal Interventions
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The other main treatment pathway for dependent heroin users involves a variety of withdrawal 
and post-withdrawal treatment services. Post-withdrawal services (e.g. counselling, therapeutic 
communities, 12 step self-help groups) generally emphasise psychosocial aspects of recovery, 
and in some cases may include pharmacotherapy, such as naltrexone. These treatment services 
generally require the individual to have previously undergone drug withdrawal, and as such 
withdrawal services provide an important avenue into subsequent treatment.
1.1.3 Evaluating withdrawal services
The role of withdrawal services
The role and objectives of withdrawal services remains subject to debate, with different 
understandings within consumer groups, service providers, researchers, and the broader 
community. These different functions have been recognised by various authors (Mattick and 
Hall 1996), and neatly summarised in the following excerpt: “although detoxification is often 
the route into treatment, many who begin detoxification do not complete it, and many 
completers do not go on to more definitive treatment. Some enter detoxification only to lower 
their level of dependence and make their habit cheaper; others fully believe that detoxification 
is all that is necessary and that they will be able to remain drug-free.” (Kleber 1997, page 79). 
It is possible to identify four different, though not necessarily mutually exclusive, common 
understandings of the role of withdrawal services:
• Withdrawal as a ‘cure ’ for heroin use. This model frames withdrawal as a treatment 
approach that results in long term abstinence, with completion of a withdrawal program 
being all that is required for individuals to stop their heroin use and return to a drug-free 
lifestyle. This understanding is (unfortunately) common among many drug users, their 
families, and workers in the generalist health and welfare sectors, and the broader 
community, who often identify ‘detoxification’ or ‘withdrawal’ as definitive treatment. 
However, this position is generally not supported by the research literature. Prospective 
follow up studies of heroin users undergoing withdrawal suggests that only a minority 
cease their heroin use on a long term basis following single episodes of withdrawal 
treatment (Valliant 1988; Gossop, Green et al. 1989; Bale, Van Stone et al. 1980). This has 
led most commentators to accept that long term abstinence is not a common outcome of 
detoxification itself, and should therefore not be considered a primary aim or objective 
(Blaine, Ling et al. 1994; Mattick and Hall 1996; Kleber 1997; Johns 1994; O'Brien and 
McLellan 1996; Frank and Pead 1995).
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Withdrawal services are the first step in a longer-term process o f rehabilitation towards 
abstinence. This model recognises the need for longer-term post-withdrawal treatment in 
order to sustain abstinence from heroin use. A central tenet in this model is that heroin users 
enter withdrawal with the goal of long-term abstinence, and that withdrawal services are the 
first of many steps in achieving this goal. However, research suggests that only a minority 
of heroin users attempting withdrawal will continue in some form of treatment. In a review 
of the opiate withdrawal studies, Lipton and Maranda (1983) estimated that only 
approximately 15% continue in structured post-withdrawal treatment. Various authors 
(Blaine, Lmg et al. 1994; Mattick and Hall 1996) have argued against too closely linking 
withdrawal services with post-withdrawal treatment, emphasising that many heroin users are 
not interested in ongoing treatment, and that willingness to enter longer-term treatment 
should not be a prerequisite for entry into withdrawal programs. Nevertheless, most 
commentators recognise that withdrawal services should aim to have longer term benefits: if 
detoxification itself is not associated with longer term changes in drug use, then retention in 
post-withdrawal treatment which can achieve these benefits should be considered an aim for 
withdrawal services (Kleber 1997; Blaine, Ling et al. 1994; O'Brien 1993).
Withdrawal services facilitate a safe and comfortable reversal o f neuoradaptation. The 
main role of withdrawal services within this framework is the reversal of tolerance to 
opioids and the alleviation of the acute withdrawal symptoms associated with the cessation 
of heroin use (or neuroadaptation reversal). The principle endpoint for withdrawal success is 
a period of abstinence from opiate use and / or a negative response to an antagonist 
challenge, emphasising short-term biological outcomes. This model has received increased 
prominence in recent years (Mattick and Hall 1996), in part due to the acknowledgment of 
the limitations of withdrawal in achieving longer term outcomes; and due to an increasing 
emphasis upon pharmacological initiatives in withdrawal research and management, such as 
the use of opioid antagonists which enable an ‘objective’ end point for conducting research 
upon the withdrawal syndrome. However, there are also limitations with this approach. The 
emphasis upon withdrawal completion and neuroadaptation reversal does not recognise 
potential benefits for individuals who reduce, but do not cease, their heroin use during a 
withdrawal attempt. Furthermore, this model pays little attention to longer term outcomes 
such as changes in heroin use, severity of dependence, psychosocial functioning or other 
parameters of drug related harm; and it is difficult to justify the allocation of treatment 
resources to services whose primary objective is limited to short term (biological) 
objectives.
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• Withdrawal services are a means by which heroin users can reduce their level o f heroin use 
and dependence in order to reduce some o f the more deleterious effects o f dependent drug 
use. This model emphasises that the primary function of withdrawal services is to assist 
heroin users to reduce their level of heroin use, seventy of dependence (including tolerance) 
and related harms. Withdrawal serves a range of functions that do not require a cessation of 
heroin use or the ‘completion’ of withdrawal, and to this extent, it differs from the previous 
model, which emphasises withdrawal ‘completion’ as the primary objective. The following 
excerpt from a review of withdrawal services conducted by a drug user group highlights this 
position:
“....we have received many comments about detoxification services which have as 
their common theme: “why do I have to lie about wanting to give up heroin (or 
speed or pills) to get into a detox?” Why must consumers pretend that their goal is 
eternal abstinence when their real goal may be “to get my heroin use back under 
control”, “to give it a miss for a few days”, “to dry out and get my head together”,
“to save up some money”, or a hundred other reasons”? (NSW Users & AIDS 
Association (1994): page7).
This model operates within a harm reduction framework and emphasises the potential 
benefits of withdrawal services to reduce the physical, psychological and social harms 
associated with dependence. However, it remains uncertain as to whether such broad 
benefits actually arise from participation in withdrawal services, or the extent to which any 
changes can be sustained. The capacity for dependent heroin users to sustain a period of 
controlled heroin use following withdrawal has not been established in the research 
literature, and remains a highly contentious issue within the treatment sector. Research has 
not adequately addressed this issue - most withdrawal studies have no (or inadequate) long­
term follow up of subjects, and sensitive measures of heroin use, severity of dependence or 
broader levels of psychosocial functioning are generally not recorded or reported. One study 
conducted in the United Kingdom in the 1980’s (Tennant 1985) suggested that there were 
indeed benefits in psychosocial functioning for heroin users undergoing multiple withdrawal 
episodes over a period of time, however further work is required in order to substantiate this 
premise.
Heroin users present for withdrawal services for a range of reasons and motivations, and each 
of the above models may be valid for different individuals, or for the same individual at 
different times. This heterogeneity is to be expected given the variety of heroin users and their 
circumstances at treatment entry. There are however, considerable differences in the key 
objectives and corresponding primary outcomes for each of the models discussed, and the
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extent to which a withdrawal attempt is considered ‘successful’ will largely depend upon the 
model being prioritised. The following ‘common’ clinical scenarios highlight the difficulties in 
assessing the ‘success’ of a particular withdrawal episode.
Case 1. A homeless patient successfully completes an 8-day inpatient withdrawal episode, 
but fails to keep any subsequent counselling appointments and resumes heavy 
regular heroin use within days of discharge.
This could be considered as a treatment failure under the first two models, as no 
long term abstinence or treatment retention were achieved; a treatment success 
with regards to successful neuroadaptation reversal; and a partial treatment 
success within the last model, as the patient at least had their short term 
accommodation needs addressed.
Case 2. A patient attempts outpatient heroin withdrawal using reducing doses of 
methadone over several weeks. He initially ceases using heroin whilst on 
methadone doses above 15 mg per day, but resumes heroin use when his 
methadone dose reduces below this level. Following discussion with his treatment 
staff, he decides to transfer to a methadone maintenance program. He 
subsequently ceases all heroin use and remains in long-term methadone 
maintenance treatment.
This could be considered a treatment failure with regards to long-term abstinence 
from opiates or neuroadaptation reversal. However, this is a treatment success 
from the perspective of the patient being retained in post-withdrawal treatment, 
not using heroin, and achieving long term stability.
Case 3. A patient undergoes a rapid opiate withdrawal under heavy sedation in hospital 
using naltrexone. She is discharged from hospital after two days, but takes her 
naltrexone for only a further 4 days prior to discontinuing all treatment. At 
follow-up several weeks later she admits to having used heroin on three or four 
occasions, has resumed part-time employment, broken up with her heroin-using 
boyfriend, and is living at home with her parents.
This could be considered a treatment success with regards to neuroadaptation 
reversal or getting her habit under control with improved psychosocial 
functioning; however, she did not fare well with regards to maintaining 
abstinence, or remaining in post-withdrawal treatment.
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Developing a framework for evaluating withdrawal services
The extent to which each of the above scenarios is considered a ‘treatment success’ depends 
upon the understanding of the role of withdrawal services. An unfortunate limitation of 
research examining the efficacy of withdrawal services is that it has often been unclear as to the 
primary goal of the withdrawal program being examined, or withdrawal studies have often used 
measures that prioritise particular outcomes and ignore others. For example, many withdrawal 
studies have examined the severity of withdrawal symptoms or response to an antagonist 
challenge as their primary outcome measures, but have included no follow-up of post­
withdrawal outcomes. In a review of treatment services for opiate dependent users, Wayne Hall 
and colleagues (National Drug Strategy 1993) identified:
There is still some debate about the goals of detoxification and therefore what the 
criteria for success are. Many papers do not indicate whether, for example, the 
detoxification process is intended as a stand alone treatment that is supposed to 
produce enduring abstinence; whether it is seen as a precursor of further drug 
treatment and therefore should result in high rates of entry to other forms of 
treatment; or whether the goal is simply successful detoxification itself (p.12).
A framework for evaluating clinical withdrawal services is required that encompasses the 
various roles of withdrawal services. Indeed, this is important given that different treatment 
approaches may be effective in achieving certain outcomes, but may be less effective in 
achieving others, as suggested by the previous case examples. Such a framework requires the 
identification of a set of objectives for withdrawal services, with corresponding outcomes and 
outcome measures. There have been previous attempts at this task. In a review of 
methodological issues in conducting drug treatment research, Blaine and colleagues (1993) 
identified several key outcomes for drug withdrawal research: cessation of drug use, reduction 
in cravings and severity of withdrawal features, and treatment retention. Mattick and Hall 
(1996) identified a set of outcomes consistent with their emphasis upon withdrawal services as 
a means of reversing neuroadaptation: rates of completion of the withdrawal process, the 
severity of symptoms, and medical complications. They recognised that there are also 
secondary objectives of opiate withdrawal, such as providing a period of respite from drug use 
and its consequences; and overcoming the barrier that withdrawal often poses to subsequent 
treatment and longer-term abstinence.
I propose the following set of objectives as the basis for evaluating withdrawal services. This 
framework emphasises multiple treatment objectives for withdrawal services, and aims to 
accommodate the various understandings of the role of withdrawal services previously
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discussed. Furthermore, each treatment objective has outcomes and measures that can be
practically assessed. This discussion is summarised in Table 1.2.
1. To prevent the development of severe withdrawal sequelae and complications. Although 
heroin withdrawal on its own is rarely (if ever) life threatening, there are three dimensions 
of safety particularly pertinent to the management of heroin withdrawal. Firstly, withdrawal 
in the context of concomitant medical or psychiatric conditions can result in severe 
complications (for example, precipitation of an acute psychotic episode in a patient with 
schizophrenia in remission; dehydration in an individual with poor baseline nutritional 
status). Treatment services themselves can have severe adverse events (Kleber and Riordan 
1982), (e.g. methadone toxicity, anaesthesia-related complications in ultra-rapid opiate 
withdrawal). Finally, increased risk of overdose and death has been reported following 
attempts at heroin withdrawal (Gearing and Schweitzer 1974). A number of factors may 
contribute to this scenario: the resumption of heroin use following a reduction in opioid 
tolerance; the combined sedative effects of heroin and medications used for the 
management of withdrawal (e.g. benzodiazepines, clonidine); and the mood disturbances 
(dysphoria, anxiety) of opiate withdrawal which may contribute to suicidal behaviour.
Measures regarding the safety of withdrawal services require careful clinical monitoring 
and recording of adverse events. A period of monitoring following the completion of the 
withdrawal episode is necessary in order to detect overdoses.
2. To alleviate the symptoms and distress o f withdrawal. Palliation of the discomfort of heroin 
withdrawal is an important reason for patients presenting for treatment and one of the 
primary aims of any withdrawal service. Reduced withdrawal severity has benefits not only 
for the patient, but also potentially places fewer demands upon community supports and 
service providers.
For the purposes of evaluating withdrawal services, instruments should be used that 
independently measure subjective (symptoms) and objective ratings (signs) of opiate 
withdrawal severity. Subjective ratings are more sensitive than objective measures of 
opiate withdrawal (Turkington and Drummond 1989; Loimer, Linzmayer et al. 1991; 
Handelsman, Cochrane et al. 1987), and there is evidence to suggest that subjective ratings 
of withdrawal are ultimately better predictors of treatment outcome (Kosten, Rounsaville et 
al. 1985).
There are a number of ways of expressing the severity of withdrawal experienced during a 
withdrawal episode (Law, Melichar et al. 1998). The total withdrawal discomfort 
experienced over a period of time can be expressed as an ‘Area Under the Curve’ with
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repeated measures over time. Hence, an individual experiencing mild symptoms over a 
prolonged period may have greater overall withdrawal discomfort than a different regime 
associated with severe symptoms for a short period of time. Peak withdrawal severity is 
also an important clinical parameter, as some individuals may not tolerate severe 
discomfort. It should be recognised that measures of withdrawal severity may be difficult 
to interpret in the context of continued heroin use, such as may occur with outpatient 
withdrawal.
3. To interrupt a pattern of heavy and regular drug use. Withdrawal arises from a cessation or
reduction in regular heavy drug use (DSM-IV), and this serves as a main objective for all 
withdrawal services. Complete cessation of heroin use is generally considered the optimal 
outcome regarding drug use during a withdrawal attempt, and is usually a prerequisite of 
inpatient admission. However, a large proportion of withdrawal attempts occur in 
outpatient settings where continued heroin use is possible, and reduction in heroin use may 
still represent a positive and worthwhile outcome for some patients. Withdrawal efficacy 
studies should also incorporate a period of follow-up beyond the immediate treatment 
episode in order to examine the longer-term impact of the intervention upon drug use. 
(McLellan and Durell 1996) have identified the first two to four weeks after the completion 
of acute substance abuse treatment episodes as the most relevant period to examine the 
impact of the intervention - outcomes beyond one month can be difficult to attribute to the 
initial intervention, and may for example, reflect the impact of ongoing treatment services.
Measures of drug use are required that are sufficiently sensitive to identify the extent of 
heroin use during a (outpatient) withdrawal episode, and in the post withdrawal period. For 
example, most commentators would recognise that a withdrawal episode in which a patient 
used heroin on two occasions over a ten-day outpatient episode is a ‘better’ outcome than 
an episode in which the same patient used on 10 occasions over the same period. The most 
sensitive measures of drug use are often based upon self-report, allowing for even small 
changes in the quantity and frequency of drug use to be estimated; however, there are 
limitations in relying exclusively upon self-report data, and objective measures of drug use 
(such as urine drug screens) should also be incorporated (Del Boca and Noll 2000; Darke 
1998; Finch and Strang 1998). An antagonist challenge is a useful investigation for those 
patients considering ongoing naltrexone treatment, however it should not otherwise be 
conducted for routine clinical purposes, given the potential for adverse events.
4. To provide linkages to appropriate post-withdrawal services that address the individual’s
drug use, physical, psychological and social needs. Heroin dependence is generally a 
chronic relapsing condition, and long-term participation in treatment is required in order to
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achieve long-term outcomes. An important role therefore of withdrawal services is to 
facilitate linkages with post-withdrawal services. This includes drug treatment services that 
aim to maintain abstinence or reduce heroin use and related harms, such as: ‘drug free’ 
counselling (e.g. relapse prevention); naltrexone treatment; residential therapeutic 
communities; self help programs; and substitution maintenance programs (e.g. methadone 
or buprenorphine). Some individuals may be unwilling or unable to continue in ongoing 
drug treatment programs, but may nevertheless benefit from linkages to welfare services 
(e.g. accommodation); general support and case management services (e.g. outreach 
workers); or primary or specialist health services.
Measures of participation in post-withdrawal services require a description of the treatment 
modality and duration of treatment. Outcome measures of psychosocial functioning are 
also required in order to assess the broader impact of the withdrawal service upon the 
individual’s quality of life.
Neuroadaptation reversal has been omitted from this framework as an objective for withdrawal 
services. A key problem with the construct of neuroadaptation reversal as an objective within a 
framework for evaluating withdrawal services is that it is difficult to operationalise, particularly 
in routine clinical practice. Neuroadaptation reversal is ‘best’ assessed using a challenge with 
an opioid antagonist, such as naloxone. However, the use of naloxone challenge tests is 
inappropriate during routine clinical practice unless the patient is considering ongoing 
naltrexone treatment, a treatment choice traditionally made by only a minority of heroin users 
entering withdrawal services. (Furthermore, routine naloxone challenge tests cannot be easily 
interpreted in the context of recent buprenorphine treatment (see Section 4.4 in this Chapter for 
discussion), complicating the assessment of neuroadaptation reversal in such patients). Thus, 
whilst neuroadaptation reversal can be easily assessed in studies incorporating naloxone or 
naltrexone treatment, the practical difficulties in establishing neuroadaptation reversal usually 
results in clinicians using ‘proxy’ measures -  such as a patient going several days (often 5 to 7 
days) without any heroin or other opiate use and with the resolution of acute withdrawal 
symptoms and signs. The patient who has accomplished this is assumed to have ‘completed’ 
neuroadaptation reversal. Hence, the assessment of neuroadaptation reversal usually involves 
the use of measures of drug use and withdrawal severity. These two outcome measures have 
already been accommodated in the proposed framework.
Recent trends in health care evaluation (Sederer and Dickey 1996; Miles and Lugon 1996) 
emphasise that a comprehensive evaluation of health services should include measures that go 
beyond the assessment of a particular clinical condition (such as the syndrome of drug 
withdrawal), and should include measures of the impact of intervention upon the general health
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Status and quality of life of the individual patient. This requires a broader assessment of the 
patient’s physical, psychological and social status, and the impact of the intervention in leading 
to improvements in these areas. Within the proposed framework for evaluating withdrawal 
services, the first two objectives (preventing complications and alleviating symptom severity) 
are particularly oriented towards the management of the primary clinical condition (opiate 
withdrawal); whereas the third and fourth objectives accommodate a broader base for 
withdrawal service evaluation, incorporating measures that reflect changes in drug use, 
psychosocial functioning and treatment participation over time.
Table 1.2. Objectives and outcome measures for evaluating withdrawal services
Objective Outcome measures
To prevent the Assessed by the monitoring of adverse events, medical and psychiatric
development of severe conditions. Overdoses should be recorded during and in the period
complications immediately after the withdrawal episode.
To alleviate the severity Frequent and regular measures of withdrawal symptoms (subjective) and
of withdrawal signs (objective). Measures should continue until withdrawal features have
discomfort returned to baseline following the cessation of any opioid medications.
To interrupt a pattern of Measures of levels of heroin use over time. Objective (e.g. urine drug
regular and heavy drug screens) and self-report measures during and after the withdrawal episode.
use Measures should have sensitivity to record abstinence, and to be able to 
describe amount of heroin use (quantity, frequency) for those continuing 
heroin use (e.g. outpatient withdrawal, post-withdrawal follow-up). For 
inpatient withdrawal, treatment retention is often a de-facto measure of 
abstinence from heroin use.
In addition to measures of levels of heroin use, measures of severity o1 
dependence can assist to describe an intervention’s impact in interrupting £ 
pattern of regular and heavy drug use
To provide linkages to Participation in ongoing alcohol and drug treatment and other health and
post withdrawal services welfare services, including description of the treatment modality and
that address the duration of treatment.
individual’s drug use,
Secondary outcome measures of psychosocial functioning are also requirec
physical, psychological
in order to assess the broader impact of the withdrawal service upon the
and social needs.
individual’s quality of life.
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In addition to a framework of outcome measures, there are important process measures 
fundamental in health service evaluation that also need to be considered in evaluating 
withdrawal services. These include:
1. Retention in withdrawal treatment. Retention in withdrawal treatment can be expressed as 
the proportion of patients who complete a predetermined protocol or end point, or in terms 
of time retained in treatment (particularly for longer term withdrawal regimes such as 
gradual methadone reductions).
2. Utilisation and cost of services. The cost of health services is increasingly becoming 
important in decisions regarding the relative allocation of resources, particularly when 
considering alternative withdrawal regimes and settings. For example, although inpatient 
withdrawal services are generally more expensive to provide than outpatient services, they 
may be justified given the higher rate of withdrawal completion (Gossop and Strang 2000). 
The large variation in costs associated with the different methods of providing services for 
heroin withdrawal (see next section) emphasises the need for cost effectiveness studies in 
order to inform decisions regarding resource allocation.
3. General measures o f patient satisfaction. Measures of patient satisfaction are becoming 
increasingly important in health service evaluation (Sederer, Dickey et al. 1996). They 
provide an opportunity for patients to broadly comment upon the services provided, identify 
areas for further improvement, and can provide insights into the interpretation of other 
treatment outcomes.
These outcome and process measures together form a more comprehensive framework for 
evaluating clinical withdrawal services. The incorporation of a multiple treatment objectives 
and outcome measures allows ’for the possibility that some withdrawal programs may have 
advantages in achieving certain treatment objectives, but be less successful in meeting others. 
Identification of the strengths and weaknesses of different withdrawal approaches should also 
assist the process of patient-treatment matching.
The scope of any evaluation, and the emphasis placed upon different outcomes will relate to the 
context in which withdrawal services are provided. For example, issues regarding safety and 
prevention of complications are paramount when evaluating non-elective withdrawal services 
provided to heroin users undergoing intensive medical or surgical inpatient hospital procedures. 
Alternatively, elective withdrawal services provided at the commencement of a long-term 
rehabilitation program (e.g. a therapeutic community, naltrexone treatment) should focus upon 
post-withdrawal treatment induction as its primary outcome.
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1.2. Non-pharmacological interventions for heroin withdrawal
There are several components to the delivery of heroin withdrawal services, including 
assessment and planning, treatment settings, supportive care, pharmacotherapy, and facilitating 
post withdrawal linkages. Non-pharmacological interventions will be briefly described prior to 
examining pharmacotherapies for heroin withdrawal in detail. This section aims to provide an 
overview of contemporary practice (emphasising the Australian treatment context), rather than 
a systematic review of the efficacy of such services.
1.2.1 Assessment
The two main objectives of assessment are: (a) to ascertain valid information in order to 
identify the most suitable treatment plan for the patient, and (b) to engage the patient in the 
treatment process - including the establishment of rapport with the patient and facilitating 
treatment plans. Key dimensions of assessment for withdrawal include: recent and past drug 
use, prior withdrawal and other treatment history, concomitant medical and psychiatric 
conditions, and assessment of psychosocial factors, including reasons for presentation, 
expectations regarding withdrawal, and current social circumstances with an emphasis upon 
barriers and supports for withdrawal (Frank and Pead 1995; NSW Health Department 1999; 
Senay 1997). The process of assessment and patient selection for withdrawal programs (and 
research studies) can have a considerable impact upon outcomes (Blaine et al 1993). For 
example, prolonged assessment periods and waiting times may discourage less motivated 
heroin users, such that only more motivated and organised patients are prone to complete the 
assessment process. Alternatively, outpatient programs that require their patients to have 
considerable home supports (e.g. drug free environment and support people), may select 
patients with better prognoses and result in more favourable outcomes than other programs 
without such stringent criteria.
1.2.2 Settings for withdrawal
Withdrawal services for heroin users can be located in intensive inpatient units (such as 
hospital wards, specialist alcohol and drug detoxification units), in community residential units 
(providing supported accommodation with limited medical staffing or monitoring), or in 
ambulatory settings (including outpatient and home-based services). Non-elective withdrawal 
also occurs in a range of settings, such as prisons or police cells.
The clinical indications for heroin withdrawal to be conducted in an intensive inpatient setting 
are generally limited to the presence of concomitant medical or psychiatric conditions, or
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concurrent withdrawal from heavy alcohol or benzodiazepine use (Frank and Pead 1995; NSW 
Health Department 1999; Chang and Kosten 1997; American Society of Addiction Medicine 
1991). Community residential units are suited to those individuals with inadequate social 
supports and for those with repeated failure at outpatient withdrawal attempts.
There are potential advantages and disadvantages to different treatment settings. Inpatient 
withdrawal settings have been shown to have higher rates of retention and completion than 
outpatient settings (Gossop, Johns et al. 1986), although improved longer-term outcomes have 
not been clearly demonstrated (Wilson, Elms et al. 1975). However, intensive inpatient services 
are usually expensive to operate, and are generally less accessible for heroin users than 
outpatient services. Outpatient withdrawal can also be associated with a more seamless 
transition between withdrawal and post-withdrawal services, with the same treatment providers 
involved in service delivery. For example, in the study by Gossop and colleagues (Gossop, 
Johns et al. 1986), the inpatient setting had a higher rate of withdrawal completion than the 
outpatient program (81% versus 17%), however, a significantly higher proportion of 
outpatients engaged in ongoing counselling after the withdrawal episode (55% versus 29%).
1.2.3 Supportive care
Supportive care refers to the provision of psychosocial support during the withdrawal episode 
and is an important component of withdrawal services, particularly as psychological factors 
appear to have a considerable impact upon withdrawal severity and outcomes (Phillips, Gossop 
et al. 1986). Supportive care usually involves regular monitoring, counselling, provision of 
information, and modification of the patient’s environment (e.g. a quiet environment away 
from other drug users) (Frank and Pead 1995; NSW Health Department 1999).
Monitoring includes frequent review of the patient to identify their general progress and 
motivation, severity of withdrawal symptoms (which can be facilitated by the use of 
withdrawal scales - see discussion below), drug use (particularly in an outpatient context), 
response to the medication(s) and complications. This is important for the individualisation of 
treatment (such as the titration of medication doses or tailoring of ancillary services) and for 
ongoing treatment planning. Evidence from other medical disciplines suggests that encouraging 
patients to self-monitor their progress during treatment (such as symptom severity, side effects) 
improves treatment adherence (Fishman, Wilsey et al. 2000; Waeber, Bumier et al. 2000; 
Denolle, Waeber et al. 2000).
Although there have been numerous opiate withdrawal scales developed, few of them are suited 
to routine use in clinical settings. In order for withdrawal scales to be clinically relevant for
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monitoring withdrawal severity, the instruments should be quick and easy to administer - 
clinicians are busy and patients in withdrawal can often have poor attention or concentration. 
The scales must have robust psychometric properties, particularly inter-tester reliability to 
accommodate different staff administering the instrument at different times during the 
withdrawal episode; sensitivity to detect changes in withdrawal severity over time; and 
specificity to ensure that the instrument is measuring opiate withdrawal and not some other 
condition. The instrument should also incorporate (and ideally differentiate) subjective and 
objective measures of withdrawal. Subjective measures can be self-completed by patients over 
the course of withdrawal, and as previously identified, tend to be more sensitive and are better 
correlated to treatment outcome. Kosten, Rounsaville et al. (1985) demonstrated that subjective 
features are better correlated to withdrawal completion than objective withdrawal ratings, and 
the authors recommended that subjective ratings be used to guide withdrawal treatment 
practices. In contrast, clinician-completed scales (usually assessing objective signs) require 
trained staff, and are less applicable for regular monitoring in outpatient withdrawal programs 
where contact with clinicians may be limited to once a day or less. There are several published 
opiate withdrawal scales that meet these requirements for use in clinical withdrawal settings, 
including the Short Opiate Withdrawal Scale (Gossop 1990) and the Subjective and Objective 
Opiate Withdrawal Scales developed by Handelsman and colleagues (Handelsman, Cochrane et 
al. 1987).
The provision of information regarding the nature and duration of withdrawal, treatment 
procedures and coping strategies can reduce the severity of opiate withdrawal symptoms 
(Green and Gossop 1988). Patients often have limited concentration during withdrawal, and 
information generally has to be repeated. To this end, specific withdrawal literature designed 
for patients has been developed (e.g. Lintzeris, Dunlop et al. 1996; Law and Dean 1998) and 
may be of benefit, although they have not been extensively evaluated.
Counselling during the withdrawal episode is generally aimed at supporting the patient 
through the withdrawal period and facilitating post withdrawal linkages. Contemporary 
approaches to withdrawal counselling generally recommend strategies that aim to allay the 
mood disturbances of withdrawal (anxiety, dysphoria), cravings, sleep disturbance and to 
maintain motivation (see for example Frank and Pead 1995; National Health and Medical 
Research Council 1991; NSW Health Department 1999). Although many patients may wish to 
address a range of long standing personal, emotional or relationship problems during 
withdrawal, such attempts can have the adverse consequence of increasing agitation and 
cravings, thereby jeopardising the withdrawal episode. It is usually recommended that these
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issues are deferred until after the withdrawal episode, and this can serve to motivate patients 
into considering post-withdrawal treatment options.
There is limited research examining the impact of counselling during heroin withdrawal. 
Rawson and colleagues (Rawson, Mann et al. 1983) examined the impact of mandatory 
counselling with a therapist during a 21-day outpatient withdrawal compared to subjects 
receiving no counselling in a randomised trial of 50 subjects. There was no difference noted in 
numbers heroin use or completion rates, however those receiving counselling had higher rates 
of participation in post-withdrawal treatment. These findings suggest that the provision of 
structured counselling sessions during withdrawal that specifically address ongoing 
participation in treatment may increase post-withdrawal treatment retention. Several studies 
indicate that behavioural interventions employing contingency management strategies can 
enhance completion rates in outpatient withdrawal programs (Bickel, Amass et al. 1994; 
McCaul, Stitzer et al. 1984). Bickel and colleagues examined 39 heroin users undergoing a 
gradual buprenorphine reduction (over 6 months). Patients were randomised to receive either 
‘standard’ counselling, or contingency management and community reinforcement approaches. 
The group receiving behavioural interventions had higher rates of retention and less heroin use 
during the withdrawal episode. McCaul and colleagues likewise demonstrated enhanced 
retention and reduced drug use for subjects randomised to contingency management 
interventions compared to those receiving standard approaches, although there were no 
differences in post-withdrawal outcomes for the two groups. Unfortunately, the capacity for 
routine withdrawal services to incorporate intensive behavioural interventions of contingency 
management is often limited.
1.3. Pharmacotherapies for heroin withdrawal
In a review of historical methods for the management of opiate withdrawal, Kleber & Riordan 
(1982) identified that numerous pharmacological approaches have been used to manage opiate 
withdrawal during the past century. The authors reflected how these had often been introduced 
with considerable initial enthusiasm, only for most approaches to be abandoned as concerns 
regarding their effectiveness or safety emerged, or newer approaches were developed. The 
changes in ‘conventional’ clinical practice and ‘wisdom’ over time emphasises the need for 
thorough evaluation of pharmacotherapies and an evidence-based approach to clinical practice.
Medication regimes for heroin withdrawal in the contemporary research literature can be 
broadly classified into four approaches (Gowing, Ali et al. 2000):
1. reducing doses of an opioid agonist, usually methadone;
Chapter 1. Introduction and Literature Review. 26
2. symptomatic medications, most notably the a.2 adrenergic agonists, clonidine and 
lofexidine, which aim to reduce the severity of withdrawal symptoms, without 
fundamentally changing the course of the withdrawal syndrome;
3. opioid antagonists, predominantly naloxone or naltrexone;
4. partial opioid agonists, predominantly buprenorphine.
The literature regarding each of these approaches will be reviewed in the remainder of this 
chapter. Each of these approaches has been the subject of recent systematic literature reviews 
(Gowing, Ali et al. 2000); including recent Cochrane reviews of buprenorphine for opiate 
withdrawal (Gowing, Ali et al. 2000) and antagonist-assisted withdrawal (Gowing, Ali et al. 
2000). Recent systematic reviews have also been published regarding the ‘newer’ approaches 
with lofexidine (Strang, Beam et al. 1999), and antagonist-assisted withdrawal (O'Connor and 
Kosten 1998). Thus, a systematic review of the research literature regarding the use of 
methadone, adrenergic agonists and opioid antagonists in heroin withdrawal has not been 
repeated as part of this thesis. Rather, key issues regarding the use of these medications, and 
relevant comparative randomised controlled trials regarding efficacy will be examined. The use 
of a number of other symptomatic medications (such as benzodiazepines) will also be briefly 
described, as they are frequently used in clinical practice (Frank and Pead 1995; NSW Health 
Department 1999; Fishbain, Rosomoff et al. 1993), although they have not been 
comprehensively evaluated. The role of buprenorphine in heroin withdrawal will be examined 
in detail in the Section 4 of this chapter.
1.3.1 Methadone and other opioid agonists
Methadone is an agonist at p. opiate receptors and can fully substitute for heroin in dependent 
individuals, thereby preventing heroin withdrawal. Although there is considerable variation in 
the manner in which methadone has been used in the treatment of heroin withdrawal, the 
general clinical principles involve:
1. Initial titration of the methadone dose to prevent features of heroin withdrawal (usually in 
the range of 20 to 40 mg daily).
2. Reduction in the methadone dose over a period of time. 10 to 21 days of methadone tapering 
is frequently described in the research literature, extending to longer programs in some 
cases (e.g. 6 week reduction regimes). There have been descriptions of longer reduction 
programs (extending up to 6 months), although these are often in the context of patients 
having limited access to methadone maintenance programs (often because of regulatory 
restrictions thereby these programs serve as ‘de-facto’ maintenance programs), or in the
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context of withdrawal from methadone maintenance treatment (rather than methadone- 
assisted heroin withdrawal regimes).
3. Adjuvant psychosocial interventions and symptomatic medication are often employed 
towards the end of the methadone reduction regime, corresponding to the period when 
withdrawal severity is greatest.
The use of methadone delays the emergence of peak withdrawal symptoms and prolongs the 
duration of withdrawal symptoms (Gossop, Griffiths et al. 1989). Methadone generally 
prevents significant withdrawal symptoms until the dose reduces to low levels, at which point 
opiate withdrawal symptoms emerge. Several studies have demonstrated that withdrawal 
symptoms peak at about the time of the last methadone dose or in the first few days after the 
cessation of methadone, with withdrawal discomfort persisting for approximately 10 to 14 days 
following a 10 to 21 day methadone reduction regime (Gossop, Griffiths et al. 1989; Strang and 
Gossop 1990; Beam, Gossop et al. 1996; Kasvikis, Bradley et al. 1990). The emergence of 
withdrawal features after the cessation of the therapeutic agent (in this case methadone) is 
referred to as rebound withdrawal. The prolongation of withdrawal discomfort and severity of 
this rebound withdrawal are among the main limitations of using methadone for heroin 
withdrawal, particularly in inpatient withdrawal programs of short duration (see discussion 
below).
It can be postulated that very short courses of low methadone doses (for example, 3 to 5 days of 
up to 30 mg per day) may result in minimal rebound withdrawal upon the cessation of 
methadone, but still provide relief of symptoms during the period traditionally associated with 
peak heroin withdrawal. Unfortunately, this has not been systematically investigated in the 
published literature. There have been several accounts of short methadone withdrawal regimes 
(e.g. Jonas, O'Dwyer et al. (1972) used a 5 day regime; Silsby and Tennant (1974) and Stem et 
al. (1974) used 7 day regimes), however these studies did not monitor withdrawal symptoms 
following the cessation of methadone dosing to examine for rebound withdrawal.
A consistent finding in the studies of methadone assisted heroin withdrawal is the high rate of 
relapse to heroin use following cessation of methadone doses. Most studies of methadone 
assisted heroin withdrawal do not report on outcomes in the post-withdrawal period, however 
studies that have reported post-withdrawal outcomes suggest very high rates of relapse to 
heroin use (for example, Wilson, Elms et al. 1974) reported that all 30 heroin users relapsed to 
heroin use within one month of ending a methadone reduction withdrawal regime; whilst in a 
later study (Wilson, Elms et al. 1975), only 5% (2 / 40) were opiate-free three months after the 
end of a methadone reduction regime). In a review of outpatient methadone assisted heroin
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withdrawal studies (n=20) conducted in the USA in the 1970’s, (Maddux, Desmond et al. 1980) 
reported that between none to 38% of subjects in these studies were abstinent at follow-up, and 
concluded that outpatient withdrawal did not lead to prolonged abstinence in most heroin users. 
Patient and treatment factors impacting upon outcomes associated with methadone-assisted 
heroin withdrawal are considered below.
From the perspective of safety, methadone is generally well tolerated by heroin dependent 
individuals, although there are concerns regarding methadone toxicity and diversion. 
Methadone doses which are generally considered to be in the therapeutic range (for example, as 
low as 20 to 30 mg) may be fatal in individuals with low levels of tolerance to opiates 
(Drummer 2000; Zador, Sunjic et al. 1997), particularly in the context of repeated dosing, 
inadequate clinical monitoring and concurrent use of other sedative medications. Diversion of 
methadone, with the concomitant risks of toxicity in non-treatment populations and methadone 
injecting are also a concern, particularly in treatment systems where take-away doses of 
methadone are widely available (Darke, Ross et al. 1996; Lintzeris, Lenne et al. 1999; 
Waldvogel and Uehlinger 1999).
The use of methadone to assist heroin withdrawal is well suited to facilitating continued 
methadone treatment as a maintenance program, particularly for those patients who do not 
cease their heroin use during the withdrawal episode, or relapse to heroin use on discontinuing 
methadone treatment. However, the prolonged withdrawal following the cessation of 
methadone can often be a barrier to entry into abstinence-oriented post withdrawal treatment 
modalities. For example, the commencement of naltrexone is generally recommended 10 days 
after the last methadone dose (Bell, Kimber et al. 1999); while many residential rehabilitation 
programs will not accept patients until several days after the cessation of methadone treatment.
Treatment factors impacting upon outcomes
The manner in which methadone-assisted withdrawal regimes are delivered may impact upon 
outcomes. There has however, been considerable variation between reported studies with 
regards to these treatment variables, thereby limiting the capacity to identify an ‘optimal’ 
approach for the use of methadone in heroin withdrawal. Treatment variables that appear to be 
important include:
• The treatment setting. Historically, long term inpatient withdrawal programs involving 
gradual methadone reductions over weeks were not uncommon. Studies examining such 
programs indicated that inpatient withdrawal programs using methadone generally resulted 
in a greater rate of program ‘completion’ than outpatient based programs. Two randomised 
trials have examined the impact of setting upon heroin withdrawal completion rates using
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methadone. Gossop, Johns et al. (1986) compared outcomes for subjects allocated to a 21- 
day inpatient reduction or to an 8-week outpatient reduction regime. The inpatient group had 
a significantly higher completion rate (81% compared to 17%). However, the study also 
reported that the outpatient group had a significantly higher rate of post-withdrawal 
treatment retention than the inpatient group; suggesting that inpatient services may result in 
better short term outcomes, however post-withdrawal treatment retention may be better 
achieved with outpatient services. Wilson, Elms et al. (1975) compared outcomes for 40 
heroin users randomly assigned to either an inpatient or outpatient 10-day methadone 
reduction regime. The authors reported that few subjects completed either regime, and 98% 
of subjects had relapsed to heroin use within 2 months of treatment. Given the poor 
completion rates for both groups, the authors concluded that outpatient services were a more 
cost-effective treatment approach. A recent systematic review of methadone withdrawal 
literature reported 78% of opiate dependent subjects attempting inpatient methadone 
withdrawal completed the regime (referring to the proportion of subjects reaching 0 mg of 
methadone), compared to 31% of outpatient attempts (p< 0.001) (Gowing, Ali et al. 2000). 
It should be noted that these proportions are for studies of heroin and/or methadone 
dependent subjects, and completion rates for stable methadone dependent subjects may be 
greater than for heroin dependent subjects (Gowing, Ali et al. 2000). Rates of successful 
completion of outpatient methadone reduction regimes (without any heroin use) vary 
considerably, with most reviewers commenting that successful rates of completion are low - 
in the range of 10 to 20% (Johns 1994; Kleber 1997; Mattick and Hall 1996).
The trend in recent years has been towards shorter inpatient withdrawal programs, often no 
longer than 7 to 10 days. This has restricted the utility of methadone as an inpatient 
withdrawal medication, given that opiate withdrawal symptoms persist for several days 
beyond the last methadone dose. Despite anecdotal reports of programs using brief inpatient 
methadone regimes (3 to 5 days), there were no published evaluations of such short 
methadone regimes identified (Gowing, Ali et al. 2000; Gowing, Ali et al. 2000).
The initial stabilisation period on methadone prior to dose reduction. Initial stabilisation on 
methadone can disrupt a pattern of heavy daily heroin use, enhance the patient’s sense of 
self-efficacy, and improve their capacity to cope with subsequent withdrawal symptoms 
(Reilly, Sees et al. 1995). Although not systematically examined in the research literature, 
the extent of continued heroin use during the period of initial stabilisation on methadone 
may impact upon subsequent withdrawal outcomes. In a study examining a 90-day 
outpatient methadone reduction regime for heroin users, subjects who continued to use 
heroin during the initial two week stabilisation period had worse outcomes than those
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subjects who had ceased heroin use during stabilisation (Stitzer, McCaul et al. 1983). There 
may be advantages in enabling sufficient time (and methadone doses) during the initial 
stabilisation period to ensure cessation of heroin use prior to dose reduction, although 
further research on this issue is required.
The rate and frequency o f dose reduction. There are both advantages and limitations with 
methadone withdrawal programs of different duration. Shorter reduction regimes appear to 
be associated with greater peak withdrawal discomfort, shorter duration of withdrawal 
symptoms (Gossop, Griffiths et al. 1989) and greater ‘completion’ rates (subjects reaching 
zero mg of methadone according to protocol) (Gowing, Ali et al. 2000). However, the 
higher completion rates for shorter regimes may merely reflect that longer programs have 
more time in which subjects can relapse to heroin use and / or drop out of treatment. Some 
authors have argued against rapid reduction regimes (e.g. 10 to 21 days), stating that many 
individuals are prematurely withdrawn and consequently resume heroin use (Maddux, 
Desmond et al. 1980). Unfortunately, most studies of outpatient reduction regimes have 
reported very low rates of abstinence from heroin following the cessation of methadone, 
regardless of the duration of the reduction regime. A longer program may be associated with 
benefits whilst treatment is being continued due to the stability afforded by (adequate doses 
of) methadone. Little is known regarding the extent to which the duration of the methadone 
reduction program impacts upon other post-withdrawal outcomes.
The degree o f flexibility in dosing regimes. The literature examining the impact of flexibility 
(or patient involvement) in dosing reduction regimes is equivocal. Two studies have 
reported higher ‘completion’ rates (subjects reaching zero mg of methadone) for fixed 
dosing regimes, although the findings regarding other outcomes, such as rates of heroin use, 
are mixed (Raynes and Patch 1973; Dawe, Griffiths et al. 1991). A larger study of 108 
heroin dependent adults using a 22-week methadone reduction regime (Senay, Dorus et al. 
1984) showed no difference between subjects randomly assigned to physician or patient- 
regulated dose reduction on any outcome measure.
The level o f psychosocial and supportive care. The research literature regarding the role of 
psychosocial interventions in methadone-assisted heroin withdrawal is limited. The 
structured provision of information to patients undergoing an inpatient 21-day methadone 
taper resulted in enhanced treatment retention and less severe withdrawal severity than 
subjects receiving information on request (Green and Gossop 1988). Another randomised 
trial examined the impact of structured counselling regarding post withdrawal treatment 
options in the context of an outpatient methadone-assisted withdrawal for heroin users 
(Rawson, Mann et al. 1983). The structured counselling group had a significantly greater
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uptake of alternative treatment options (48%) compared to the Control group receiving 
information on request (12%). A randomised trial of the use of contingency management in 
an outpatient methadone assisted heroin withdrawal resulted in improved short term 
outcomes (such as less severe withdrawal symptoms, heroin use and treatment retention), 
however did not demonstrate any longer term benefit, with all subjects relapsing to heroin 
use after methadone was discontinued (McCaul, Stitzer et al. 1984).
• The use o f adjuvant symptomatic medications. Systematic evaluation of adjuvant 
medications in addition to methadone reductions has been limited. The use of a high-dose 
clonidine regime throughout a 10-day inpatient methadone reduction resulted in higher drop 
out rates than the placebo and methadone group, due to hypotensive side effects of clonidine 
(Ghodse, Myles et al. 1994). Little systematic research has examined the use of 
benzodiazepines in this context. Diazepam was found to enhance treatment retention and 
reduce heroin use during an outpatient methadone regime compared to the tricyclic 
antidepressant doxepin (McCaul, Stitzer et al. 1984). Srisurapanont and Jarusuraisin (1998) 
found amytriptilline and lorazepam to be equally effective in managing sleep disturbances 
during withdrawal from methadone maintenance treatment.
• The availability o f transfer to maintenance substitution treatment (and the extent to which 
this is encouraged by treatment staff). Many patients undergoing methadone-assisted heroin 
withdrawal will take up the option of transferring to methadone maintenance treatment if it 
is available (Rawson, Mann et al. 1983), and the enhanced long term outcomes associated 
with methadone maintenance treatment warrants its promotion to all patients undergoing 
heroin withdrawal, particularly in circumstances where other effective treatment modalities 
are not being considered. However, the decision for a patient to discontinue a withdrawal 
regime and transfer to methadone maintenance complicates the interpretation of withdrawal 
outcomes, and withdrawal research studies have not usually included (or reported) such 
options in their protocols.
Patient factors impacting upon outcomes
The importance of patient characteristics upon withdrawal outcomes is even less clear. 
Whereas anecdotal reports and conventional ‘wisdom’ (Kleber 1981) suggests that withdrawal 
severity is related to duration and levels of heroin use, findings from research directly 
examining this issue are equivocal. Significant associations between withdrawal severity and 
quantity of opiate use have been reported (Andrews and Himmelsbach 1944; Smolka and 
Schmidt 1999); however most researchers have found no significant association between 
baseline heroin consumption and subsequent withdrawal severity (Phillips, Gossop et al. 1986;
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Gossop, Bradley et al. 1987; Gossop and Strang 1991). Smolka and Schmidt (1999) also 
identified a relationship between route of administration and withdrawal seventy, with greater 
withdrawal reported by those injecting, rather than smoking, equivalent amounts of heroin.
Psychological factors have been shown to impact considerably upon withdrawal severity and 
treatment retention. Phillips, Gossop et al. (1986) examined a range of patient and treatment 
factors in heroin and methadone users undergoing a 21-day methadone assisted withdrawal. 
Methadone dose at the commencement of the withdrawal and duration of opioid use were not 
predictive of withdrawal severity, whereas level of neuroticism and expectancy regarding 
withdrawal severity were significantly associated with withdrawal severity. Similar findings 
have been reported for individuals undergoing withdrawal from methadone maintenance 
treatment. Kosten, Rounsaville et al. (1984) found higher scores for depression at baseline (as 
measured by the Beck Depression Inventory) to be a significant predictor of failure at attempts 
to withdraw from methadone maintenance treatment. Kanof, Aronson et al. (1993) reported that 
subjects with increasing levels of dysphoria during the withdrawal episode (but not necessarily 
high scores at baseline) complained of greater withdrawal discomfort and had less success in 
completing withdrawal; however directions of causality cannot be determined from such 
findings (increased dysphoria may have been a consequence of greater withdrawal discomfort).
Perhaps one of the most important factors impacting upon withdrawal outcomes is the extent to 
which patients presenting for treatment are committed to long-term abstinence and have the 
(psychological and social) resources available to achieve abstinence. These are difficult 
parameters to measure in both clinical and research settings, and as such, their importance may 
be underestimated in the research literature.
Other opioid agonists in the management of heroin withdrawal
A range of opioid agonists has been used historically in the management of withdrawal from 
other opiates. Injectable morphine was used in the nineteenth century to treat withdrawal from 
opium until concerns were raised regarding the difficulties of withdrawal from morphine. By 
the turn of the century, heroin was being advocated as a treatment for morphine addiction 
(Kleber & Riordan 1982). As heroin became an ever-increasing drug of abuse, opiates such as 
morphine and codeine were used to assist in the management of heroin withdrawal. The 1960’s 
saw the introduction of methadone for treating heroin dependence, and since the 1970’s it has 
become the primary substitution withdrawal medication. A number of other opioid agonists 
have also been used and evaluated for heroin withdrawal, most notably propoxyphene, codeine, 
and LAAM.
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Propoxyphene has been described in a number of trials of heroin withdrawal (Inaba, Gay et al. 
1974; Tennant, Russell et al. 1977; Tennant, Russell et al. 1975). Propoxyphene and methadone 
were directly compared in an outpatient randomised controlled trial of 72 heroin users using 
21-day reduction regimes (Tennant, Russell et al. 1975). Subjects randomised to methadone 
reported significantly less severe withdrawal features and had higher treatment retention rates, 
although similar rates of heroin use were reported during the withdrawal episode. The initial 
enthusiasm shown with propoxyphene has been tempered with more recent reports of adverse 
events and abuse of the medication (Dore 1996; Matusiewicz, Wallace et al. 1999; Jonasson, 
Jonasson et al. 1998).
LAAM, a long acting synthetic opioid, was compared to methadone for heroin withdrawal in a 
randomised controlled trial of 61 male heroin users using a 9 week outpatient treatment 
protocol (Sorensen, Hargreaves et al. 1982). Reported outcomes (withdrawal symptoms, 
retention rates and heroin use) were similar for the two groups. Despite the generally 
favourable outcomes of LAAM for managing heroin withdrawal, it has not been widely used in 
clinical practice for this purpose.
Codeine is another opiate medication used in Australia (and elsewhere) for assisting heroin 
withdrawal. In Australia this occurs in the context that codeine in combination with 
paracetamol or aspirin is registered as a ‘Schedule 4’ medication, and can be prescribed by 
doctors without the regulatory controls (such as individual permits from jurisdictional health 
authorities) associated with most other opioids, which are generally ‘Schedule 8’ medications. 
No randomised trials of codeine for managing heroin withdrawal were identified in the 
systematic literature search conducted by Gowing and colleagues (Gowing, Ali et al. 2000).
1.3.2 Alpha adrenergic agonists
A number of ot2 adrenergic agonists have been investigated for the management of heroin 
withdrawal, including clonidine, lofexidine, guanfacine and guanabenz acetate; although only 
two, clonidine and lofexidine, are widely used clinically, and the discussion will be limited to 
these medications.
The main mechanism of action postulated for the alpha adrenergic agonists is that they reduce 
the noradrenergic hyperactivity in the locus ceruleus seen during opiate withdrawal 
(Maldonado 1997), although other neurotransmitter systems may be implicated, including 
serotonergic and cholinergic systems (Greenstein, Fudala et al. 1997). Clonidine appears to be 
most effective in reducing certain withdrawal features, such as restlessness and the ‘autonomic’ 
features of withdrawal (diarrhoea, nausea, abdominal cramps, sweating, rhinorrhoea,
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lacrimation); however appears less beneficial in alleviating sleep disturbances, body and 
muscle aches or cravings (Jasinski, Johnson et al. 1985; Gossop 1988).
The time frame of withdrawal symptoms when using alpha-adrenergic agonists is comparable 
to unmedicated heroin withdrawal, peaking in severity within the first 2 to 4 days of heroin 
cessation. Most objective features resolve within 5 to 7 days, although subjective symptoms 
generally persist for longer. Unlike opioid agonists, clonidine has the advantage of not 
significantly prolonging the duration of opiate withdrawal. This facilitates shorter treatment 
programs and enhances the capacity for induction onto naltrexone as a post-withdrawal 
treatment option.
Clonidine dosing regimes generally involve titration of the dose according to the patient’s 
experience of withdrawal symptoms and adverse events. The main adverse events reported are 
features of hypotension (experienced as dizziness, fainting, light headedness), fatigue or 
lethargy, and dry mouth. It is the former cluster of side effects that frequently restricts upper 
dosing levels, and indeed has often limited the use of clonidine in outpatient settings where 
patients can be less readily monitored. Whilst most authors suggest doses of clonidine should 
be individually titrated, maximum dosing levels of 1 to 1.2 mg (or 15 pg / kg / day) orally per 
day (in three or four divided doses) have been frequently used in research studies (Washton and 
Resnick 1981; Kleber, Riordan et al. 1985) and recommended in clinical guidelines (Fishbain, 
Rosomoff et al. 1993; Greenstein, Fudala et al. 1997; Frank and Pead 1995).
Lofexidine is another adrenergic agonist that has the advantage of producing less hypotensive 
side effects than clonidine, thereby improving its safety and applicability in the outpatient 
context. Three randomised controlled trials comparing lofexidine to clonidine in inpatient 
settings have shown similar efficacy regarding withdrawal severity and completion rates (Lin, 
Strang et al. 1997; Kahn, Muford et al. 1997; Camwath and Hardman 1998). Unfortunately, 
lofexidine is not registered in many countries outside of Europe, and is unavailable in Australia 
at the time of writing. Another (considerable) drawback is its expense, costing in excess of 
$(AUS) 200 for a typical one week withdrawal regime (compared to less than $10 for a similar 
duration of clonidine treatment).
There is considerable variation in the reported outcomes for adrenergic agonist-assisted heroin 
withdrawal. Some studies have reported very high proportions of subjects successfully 
completing withdrawal - for example, Benos (1985) reported 88% of subjects completed 
inpatient withdrawal, while Lemer and colleagues (Lemer, Gelkopf et al. 1995) reported 96% 
completed a home based withdrawal regime using clonidine. In contrast, others have reported 
very low rates of successful withdrawal completion. For example, Spencer and Gregory (1989)
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reported that 5% of heroin addicts completed an outpatient clonidine withdrawal regime, and 
stated that this outcome was consistent with conventional experience at their clinic. Tennant 
and Rawson (1984) reported that only 11% of subjects remained opiate-free for at least several 
days in an outpatient program. There are a number of reasons for the marked difference in 
reported outcomes between studies: (a) the use of different outcome measures or endpoints 
between studies; (b) enrolment of patient populations with different characteristics; and (c) 
differences in the delivery of treatment services. The marked variations between studies 
emphasises the necessity of considering findings from randomised controlled trials in order to 
compare the efficacy of different treatment regimes.
Efficacy of alpha adrenergic agonists
The research evidence from randomised controlled trials comparing the efficacy of clonidine or 
lofexidine and methadone in managing heroin withdrawal is limited (comparisons between 
clonidine and antagonist-accelerated withdrawal regimes, and with buprenorphine, are 
considered in detail later in this chapter). In their systematic review of opiate withdrawal, 
Gowing and colleagues (Gowing, Ali et al. 2000) identified five randomised controlled trials 
comparing clonidine and methadone in managing heroin withdrawal (Cami, De Torress et al. 
1985; Vilalta, Treserra et al. 1987; San, Cami et al. 1990; Jiang 1993; Dawe and Gray 1995), 
and one randomised trial comparing lofexidine and methadone (Beam, Gossop et al. 1996). 
Several other randomised trials (for example, Washton and Resnick 1981; Washton and 
Resnick 1980; Strang et al 1997) examined subjects withdrawing from either heroin or 
methadone maintenance programs, without differentiating the findings according to the primary 
drug of dependence; consequently, these studies are difficult to interpret in considering the 
management of heroin withdrawal, and will not be considered in detail in this report.
The first published randomised trial comparing clonidine with methadone for the management 
of heroin withdrawal was by Cami and colleagues (Cami, De Torress et al. 1985) with 30 
heroin users enrolled in a 12-day inpatient program. The study demonstrated comparable 
completion rates between clonidine and an 8 to 10 reduction regime of methadone. The 
clonidine group experienced greater peak symptoms early in the withdrawal regime, with 
resolution of withdrawal symptoms by discharge. In contrast, the methadone subjects reported 
less peak withdrawal severity, but were still complaining of withdrawal symptoms on 
discharge.
Similar findings have been reported in most other randomised trials comparing methadone and 
adrenergic agonist medications. No significant differences were reported regarding completion 
rates in two trials with small subject numbers (n = 22, Vilalta, Treserra et al. 1987; and n = 16,
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Dawe and Gray 1995); nor in a larger randomised trial of 200 subjects (Jiang 1993), albeit a 
proportion of these subjects were undergoing treatment involuntarily and therefore completion 
rates are difficult to interpret. All these studies consistently demonstrated that methadone 
subjects reported delayed peak withdrawal severity compared to the subjects randomised to 
clonidine. The one randomised trial which examined 10-day inpatient regimes of lofexidine 
versus methadone reductions (Beam, Gossop et al. 1996) similarly demonstrated comparable 
completion rates for the two groups (69% for the lofexidine group, 77% for the methadone 
group).
San, Cami et al. (1990) is the only randomised trial to report a difference in retention rates 
between the two medication approaches. The 12-day inpatient trial compared 3 groups: 
methadone, clonidine, and guanfacine (another adrenergic agonist), and continued to recruit 
subjects until 30 successful withdrawals had occurred for each condition. Methadone had the 
highest completion rate: 75% of subjects commencing methadone successfully completed the 
regime, compared to 48% of subjects commencing guanfacine and 44% of subjects 
commencing clonidine. Again, the methadone group complained of less severe withdrawal 
early in the withdrawal (days 2 to 5), however, had more symptoms towards the end of the 
admission.
Unfortunately, there have been no randomised trials comparing methadone reductions to 
adrenergic agonists for the management of heroin withdrawal in outpatient settings. Studies 
examining outpatient withdrawal from methadone maintenance treatment suggest that 
completion rates with clonidine may be comparable (Kleber, Riordan et al. 1985; Rounsaville, 
Kosten et al. 1985); or inferior (Washton and Resnick 1980) to methadone reductions.
Clonidine has been shown to result in better outcomes than placebo for the management of 
inpatient heroin withdrawal (Benos 1985; Gerra, Marcato et al. 1995); and less withdrawal 
severity than tranquillisers (chlordiazepoxide and chlorpromazine) (Gupta and Jha 1988).
Patient and treatment factors impacting upon outcomes
Many similarities can be identified with the methadone-assisted heroin withdrawal literature 
regarding the impact of patient and treatment factors:
• As for methadone withdrawal, withdrawal services in inpatient settings generally report 
better outcomes (such as completion rates) than withdrawal undertaken in outpatient settings 
(Gowing, Ali et al. 2000).
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The provision of psychosocial interventions would be expected to impact upon withdrawal 
outcomes, although there has been little research systematically examining psychosocial 
interventions in clonidine-assisted withdrawal.
The availability o f post-withdrawal treatment influences withdrawal retention rates. The 
option of enrolling in post-withdrawal treatment was shown to enhance withdrawal 
completion in a study conducted by Rawson, Washton et al. (1984). Subjects who had 
access to naltrexone at the end of the withdrawal regime had higher rates of completion for 
clonidine-assisted outpatient heroin withdrawal than subjects without access to naltrexone. 
Perhaps of even greater importance in interpreting and comparing findings between studies 
is the extent to which the withdrawal component of a study is the beginning of a long-term 
treatment program, such as ongoing naltrexone treatment. This may significantly impact 
upon withdrawal outcomes by recruiting highly motivated patients interested in long-term 
abstinence oriented treatment. For example, in the study reported by Gerra, Marcato et al. 
(1995), subjects were enrolling into a 6 month naltrexone study. The initial week of 
treatment involved a withdrawal episode, however the outcomes for subjects in this group 
were remarkably positive for an outpatient population (96% ‘completion’ rates for clonidine 
group, 74% for placebo). It may be difficult to generalise findings from such studies to 
conventional withdrawal programs recruiting a population of heroin users with diverse 
different treatment goals.
Opioid use prior to withdrawal. A common practice in many studies using clonidine is to 
stabilise patients on methadone for a number of days prior to commencing clonidine 
treatment (for example, Cuthill, Beroniade et al. 1990; Washton and Resnick 1981). This 
practice may result in beneficial withdrawal outcomes, which are attributed to clonidine 
treatment without adequate recognition of the role of a (temporary) period of stabilisation 
on methadone. A number of studies with clonidine have demonstrated worse outcomes for 
subjects actively using heroin at the time of enrolment compared to those stabilised on 
methadone (McCann, Miotto et al. 1997; Brown and Fleming 1998), and the initial period of 
stabilisation on methadone may confer benefits that are not associated with clonidine-only 
regimes.
Patient characteristics may play an important role in determining treatment outcomes. 
Factors such as the severity of dependence, the extent to which patients are motivated to 
achieve abstinence, recruitment processes and program selection criteria may impact 
considerably upon outcomes (Blaine, Ling et al. 1994), although these have not been 
systematically examined in heroin withdrawal.
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Summary of alpha adrenergic agonists in heroin withdrawal
Despite the methodological problems of comparing outcomes between studies, there is 
sufficient evidence to suggest that clonidine and lofexidine are effective pharmacotherapies for 
heroin withdrawal. Although not successful in reducing all the features of heroin withdrawal, 
such as cravings, adrenergic agonists nevertheless have an advantage over methadone in not 
prolonging the duration of the withdrawal syndrome, which favours their use in short term 
inpatient withdrawal admissions. The use of clonidine outside of inpatient settings is somewhat 
restricted by its side effect profile, particularly by inexperienced service providers. Whilst side 
effects are less of a concern with lofexidine, it is considerably more expensive and has limited 
availability outside of Europe.
1.3.3 Accelerated withdrawal using opioid antagonists
The opioid antagonists naloxone and naltrexone have been used to accelerate the onset and 
reduce the duration of acute heroin withdrawal. It is postulated that shortening the withdrawal 
process reduces the risk (or opportunity) of relapse to heroin use, and enables earlier initiation 
onto post withdrawal treatment involving naltrexone for relapse prevention.
The compression of acute withdrawal symptoms is associated with a considerable increase in 
the severity of withdrawal, such that other medications are required to make the process 
tolerable for patients. Whilst the techniques used have varied considerably (see (O'Connor and 
Kosten 1998) and (Gowing, Ali et al. 2000) for systematic reviews), two broad approaches 
have been described:
• Rapid detoxification procedures in which the patient is only mildly sedated - antagonists 
are combined with symptomatic medications such as clonidine, benzodiazepines and anti­
emetics. Rapid detoxification programs have been provided in a variety of treatment 
settings, ranging from intensive hospital settings to (supervised) outpatient day programs
• Ultra-rapid detoxification procedures in which the patient is inducted onto antagonists 
whilst under general anaesthesia or heavy sedation in highly supervised (hospital) setting.
Following the acute withdrawal process, a comprehensive post-withdrawal program involving 
continuation in naltrexone treatment and structured counselling for several months is generally 
recommended by service providers.
These treatment approaches have received considerable attention in recent years, and have been 
the subject of much clinical and media debate. Antagonist accelerated withdrawal programs are 
available in most Australian cities in the private sector (usually at considerable cost to the
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patient), although the research evidence regarding the role of these services is neither 
comprehensive nor conclusive. Three reviews of the available research literature have recently 
been published (O'Connor and Kosten 1998; Gowing, Ali et al. 2000; Tucker and Ritter 2000).
Rapid detoxification
Two randomised controlled trials have been published comparing rapid detoxification to 
conventional approaches for heroin withdrawal. Gerra, Marcato et al. (1995) compared four 
randomly assigned outpatient treatment groups in 152 heroin users: (1) clonidine only, (2) 
naltrexone plus clonidine; (3) naloxone plus clonidine; and (4) placebo. Outcomes reported 
included withdrawal severity; proportion of subjects taking naltrexone on day 8 (withdrawal 
completion rates); and post-withdrawal outcomes at 6 months follow up. The study reported 
very high levels of retention in withdrawal treatment for all groups (74% for placebo; and over 
90% for the other three groups). Unfortunately the study report had a number of 
methodological flaws, including lack of clarity regarding: the method of randomisation, the 
proportion of subjects reporting continued heroin use (the proportions of all urine samples 
testing positive were reported), and the handling of missing data (e.g. treatment drop outs). The 
mean proportions (± standard deviations) of morphine positive urine results during the first 5 
days were 30 ±21% for the clonidine group; 5 ± 6 % for the naltrexone - clonidine group, 11 ± 
7% for the naloxone - clonidine group, and 48 ± 8% for the placebo group. At six months 
follow up, the mean proportion of positive morphine urine results was 60 ± 7% in the clonidine 
group, 74 ± 12% of the placebo group, 20 ± 5 % for the naloxone - clonidine group and 18 ± 
4% for the naltrexone - clonidine group.
Despite problems in the way this study was reported, the findings suggest that there are no 
immediate benefits in using antagonists during withdrawal compared to using clonidine on its 
own, given the very similar proportions of individuals in the clonidine and antagonist - 
clonidine groups who were inducted onto naltrexone by the end of the first week. The study 
findings did indicate a significant difference with regard to post-withdrawal outcomes, 
suggesting that the early use of antagonists during withdrawal may enhance retention in longer- 
term naltrexone treatment. However, the study reported remarkably high rates of withdrawal 
completion and post-withdrawal abstinence rates for all groups - including 74% completion 
rates for outpatient heroin withdrawal using placebo! As identified earlier, the findings of this 
study may be difficult to generalise to broader populations of heroin users undergoing 
withdrawal treatment - subjects in this study were concurrently recruited into a six month 
naltrexone study, suggesting that they were highly motivated to achieve and maintain 
abstinence, with good psychosocial supports during and after the withdrawal episode.
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The other randomised trial of rapid detoxification was conducted in an outpatient primary care 
setting in the USA (O'Connor, Carroll et al. 1997). This study examined short term withdrawal 
outcomes in 162 heroin dependent users randomly allocated to three groups: (1) clomdine only 
during the first 7 days, receiving naltrexone on day 8; (2) naltrexone commencing on day 2 at 
12.5 mg, increasing to 50 mg daily by day 3, together with clonidine; and (3) buprenorphine 
from days 1 to 3 with clonidine and naltrexone commenced on day 4 at 25 mg increasing to 50 
mg by day 5. Findings regarding the use of buprenorphine are considered later in this chapter; 
however, the data regarding clonidine compared to clonidine - naltrexone indicated that the two 
regimes were comparable with regards to rates of induction onto naltrexone (both in terms of 
proportion taking a full 50 mg dose and the proportion in treatment at day 8); and had similar 
severity of reported heroin withdrawal. Unfortunately, the report did not indicate: (a) the 
proportions of subjects using heroin during the withdrawal episode; (b) the need for ‘rescue’ 
medications during withdrawal; (c) the incidence of adverse events; nor (d) the proportion of 
subjects in the clonidine group who remained in naltrexone treatment beyond one dose. 
Nevertheless, the study demonstrated that antagonist-assisted withdrawal is possible in an 
outpatient setting, with comparable short-term outcomes to a conventional clonidine regime.
There has been considerable variation in the reported outcomes of cohort studies employing 
rapid detoxification. “Successful” withdrawal outcomes have usually been defined as the 
proportion of subjects receiving a full dose of naltrexone (e.g. 50 mg) after several days 
(usually day 3 to day 8). Completion rates have been reported as high as 100% to as low as 7% 
remaining in inpatient treatment at 2 weeks (Azatian, Papiasvilli et al. 1994), with a mean 
completion rate of 83% (Gowing, Ali et al. 2000).
Unfortunately, few studies have included any significant follow-up information. The findings 
of the study by Gerra, Marcato et al. (1995) were previously discussed. Seoane, Carrasco et al. 
(1997) reported that 93% of 300 heroin users self-reported to be opiate-free and provided an 
opiate-negative urine test one month after a rapid withdrawal procedure. Bell, Young et al. 
(1999) conducted rapid detoxification in an inpatient setting on 15 heroin dependent users and 
15 methadone patients, with outcomes reported at day 7- and at three months. The methadone 
group performed better at three months than the heroin group, a finding consistent with 
previous research with clonidine and methadone-assisted withdrawal programs. 13 (87%) of the 
heroin users were taking naltrexone at day 7, and 10 (67%) were taking naltrexone after four 
weeks. At three months follow up, 4 (27%) were taking naltrexone (of whom one was not using 
heroin), 5 (37%) were in methadone treatment, 4 (27%) had relapsed into dependent heroin use, 
one person was abstinent but not in treatment, and one person was dead.
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The pattern of withdrawal symptoms using rapid detoxification is related to the procedure 
utilised. The typical profile reported is that of severe withdrawal following the initial dose of 
antagonist medication, with symptoms abating thereafter, although many studies have 
described continued (subjective) withdrawal symptoms persisting for several days after the first 
antagonist dose (Kleber, Topazian et al. 1987; Loimer, Schmid et al. 1990). To this extent, the 
claims that rapid detoxification procedures markedly reduce the duration of withdrawal 
symptoms may be exaggerated. Rather, antagonist-assisted withdrawal regimes appear to be a 
useful means of inducting heroin users into antagonist treatment early in the treatment process, 
thereby reducing drop out rates and diminishing the capacity for continued heroin use, in those 
patients for whom long term treatment with naltrexone is indicated.
Ultra-rapid detoxification
This procedure entails the introduction of opioid anatagonists under heavy sedation and / or 
general anaesthesia. Several case series have been reported in the literature, however there have 
been no control groups, and different studies have reported markedly different long-term 
outcomes, thereby limiting the capacity to draw conclusions regarding the efficacy of this 
approach (O'Connor and Kosten 1998; Gowing, Ali et al. 2000). Some studies have reported 
longer term outcomes consistent with the naltrexone relapse prevention literature - for example, 
Cuccia, Bertschy et al. (1996) reported 40% retention on naltrexone at one month, and 20% 
retention at 6 months; whereas other studies have reported very high abstinence rates that are 
not routinely seen in naltrexone programs for heroin addicts - Brewer, Gooberman et al. (1997) 
reported 76% of 510 successfully withdrawn subjects were abstinent at 4 months, while 
Rabinowitz, Cohen et al. (1997) reported that 57% of subjects followed-up (follow up rate of 
approximately 70%) self-reported no routine opiate use 12 months after the procedure. 
Legarda and Gossop (1994) reported that all 11 subjects were still taking naltrexone 30 days 
after ultra-rapid detoxification.
These widely divergent outcomes raise questions regarding the similarity (or lack thereof) in 
the treatment populations and post-withdrawal treatment schedules across studies. Properly 
controlled and carefully monitored research trials are required in order to establish the role of 
ultra-rapid detoxification procedures (Kleber 1998; O'Connor and Kosten 1998; Tucker and 
Ritter 2000). There have also been a number of concerns raised regarding:
(a) the safety of the procedure (with several reports of anaesthesia related deaths (Dyer 
1998; Brewer 1997) and reports of complications requiring prolonged hospitalisation 
(Seoane, Carrasco et al. 1997; Pfab, Hirtl et al. 1999; Scherbaum, Klein et al. 1998);
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(b) the intensity and associated cost of service provision;
(c) studies that have examined subjective symptoms report persistent symptoms / adverse 
events for up to one-week post-anaesthesia (Loimer, Linzmayer et al. 1991; 
Scherbaum, Klein et al. 1998; Cuccia, Bertschy et al. 1996).
Given the availability of (less dramatic) alternatives, it is unlikely that ultra-rapid detoxification 
procedures will have a significant role for heroin detoxification outside of private treatment 
settings.
Summary of antagonist assisted heroin withdrawal
The safety and efficacy of antagonist-accelerated withdrawal for heroin users is yet to be 
established in the research literature (Tucker and Ritter 2000; O'Connor and Kosten 1998). This 
approach does have the advantage of inducting heroin users into a form of post-withdrawal 
treatment: naltrexone maintenance treatment for relapse prevention. Unfortunately, naltrexone 
treatment is not particularly attractive to many heroin users who may be contemplating 
withdrawal (Tucker and Ritter 2000; O'Brien, Greenstein et al. 1978), nor is it particularly 
effective in retaining heroin users in treatment compared to substitution maintenance treatment 
(O'Brien, Greenstein et al. 1978; Grey, Osborn et al. 1986; Osborn, Grey et al. 1986); and no 
better than placebo in double-blinded randomised trials (Lemer, Sigal et al. 1992; San, Pomarol 
et al. 1991). As such, antagonist accelerated approaches to withdrawal treatment are likely to 
only be indicated for individuals who are suited to longer term naltrexone treatment, such as 
opiate users highly motivated for abstinence and with good social support systems.
1.3.4 Summary of pharmacotherapies (other than buprenorphine)
In summary, each of the three main pharmacological approaches for heroin withdrawal 
reviewed thus far is well suited to particular treatment populations and clinical settings; 
however, they each have their limitations when the broader objectives and outcomes of 
withdrawal services are considered.
Methadone assisted withdrawal has been shown to be a safe, effective and acceptable approach. 
The initial period of stability afforded by methadone prior to the onset of significant 
withdrawal symptoms enables heroin users to distance themselves from daily heroin use. 
Methadone assisted withdrawal has an advantage in that patients are engaged in a treatment 
modality that can be easily continued into a longer term methadone maintenance program, 
thereby facilitating linkage with post withdrawal treatment. Unfortunately, methadone delays 
and prolongs the withdrawal syndrome, which limits its use in brief inpatient settings, and
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complicates induction onto naltrexone as a post withdrawal approach for those patients 
considering longer term abstinence from all opiates. Methadone also carries considerable 
negative stigma among certain groups of heroin users, health professionals and the broader 
community, and in certain countries is associated with considerable regulatory control that 
limits the capacity for its widespread use for withdrawal. For example, only authorised medical 
practitioners can prescribe methadone in Australia, and fewer than 5% of general practitioners 
are authorised to do so.
Most research literature regarding symptomatic medication approaches has focussed upon the 
use of the alpha-adrenergic antagonist clonidine, and more recently lofexidine. These 
medications have the advantage over methadone in not prolonging the withdrawal syndrome, 
thereby making them well suited to brief inpatient withdrawal programs. Their use does not 
delay induction onto naltrexone as a post withdrawal medication, although the use of 
symptomatic medications for withdrawal is perhaps less likely to facilitate post withdrawal 
referrals into substitution maintenance treatment to the same extent as methadone assisted 
withdrawal treatment. The high incidence of side effects (particularly hypotension and 
lethargy), and their inability to relieve cravings and mood disturbances reduces their safety and 
effectiveness in outpatient settings. Lofexidine has a lower incidence of hypotension-related 
side effects, however is not registered in most countries, is considerably more expensive than 
clonidine, and has not been shown to significantly improve key treatment outcomes compared 
to clonidine.
The research evidence regarding the safety and efficacy of antagonist assisted withdrawal 
approaches has not been clearly established, although these approaches have gained in 
popularity in certain quarters, and there are clinicians with considerable experience in 
delivering these withdrawal techniques. Ultimately, antagonist-assisted withdrawal is likely to 
only be of benefit to those heroin users contemplating long term naltrexone treatment for 
relapse prevention, and estimates would suggest that this represents less than 10 to 20 % of 
heroin users presenting to conventional treatment services (Tucker and Ritter 2000).
Key issues regarding the use of these medications will be revisited in Chapter 5 when 
considering the tailoring of medication regimes for individual patients attempting heroin 
withdrawal, and include a comparison to the use of buprenorphine for this purpose (see Tables 
5. 1 and 5.2). The next section in this chapter will review the literature regarding the use of 
buprenorphine for heroin withdrawal.
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1.4. Buprenorphine in the management of heroin withdrawal
Buprenorphine is a derivative of the morphine alkaloid thebaine that was originally developed 
and registered as an analgesic. There has been increasing research and interest in its use as a 
treatment for heroin dependence since the late 1970’s, and it is registered for this purpose in a 
number of European countries. Most research with buprenorphine has addressed issues of 
maintenance treatment, with several large scale randomised controlled trials demonstrating it to 
be of similar safety and efficacy to methadone maintenance treatment. There has also been 
increasing interest in its use in the management of withdrawal from heroin and other opiates. 
This section will examine the clinical pharmacology of buprenorphine relevant to the 
management of heroin withdrawal, and then consider efficacy and clinical issues in the use of 
buprenorphine for withdrawal.
1.4.1 Clinical pharmacology and rationale for buprenorphine in the 
management of heroin withdrawal
Buprenorphine is a partial agonist at the p opiate receptor. A partial agonist is defined as a 
compound that “even at full saturation of the receptor system (the) effect is still less than the 
maximal effect obtainable with full agonists” (Ariens 1983). Buprenorphine has low intrinsic 
activity, only partially activating p opiate receptors, resulting in milder, less euphoric and less 
sedating opiate effects than are achieved with full opioid agonists such as heroin, morphine or 
methadone (Jasinski, Pevnick et al. 1978; Lewis 1985). Nevertheless in adequate doses, 
buprenorphine effects are sufficient to diminish cravings for heroin and prevent or alleviate 
opiate withdrawal features in dependent heroin users, important characteristics in retaining 
individuals in treatment (Johnson, Cone et al. 1989).
Buprenorphine has a rapid onset of action and a long duration of action. Peak plasma 
concentrations are achieved one to two hours after sublingual administration, with peak effects 
described within one to four hours after sublingual administration (Walsh, Preston et al. 1994). 
The duration of action of buprenorphine is related to the dose of buprenorphine administered, 
with higher doses resulting in more prolonged effects than lower doses. The duration of 
discernible effects of buprenorphine ranges from 12 hours (at doses of 2mg) to as long as 72 
hours (at higher doses of 16 or 32 mg) (Walsh, Preston et al. 1994). Buprenorphine’s long 
duration of action allows for a once-a-day dosing regime, unlike other medications frequently 
used for heroin withdrawal (including clonidine, benzodiazepines, or short-acting opioids such 
as codeine or propoxyphene). The capacity for a once-a-day dosing regime potentially reduces
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the risks of diversion or abuse of the medication in outpatient settings, and potentially reduces 
the cost of administration in inpatient withdrawal settings.
Buprenorphine undergoes extensive first pass metabolism when taken orally, and more potent 
effects are experienced through injected or sublingual routes of administration (Jasinski 1981). 
Contemporary preparations of buprenorphine for the treatment of heroin dependence utilise 
sublingual tablets, whereas injected preparations are generally reserved for the management of 
acute pain. Buprenorphine is principally metabolised by two hepatic pathways: conjugation 
with glucuronic acid and N-dealkylation (Green, Belanger et al. 1997; Iribame, Picart et al. 
1997). The metabolites to do not cross the blood brain barrier, and are excreted in the biliary 
system with enterohepatic cycling of buprenorphine and its metabolites (Brewster, Humphrey 
et al. 1981). The majority of the drug is excreted in the faeces and urine (see Walter (1997) for 
overview).
Rebound withdrawal
A major limitation to the use of methadone or other opiate agonists for the management of 
heroin withdrawal is the rebound withdrawal (increase in withdrawal features) experienced 
following the reduction or cessation of the prescribed opioid (see earlier discussion in Section 
1.3.1). In contrast, the withdrawal syndrome following the cessation of buprenorphine appears 
to be milder than is typically described for other opiates. Objective withdrawal features (as 
measured by the Himmelsbach Scale (Himmelsbach 1941) in the 10 days following 
discontinuation of equivalent doses of morphine and buprenorphine were compared in some of 
the early buprenorphine research conducted by Jasinski and colleagues (Jasinski, Pevnick et al. 
1978). Measures of withdrawal severity, including peak and total area under the curve, were 
considerably less for buprenorphine than morphine.
There are a number of mechanisms hypothesised for the mild rebound withdrawal seen 
following the reduction or cessation of buprenorphine. The most widely cited explanation is 
that buprenorphine has a very high affinity for and slow dissociation from mu opiate receptors, 
such that once bound to these receptors it is only slowly dislodged (Cowan, Lewis et al. 1977). 
Buprenorphine is also very lipophilic (Hambrook and Ranee 1976), such that it continues to be 
slowly released from fat stores following the cessation of chronic dosing. These mechanisms 
result in the maintenance of homeostasis following its cessation, which reduces the emergence 
of a pronounced withdrawal syndrome (Dum, Blasig et al. 1981). The relatively low intrinsic 
activity of buprenorphine at the mu receptor may contribute to the milder withdrawal 
syndrome. However, intrinsic activity appears to be less important than the rate of dissociation 
(Negus and Woods 1995): other partial agonists (for example, nalbuphine) with low intrisinc
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opioid activity but rapid dissociation result in more severe withdrawal syndromes (Woods and 
Gmerek 1985). Other authors have suggested that the slow rate of dissociation does not 
adequately explain the mild withdrawal syndrome, and have hypothesised that it may be related 
to buprenorphine’s potent antagonist properties at kappa opiate receptors (Jasinski and Preston 
1995).
The onset, severity and duration of rebound withdrawal symptoms appear to be related to the 
duration of buprenorphine treatment. Unfortunately, no study has directly examined the impact 
of treatment duration upon the severity of rebound withdrawal following buprenorphine’s 
discontinuation. There are a number of methodological difficulties in comparing reports of 
withdrawal severity across studies that have used different instruments for measuring 
withdrawal severity, different study populations, and dosing regimes. Nevertheless, the 
published studies that have reported the emergence of withdrawal features following the 
cessation of buprenorphine in heroin dependent users are summarised in Table 1.3, in 
ascending order for duration of buprenorphine treatment. Excluded from this series are those 
studies that did not report withdrawal severity or had inadequate follow up time (less than 3 
days) following the last dose of buprenorphine (Bickel, Stitzer et al. 1988; Nigam, Ray et al. 
1993; Diamant, Fischer et al. 1998; Vignau 1998; Liu, Cai et al. 1997); those studies that 
introduced naltrexone prior to the possible emergence of rebound withdrawal (O'Connor, 
Carroll et al. 1997; Kosten and Kleber 1988; Kosten, Morgan et al. 1991); or those studies 
examining subjects transferred from methadone maintenance treatment (Kosten and Kleber 
1988; Kosten, Morgan et al. 1991; Janiri, Mannelli et al. 1994).
The general trend of these studies suggest that the severity and duration of withdrawal features 
following the cessation of buprenorphine is related to the duration of buprenorphine use, with 
longer periods of treatment being associated with a delayed onset of peak symptoms and more 
prolonged withdrawal symptoms. Buprenorphine’s high lipophilicity may account for this 
trend: following the cessation of chronic treatment, low levels of buprenorphine are slowly 
released from fat stores, resulting in a delay in the emergence of peak withdrawal symptoms.
Short courses of less than one week of buprenorphine appear to result in minimal, or in mild 
and transient symptoms that subside within two to three days after the cessation of 
buprenorphine. This has significant implications for withdrawal management, in that it 
potentially enables the use of buprenorphine in short courses to alleviate withdrawal and 
diminish cravings during the period of peak severity of heroin withdrawal (the first four to five 
days), without considerably prolonging the course of withdrawal. This potentially overcomes 
some of the difficulties encountered with other substitution medications such as methadone 
(although there is limited research examining rebound withdrawal following very short courses
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of methadone -  see Section 1.3.1). Longer courses of buprenorphine (for example, several 
weeks) are associated with a rebound withdrawal, which appears to be milder but of similar 
duration to rebound withdrawal seen following comparable courses of methadone (Jasinski, 
Boren et al. 1984; Bickel, Stitzer et al. 1988).
Blocking effects on heroin use
Buprenorphine reduces the effects of additional heroin (or other opiate) use in a dose related 
manner: doses of 2 mg or more are required to produce such a response, with higher
buprenorphine doses (e.g. 8 mg) resulting in greater blockade effects (Bickel, Stitzer et al. 
1988; Rosen, Wallace et al. 1994). The proposed mechanism of action for this ‘blockade’ is 
thought to be due to buprenorphine’s high affinity for opiate receptors, which prevents heroin 
from occupying these receptors (Jasinski, Pevnick et al. 1978; Bickel, Stitzer et al. 1988; 
Rosen, Wallace et al. 1994; Johnson, Risher-Flowers et al. 1993). It has been postulated that the 
suppression of withdrawal symptoms and the blockade of additional heroin use are the two 
mechanisms responsible for reduced self-administration of heroin by patients taking 
buprenorphine (Mello, Mendelson et al. 1982).
Safety and side effects
The profile of side effects with buprenorphine is similar to other opiates, with constipation, 
headache, disturbed sleep, drowsiness, sweating and nausea the commonest reported side 
effects (Ling, Charuvastra et al. 1998; Lange, Fudala et al. 1990; Teoh, Mendelson et al. 1993). 
These authors report that buprenorphine in therapeutic doses appears to have minimal impact 
upon hepatic function. One potential adverse event of buprenorphine that is not seen with the 
use of opioid agonists is that of precipitated withdrawal (Jacobs and Bickel 1999). As indicated 
earlier, buprenorphine has a higher affinity for mu opiate receptors, but a lower intrinsic 
activity than most other agonists, including heroin. If a heroin dependent person has their first 
dose of buprenorphine soon after using heroin, the heroin is displaced from the mu opiate 
receptors and substituted with buprenorphine, which has less activity at these receptors. This 
process can result in a significant opiate withdrawal syndrome being precipitated, typically 
occurring within 1 to 2 hours after the first buprenorphine dose, and subsiding thereafter. 
Fortunately, heroin is a short acting drug, whose principal activity lasts for less than 4 to 6 
hours, and the initial dose of buprenorphine can generally be delayed for at least 6 hours after 
the last use of heroin in order to avoid this adverse event. The phenomenon of precipitated 
withdrawal is of much greater concern for subjects transferring from long acting opiates such 
as methadone to buprenorphine (Schuh, Walsh et al. 1996).
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A considerable advantage of buprenorphine over full opioid agonists derives from its safety 
profile. Dose response studies demonstrate that buprenorphine has ‘ceiling’ effects, so that high 
doses (16 mg or more) do not result in substantially greater respiratory depression or sedation 
than lower doses (8 or 12 mg) (Walsh, Preston et al. 1994). Very high doses (many times 
higher than normal therapeutic doses) appear to be well tolerated and do not generally result in 
significant respiratory depression even in non-opiate dependent individuals (Walsh, Preston et 
al. 1994). Although the risk of overdose from buprenorphine alone appears considerably less 
than other opioids such as methadone or morphine, there is the capacity for buprenorphine to 
contribute to sedation, respiratory depression and death from overdose in combination with 
high doses of other sedative drugs, such as alcohol or benzodiazepines (Reynaud, Petit et al. 
1998; Tracqui, Toumoud et al. 1998).
Antagonist effects at k opiate receptors
Buprenorphine also exhibits antagonist effects at the kappa (k) opiate receptor (Cowan, Lewis 
et al. 1977). The role of kappa opiate receptors in humans remains poorly understood, however 
excess endogenous k agonists are thought to be implicated in affective and psychotic 
conditions (Nutt, Groves et al. 1995). Buprenorphine’s antagonist effects at the k receptor are 
thought to result in buprenorphine having some temporary antidepressant (Emrich, Vogt et al. 
1982; Kosten, Morgan et al. 1990; Mongan and Callaway 1990; Bodkin, Zomberg et al. 1995) 
and antipsychotic properties (Schmauss, Yassouridis et al. 1987; Groves and Nutt 1991) in 
certain individuals. This temporary effect upon mood may be quite beneficial during the 
management of heroin withdrawal, which is typically associated with dysphoria and other 
mood disturbances.
Transition to naltrexone
Another consideration in the use of buprenorphine as a withdrawal medication is the relative 
ease of transition onto opioid antagonist treatment (Kosten, Krystal et al. 1990; Rosen and 
Kosten 1995; O'Connor, Carroll et al. 1997; Umbricht, Montoya et al. 1999). Buprenorphine 
has a similar affinity for mu opioid receptors to naltrexone (Lewis 1985), and as such, 
naltrexone can be commenced without completely displacing buprenorphine or precipitating 
very severe withdrawal symptoms. The ability to commence naltrexone without considerable 
delays is a considerable advantage of buprenorphine over the use of other opioid agonists such 
as methadone for managing heroin withdrawal, where a recommended interval of 7 to 10 days 
between last methadone dose and first naltrexone dose is recommended (Bell, Kimber et al. 
1999). A number of different approaches have been used to induct heroin users onto naltrexone
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either soon after, or during buprenorphine dosing, the details of which will be reviewed later in 
this Chapter.
Buprenorphine can also be continued as an effective substitution maintenance medication. 
Given the high rates of relapse to heroin use during or immediately following withdrawal, the 
ability to link patients into longer-term maintenance substitution treatment is a key objective of 
withdrawal services. In this respect, buprenorphine has similarities to the use of methadone for 
the management of heroin withdrawal, and may have advantages over non-substitution 
approaches to heroin withdrawal (clonidine, antagonist accelerated withdrawal).
The pharmacological properties of buprenorphine with regards to its use as a withdrawal 
medication are summarised in Table 1.4.
Table 1.4. Properties o f buprenorphine relevant for the management o f heroin withdrawal
•  Buprenorphine alleviates or prevents withdrawal from opiates
• Buprenorphine exerts opiate-like effects, thereby reducing cravings and increasing treatment 
retention.
• The withdrawal syndrome on ceasing buprenorphine appears to be less severe than heroin or 
morphine withdrawal. Short courses of buprenorphine appear to be associated with minimal 
rebound withdrawal (increase in opiate withdrawal features) upon the cessation of 
buprenorphine. Longer treatment periods (weeks or months) are associated with clinically 
significant rebound withdrawal.
• Buprenorphine diminishes the effects of heroin, thereby reducing continued heroin use 
during withdrawal.
• Buprenorphine is generally well tolerated by heroin users, with mild and transient side 
effects reported. The risk of precipitated withdrawal requires some degree of supervision. 
Buprenorphine exhibits ceiling opiate effects on a range of physiological and subjective 
measures, suggesting that it should be safer than methadone for heroin withdrawal.
• Once-a-day dosing is possible, thereby reducing risk of diversion and abuse of medication
• There are increased post-withdrawal treatment options available with buprenorphine. 
Naltrexone can be commenced during or soon after the cessation of buprenorphine 
treatment. Alternatively, buprenorphine can be continued on a long-term basis as a 
maintenance medication.
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1.4.2 Studies examining the efficacy of buprenorphine in heroin 
withdrawal
Buprenorphine has a range of properties that make it a promising medication for the 
management of heroin withdrawal, however, as identified earlier, comparative studies with 
other withdrawal medications using randomised controlled designs are required to properly 
assess the role of a medication. The literature predating the year 2000 had recently been 
systematically reviewed (Gowing, Ali et al. 2000), which identified four randomised trials 
comparing buprenorphine to other medication regimes for heroin withdrawal (Bickel, Stitzer et 
al. 1988; Cheskin, Fudala et al. 1994; Nigam, Ray et al. 1993; O'Connor, Carroll et al. 1997). 
The Cochrane review also identified one other randomised trial comparing buprenorphine to 
other medications in the management of withdrawal from methadone maintenance treatment, 
and as such is not considered in this review (Janiri, Mannelli et al. 1994). For the purpose of 
achieving an up-to-date review for this thesis, the published literature was again searched (to 
May 2001 using Medline, Embase, Psychlit) for randomised trials using buprenorphine for 
heroin withdrawal published since the completion of the Cochrane review. This search 
identified one further study (Schneider, Paetzold et al. 2000). Hence, in total, the efficacy of 
buprenorphine in comparison to other medications for the management of heroin withdrawal 
has been examined in only five published randomised controlled trials - these are summarised 
in Table 1.5.
The first randomised trial conducted examined gradual withdrawal treatment regimes in an 
outpatient setting in the USA. Bickel, Stitzer et al. (1988) examined the efficacy of 
buprenorphine or methadone outpatient treatment in 45 heroin dependent individuals. Subjects 
were randomised to receive either seven weeks of buprenorphine (three weeks at 2mg 
sublingual, then gradual reductions over the subsequent four weeks), or methadone (30 mg for 
three weeks then gradual reductions over the next four weeks). There were no significant 
between group differences for mean retention in treatment (48.5 days for buprenorphine group 
compared with 40 days for methadone group), levels of heroin use or severity of withdrawal 
symptoms during the first six weeks of treatment. There was considerable drop out in both 
groups when doses approached zero mg, such that post-withdrawal outcomes were not 
reported. The authors concluded that buprenorphine was as effective as methadone, however 
cautioned: ‘the results from both groups are poor with respect to illicit heroin use and retention. 
However, this is not surprising because most studies of detoxification show poor retention and 
relapse to opioid use during dose reduction’ (ibid p.77).
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Three other studies have compared buprenorphine to clonidine in short treatment regimes. In an 
open label study conducted in India, Nigam, Ray et al. (1993) randomised 44 heroin or opium 
dependent (non-injecting) users to receive ten days of either buprenorphine (maximum daily 
dose of 1.2mg sublingually, total dose of 10 mg) or clonidine (total dose of 7.2 mg over ten 
days). Ratings of opiate withdrawal were recorded over eleven days using the Subjective and 
Objective Opiate Withdrawal scales (Handelsman, Cochrane et al. 1987). The buprenorphine 
group had significantly lower withdrawal scores during days 3 to 6, significantly lower peak 
withdrawal scores, and fewer side effects than the clonidine group. The authors concluded that 
buprenorphine was superior to clonidine for the management of heroin withdrawal symptoms. 
However, data regarding the experience of withdrawal symptoms several days after the 
cessation of buprenorphine was not collected, and the possibility of (rebound) withdrawal 
symptoms emerging two or three days after the cessation of buprenorphine can not be 
discounted. The authors also cautioned that withdrawal symptoms were less severe in this 
group of subjects than reported in other studies, perhaps due to the short duration of 
dependence, non-injecting routes of administration, and opium use. The recent Cochrane 
review of buprenorphine in heroin withdrawal (Gowing, Ali et al. 2000) provided additional 
information regarding completion rates for this study: 72 subjects were recruited to the study - 
38 in the clonidine group and 34 to the buprenorphine group. 19 subjects in the clonidine group 
completed the regime (50%), compared to 22 in the buprenorphine group (65%), indicating a 
non-significant trend.
Cheskin, Fudala et al. (1994) compared buprenorphine to clonidine for the management of 
inpatient heroin withdrawal in 25 dependent users. In a double-blind, double-dummy study, 
subjects were randomised to receive either a three-day regime of sublingual buprenorphine in 
solution (day 1: 2 mg qid; day 2: 2 mg tds; day 3: lmg tds; total dose of 17 mg), or clonidine 
(2.7 mg orally over 5 days). Outcomes included objective and subjective features of opioid 
withdrawal and craving measures. The buprenorphine groups reported significantly lower 
subjective withdrawal scores and lower cravings during the first three days compared to the 
clonidine group. There were no significant differences beyond day three, although there was a 
trend for greater dysphoria over the 10-day period reported in the clonidine group. The mean 
total withdrawal severity over the admission (area under the curve) was reported as being 88% 
greater for the clonidine group. Importantly, buprenorphine did not appear to produce a 
rebound in withdrawal symptoms after its abrupt cessation after day three. The completion 
rates for withdrawal were not significantly different for the two groups (83% for buprenorphine 
compared to 62% for clonidine), although this may reflect the small sample size.
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O'Connor, Carroll et al. (1997) comparing buprenorphine to other withdrawal medication in a 
randomised controlled trial conducted in an outpatient setting under double-blinded conditions 
with 162 heroin dependent users, although the authors commented that the blind was difficult to 
sustain. Three medication regimes were compared: (1) Clonidine (C) up to 1.2 mg daily for 7 
days in six divided doses, followed by naltrexone 50 mg on day 8; (2) Clonidine + Naltrexone 
(C+N): clonidine regime as above with naltrexone doses of 12.5 mg on day 1, 25 mg day 2, then 
50 mg daily for the remainder; and (3) Buprenorphine (B): Days 1-3: buprenorphine 3 mg 
sublingually per day for the first three days, then clonidine from day 4 onwards (as above) and 
naltrexone commencing at 25 mg on day 4, then 50 mg daily on days. The end point of the 
study was to induct heroin users onto naltrexone treatment, such that the buprenorphine group 
received naltrexone and clonidine from day 4 onwards. Reported outcomes for the study 
included withdrawal severity (total scores over 8 days; and peak withdrawal severity); 
completion rates represented as those receiving a 50 mg dose of naltrexone (different time 
frames for the three groups) and the proportion of subjects in treatment at day 8. The 
buprenorphine subjects reported lower total withdrawal scores and lower peak withdrawal 
scores than the clonidine and clonidine - naltrexone groups. Unfortunately, the report did not 
indicate the proportion of subjects using heroin or requiring available rescue medications, 
thereby confounding the interpretation of withdrawal severity as a key outcome measure. The 
study reported no statistically significant differences between groups regarding the proportion of 
subjects receiving a 50 mg naltrexone dose (65% for C; 81% for C+N; 81% for B); nor the 
proportion of subjects in treatment at day 8 (65% for C; 54% for C+N; 60% for B). 
Unfortunately, no description of post-withdrawal retention in naltrexone treatment was reported, 
and it is somewhat inappropriate to compare regimes requiring several doses of naltrexone (as 
for the C+N and B) groups to the Clonidine group who had taken their first and only dose of 
naltrexone at day 8. In summary, only guarded conclusions can be made from this study, which 
suggested that the buprenorphine regime was associated with less withdrawal severity than the 
other medication regimes, and that there were similar rates of induction onto naltrexone across 
the three groups at one week.
A recent randomised trial has compared buprenorphine and carbamazepine to oxazepam ad 
carbamazepine in a 21-day inpatient admission (Schneider, Paetzold et al. 2000). There were a 
number of limitations in this study: it was open label, had small numbers (N=27, n = 15 in 
buprenorphine and n = 12 in oxazepam group), and the subjects consisted of both methadone 
and heroin users (14 methadone only, 8 heroin only, 5 both heroin and methadone). The 
buprenorphine regime (using an unspecified preparation) was: 3 mg per day on days 1 to 7, 2 
mg on day 8, 1 mg on day 9 and 0.4 mg on day 10 (total = 24.4 mg). The oxazepam group
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received 90 mg per day on days 1 to 7, reducing to zero by day 14. All subjects received 
carbamazepine until day 19 in identical regimes. The findings were consistent with previously 
described inpatient studies: the subjects receiving buprenorphine described significantly less 
severe withdrawal (using the Short Opiate Withdrawal Scale (Gossop 1990)) early in the 
withdrawal period (during the first 7 days), and had lower scores over subsequent days (but not 
statistically significant). 11 of the 15 buprenorphine subjects (73%) completed the regime, 
compared to 7 / 12 (58%) oxazepam subjects group, which was not statistically significant.
Some cautious conclusions can be made regarding the efficacy of buprenorphine from the 
available evidence. Buprenorphine is associated with less withdrawal severity than clonidine 
(Cheskin, Fudala et al. 1994; Nigam, Srivastava et al. 1994; O'Connor, Carroll et al. 1997), 
clonidine - naltrexone (O'Connor, Carroll et al. 1997), and oxazepam (Schneider, Paetzold et 
al. 2000). Although all studies have shown a trend for greater completion rates among subjects 
using buprenorphine compared to clonidine, no study has demonstrated any significant 
advantage with buprenorphine on this outcome, which may reflect the small subject numbers 
enrolled in these trials. The limited evidence comparing gradual buprenorphine to methadone 
reductions (Bickel, Stitzer et al. 1988) suggests no substantial difference in efficacy between 
the two approaches. There is little information available regarding a range of other withdrawal 
outcomes, such as impact upon heroin use in outpatient treatment settings, adverse events, or 
importantly, retention in post-withdrawal treatment.
There have been several other studies examining opiate withdrawal with buprenorphine that 
have employed randomised controlled trial designs. Withdrawal from long-term methadone 
treatment was examined by in Italy (Janiri, Mannelli et al. 1994), comparing buprenorphine to 
the adrenergic agonists clonidine and lefetamine. Amass and colleagues (Amass, Bickel et al. 
1994) examined different rates of buprenorphine dose reduction (rapid versus gradual) 
following maintenance buprenorphine treatment. As these studies were confined to withdrawal 
from maintenance treatment, they are beyond the scope of this review. Other randomised trials 
have examined the impact of ancillary interventions (Bickel, Amass et al. 1997); different 
buprenorphine dosing schedules in short inpatient withdrawal (Liu, Cai et al. 1997); and 
different naltrexone induction schedules following short courses of buprenorphine (Umbricht, 
Montoya et al. 1999). These studies will be considered in the following section examining 
clinical issues in the use of buprenorphine for heroin withdrawal.
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1.4.3 Clinical issues for withdrawal: Buprenorphine dosing regimes
The pharmacology and efficacy studies indicate that buprenorphine has considerable promise 
as a withdrawal medication, however there a number of outstanding issues regarding the use of 
buprenorphine for this purpose. Two important clinical issues warrant further consideration: (a) 
‘optimal’ dosing regimes, and (b) optimal methods for induction onto naltrexone (Section 
1.4.4). The ‘optimal’ dosing regime for buprenorphine has not been identified in the literature. 
Two issues are particularly pertinent: the duration of the reduction regime, and the 
buprenorphine doses used.
Duration of dosing regime
There are two broad approaches to using buprenorphine for managing heroin withdrawal: short 
buprenorphine regimes of several days (for example, Cheskin, Fudala et al. 1994; O'Connor, 
Carroll et al. 1997; Umbricht, Montoya et al. 1999), and longer or gradual reduction regimes 
over weeks, similar to methadone regimes for heroin withdrawal (for example, Bickel, Stitzer 
et al. 1988; Bickel, Amass et al. 1997; Kosten and Kleber 1988).
Only one study has been reported comparing the two approaches (Pycha, Resnick et al. 1993), 
with the findings failing to demonstrate any particular advantage of either approach. This single 
blind outpatient study compared 58 heroin dependent subjects randomised (in a 2:1 ratio) to 
receive either a short buprenorphine regime (n = 39, mean number of days = 9, range 7 to 13) 
or a gradual reduction regime (n=19, mean number of days = 28, range 22 to 37), with all 
subjects receiving placebo for 10 days after their last buprenorphine dose. Unfortunately, 
limited information is available regarding the study (for example, buprenorphine doses not 
described, withdrawal severity not reported). However, the primary outcome reported was 
completion rates, with 36% of the short regime and 21% of the gradual reduction regime 
completing the respective regimes. The authors commented that this difference may be 
attributed to the longer treatment time and increased opportunity for drop out in the gradual 
reduction regime. The authors noted that there was no significant difference between the two 
groups regarding continued heroin use (although details not provided). At three months follow 
up, 6 subjects (10%) were reported to be abstinent (three from each group). The authors 
concluded that: “outcome success was not related to rate of dose reductions and appeared 
limited to highly motivated individuals” (page 453).
There have been no other studies comparing short and gradual reduction regimes, and as such, 
the relative advantages and limitations can only be hypothesised, or extrapolated from the 
methadone literature. The rationale behind a short regime is to use buprenorphine for a limited
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period of time to cover the period of maximal withdrawal severity (typically the first 3 to 5 
days). The shorter regime has the potential advantages of avoiding significant rebound 
withdrawal upon the cessation of buprenorphine and thereby not significantly prolonging the 
duration of withdrawal discomfort (see Table 1.3). This should make it more suited to inpatient 
settings, and the shorter withdrawal episode should reduce costs of service delivery in 
outpatient settings. The shorter regime may also facilitate patients progressing beyond the 
withdrawal phase of treatment and engaging in post-withdrawal services (e.g. naltrexone, 
buprenorphine maintenance treatment, counselling), rather than remaining in ‘withdrawal’ for 
several weeks.
However, short-term regimes may be less successful in reducing heroin use during the 
withdrawal episode, in that some patients may be prematurely withdrawn off buprenorphine, as 
has been suggested in the methadone withdrawal literature (Maddux, Desmond et al. 1980). To 
this end, a longer reduction regime of several weeks (or months) may be advantageous. The 
principles behind such a regime would be to stabilise heroin users on an adequate dose of 
buprenorphine for 1 to 2 weeks in order to assist them to cease their heroin use. The dose can 
then be gradually reduced over several weeks. Whilst a longer period of time on buprenorphine 
is likely to provide patients with a longer period of stability, there are potential disadvantages 
with such an approach. Rebound withdrawal phenomena are more likely to be clinically 
significant, requiring specific management towards the end of buprenorphine regime, and 
potentially increasing relapse rates. The prolongation of the withdrawal episode may result in 
more patients dropping out without engaging in post-withdrawal treatment modalities, either 
due to relapse to heroin use (limiting naltrexone uptake), or due to some patients believing they 
do not need to participate in longer-term treatment after achieving a period of stability. 
Alternatively, the option of a more prolonged withdrawal regime may increase the proportion 
of patients making the transition to buprenorphine maintenance treatment.
These issues have not been systematically examined, and further research is required to address 
the issue of the ‘optimal’ duration of the reduction regime. In clinical practice, the duration of 
the regime is often tailored to the treatment setting (inpatient versus outpatient), resource 
availability, or other factors such as the patient’s capacity or willingness to participate in long­
term services. In the Australian treatment context, heroin withdrawal is usually conceptualised 
as a short-term intervention, usually limited to 6 to 10 day inpatient programs, or 1 to 2 week 
outpatient programs. The provision of methadone-assisted withdrawal programs using gradual 
dose reductions over weeks or months is uncommon (Frank and Pead 1995; NSW Health 
Department 1999), and the use of methadone as a withdrawal agent has not been encouraged at 
a national and jurisdictional policy level (National Drug Strategy 1993). In contrast, brief
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withdrawal episodes using symptomatic medication have been recommended in influential 
clinical guidelines (Frank and Pead 1995; NSW Health Department 1999). Importantly, 
withdrawal services are usually funded as short-term interventions, and this appears to have 
become standard clinical practice.
Doses of buprenorphine
Greater attention has been given to the impact of buprenorphine doses upon withdrawal 
outcomes than the duration of treatment, although the dose ranging studies in this area are not 
conclusive, with considerable variation in the types of doses used in different withdrawal 
studies (see Table 1.6 for details regarding inpatient studies and Table 1.7 for outpatient 
studies). In part, the variation in withdrawal dosing regimes reflects two inter-related factors:
• the era in which the research was conducted. Early research with buprenorphine for both 
maintenance and withdrawal treatment used comparatively low doses - up to approximately 
2 mg per day (Jasinski, Pevmck et al. 1978; Bickel, Stitzer et al. 1988). This reflected the 
types of doses in which buprenorphine had been routinely used as an analgesic in pain 
management. Subsequent research demonstrated that higher doses were safe in this 
population and more effective in reducing withdrawal symptoms and heroin use, producing 
blockade and retaining patients in treatment. This resulted in a general trend towards 
increased buprenorphine doses for managing heroin dependence in both withdrawal and 
maintenance research.
• the buprenorphine preparations used. Much of the early research with sublingual 
buprenorphine used an aqueous solution of higher bioavailability than the commercially 
available tablet preparation, Subutex®. Recent studies suggest that the bioavailability of the 
tablet is between 50% to 75% of the liquid preparation (Nath, Upton et al. 1999; Schuh and 
Johanson 1999; Ajir, Ling et al. 1998). These differences should be taken into consideration 
when comparing dosing regimes across studies, particularly for short-term regimes where 
the differences in bioavailability appear to be more clinically relevant. Furthermore, some of 
the early research with tablets employed low dose tablets (0.2 mg) available as analgesics. 
The use of low dose buprenorphine tablets may have restricted the use of high doses - for 
example, 60 x 0.2 mg tablets would be required in order to achieve a daily dose of 12 mg!
Only one study of heroin withdrawal has directly compared different short-term buprenorphine 
dosing regimes. Liu, Cai et al. (1997) assigned 60 heroin users (in China) according to severity 
of dependence to one of three regimes: low dose (maximum daily dose of 3.0 mg, mean dose of 
2.0 mg); medium (maximum dose of 4.5 mg, mean dose of 2.9 mg); and high dose (maximum 
dose of 6.0 mg, mean dose of 3.6 mg) in a 10-day inpatient withdrawal regime. There were no
Chapter 1. Introduction and Literature Review. 60
reported differences between the three groups for completion rates, cravings or withdrawal 
severity as measured by the CINA (Peachey and Lei 1988). The similar outcomes for the three 
groups may reflect that higher doses are required for individuals with higher levels of heroin 
use and dependence; that the differences in the three dosing regimes used were minor and 
inadequate to demonstrate the impact of different doses; or that there are indeed no differences 
in outcomes at the different buprenorphine doses used.
Several other uncontrolled studies have explored short-term heroin withdrawal using 
buprenorphine. In an open label single group study of 50 heroin dependent users in Austria, 
Diamant and colleagues (Diamant, Fischer et al. 1998) titrated buprenorphine doses according 
to clinical response over a 10-day outpatient withdrawal program. The study used 0.2 mg 
buprenorphine tablets, with a maximum daily dose of 4 mg during the first 3 days, reducing to 
zero over the 10 days. The authors provided no rationale for the doses used in this study; 
although the low dose tablets must have limited the doses used -  with 20 tablets in a day 
required to achieve the 4 mg maximum dose. Subjects attended the clinic daily for clinical 
review and dose titration, with objective measures of opiate withdrawal made using the WANG 
scale. 35 subjects (70%) completed the program, with minimal withdrawal discomfort and 
minimal use of additional medications. The maximum mean daily buprenorphine dose 
dispensed was 2.58 ± 0.6 mg (on day 2). The authors described “no increase in withdrawal 
symptoms” (p.201) as the buprenorphine dose was reduced, although there was no systematic 
follow-up of subjects after the last dose to examine for rebound withdrawal. 24 subjects (48% 
of total sample) provided an opiate negative urine result on day 10.
A single group, open label, short inpatient withdrawal regime was described in 36 heroin users 
in France (Vignau 1998). Buprenorphine doses were individually titrated up to 8 mg per day, 
and reduced using a flexible regime over a 10-day period. The authors described withdrawal as 
mild, requiring minimal ancillary medication; however there was no systematic reporting of 
withdrawal severity. 21 subjects (58%) completed the 10-day withdrawal regime, and 9 
subjects (25%) transferred to maintenance treatment, with only 17% of subjects not completing 
withdrawal or continuing in maintenance treatment.
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Parran and colleagues (Parran, Adelman et al. 1994) have described using parenteral 
buprenorphine doses to treat individuals withdrawing from heroin (n=22) or other opioids 
(n=43). Buprenorphine doses were administered subcutaneously every 4 hours over a 6-day 
period in an inpatient setting. Dose were titrated on day 1 in the range of 0.15 mg to 0.45 mg 
every 4 hours (0.9 to 2.7 mg per day); and reduced over subsequent days. These doses would 
be approximately equivalent to 1.5 to 4 mg sublingual solution, adjusting for the different 
bioavailability of subcutaneous buprenorphine (Jasinski, Fudala et al. 1989). The authors 
reported positive withdrawal outcomes, with no withdrawal discomfort experienced by 16 
(73%) subjects, 5 reported some transient withdrawal discomfort, and only one subject 
reported persistent withdrawal features (anxiety, restlessness and insomnia).
A range of other studies (generally examining maintenance treatment) have randomly 
allocated subjects to different buprenorphine doses and reported measures that are relevant to 
withdrawal treatment, such as severity of withdrawal features, cravings or heroin use. The 
relevant aspects of these studies are briefly described below.
• Kosten, Schottenfeld et al. (1993), in a double blinded RCT comparing buprenorphine 2 
mg to buprenorphine 6 mg over a 24 week period of maintenance treatment. The 2mg 
group reported significantly more withdrawal symptoms, heroin use and cravings than the 
6 mg group.
• Seow, Quigley et al. (1986) compared 2 mg to 4 mg in a randomised blinded study of 32 
heroin dependent individuals over a 3-week period. The 2 mg group complained of 
significantly more withdrawal symptoms than the 4 mg group, with the authorsconcluding 
that even higher doses would be required to adequately alleviate withdrawal discomfort.
• Schottenfeld, Pakes et al. (1997) compared buprenorphine 12 mg to buprenorphine 4 mg in 
a double blinded randomised trial comparing retention and heroin use over a 24 week 
period. The higher dose was more effective in reducing heroin use than the 4 mg dose.
• Johnson, Eissenberg et al. (1995) subjects randomised 150 heroin dependent subjects to 2 
weeks on either placebo (n=60), 2 mg (n=60) or 8 mg (n = 30) buprenorphine. The 
subjects in the 8 mg group had a higher rating of dose adequacy and less heroin use than 
the 2 mg group, which in turn had better outcomes than the placebo group.
• Schottenfeld, Pakes et al. (1993) examined the effects of different doses of buprenorphine 
in a blinded study with 15 subjects dependent to both heroin and cocaine. Doses were 
progressively increased every three weeks from 2, 4, 8, 12 and 16 mg daily, and then 
reduced every 3 weeks using the same doses. Withdrawal severity was related to dose for
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both ascending and descending arms of the regimes: with greater withdrawal scores at low 
doses and with optimal reduction in withdrawal severity at 12 and 16 mg of buprenorphine 
per day (60 to 70 % of subjects reported uncomfortable withdrawal at 2 mg, 50% at 4 mg; 
30% at 8 mg, 10% at 12 mg and 0% at 16mg).
• Johnson, Cone et al. (1989) in a dose induction study with 19 heroin users dosed patients on 
consecutive days with 2, 4 and 8 mg. Subjects reported considerably less withdrawal 
discomfort as the burpenorphine dose increased, although this may also be related to dose 
accumulation with consecutive day dosing.
• Kosten and Kleber (1988) inducted 8 heroin dependent and 8 methadone patients onto 
randomly assigned doses of buprenorphine: 2 mg (n=10), 4 mg (n = 4), and 8 mg (n=2). The 
results are difficult to interpret given the very small subject numbers, and results were 
grouped for both heroin and methadone patients. Nevertheless, the general finding was that 
the 4 mg group complained of less withdrawal than the 2 mg group.
• Kosten, Morgan et al. (1991) compared withdrawal ratings for heroin users and methadone 
patients randomised to different buprenorphine doses (2mg, 3 mg, 4 mg and 6 mg). 
Unfortunately, the grouping of data of both heroin and methadone users limits 
interpretation.
• Ling, Charuvastra et al. (1998) reported on measures of heroin use and cravings in over 736 
heroin users randomised to 1,4, 8 or 16 mg sublingual buprenorphine solution over a 16 
week period. In general, subjects in the 16 mg group performed best, with higher treatment 
retention, less heroin use and lower severity of cravings than subjects on lower doses. 
Authors concluded that 8 mg or more of buprenorphine sublingual solution are more 
effective than lower doses.
It should be emphasised that these were not withdrawal studies, and that they merely report the 
severity of withdrawal symptoms (or other related outcomes) in heroin users on different 
buprenorphine doses (often in long term programs). As such, these studies are not conclusive 
with regard to establishing optimal dosing regimes for heroin withdrawal. Nevertheless, they 
suggest that buprenorphine doses of greater than 4 mg per day are more effective in 
suppressing withdrawal symptoms and heroin use. The optimal maximum dose appears to be in 
the range of 4 mg to 16 mg sublingually per day.
Whilst higher doses appear to more effectively reduce withdrawal severity, there are some 
concerns however, with the use of high buprenorphine doses for withdrawal management. 
Higher doses may result in a higher incidence of side effects, and there is evidence from three
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studies that higher doses may be associated with greater rebound withdrawal following the 
discontinuation of buprenorphine:
• Kosten and Kleber (1988) treated 16 opioid dependent patients for one month at three doses 
- 2mg (n=10), 4 mg (n=4), and 8mg (n=2). Upon abrupt cessation, the 8mg group (but not 
the 2 or 4 mg groups) reported a marked increase in measures for opiate withdrawal, 
suggesting greater rebound withdrawal with higher doses, although the numbers in this 
study are very small.
• Seow, Quigley et al. (1986) randomly assigned 32 subjects (heroin users with a history of 
buprenorphine abuse) to either 2 mg or 4 mg buprenorphine (sublingual solution) daily in an 
outpatient setting for 2 weeks, and then abruptly transferred subjects to placebo for one 
week. Subjects in the 4 mg group reported less withdrawal whilst on buprenorphine, but 
more severe withdrawal on placebo compared to subjects in the 2 mg group. This suggests 
that rebound withdrawal is more severe following cessation of higher buprenorphine doses.
• Resnick, Galanter et al. (1992) titrated 29 dependent heroin users onto buprenorphine doses 
according to clinical response (range 1.5 to 8 mg per day) and maintained them on these 
doses for 4 to 12 weeks. Doses were then gradually reduced at 5 - 10% every 3 to 4 days. 28 
of the 29 subjects relapsed to heroin use either during or soon after the reduction regime. 
Whilst systematic measures of opiate withdrawal were not reported, those individuals who 
required lower initial buprenorphine doses (~2 mg) did not describe relapse to heroin use or 
withdrawal features until after cessation of buprenorphine, whereas those on higher doses 
(8mg) relapsed or described withdrawal during dose reductions. The interpretation of this 
study is difficult due to the non-randomised assignment, the lengthy dosing regime, and it 
may be that those subjects prone to greater withdrawal discomfort or heroin use required 
higher initial doses, thereby accounting for the outcomes upon dose reduction. Nevertheless, 
the study suggests that the use of high doses of buprenorphine may be associated with some 
negative consequences following dose reduction.
In summary, the available evidence regarding optimal buprenorphine doses suggests that doses 
in the range of 4 to 16 mg per day may be optimal in reducing withdrawal discomfort and 
heroin use. Whilst most evidence points towards higher doses being more effective in reducing 
withdrawal symptoms and heroin use, there are some concerns regarding the use of high doses 
during withdrawal due to the possibility of greater side effects and rebound withdrawal 
phenomena.
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1.4.4 Clinical issues for withdrawal: Induction onto naltrexone
There continues to be considerable interest in finding ways to successfully induct heroin users 
onto naltrexone without significant delays (thereby avoiding treatment drop out), and without 
the experience of severe withdrawal symptoms as seen with antagonist-assisted ‘rapid’ 
withdrawal procedures. This work is possible due to the comparable affinity of naltrexone and 
buprenorphine for mu receptors (Lewis 1985). It has been postulated that buprenorphine is not 
rapidly displaced after a (small) dose of naltrexone and can continue to exert some agonist 
effects. This avoids the severe precipitation of withdrawal that is seen with doses of naltrexone 
following conventional opioid agonists. Laboratory studies (Eissenberg, Greenwald et al. 1996) 
suggest that the severity of withdrawal precipitated by naltrexone is related to the dose of 
buprenorphine, and the dose of naltrexone used.
The early clinical work in this area was conducted at Yale University, with two studies reported 
in the literature. Kosten and Kleber (1988) reported that 7 subjects who had completed a 30-day 
outpatient regime of daily buprenorphine doses (2 or 4 mg) took up the offer of commencing 
naltrexone 24 hours after last dose of buprenorphine. The initial 1 mg dose of oral naltrexone 
did not precipitate withdrawal in any of the seven subjects, however only 2 of the 7 subjects 
continued naltrexone to doses of 50 mg, with no details provided in the report.
A similar study (Kosten, Morgan et al. 1991) was later conducted in which 39 subjects were 
maintained on buprenorphine doses (ranging from 2 to 6 mg daily) for 30 days, after which 
subjects were allowed to choose to enter naltrexone treatment. Naltrexone was commenced 24 
hours after abruptly ceasing buprenorphine, with 1 mg, 6 mg, 12.5mg, 25 mg and 50 mg 
administered on consecutive days. 20 subjects took at least one 6 mg dose of naltrexone, 
although only 4 subjects were retained in naltrexone treatment for 2 weeks. The authors 
reported that minimal withdrawal was precipitated using this regime. Some additional data 
from this work was subsequently reported (Rosen and Kosten 1995) with more details 
regarding the use of high dose naloxone rather than low dose naltrexone as the initial opioid 
antagonist in 5 subjects. The high dose naloxone precipitated greater withdrawal initially, but 
also enabled a more rapid induction onto high doses (50 mg) of naltrexone.
The randomised trial by O’Connor and colleagues at Yale (O'Connor, Carroll et al. 1997) has 
been discussed in detail earlier. This study used 3mg buprenorphine daily for three days, then 
commenced naltrexone on day 4 at 25 mg, increasing to 50 mg thereafter, with a marked 
increase in withdrawal discomfort reported 24 hours later (on day 5), but unfortunately 
withdrawal data was not collected in the hours after each naltrexone dose, nor on days 6 and 7.
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Mann and colleagues (Mann, Montoya et al. 1994) reported brief details regarding the 
introduction of naltrexone during a short course of buprenorphine for 45 subjects undergoing 
inpatient heroin withdrawal. Buprenorphine was used for only 4 days (4 mg, 6 mg, 4 mg and 2 
mg daily), with comparison of the impact of introducing naltrexone (daily doses of 12.5, 25 and 
50 mg) at different stages in the 8-day withdrawal episode. The introduction of naltrexone on 
day 5 resulted in severe opiate withdrawal; whereas the introduction of naltrexone on day 2 
resulted in more tolerable features of withdrawal.
A more comprehensive randomised study from the same research group examined the timing of 
introduction of naltrexone in heroin users undergoing withdrawal using buprenorphine in an 
inpatient setting (Umbricht, Montoya et al. 1999). All subjects received a 4-day course of 
sublingual buprenorphine solution (12 mg, 8 mg, 4 mg and 2 mg). One group (n=32) received 
increasing dose of naltrexone commencing on day 2 of the admission (12.5 mg on day 2 and 3, 
25mg on day 4, and 50mg daily thereafter). The other group (n=28) received placebo until day 
when 50 mg naltrexone was commenced. The early induction group had greater withdrawal 
signs early (days 2 to 5) with resolution of objective withdrawal features thereafter; whereas 
the buprenorphine - placebo group had a milder withdrawal early in the regime, but increased 
withdrawal on day 8 commencement of naltrexone. Treatment retention (day 8) was 
significantly greater for the late induction group than the early naltrexone group, however there 
was no follow up beyond day 8. The study indicated that both procedures were feasible, with 
early induction resulting in a more rapid resolution of withdrawal discomfort, but at the 
expense of greater treatment drop out.
There continues to be considerable uncertainty with regard to the optimal techniques for 
inducting patients onto naltrexone following courses of buprenorphine. Thus far, the studies 
reporting on these procedures have not specifically described the profile of precipitated 
withdrawal (Kosten and Kleber 1988; Kosten, Morgan et al. 1991; Mann, Montoya et al. 1994), 
did not collect continuous data following naltrexone administration (O'Connor, Carroll et al. 
1997) or have relied exclusively on objective measures of withdrawal severity (Umbricht, 
Montoya et al. 1999), which are less sensitive than subjective measures. Further research 
overcoming these limitations, and examining different dosing regimes for naltrexone induction 
are required. Nevertheless, it appears that naltrexone can be safely introduced either during or 
soon after the cessation of buprenorphine treatment, resulting in less severe withdrawal than is 
typically seen in naltrexone - clonidine induction techniques.
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1.5. Developing a research agenda
1.5.1 Outstanding questions regarding buprenorphine in the 
management of heroin withdrawal
The literature regarding the use of buprenorphine in the management of heroin withdrawal has 
been reviewed in this chapter. Buprenorphine has favourable pharmacological properties, and 
randomised clinical trials have identified that buprenorphine is more effective than clonidine in 
reducing withdrawal severity in inpatient settings (Nigam, Ray et al. 1993; Cheskin, Fudala et 
al. 1994). Completion rates for buprenorphine subjects were higher in both studies (though not 
statistically significant). The findings suggest that buprenorphine is safe and effective for 
managing inpatient heroin withdrawal.
The evidence regarding its efficacy in outpatient heroin withdrawal is less clear, and further 
randomised controlled trials are required examining the efficacy o f buprenorphine in 
outpatient withdrawal settings compared to conventional withdrawal approaches (adrenergic 
agonists for short regimes, and methadone reductions for gradual reduction regimes). Bickel, 
Stitzer et al. (1988) compared gradual reduction regimes of methadone versus buprenorphine in 
a small number of subjects, with comparable but poor outcomes for both groups. The other 
randomised trial by O'Connor, Carroll et al. (1997) examined induction onto naltrexone 
following short buprenorphine, clonidine, or naltrexone and clonidine regimes. The 
buprenorphine group complained of less severe withdrawal symptoms than the other two 
groups, suggesting a possible advantage in using buprenorphine. However, measures of 
withdrawal severity in an outpatient study should not be the primary outcome (given the 
propensity for continued heroin use), and greater emphasis should be placed upon other 
outcome and process measures, such as rates of heroin use during (and after) the withdrawal 
episode, treatment retention rates, and rates of induction into post-withdrawal services (see 
Section 1.1.3 for discussion on evaluating withdrawal services). O'Connor, Carroll et al. (1997) 
did not adequately examine for these outcomes, and as such it is not possible to draw strong 
conclusions regarding the efficacy of buprenorphine for outpatient withdrawal. One other 
outpatient study has reported favourable outcomes with short buprenorphine regimes (Diamant, 
Fischer et al. 1998), however the absence of appropriate comparison groups in this studies 
limits its interpretation.
Further research is also required to examine for several important withdrawal outcomes (see 
Section 1.1.3) that have not been examined in either setting for buprenorphine in comparison to
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other treatment approaches -  most importantly, cost effectiveness, and post-withdrawal 
outcomes (such as treatment retention, drug use, psychosocial functioning). Although several 
studies have examined induction onto naltrexone (Kosten and Kleber 1988; Kosten, Morgan et 
al. 1991; O'Connor, Carroll et al. 1997; Umbricht, Montoya et al. 1999), none have reported 
retention on naltrexone beyond the initial induction doses, and only Vignau (1998) in a single 
group study has reported retention in other post-withdrawal treatment options (e.g. 
buprenorphine maintenance treatment).
Separate to establishing the safety and efficacy of buprenorphine as a withdrawal agent are 
issues as to how buprenorphine should be used clinically. The evidence regarding optimal 
buprenorphine dosing regimes for managing heroin withdrawal is not conclusive (reviewed in 
Section 1.4.3). It is important to determine buprenorphine dosing regimes that are safe, 
effective and can be easily implemented in routine clinical practice. The use of doses which are 
too low are likely to inadequately prevent withdrawal discomfort or diminish cravings for many 
heroin users, with possible consequences of increased treatment drop out, and/or increased use 
of heroin or other drugs (such as benzodiazepines). Alternatively, doses which are too high may 
unnecessarily increase the severity of rebound withdrawal and prolong the duration of opiate 
withdrawal symptoms following the cessation of buprenorphine, increase side effects, and/or 
contribute to the risk of overdose in combination with other sedative drug use. As with the use 
of other opioids such as methadone, there is likely to be considerable individual variation in 
buprenorphine dosmg requirements for heroin users. There is currently a poor understanding of 
the factors contributing to individual variation in dosing requirements for buprenorphine. 
Further research is required to examine the impact o f various patient characteristics upon 
buprenorphine doses for withdrawal - specifically, whether factors such as the amount or 
duration o f heroin use, psychological morbidity, expectancy, or body size impact upon dosing 
requirements. Finally, a better understanding o f suitable procedures for inducting and 
retaining patients in naltrexone treatment following buprenorphine-assisted withdrawal is 
required for those patients interested in long-term antagonist treatment.
1.5.2 Overview of research conducted
In order to address the more important limitations in the current literature regarding the use of 
buprenorphine in managing heroin withdrawal, a series of research studies were undertaken, 
summarised in Table 1.8. The specific research questions for each study are presented in later 
chapters.
Inpatient heroin withdrawal was examined in the Inpatient Titration Study. This study 
addressed two issues: (a) the range of buprenorphine doses required to manage heroin
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withdrawal in inpatient settings using the sublingual tablet preparation (Subutex®), and (b) the 
impact of patient characteristics upon dosing requirements.
Outpatient withdrawal was examined in two studies. The first study (Outpatient Titration 
Study) was aimed at developing a better understanding of the types of doses required to 
manage heroin withdrawal in a short outpatient treatment program, and to establish a suitable 
clinical regime for this purpose using sublingual buprenorphine tablets (Subutex®). Having 
developed a suitable short, outpatient dosing regime, a randomised controlled trial was 
conducted to examine the safety, efficacy and cost effectiveness of buprenorphine as a 
withdrawal agent in outpatient settings, compared to conventional symptomatic medications 
(including clonidine). The randomised trial examined a variety of withdrawal and post­
withdrawal outcomes (as identified in Section 1.3 of this chapter).
Table 1.8. Overview of research studies
Study title Principal aim(s) of the study Brief description
Inpatient Titration To identify range of Single blinded study (N = 32
Study buprenorphine doses appropriate completers). Maximum of 5
(Chapter 2) for the management of inpatient
days of buprenorphine in an 8 to
heroin withdrawal; and to identify 10 day inpatient admission.
impact of patient characteristics Doses titrated against subjective
upon buprenorphine doses. withdrawal severity.
Outpatient Titration To identify range of Open label study (N=18).
Study buprenorphine doses appropriate Buprenorphine doses titrated
(Chapter 3) for the management of brief
against clinical response in
outpatient heroin withdrawal dependent heroin users 
attending outpatient service. 
Short (5 day) dosing regime 
examined.
Randomised trial of To examine efficacy of Randomised open label trial
buprenorphine in buprenorphine compared to a (N=l 14) comparing
management of symptomatic medication regime buprenorphine and symptomatic
outpatient heroin (including clonidine and medications over an 8-day
withdrawal. benzodiazepines) across variety withdrawal episode. 4-week
(Chapter 4)
of withdrawal and post- follow-up examining post-
withdrawal outcomes. withdrawal outcomes, with
subjects self-selecting post­
withdrawal treatment.
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Following a description of these trials (Chapters 2, 3 and 4), a number of issues will be 
explored regarding the implementation and uptake of buprenorphine for this clinical indication, 
particularly in the Australian context. This will be approached from two perspectives:
• An exploration of the processes involved in tailoring medications to the needs of individual 
patients attending for heroin withdrawal, using an evidence-based framework for clinical 
decision making. This will entail consideration of the relative merits and limitations of 
each of the four withdrawal approaches (buprenorphine, methadone, adrenergic agonists 
and naltrexone) with regards to factors such as safety, efficacy, resource implications and 
patient preferences, building on the reviews conducted in this chapter together with the 
evidence acquired from the research trials conducted as part of this thesis.
• An examination of some of the systemic factors likely to impact upon the uptake of 
buprenorphine in the management of heroin withdrawal by treatment providers and 
patients. This will conclude with a brief description of the development of Australian 
clinical guidelines regarding the use of buprenorphine and national training programs for 
health professionals, both of which have been based work emanating from this thesis.
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Chapter 2: Inpatient Dose Titration Study
2.1. Study Objectives
This exploratory study aims to identify a suitable dosing regime of buprenorphine in inpatient 
treatment settings, and to identify the impact of a number of patient characteristics upon the 
buprenorphine doses. As described in Section 1.4.3, dosing regimes using the sublingual 
buprenorphine tablet preparation in the management of heroin withdrawal are not well 
established, with considerable variation in the types of doses and preparations previously used. 
There is also a very limited understanding of which factors impact upon the medication 
requirements of heroin users undergoing withdrawal. This is of clinical importance, in that 
during routine practice, medical practitioners usually prescribe a fixed medication regime at the 
outset of the withdrawal, which may then be modified according to the patient’s response to the 
medication. Decisions regarding initial dosing regimes can be better tailored if there is an 
understanding of the impact of various patient characteristics upon the dose required to 
alleviate withdrawal comfortably.
Different patient characteristics are thought to impact variably upon the severity of heroin 
withdrawal (see Section 1.3 for discussion). Various studies have identified withdrawal severity 
to be significantly related to amount of opiate use (Andrews and Himmelsbach 1944; Smolka 
and Schmidt 1999); mode of administration (Smolka and Schmidt 1999; Strang, Griffiths et al. 
1999); expectancy regarding withdrawal severity and psychological profile (Phillips, Gossop et 
al. 1986); whereas other factors, such as age and duration of opioid use, have consistently been 
found to be less important (Phillips, Gossop et al. 1986; Kosten, Jacobsen et al. 1989; Smolka 
and Schmidt 1999). It may be expected therefore, that similar factors may also contribute to the 
doses of medication required to alleviate withdrawal severity, although research is yet to 
examine their relative importance with regard to buprenorphine requirements. The specific 
study objectives were to:
• identify the range of buprenorphine doses required to comfortably alleviate withdrawal 
symptoms in subjects undergoing heroin withdrawal in residential withdrawal settings 
using a symptom-triggered titration dosing regime; and
• identify the patient characteristics that impact upon the buprenorphine dose requirements 
for withdrawal.
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2.2. Trial Design and Methodology
2.2.1 Overview of trial design and procedures
The study was an exploratory, single-blinded case series with no comparison group using a 
symptom-triggered titration regime. It was conducted as a multicentre study in two inpatient 
withdrawal units: Depaul House, Department of Drug and Alcohol Studies, St.Vincent’s 
Hospital, Melbourne; and the Detoxification Unit of the Canberra Hospital. Subjects underwent 
an inpatient admission for up to 10 days, with buprenorphine available over the first five days, 
corresponding to the duration of peak features of heroin withdrawal. Doses of buprenorphine 
were determined using a symptom-triggered titration regime against the severity of opiate 
withdrawal symptoms reported by patients using the Subjective Opiate Withdrawal Scale 
(Handelsman, Cochrane et al. 1987), with maximal doses of 16 mg per day in four divided 
doses. Patients were blinded to the specific dosing protocols, and to their dose of buprenorphine 
by the use of placebo tablets. Signs and symptoms were monitored until discharge from the 
unit. Other medications for the management of withdrawal were not routinely available. 
Conventional approaches to withdrawal counselling and support were used (Section 1.2.3).
The principal outcome measure (dependent variable) for each patient was the dose of 
buprenorphine required to alleviate moderate to severe opiate withdrawal symptoms. Data was 
collected at intake regarding key (independent) variables thought to possibly impact upon 
medication requirements during withdrawal: (i) amount of heroin use in the four weeks 
preceding intake, (ii) severity of heroin dependence, (iii) expected withdrawal severity, (iv) 
psychosocial functioning, (v) body weight and (vi) sex. Multiple regression analysis was 
conducted to identify the impact of each of these variables upon the doses of buprenorphine 
administered.
2.2.2 Subjects
2.2.2.1 Estimation of subject numbers
The study aimed to recruit until at least 30 to 35 subjects completed the buprenorphine dosing 
regime. The number of subjects was calculated on the basis of the numbers required to conduct 
a multiple regression analysis - it has been suggested that at least five subjects are required for 
each variable being entered into the regression analysis (Tabachnik and Fidell 1983). Six 
independent variables (describing patient characteristics at intake) were identified for this 
analysis; hence a target of at least 30 subjects completing the dosing regime was identified. It
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was estimated that between 50 to 70 subjects would need to be recruited in order to have 35 
subjects complete the regime (at an estimated completion rate of between 50 to 70%).
2.2.2.2 Selection criteria
The selection criteria, methods of assessment and their rationale are described in Table 2.1 
Table 2.1. Selection criteria
Selection criteria Method of assessment and rationale
1. Aged 18 years or more Proof of identity.
2. Heroin dependent and 
injecting as main route of 
administration
Assessed clinically against DSM IV 304.0 criteria. Non-injectors were 
excluded as route of administration has been identified as confounding the 
relationship between amount of heroin use and withdrawal severity (Smolka 
and Schmidt 1999).
3. Recent heroin use 
(within past 48 hours)
Assessed by self-report and positive urine test for opiates (Accusign® 
antibody diagnostic tests (EMIT) were used to avoid delays in confirming 
laboratory urine results (Wennig, Moeller et al. 1998). The rationale was to 
recmit subjects who had recently used heroin and had not progressed beyond 
the early stages of withdrawal. Peak withdrawal symptoms generally occur 
after opiate metabolites (morphine) are no longer present, as indicated by a 
negative urine test.
4. Not in methadone 
treatment within the past 8 
weeks
Rationale was to avoid individuals who had recently ceased methadone 
treatment and who may be experiencing a methadone withdrawal syndrome. 
Assessed by self-report and confirmed with the relevant statutory government 
bodies responsible for issuing methadone permits in Victoria and the ACT.
5. Not dependent upon, or 
withdrawing from other 
drugs (alcohol, 
benzodiazepines, cannabis)
Individuals undergoing concurrent drug withdrawal may have a different 
profile of symptoms and often require additional withdrawal medication, 
thereby invalidating the titration approach used in the study. Dependence was 
assessed by clinical history and examination, urine drug screen, and 
breathalysed alcohol level where indicated.
6. Not pregnant or 
breastfeeding
The safety of buprenorphine in pregnancy and breastfeeding is yet to be 
established. Assessed by a urine bHCG level, using Answer ® dipstick tests to 
avoid delays in screening.
7. Able to remain in 
inpatient unit for duration 
of study
Patients unable to remain in the unit for at least 7 days were considered 
ineligible.
8. No active or unstable 
medical or psychiatric 
condition
Active or unstable medical or psychiatric conditions would potentially 
complicate the management of withdrawal and / or the interpretation of 
symptoms, thereby potentially invalidating dose titration.
9. Able and willing to give 
informed consent
Participation in the study was voluntary, and patients had alternative 
withdrawal and other treatment options. Capacity to give informed consent 
was assessed by the clinical team and research assistant prior to induction.
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2.2.2.3 Recruitment
Subjects were recruited from consecutive patients presenting to the two residential units for 
heroin withdrawal. Participation in the study was voluntary with informed consent for the 
trial’s clinical and research activities. Patients not wishing to participate in the study had access 
to routine withdrawal and other clinical services. There was no active promotion or advertising 
for the study in order to minimise the potential for uncharacteristic patients presenting for 
treatment with a new ‘trial’ medication.
All patients were initially screened by a nurse on presentation to the unit. Interested and 
potentially eligible patients were further assessed by medical staff and presented with written 
Plain Language Statements regarding the study. Those willing to participate had relevant urine 
testing for opiate use and pregnancy conducted, and had their methadone treatment status 
confirmed with the relevant government authority (see selection criteria Table 2.1). Eligible 
patients were then interviewed by the research assistant, at which time written informed 
consent and baseline data were collected. Study treatment procedures were then commenced.
In total, 63 subjects were recruited to the study, 32 in Melbourne and 31 in Canberra. 
Recruitment at the Melbourne site was conducted over a five-month period (October 1998 to 
February 1999). 77 patients seeking inpatient heroin withdrawal were assessed at Depaul House 
during this period. 36 patients (47% of those screened) were considered ineligible for the study, 
with reasons for exclusion shown in Table 2.2 (five patients had multiple reasons for exclusion 
from the study). 41/77 (53%) patients were assessed as eligible for the study -  although eight 
patients did not enter the study: seven choosing conventional management, and one patient did 
not attend beyond her initial assessment. 33 subjects were recruited to the study in Melbourne, 
representing 43% of all patients assessed.
Table 2.2: Reasons for exclusion from study at Melbourne site
Reasons for exclusion from study Number
Patient also dependent to other substance(s): alcohol (2), benzodiazepines (3), cannabis (3), 12
pethidine (1), or multiple drugs (3)
Significant medical / psychiatric condition complicating withdrawal management: pregnancy 
(1), chronic pain condition (2), carpal tunnel syndrome (1), pelvic inflammatory disease 
(1), depression (2), alcohol-related brain injury (1), attention-deficit disorder (1), chronic 
insomnia (1), chronic intractable hiccups treated with psychotropic medication (1).
13
No heroin use in past 48 hours
Patient under 18 years of age
Patient in methadone program within past 8 weeks
Unable to give informed consent on admission (intoxicated)
Patient smoking heroin only (no history of injecting drug use)
6
3
3
3
1
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The first subject recruited to the study was considered a pilot case to enable review of the 
clinical and research procedures. The experience of the first subject resulted in a review of the 
treatment procedures for the study: titrations were originally commenced on the second day of 
admission, however this resulted in significant withdrawal discomfort by day 2. Following this 
experience, the protocol was amended, with commencement of buprenorphine titration on the 
day of admission. Data for the first pilot subject is excluded from all subsequent analyses, and 
data is reported for the 32 subjects from the Melbourne site.
Thirty-one subjects were recruited at the Canberra site over a four-month period from 
November 1999 to February 2000. Unfortunately data regarding the number of eligible and 
ineligible patients, or the reasons for exclusions, was not available for this site.
2.2.3 Treatment procedures
2.2.3.1 Description and justification for the buprenorphine dosage regime
Issues regarding the parameters of a buprenorphine withdrawal regime were considered in 
detail in Section 1.4.3. Short courses of buprenorphine treatment were used in this study, with 
the duration of the buprenorphine regime dependent upon the duration of moderate or severe 
withdrawal discomfort, and limited to a maximum of five days from the day of admission.
Two general approaches can be used for determining the amount and duration of withdrawal 
medication. One approach is the titration method, where the amount of a medication is linked 
to the severity of withdrawal symptoms. Signs and symptoms are monitored throughout the 
course of treatment (using a reliable instrument or withdrawal scale), and doses of medication 
are administered in response to the severity of withdrawal features. An example is the titration 
of benzodiazepines in the management of alcohol withdrawal, where the titration approach has 
been shown to better match the dose and duration of withdrawal medication to individual 
patient requirements than fixed dose regimes (Sullivan, Swift et al. 1991; Saitz, Mayo-Smith et 
al. 1994).
The alternative, and more ‘traditional’ approach to examining different dosing regimes is to use 
a blinded randomised controlled study design in which subjects are randomly assigned to 
different fixed dosing schedules, and outcomes compared between groups of subjects at 
different doses. Such an approach provides information about groups of subjects, and 
minimises selection bias in accounting for differences in outcomes. However, there are 
limitations with a randomised dose design during an exploratory phase of research. A practical 
issue is that large numbers of subjects are often required to demonstrate statistically significant 
differences between groups of subjects, particularly if the response to medication is not
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consistent across subjects within a group, or if several different dosing regimes need to be 
examined. This is a relevant issue, given the wide variety of buprenorphine doses previously 
reported in the research literature (Table 1.6); and the nature of withdrawal regimes (different 
doses are routinely used on different days of the withdrawal episode), such that several 
different dosing regimes would need to be explored in order to identify ‘optimal’ practice. 
Another limitation is that the evidence from randomised designs cannot automatically be 
applied in clinical settings, as it does not accommodate individual variation in dosing 
requirements. For example, a randomised study that shows that more subjects did well at a 
certain dose (for example, 8 mg) does not mean that all future patients should receive that 
particular dose. Some patients may experience side effects or other complications at this level, 
but may have a favourable response on a lower dose (e.g. 4 mg). Others may require higher 
doses to achieve their desired outcome. In clinical practice, evidence from randomised dose 
efficacy studies should provide a guide to dosing regimens; however, doses should be 
individualised according to the response to the medication, the severity of the underlying 
condition being treated, the emergence of adverse events, and (informed) patient preferences.
The dose titration approach was thought to be better suited to the exploratory nature of this 
research. Also, the second study objective was to examine the impact of various patient 
characteristics upon the doses of buprenorphine required to facilitate a comfortable withdrawal. 
The symptom-triggered titration approach was considered to be more appropriate for this 
objective, with regression analysis examining for the impact of key variables upon the total 
dose required for each subject. However, titration methods with buprenorphine have not 
previously been described in the published literature, and as such, the rationale and justification 
of the titration procedures used in this trial needs to be systematically described. The key 
parameters in the development of titration dosing techniques involve:
(a) the assessment and monitoring of the severity of opiate withdrawal at set intervals over the 
course of the withdrawal episode; and
(b) the administration of buprenorphine in response to moderate or severe withdrawal 
symptoms.
Measuring the severity of opiate withdrawal
In order for a titration regime to be implemented, a valid and easy to administer scale is 
required that scores the severity of opiate withdrawal features, with good inter-rater and test- 
retest reliability. The Subjective Opiate Withdrawal Scale (SOWS) and the Objective Opiate 
Withdrawal Scale (OOWS) (Handelsman, Cochrane et al. 1987) were ideally suited to this 
purpose. These instruments have good psychometric properties (Handelsman, Cochrane et al.
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1987), and measure withdrawal symptoms at a particular point in time, and are therefore ideal 
for use in a titration regime that involves multiple dosing points each day. These scales were 
already routinely used at the Canberra site.
As identified in Section 1.2.3, subjective ratings of opiate withdrawal severity are considerably 
more sensitive than objective measures, (Turkington and Drummond 1989; Loimer, Linzmayer 
et al. 1991; Handelsman, Cochrane et al. 1987); are better correlated to treatment outcome and 
should be used to guide prescribing practices during withdrawal (Kosten, Rounsaville et al. 
1985). Hence, in this study, buprenorphine doses were linked to subjective ratings of 
withdrawal severity using the Subjective Opiate Withdrawal Scale. This scale consists of 16 
common symptoms of opiate withdrawal, with each item rated on a scale of 0 to 4, and a total 
score of 0 to 64. Although there is considerable variation between individuals in their rating of 
withdrawal severity, previous clinical experience with the SOWS had indicated that scores 
below the mid-teens generally reflect minimal or mild withdrawal discomfort, scores in the 
high-teens to low-thirties generally reflect moderate withdrawal discomfort, and score above 
the mid - 30’s reflect severe withdrawal severity.
The collection of objective measures of withdrawal (OOWS), physiological (blood pressure, 
pupillary size and pulse) and behavioural parameters of intoxication (level of consciousness, 
speech and gait) enhanced the safety of the titration procedure, and assisted in maintaining the 
blind, as subjects were unaware of which of the various measures were used to determine 
doses.
Frequency of monitoring and dosing
The principal determinants of the time interval between reviews are the time to peak effect, and 
the duration of peak effect of the medication being used. Reviews should not be more frequent 
than the time taken for buprenorphine to reach its peak effect, or else accumulation of the 
medication (and over-sedation) may occur. The interval should not be less frequent than the 
approximate duration of peak effect, or else the patient may experience increased withdrawal 
symptoms prior to their next dose of medication. For buprenorphine, the time to peak effect is 
approximately 60 to 120 minutes, and the duration of peak agonist effect is approximately 4 
hours for low buprenorphine doses (2 or 4 mg) (Walsh, Preston et al. 1994). This suggests that 
4 to 6 hourly reviews should be adequate when using such buprenorphine doses at each time 
point. Thus, ratings of withdrawal severity for the purposes of dose titration were conducted 
four times a day: at 7 am, 12 midday, 5 pm and 11 pm -  these times being suited to nursing 
routines in the units.
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Buprenorphine doses dispensed
Current evidence indicates that sublingual doses of 2 mg buprenorphine solution suppress 
heroin withdrawal features, although higher doses have been found to be more effective in this 
regard, and maximal relief of withdrawal symptoms has been reported at daily doses of 16 mg 
(see Section 1.4.3 for review). Hence, daily doses of up to 16 mg (in 2 mg increments) were 
considered as appropriate upper dosing limits for the titration study (although subjects not 
experiencing withdrawal could receive no buprenorphine).
A dose of buprenorphine was administered if the subject reported uncomfortable (moderate or 
severe) features of withdrawal on the Subjective Opiate Withdrawal Scale. Based on earlier 
experience with the SOWS, the following titration regime was developed.
Table 2.3: Titration schedule of buprenorphine vs. withdrawal severity
SOWS score Buprenorphine dose Tablets administered
(range 0 - 64) administered (S/L)
Oto 16 0 mg 2 x placebo tablets
17 to 32 2 mg 1 x 2 mg buprenorphine + 1 x placebo tablet
33 to 64 4 mg 2 x 2  mg buprenorphine tablets
Each subject received two tablets at each dosing time, containing either 0, 2 or 4 mg 
buprenorphine. Subjects were blinded to the dose of buprenorphine they received, and were not 
informed of the threshold scores at which buprenorphine was administered in order to 
discourage subjects from over-reporting symptoms to receive a dose of medication. Staff 
involved in dispensing medication were not blinded to the doses administered.
Individual variation in the experience of withdrawal symptoms is to be expected, and there is 
always the potential for some individuals to over- or under-report subjective withdrawal 
symptoms. Clinical staff regularly matched subjective (SOWS) with objective (OOWS) ratings 
of withdrawal, and significant discrepancies generally prompted a discussion with the subject 
regarding their scoring. For example, a subject who reported no (0) or minor (1) severity for a 
number of withdrawal features that were clearly observable by staff on the Objective Scale 
(e.g. yawning, sweating, runny nose, goose bumps) would be prompted to reconsider their 
score following a re-explanation of the method of scoring of the SOWS. Alternatively, subjects 
who rated extreme (4) or very severe (3) for items that were not observed by staff were 
similarly directed to reconsider their score. In this way, gross under- and over- reporting was 
minimised.
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Dosing according to the above titration regime was commenced on the day of admission, and 
continued until day 4 of admission. The day 5 dose was calculated as up to half of the total day 
4 dose split in two divided doses (administered at 12 noon and 11 PM). Subjects receiving 0 or 
2 mg of buprenorphine on day 4 were dosed with placebo tablets only on day 5. All subjects 
received placebo tablets on day 6 of the admission to further enhance the blinding of subjects. 
Recordings of the severity of withdrawal continued throughout the period of the admission (up 
to ten days). The procedures are summarised in the following Table.
Table 2.4: Summary o f dosing procedures
Day Frequency o f Monitoring Medication
1-4 Four times per day 
0700; 1200; 1700; 2300
No buprenorphine if SOWS score <16 points or 
intoxicated
Buprenorphine 2 mg if SOWS score 17 to 32 points 
Buprenorphine 4 mg of SOWS score >32 points
5 Four times per day 
0700; 1200; 1700; 2300
50 per cent of the Day 4 buprenorphine dose in two 
divided doses (1200 and 2300).
6 Four times per day 
0700; 1200; 1700; 2300
Placebo tablets at 1200 & 2300.
7-10 Four times per day 
0700; 1200; 1700; 2300
No medication routinely available
Subjects were able to refuse medication at any time during the study, however continued 
participation in the study required participation in the data collection procedures. Subjects 
could voluntarily withdraw from the study at any time, and remain eligible for conventional 
treatment. Patients were told of the doses of buprenorphine they received on completing their 
participation in the study - that is, following the final discharge interview with the research 
assistant.
2.23.2 Other medications and treatment procedures
Other medications for the management of heroin withdrawal were not routinely used. The one 
exception was for subjects complaining of persistent insomnia, who were allowed one or two 
nights of low doses of diazepam (5 or 10 mg orally). Subjects were expected to participate in 
all individual and group counselling and case management sessions according to the usual 
routine within the withdrawal units. Subjects were expected to comply with the rules of the 
agency, and failure to comply with these rules would result in administrative discharge from 
the program and the study.
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2.2.4 Outcome measures, data collection and management
The primary outcome for the study was the dose o f buprenorphine dispensed to each subject 
over the course o f the withdrawal regime. Other outcome measures included:
• The severity o f opiate withdrawal over the course of the withdrawal episode, as measured 
four times a day using the SOWS and 0 0 WS.
• Adverse events. Adverse events were elicited from subjects and assessed by clinicians daily.
• Measures o f patient satisfaction with buprenorphine. Data was collected by the research 
assistant at a discharge interview, using both structured and semi-structured interview 
techniques. Subjects were asked to rate (a) the severity o f withdrawal experienced using a 
Visual Analogue Scale (with 0 = no discomfort, and 100 mm = most severe discomfort ever 
experienced); (b) adequacy o f the buprenorphine dose measured on a 5 point Likert scale (1 
= “much too low”, 2 = “too low”, 3 = “about right”, 4 = “too high”, and 5 = “much too 
high”); (c) ranking of different medication regimes used for heroin withdrawal from best to 
worst; and (d) open ended questions regarding the positive and negative aspects o f using 
buprenorphine for heroin withdrawal.
In addition to the data collected during the withdrawal episode and at the discharge interview, 
data was also collected at intake regarding a range of patient characteristics that were thought 
to possibly impact upon the severity of withdrawal, and hence upon buprenorphine dosing 
requirements. These variables and their operational measures are shown in Table 2.5 below.
2.2.4.1 Monitoring of Trial
The trial was externally and independently monitored by Panacea Research and Evaluation Pty 
Ltd, as part of the National Evaluation of Pharmacotherapies for Opioid Dependence project 
coordinated by the National Drug and Alcohol Research Centre in Sydney. Monitoring 
included independent confirmation of all subject records, and independent double entry of key 
data.
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Table 2.5 Baseline variables potentially impacting upon dosing requirements
Variable Measure
Quantification of 
recent heroin use
Measured using the Drug Use Section of the Opiate Treatment Index 
(Darke, Heather et al. 1991). This instrument measures frequency of 
heroin use within the past 4 weeks, represented as a Q score.
Severity of heroin 
dependence
Measured using the Leeds Dependence Questionnaire (Raistrick, 
Bradshaw et al. 1994). A validated, 10-item scale measuring physical, 
cognitive and behavioural components of dependence. Scores 0 to 30, 
with mild (< 17 points), moderate (18 - 23) to high (>24) degree of 
dependence.
Expectancy 
regarding the 
severity of this 
withdrawal episode
Measured using a Visual Analogue Scale (0 to 100 mm) in response to 
the question: “How severe do you think this withdrawal episode will be? 
Please indicate on the following line with 0 = no discomfort, and 100 = 
the most severe withdrawal symptoms you have ever experienced”
Psychosocial
distress
Measured using the BASIS-32 (Eisen, Dill et al. 1994), a validated 32- 
item scale assessing 5 parameters (subscales) of psychosocial 
functioning, including: relationship with self and others; depression and 
anxiety; functioning in daily role; impulsive and addictive behaviour, 
and psychosis. Average and subscale scores are represented on a 0 to 4 
scale, with higher scores representing greater dysfunction or problems.
Body weight Measured in kilograms.
Sex Male or Female
2.2A.2 Data handling and analysis
The principal investigator and research assistants were responsible for the security of 
confidential data and consent forms. All subjects received a coded number as a unique 
identifier. Research data forms only utilised these numerical codes, with the register linking the 
subject’s name to the coded number and the consent forms (with both the subject’s name and 
code number) stored in a locked filing cabinet separate from the remaining data. Data entry, 
and descriptive and regression analysis were conducted by the principle investigator using the 
program SPSS 10.1 for Windows (SPSS 2000).
Research data are held on the premises of Turning Point Alcohol and Drug Centre. Turning 
Point is a research, clinical and training institution with experience in storage of confidential 
records, and with a number of security systems for this purpose. Data will be held for at least 
fifteen years after the completion of the study, in keeping with the requirements of Clinical 
Trial Notification Scheme of the Therapeutic Goods and Administration (Therapeutic Goods 
Administration 1997).
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2.3. Results
2.3.1 Subjects
Demographic characteristics of subjects at intake from the two sites, and for the total sample 
are shown in Tables 2.6 and 2.7. The majority of subjects were male (70%), unemployed (81%) 
and had not completed tertiary education (92%). There were no statistically significant 
differences for the two sites regarding sex (x^(l) = 2.37, p < 0.2), education level (x^(3) = 
2.64, p< 0.5), or employment status (x^(4) = 5.0, p < 0.3).
Table 2.6 Demographic characteristics of subjects
Study site
Melbourne 
n=32(%)
ACT 
n=31(%)
Total 
N=63(%)
Sex
Female 13(41) 7(23) 20 (32)
Male 19 (59) 24 (77) 43 (68)
Highest level education completed
7- 10 13(41) 17(55) 30 (48)
11 - 12 16(50) 11(35) 27 (43)
Tertiary 2(6) 3(10) 5(8)
Unknown 1 (3) 1(2)
Employment status
Full time employment 1(3) 3(10) 4(6)
Part time employment 2(6) 2(6) 4(6)
Home duties 1(1) 1(2)
Unemployed 25 (78) 26 (84) 51 (81)
Pension 3(9) 3(5)
Percentages may not equal 100% due to rounding off
The mean age was 27.6 ± 6.4 years (median = 26, range 18.0 to 46.7), and subjects generally 
described long-term dependent or regular opioid use (mean = 4.4 years, median = 2.8, range = 
0.5 to 19.8 years). In general, subjects were using heroin heavily at intake, injecting on average 
3.7 times a day (OTI Q score) (median = 3.25, range = 0.67 to 12), with moderate to high 
severity of dependence on heroin (mean LDQ of 23.5, median = 24, range = 11 to 30). The 
group described spending on average approximately $190 ± 142 per day on heroin (median = 
$160 per day, range $25 to $600).
Comparison between the two sites for these variables indicated that the only significant 
difference between the two sites was for ‘expectancy regarding withdrawal severity’, with the
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Melbourne subjects having a significantly lower mean score on this measure (t(59) = 3.37, p < 
0.01, 95% Cl = 9 to 35). The Melbourne subjects also had a non-significant trend for higher 
OTI Q scores for heroin than the Canberra subjects (t (61) = 1.98, p < 0.06, 95% Cl = -0.01 to 
2.05).
Table 2.7. Subject characteristics at intake for total sample and each site (continuous 
variables)
Melbourne 
(n=32) 
Mean ± SD
Canberra 
(n=31) 
Mean ± SD
Total 
(N=63) 
Mean ± SD
Significant ages (years)
Age 27.4 ±6.1 27.8 ±6.7 27.6 ± 6.4
Age first used heroin 21.0 ±5.3 19.6 ±4.3 20.3 ±4.9
Age first regular heroin use 22.6 ±5.2 21.4 ±5.0 22.0 ±5.1
Duration regular heroin use (yrs) 4.1 ±4.1 4.8 ±4.0 4.4 ±4.1
Measures of drug use
Heroin OTI Q score 4.17 ±2.40 3.17 ± 1.56 3.69 ±2.09
Alcohol OTI Q score 0.18 ± 0.33a 0 0.09 ± 0.25 a
Cannabis OTI Q score 1.64 ±3.08 2.91 ±6.01 2.27 ± 4.76
Tranquilliser OTI Q score 0.66 ± 1.41b 0.05 ±0.21 0.35 ± 1.05 b
Severity of dependence (LDQ) 23.6 ±4.7 23.4 ±4.3 23.5 ±4.4
Expectancy withdrawal severity 41 ±22 62 ±27 51 ±27
(0-100 VAS)
BASIS-32 average score 1.66 ±0.70 1.81 ±0.76 1.73 ±0.73
Body weight (kg) 67.6 ± 12.3 73.2 ± 13.7 69.9 ± 13.1
a data from 2 subjects excluded as outliers ; b data from 1 subject excluded as outlier
2.3.2 Completion rates and comparisons between completers and non­
completers
Thirty-two of the 63 subjects (51%) completed the dosing regime, defined as reaching day 5 of 
the admission. Four of the non-completers discharged themselves within hours of admission, 
prior to the onset of withdrawal and without receiving medication. Hence, 32 of the 59 subjects 
(54%) commencing treatment completed the dosing regime.
There was a significant difference in completion rates between the two sites (x^ (1) = 5.72, p < 
0.05). In Melbourne, 21 subjects (66%) completed the regime. Four of the 11 non-completers 
voluntarily discharged themselves from the inpatient unit prior to the onset of significant
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withdrawal symptoms, and without receiving a dose of buprenorphine. The remaining seven 
non-completers discharged themselves after receiving at least one active dose of buprenorphine 
but before the completion of the medication regime. One of these subjects transferred directly 
to a methadone maintenance program.
Comparison of intake variables (age, sex, duration dependent opiate use, levels of drug use, 
severity of dependence, psychosocial functioning, body weight, expectancy regarding 
withdrawal severity) between completers and non-completers at the Melbourne site indicated 
that the only significant difference was that the completers had more severe psychosocial 
dysfunction as measured by the BASIS-32 average score (1.84 ± 0.66) compared to the non­
completers (1.31 ± 0.67) (t (30) = 2.18, p < 0.05, 95% Cl = 0.03 to 1.03). There was also a non­
significant trend for higher completion rates among men (79% completed) than women (46% 
completed).
A quite different pattern was observed at the Canberra site, with 11 of the 31 subjects (35%) 
completing, and 20 subjects (65%) discharging prior to completion of the dosing regime. Drop­
out at the Canberra site was high during the early stages of the study (for example 16 of the 
first 20 subjects dropped out), with most subjects discharging themselves on days 3 or 4 (11 of 
the first 20 subjects). In response to this high drop out rate, a concerted effort was made by 
staff to encourage subjects to remain in the unit until the completion of their medication regime 
(day 6), at which point the subject could be more confident of having completed withdrawal. 
This resulted in a considerable improvement in retention rates, with the majority (7 of 11) of 
the last subjects enrolled in the study ‘completing’ the titration regime.
15 of the 20 drop outs from Canberra site were followed up after discharge, with the following 
reasons cited by subjects for leaving the unit: n = 4 (27%) for personal or relationship issues; n 
= 3 (20%) due to withdrawal symptoms; n = 3 (20%) left to use heroin; n = 2 (13%) were 
discharged due to administrative reasons; n = 2 (13%) described the withdrawal episode as 
“generally unsuitable”; and n = 1 (7%) “felt fine, but bored” in the unit.
Comparison of intake variables indicated that the only significant differences between 
completers and non-completers at the Canberra site was for measures of heroin use at intake: 
specifically the mean OTI Q score was significantly higher in non-completers (3.73 ± 1.31), 
compared to completers (2.17 ± 1.51) (t(29) = 2.99, p < 0.01, 95% Cl = 0.49 to 2.61)). In 
contrast, the mean severity of heroin dependence (as measured by the LDQ) was significantly 
lower in non-completers (22.1 ± 4.5) than completers (25.7 ± 2.6) (t(29) = 2.5, p<0.05; 95% Cl 
= 0.7 to 6.7). These differences appear difficult to interpret, as amount of heroin use (Q score) 
and severity of dependence (LDQ) should be (intuitively) positively correlated. Pearson’s
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correlation test indicated a non-significant negative correlation between these two variables for 
the Canberra subjects (r = - 0.12). There was also a trend for higher completion rates among 
women at the Canberra site, with 5 out of 7 women enrolled (71%) completing the regime, 
compared to 6 out of 24 men (25%), although this was not statistically significant (Fisher’s 
exact test, p < 0.1). The differences in completion rates for men and women at the two sites 
may be a chance occurrence due to the small subject numbers, although it does raise attention 
to the importance of cultural and contextual factors within an inpatient withdrawal unit upon 
such outcomes.
When combining the samples from the two sites (n=63), there were no significant differences at 
intake regarding completers and non-completers on the variables described. Table 2.8 provides 
summary details for the total sample, and separately for completers and non-completers. 22 of 
43 men (49%), and 11 o f 20 women (55%) completed the withdrawal regime.
Table 2.8 Characteristics at intake of completers and non-completers
Completers 
(n=32) 
Mean ± SD
Non-completers 
(n=31) 
Mean ± SD
Age (yrs) 27.6 ±7 .2 27.6 ±5.5
Age first heroin use (yrs) 20.8 ±5 .2 19.8 ±4.5
Age first regular heroin use (yrs) 22.0 ±5.3 22.0 ± 5.0
Duration regular heroin use (yrs) 4.1 ±3 .2 4.7 ±4.8
Body weight (kg) 70.2 ± 13.2 69.5± 13.2
Heroin OTI Q score 3.51 ±2.35 3.87 ± 1.79
Alcohol OTI Q score 0.14 ±0.32 a 0.03 ± .13
Cannabis OTI Q score 2.28 ±4.44 2.26 ±5.13
Tranquilliser OTI Q score 0.59 ± 1.40 0.10 ±0.31 b
Leeds Dependence Questionnaire 23.9 ± 4 .4 23 .0 ± 4.5
Expectancy re: withdrawal severity 49 ± 26 54 ± 28
BASIS-32 average score 1.87 ±0.73 1.59 ±0.72
a data from 2 subjects excluded as outliers ; b data from 1 subject excluded as outlier
2.3.3 Buprenorphine doses administered .
2.3.3.1 Completers
The key study objective was to establish the buprenorphine dosing requirements o f heroin users 
by titrating doses according to the severity of withdrawal experienced. Dosing details are 
presented in Table 2.9 by site and for the entire 32 subjects completing the regime. The mean 
total dose was 17.4 mg over the 5 day dosing regime, ranging from 4 to 40 mg (from a total
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possible dose of 72 mg). The maximum dose dispensed on any one day was 12 mg, from a 
possible maximum daily dose of 16 mg.
Comparison of doses between the two sites indicates a very similar pattern of dosing 
requirements, with no significant differences regarding total or daily doses. The Canberra site 
had a trend for higher doses dispensed on day 1, possibly reflecting different admission 
procedures between the two sites, with early morning admissions at the Canberra site, resulting 
in an earlier onset of withdrawal symptoms.
Table 2.9. Buprenorphine doses for subjects completing dosing protocol (n=32)
Buprenorphine dose (mg in sublingual tablets)
Day 1 Day 2 Day 3 Day 4 Day 5 Total
Melbourne (n=21)
Mean ± SD 3.1 ±3.0 5.5 ±3.2 4.5 ±3.0 2.3 ±2.6 0.9 ± 1.4 16.3 ±9.1
Median 2 6 4 2 0 16
Range 0-10 0- 10 0 - 8 0 - 8 0 - 4 4- 36
% subjects receiving 67% 86% 86% 62% 32% 100%
buprenorphine
Canberra (n=l 1)
Mean ± SD 5.1 ±2.1 6.4 ±3.3 5.3 ±3.8 2.4 ±2.7 0.6 ± 1.3 19.6 ± 10.7
Median 6 6 4 2 0 20
Range 2 -8 2- 10 0-  12 0 - 8 0 - 4 4- 40
% subjects receiving 100% 100% 91% 64% 18% 100%
buprenorphine
T O TA L (n=32)
M ean  ±  SD 3.8 ± 2.8 5.8 ±  3.2 4.8 ±  3.3 2.3 ± 2.6 0.8 ±  1.3 17.4 ±  9.7
25th  percen tile 2 4 2 0 0 10
M edian 4 6 4 2 0 17
75th  p ercen tile 6 8 8 4 2 26
R ange 0 - 1 0 0 - 1 0 0 - 1 2 0 - 8 0 - 4 4 - 4 0
% subjects receiving 78% 91% 88% 63% 28% 100%
buprenorphine
Although the dosing protocol allowed for buprenorphine doses to be administered for up to 5 
days, only a minority of subjects (28%) required dosing into the fifth day of admission. The 
duration of buprenorphine dosing for the completers is shown in Table 2.10.
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Table 2.10. Duration o f buprenorphine dosing for completers (n=32)
Day Number of subjects (%) Cumulative % of subjects
1 1(3) 3
2 3(9) 13
3 7(22) 34
4 12(38) 72
5 9(28) 100
2.3.3.2 Non-completers
The doses for the 27 subjects who did not complete the dosing regime are shown in the Table 
2.11 (note that 4 subjects did not receive any active buprenorphine and are therefore excluded 
in this analysis). There were no statistically significant differences in buprenorphine doses on 
days 1, 2 and 4 between completers and non-completers, however the non-completers had a 
significantly lower mean dose on day 3 compared to the completers (t (46) = 2.65, p < 0.05, 
95% Cl = 0.6 to 4.4). This most likely reflects that a considerable number of subjects (12) left 
during day 3 prior to receiving the full amount of medication available on that day.
Table 2.11. Buprenorphine doses for subjects not completing dosing protocol (n=27)
Buprenorphine dose (mg in sublingual tablets)
Day 1 Day 2 Day 3 Day 4 Day 5
n
Mean ±SD
26
3.0 ±3.4
23
6.3 ± 3.7
16
2.3 ±2.6
4
0.5 ±1.0
N/A
2.3.3.3 Subject ranking of dose adequacy
30 subjects (27 completers, 3 non-completers) rated the adequacy of their doses of 
buprenorphine at the final discharge research interview using a 5-point Likert Scale (1 = much 
too low; 2 = too low; 3 = about right; 4 = too high; 5 = much too high), prior to being informed 
of the dose they had received. 87% (26 / 30) of subjects completing this interview indicated 
that the dose of buprenorphine was ‘about right’; 10% (n=3) indicated that the dose was ‘too 
low’; and one subject (3%) indicated that the dose was ‘much too high’. The three non­
completers who responded all rated their doses as ‘about right’.
2.3.4 Withdrawal Severity
2.3.4.1 Subjective ratings of withdrawal severity
Data for withdrawal severity are presented in a number of ways. Table 2.12 displays the mean 
daily SOWS scores (mean of 0700, 1200, 1700 and 2300 scores). There were no significant 
differences regarding mean daily SOWS scores between the sites.
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Table 2.12 Mean daily SOWS scores for completers (n=32)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8*
n 32 32 32 32 32 26 18 1
Mean 21.1 20.9 16.8 12.5 10.8 7.8 9.3 7.9
SD 11.2 6.0 6.3 6.3 7.2 6.7 7.9 9.0
* Day 8 data from the 5 subjects commencing naltrexone (day 7) are excluded from this analysis.
Figure 2.1 displays the range of mean daily SOWS scores (± 95%CI for means) over the first 8 
days of the admission for both completers and non-completers, The small subject numbers 
remaining at day 4 for the non completers (n=4) and day 8 for the completers (n=7) has resulted 
in wide confidence intervals at these time points; nevertheless, ratings of subjective withdrawal 
between the two groups were generally similar.
Figure2.1: Mean Daily SubOWS scores for completers and non-completers
♦— Completers 
■ — Non-completers
Withdrawal discomfort was greatest during the first 2 days of admission, with resolution of 
symptoms thereafter, and with minimal rebound withdrawal following the discontinuation of
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buprenorphine dosing (generally days 3 to 5). There was a small increase in mean daily SOWS 
scores noted on day 7 (9.3) compared to day 6 (7.8). Two factors may have contributed to this 
increase: a degree of rebound withdrawal, (which tended to be mild (as suggested by the low 
SOWS scores) and transient for most subjects); and selective retention of subjects beyond day 6 
(cessation of placebo dosing). Many subjects who were feeling well, with no or mild withdrawal 
discomfort for several days left the unit on day 6. In contrast, those subjects with greater 
discomfort were often more prepared to remain in an inpatient unit to manage their symptoms.
The issue of rebound withdrawal following the discontinuation of buprenorphine can also be 
examined by considering the number of subjects who reported a SOWS score at any time after 
their last buprenorphine dose (e.g. day 6 or day 7) that was higher than the SOWS score 
reported at the time of their last dose. This was reported by only 2 of the 32 subjects (6%).
2.3.4.2 Peak withdrawal severity
The mean peak SOWS for all subjects was 33.4 ± 11.8, consistent with moderate withdrawal 
severity. There was no significant difference in peak SOWS scores for completers (31.7 ± 9.7) 
compared to non-completers (35.3 ± 13.7). The timing of peak withdrawal symptoms for those 
completing withdrawal regimes are shown in the Table 2.13, emphasising that the greatest 
withdrawal discomfort was experienced early in the withdrawal episode, not after the cessation 
of buprenorphine.
Table 2.13. Time ofpeak withdrawal severity for completers (n=32)
Day Number (%) Mean SubOWS Score
Day 1 13(41) 33.5
Day 2 14(44) 31.9
Day 3 3(9) 31.7
Day 4 1(3) 25
Day 5 1(3) 29
Day 6 or later 0
2.3.4.3 Subject global ratings of withdrawal severity
Subjects were asked to rate the severity of withdrawal experienced on a Visual Analogue Scale, 
(0 mm = no withdrawal symptoms experienced, 100 mm = extreme withdrawal symptoms 
experienced). 29 subjects completed this section of the discharge interview (27 completers, and 
2 non-completers). The mean score of global withdrawal severity experienced was 15 ± 11, 
median = 11, range 0 to 50. Paired t-test comparing expected with experienced withdrawal 
severity for the 29 subjects with complete data indicates a significant reduction from a mean
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expected severity of 49 ± 25, to a mean experienced seventy of 15 ± 11 (t(28) = 6.45, p < 
0.001; 95% Cl difference of the mean = 24 to 46).
2.3.5 Adverse events
Subjects reported any side effects or ‘unusual experiences’ on a daily basis during their 
admission, shown below. Four subjects received no active buprenorphine and are excluded 
from this Table. The majority of subjects reported no adverse events, and there were no serious 
adverse events. Headache, constipation, flushes, dry mouth, and itchiness were all anticipated 
adverse events, which with the exception of constipation, were generally reported early in 
treatment and subsided within two or three days. One subject reported continued hot flushes 
into the sixth day of admission, which may have been withdrawal symptoms rather than 
buprenorphine effects. Other adverse events reported may also have been withdrawal features 
rather than side effects to the medication (e.g. stomach cramps, anxiety, fatigue). One subject 
reported a papular skin rash that emerged during the first few days of admission. This may have 
been related to a concurrent viral upper respiratory tract infection, which became clinically 
apparent during the course of the episode. The rash subsided with no treatment required.
Table 2.14. Adverse events
Adverse event Number of subjects reporting % of subjects (N=59)
Nil reported 36 61
Headache 13 22
Constipation 6 10
Stomach cramps 3 5
Fatigue, tiredness 3 5
Anxiety / restlessness 3 5
Hot flushes 2 3
Dizziness after initial dose 2 3
Dry mouth 2 3
Sublingual irritation 2 3
Itchiness 1 2
Skin rash 1 2
2.3.6 Measures of Subject Satisfaction
Satisfaction with buprenorphine was elicited in a number of ways. Subjects were asked to 
identify the ‘good things’ and ‘bad things’ about using buprenorphine in withdrawal. 
Responses were recorded and coded according to themes (Table 2.15).
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Table 2.15. Positive and negative experiences o f buprenorphine identified by subjects (n=20)
Positives or ‘good things’ % Negative or ‘bad things’ %
No or mild withdrawal discomfort 90% None identified when prompted 55%
No or reduced cravings 60% Side effects 35%
Clear headed / not drowsy 35 % Taste of tablets 5 %
No or reduced anxiety / mood 25% Rebound withdrawal after 5%
disturbances ceasing buprenorphine
Slept well 25%
Felt ‘normal’ 20%
Other 35%
Subjects were asked to rank the various medication regimes that they had previously used for 
withdrawal in descending order (1 = “best”). All but one subject had utilised other forms of 
medication during withdrawal from heroin, although few had previously attempted a 
naltrexone-assisted withdrawal or short-term methadone withdrawals.
Table 2.16. Ranking o f medication regimes for withdrawal (n=20)
Medication for withdrawal Mean Ranking 
(descending order)
Number of subjects 
experienced (n=20)
Buprenorphine 1 20
Naltrexone assisted 2 1
D-propoxyphene 2.8 8
Benzodiazepines 3 18
Other symptomatic 3.4 14
Codeine - paracetamol 3.5 10
Clonidine 4.8 5
Short term methadone 5 1
2.3.7 Variables impacting upon buprenorphine dose
As identified in the research objectives, the study aimed to examine the impact of a number of 
patient characteristics at intake upon the total dose of buprenorphine dispensed. Multiple 
regression analysis was conducted to examine the impact of the six baseline (independent) 
variables upon the total dose of buprenorphine titrated for each subject completing the dosing 
regime (dependent variable). The independent variables included in the analysis were described 
in Table 2.5, all continuous variables, with the exception of sex, which was dummy coded (0 
and 1).
A considerable proportion of the variance of buprenorphine dose was accounted for by the 
above 6 independent variables (R^ = 0.513), with significant variables being BASIS average 
score (F = 10.19, p < .005) (greater psychosocial dysfunction was associated with higher 
doses); sex (F = 10.19, p < 0.05) (women used higher doses than men); Q score for heroin use
Chapter 2: Inpatient Dose Titration Study 93
(F = 6.46, p < 0.05), and severity of heroin dependence (LDQ) (F= 6.26, p< 0.05). The other 
variables (expectancy of withdrawal severity, and body weight) were not significant predictors 
of buprenorphine dose. Using backward stepwise regression with removal of the least 
significant variables resulted in a marked reduction in R.2. -Similar findings were obtained 
using a forward selection stepwise regression of the 6 predicted variables. These findings are 
discussed in the section 4.4.
The finding that sex was significantly related to total buprenorphine dose warranted a closer 
examination of the doses administered to men and women. Women received a mean total dose 
of 22.4 ± 8.9 mg, significantly greater than the mean total dose for men of 14.9 ± 9.2 mg (t(30) 
= 2.22, p< 0.05, 95%CI = 0.6 to 14.4 mg).
2.4. Discussion
2.4.1 Summary of study findings
This was an exploratory study with two broad aims: to identify the dosing requirements of 
buprenorphine in the management of inpatient heroin withdrawal; and to identify the impact of 
patient characteristics upon buprenorphine dosing requirements. A number of conclusions can 
be drawn from the findings of the study. The similarity of doses across the two sites is 
encouraging from the perspective of generalising the findings to broader populations of heroin 
users attending inpatient services, rather than merely reflecting heroin users at a particular 
treatment site. Despite the wide range of doses available to subjects (up to 16 mg per day and 
total dose up to 72 mg), withdrawal severity was generally well contained on doses not greater 
than 10 mg per day. The mean total dose of buprenorphine used by subjects was 17.4 ± 9.7 mg, 
(median = 17 mg, range 4 to 40 mg), with 94% of subjects requiring a total dose of 30 mg or 
less. Higher daily doses were required during the first three days of the withdrawal: most 
subjects required doses between 2 and 6 mg on day one, 4 and 8 mg on day two, 2 and 8 mg on 
day three, and between 0 and 4 mg on day 4. Most subjects required buprenorphine for only 3 
or 4 days, making the dosing regime suitable for use in inpatient withdrawal episodes of brief 
duration.
Subjects generally described mild and tolerable withdrawal discomfort during the withdrawal 
episode, with daily mean SOWS scores greatest during the first two days (and generally less 
than 20), and mean peak SOWS scores of 33 ± 12. Most subjects (87%) rated the adequacy of 
their buprenorphine doses as being ‘about right’, and experienced significantly less severe 
withdrawal than they had expected. Qualitative responses by subjects commended
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buprenorphine’s ability to considerably reduce withdrawal discomfort, minimise cravings, 
enable sleep, and to achieve these outcomes without producing significant drowsiness or 
sedation, as is commonly associated with other withdrawal medications (e.g. benzodiazepines, 
clonidine). Negative aspects when prompted were generally limited to side effects. The side 
effects reported were in most cases anticipated, and their incidence was consistent with earlier 
experiences reported in large studies with buprenorphine (Ling, Charuvastra et al. 1998; Lange, 
Fudala et al. 1990).
There appeared to be only minimal rebound withdrawal upon the cessation of buprenorphine 
dosing for the majority of subjects. No subjects report their peak withdrawal score following 
the discontinuation of buprenorphine dosing. Although many subjects experienced a transient 
increase in withdrawal severity after their last buprenorphine dose, this was generally mild (< 
16 points on SOWS) and resolved within 48 to 72 hours after the last dose without the use of 
additional medications. The findings enhance the premise that there is minimal rebound 
withdrawal upon the discontinuation of short courses (several days) of buprenorphine in the 
management of heroin withdrawal. This is very encouraging for inpatient withdrawal services, 
where there is an increasing trend for admission lengths to be limited to between 6 and 8 days. 
The vast majority of heroin users in this study required doses for only 3 or 4 days, and 
experienced minimal rebound withdrawal in the 2 to 3 days after the last buprenorphine dose. 
Hence, buprenorphine w'ould be ideally suited to a 7-day inpatient withdrawal episode.
2.4.2 Comparisons with earlier inpatient research
These doses are consistent with the range of doses used in most previously reported studies of 
short buprenorphine regimes for inpatient heroin withdrawal. As identified in Chapter 1, 
Section 4.3, comparison of different buprenorphine dosing regimes is complicated by a degree 
of uncertainty regarding the relative bioavailability of various buprenorphine preparations. 
Adjusting for differences in the bioavailability of the tablet and solution preparations using a 
conversion factor of 1.4:1 (Ajir, Ling et al. 1998), the mean total dose in this study (17.4 ± 9.7 
mg) is approximately equivalent to 12.4 ± 6.9 mg of sublingual solution. The daily doses of 
between 2 and 10 mg (tablet) commonly used during the first three days in this study are 
comparable to approximately 1.5 to 8 mg of solution per day. Most subjects in the study 
received a total dose (tablet) of between 10 (25*h percentile) to 26 mg (75™ percentile), 
approximately equivalent to 7 to 19 mg of buprenorphine solution.
The doses used in this and other inpatient studies of short-term heroin withdrawal reported in 
the literature are compared in Table 2.17. Nigam, Ray et al. (1993) used lower doses in non­
injecting opiate users; whereas Umbricht, Montoya et al. (1999) used much higher doses prior
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to naltrexone induction. Similar doses to the ones identified in this study have been described 
by (Parran, Adelman et al. 1994; Cheskin, Fudala et al. 1994; Liu, Cai et al. 1997). Vignau 
(1998) is the only published short-term inpatient heroin withdrawal study using the Subutex® 
preparation. This study used very similar daily doses over the first 3 to 4 days o f the 
withdrawal; however gradually reduced the buprenorphine dose over a 10 to 12 day period, 
such that the total dose used in the withdrawal regime was considerably greater than in the 
current study.
Table 2.17 Comparison o f study dosing regimen with previous inpatient studies.
Study S/L
Preparation
Dosing regime Equivalent total dose 
in S/L tablets
Nigam et al 
1993
tablet Range of daily doses =  0.6 to 1.2 mg per day over 
10 days
10 mg
Liu et al 
1997
not specified 3 groups. Doses commenced at between 3 to 6 mg 
per day & titrated to 0 over 7 -8  days
~ 14 to 26 mg
Parran et al
1994 a
subcutaneous
injection
0.9 to 2.7 mg / day x 2 days, 0.45 to 1.35 mg / day 
x 2 days; 0.2 to 0.7 mg / day x 2 days
6.6 to 20 mg
Current
study
tablet D ay 1 mean = 3.8 mg (most subjects between 2 to 
8mg); day 2 mean = 5.8 mg (4 to lOrng); day 3 
mean = 4.8 m g (2 to 8mg); day 4 = 2.3 m g (0 to 4 
mg); day 5 = 0.8 (0 to 2 mg).
mean = 17.4 mg  
(25*h percen tile= 10 
mg; 7 5 ^  percentile  
=  26 mg)
Cheskin et 
al 1994
solution Day 1 =  8 mg, day 2 = 6 mg; day 3 = 3  mg. Total 
dose =17 mg
~  24 mg
Vignau
1998
tablet Doses titrated daily. Day 1 mean =  6.1 mg (range 
4.4 to 9.0); day 2 mean =  6.4 mg (range 5 to 9); 
day 3 mean =  5.5 mg (range 4 to 7.6); then 
progressively reducing to zero mg by day 12.
Total mean ~  35 mg 
(data presented 
graphically)
Umbricht et 
al 1999
solution Day 1 = 12 mg; day 2 =  8 mg; day 3 = 4  mg; day 4 
=  2 mg. Total dose = 26 mg
~ 36 mg
“subcutaneous injection has a bioavailability of approximately .1.5 times greater than sublingual solution
(Jasinski, Fudala et al. 1989).
2.4.3 Use of low dose sublingual tablets
The majority o f completers (88%) required doses greater than 4 mg. This effectively 
disqualifies the use of analgesic preparations of low dose buprenorphine sublingual tablets (e.g. 
0.2 mg tablets registered in Australia as Temgesic®) as an effective stand-alone withdrawal 
medication for the majority o f heroin users. Perhaps the use o f low dose buprenorphine (e.g.
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0.4 mg Subutex® tablets) may be appropriate in the context of a pharmacotherapy regime 
including symptomatic medication for heroin withdrawal (e.g. benzodiazepines, clonidine); 
however the use of 2 mg buprenorphine tablets should be generally preferred to achieve the 
doses required.
2.4.4 Factors impacting upon doses
The range of buprenorphine doses used in this study highlights the considerable variation 
between heroin users as to their experience of withdrawal and their medication requirements. 
The patient variable at intake most strongly predictive of total buprenorphine dose 
requirements was global psychological functioning (as measured by the BASIS-32) (F = 10.19, 
p < 0.005). Although this analysis was conducted examining dose requirements rather than 
withdrawal severity, the symptom-triggered dosing design would suggest that the same factors 
which contribute to withdrawal severity should also contribute to amount of medication used. 
In this regard, the finding is consistent with previous research linking withdrawal severity to 
psychological profile.
There was also a significant trend for women to have higher total buprenorphine doses (F = 
10.19, p < 0.005). This finding may genuinely reflect higher buprenorphine requirements in 
women. Research with buprenorphine as an analgesic indicates that sex does not affect plasma 
concentrations, although in one study, women required less buprenorphine than men for post­
operative analgesia (McQuay, Bullingham et al. 1980). Research in the addiction field has 
yielded contradictory findings with regards to treatment outcome, with women reporting more 
heroin use than men in one maintenance study (Schottenfeld, Pakes et al. 1998), but less heroin 
use than men in another (Johnson, Eissenberg et al. 1995). Alternatively, the gender difference 
may reflect a common observation that women routinely report more psychological symptoms 
than men (Kroenke and Spitzer 1998; van Wijk and Kolk 1997) and may have had a tendency 
to score themselves higher on the Subjective Opiate Withdrawal Scale, thereby receiving 
higher buprenorphine doses as part of the symptom-triggered titration regime employed in this 
study.
There was also a significant association (F = 6.46, p < 0.05) for frequency of recent heroin use 
(OTI Q score) and total buprenorphine dose; and severity of heroin dependence (LDQ) 
(F=6.26, p<0.05). This former finding is consistent with earlier work demonstrating a 
significant association between amount of heroin consumption and withdrawal severity 
(Andrews and Himmelsbach 1944; Smolka and Schmidt 1999).
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2.4.5 Study limitations
There are a number of study limitations that are worth noting. The first relates to the extent that 
we can generalise from the findings of this study. The study was conducted on a selected 
sample of heroin dependent individuals seeking treatment at inpatient withdrawal units in 
Melbourne and Canberra. Almost half of all patients (47%) admitted to Depaul House during 
the conduct of the study were ineligible to participate, generally for medical or psychiatric 
(17%), and / or dependence to multiple substances (16%) that would have considerably altered 
the experience of withdrawal. The impact of such factors upon the dosing requirements of 
buprenorphine requires further investigation. However, it is possible to postulate that the mild 
withdrawal syndrome experienced with buprenorphine would be favourable for those patients 
with concomitant medical and psychiatric conditions, or those withdrawing from multiple 
substances, and buprenorphine has previously been successfully used in such populations 
(Parran et al 1990).
The extent to which subjects remained blinded to the titration dosing regime and their 
individual doses was not systematically examined. Nevertheless, the general impression gained 
by the principal investigator (NL) on asking subjects at the Melbourne site at the end of their 
participation in the study was that although subjects could identify occasions when they had 
been dosed with only placebo tablets, in general most subjects were unable to accurately 
identify the dose of buprenorphine they had received, nor the time oflast active buprenorphine 
dosing. To this extent, the single blind design achieved its aim.
A potential limitation of this study was the use of a previously undocumented and untested 
titration regime. The advantages of using a symptom-triggered titration technique were 
discussed previously, most notably the capacity to individualise doses according to each 
subject’s needs. Nevertheless, there is the possibility that the study regime was inadequate to 
accommodate a number of subjects who dropped out of treatment prior to the completion of 
their dosing regime. Most non-completers described mild withdrawal discomfort at the time of 
discharge, however 12 subjects (39% of treatment drop-outs and 19% of the entire sample) 
reported their final SOWS score prior to discharge at 20 points or more, and it is possible that a 
proportion of these subjects did not complete their withdrawal episode due to inadequate relief 
of withdrawal symptoms. At the Canberra site, 20% (n=3) of treatment drop-outs who were 
followed up after discharge indicated that withdrawal discomfort were their main reason for 
prematurely discharging themselves from the unit. In real clinical practice, the capacity for 
additional buprenorphine doses may have altered the outcome for these subjects, however the 
structured titration regime used for the research was less accommodating.
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Nevertheless, factors other than withdrawal severity or adequacy of buprenorphine doses were 
most likely responsible for many of the cases of treatment drop-out. This is suggested by a 
number of reasons - firstly, completers and non-completers reported similar scores for 
withdrawal severity. Non-completers at the Canberra site generally cited reasons other than 
withdrawal severity for leaving the residential unit prematurely, and retention at the Canberra 
site improved markedly towards the end of the study, after there had been a concerted effort by 
staff to retain subjects until day 6, but with no change in dosing procedures. The differential 
drop-out rate for the two units is also suggestive that contextual factors within the treatment 
units impacted considerably upon treatment retention. For example, gender sensitivity within 
units may impact upon treatment retention: a very low proportion of women (42%) completed 
the regime in Melbourne (compared to 80% of men completing), whereas women had a much 
higher rate of completion (71%) at the Canberra site (compared to 25% of men completing). 
These factors are not directly attributable to inadequate doses of buprenorphine, and emphasise 
that outcomes for withdrawal are not confined to issues of pharmacotherapy.
Finally, whilst this shady has identified a range of buprenorphine doses which were generally 
successful in managing inpatient heroin withdrawal in this sample of heroin users, double- 
blinded randomised dose efficacy studies are required in order to compare the efficacy of the 
doses described in this study to regimes employing lower or higher buprenorphine doses. In 
clinical practice, individual titration of doses is likely to lead to enhanced treatment outcomes 
for each patient, and the findings of this study provides a basis for the development of 
guidelines to assist clinical decision making.
2.4.6 Conclusion
In conclusion, this study examined dosing requirements for the management of heroin 
withdrawal in inpatient settings using a symptom-triggered dose titration regime. Most subjects 
required a total amount of buprenorphine of between 10 and 26 mg over the course of 
treatment. Daily doses in the range of 2 to 6 mg on day 1, 4 to 8 mg on days 2 and 3, and 2 to 4 
mg on day 4 were generally sufficient to prevent or alleviate moderate to severe withdrawal 
discomfort, with minimal side effects, minimal rebound withdrawal upon the cessation of 
buprenorphine, and without the need for routine use of other symptomatic medication. Subjects 
expressed high levels of satisfaction with the adequacy of their buprenorphine doses, and with 
buprenorphine as a medication for heroin withdrawal. The range of doses used in this study is 
consistent with research suggesting that daily doses of 4 mg or more are generally required to 
comfortably alleviate heroin withdrawal, and is comparable to dosing regimes described in 
most previous inpatient withdrawal studies. Factors predictive of the total buprenorphine dose
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for each subject were global psychological distress at intake, frequency of heroin use at intake 
and sex (with women requiring higher doses - although this last factor may be an artefact of the 
symptom-triggered titration regime employed).
The development of the relevant section in the National Clinical Guidelines (Lintzeris, Clark et 
al. 2001) regarding the use of buprenorphine in the management of heroin withdrawal in 
inpatient settings has drawn upon findings of this study, together with the review of the 
relevant literature in Chapter 1. The development of these guidelines is discussed in Chapter 5, 
and the guidelines are included as Appendix 3.
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Chapter 3: Outpatient dose titration study
3.1. Study objectives and research questions
The primary objective of this study was to identify the range of doses of buprenorphine 
required by heroin users to safely and comfortably complete heroin withdrawal in an outpatient 
treatment setting, from which a suitable dosing regime could be developed. Specifically, the 
primary research question for the study is: what doses o f buprenorphine are required to achieve 
a safe and comfortable withdrawal from heroin in an outpatient setting?
This was an exploratory study, representing the first time buprenorphine was used for this 
purpose in an Australian treatment setting, the first description of a short outpatient withdrawal 
regime using the commercially available Subutex® tablet preparation; and among the first 
international descriptions of a short outpatient buprenorphine withdrawal regime (Table 1. 7). 
Consequently, other secondary research questions related to gaining general experience from 
using buprenorphine for this purpose, specifically:
• What is the pattern and severity of withdrawal experienced by subjects? In particular, to 
what extent does buprenorphine relieve opiate withdrawal discomfort, and do subjects report 
a clinically significant increase (rebound) in withdrawal features on ceasing buprenorphine?
• What are the other short-term outcomes of withdrawal treatment - in particular, what are the 
withdrawal treatment retention rates; levels of heroin and other drug use during the 
treatment episode; and safety issues (adverse events and effects of additional heroin use)?
• What are the patient perspectives and levels of satisfaction with the medication?
Although the findings of the inpatient titration study provide some insights as to suitable 
outpatient dosing regimes, there are a number of significant differences in the delivery and 
context of treatment that may impact upon the dosing requirements for outpatient settings. 
Inpatient services can generally provide more intensive supportive care, whilst environmental 
triggers may increase cravings in outpatient settings. The general limitation of once-a-day 
supervised dosing for outpatients may also necessitate higher single doses than multiple 
inpatient doses. From these factors, it was hypothesized that outpatient dosing requirements 
may be higher than used in the inpatient setting.
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3.2 Trial design and methodology
3.2.1 Overview of trial design and procedures
This was an open label, multiple case series of 18 heroin dependent subjects undergoing 
outpatient withdrawal, with no comparison group. The study employed a dose titration design, 
with buprenorphine doses (2 mg sublingual Subutex® tablets) titrated on a daily basis. The 
relative advantages and disadvantages of a study design employing dose titration compared to 
randomised fixed doses were discussed in Chapter 2.2.3. As identified in Chapter 1.1.3, 
treatment objectives for outpatient withdrawal management upon which doses were titrated 
were: (a) the comfortable alleviation of withdrawal discomfort, (b) the cessation or reduction of 
heroin and other drug use, (c) the minimisation of adverse events or other complications during 
the withdrawal episode, and (d) patient satisfaction. Systematic examination of post-withdrawal 
outcomes was beyond the scope of this dose-ranging study.
Subjects were reviewed daily during the 8 day withdrawal episode, with regular monitoring of 
withdrawal features, drug use, adverse events and subject perceptions regarding dose adequacy. 
Buprenorphine was available for the first 5 days of the withdrawal episode under conditions of 
supervised dispensing. Standard supportive counselling was provided during the treatment 
episode. Other medications for withdrawal were not routinely used. Subjects underwent 
research interviews at induction and on discharge from the study.
3.2.2 Subjects and recruitment
Subjects were recruited from patients seeking outpatient heroin withdrawal at the Clinical 
Services Department of Turning Point Alcohol and Drug Centre in Melbourne, over a four 
month period in 1998. The number of subjects required for the trial was estimated as the 
number at which trends regarding suitable doses would emerge. This was estimated by a 
number of senior and experienced medical practitioners as between 15 to 20 ‘completers’ (i.e., 
not including treatment drop outs).
Recruitment to the trial was voluntary, with informed consent, and there was no active 
promotion or advertisement for the study. The study aimed to recruit dependent injecting 
heroin users with no concomitant medical or psychiatric condition, not dependent on or 
withdrawing from alcohol or benzodiazepines, and with no recent methadone treatment. The 
specific selection criteria (and their rationale) were the same as for the inpatient titration study 
(see Table 2.1, Chapter 2 for description), with one addition: that subjects had some form of
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stable (but not necessarily drug free) accommodation - homeless patients were not considered 
appropriate for outpatient withdrawal (see Section 1.2.2), and were referred to inpatient 
services.
Thirty-four consecutive heroin users seeking outpatient heroin withdrawal were clinically 
screened for the study, with 28 (82%) assessed as eligible. Six patients (18% of those screened) 
were ineligible for the study for the following reasons: under 18 years of age (n=l); concurrent 
chronic pain disorder (1); active psychiatric disorder (1); concurrent benzodiazepine 
dependence (2), and one patient had an unstable social environment and was referred to 
inpatient treatment. A further ten patients (29% of those screened) were assessed as eligible but 
chose not to participate in the study, opting for conventional outpatient withdrawal services at 
the clinic (seven chose a short methadone reduction over 10 to 21 days, and three chose 
symptomatic medication). Eighteen subjects were recruited to the study, representing 53% of 
the patients screened.
3.2.3 Treatment procedures
The principal parameters of a buprenorphine withdrawal regimen, such as dose and duration of 
treatment, were discussed in detail in Section 1.4.3. In summary, this study examined short­
term withdrawal episodes (consistent with conventional Australian withdrawal services) using 
buprenorphine doses within the range of 4 to 16 mg daily for four days (corresponding to the 
period of peak heroin withdrawal severity), followed by a dose reduction on day 5, prior to its 
abrupt cessation.
Careful consideration had to be given to the procedures for induction into treatment with an 
opioid medication, in order to minimise the risks of side effects, opioid toxicity in patients with 
low tolerance, and in the case of buprenorphine, to avoid precipitating withdrawal following 
the initiation of treatment (see Section 1.4.1). Various outpatient induction regimes have been 
described in the buprenorphine clinical literature, with doses in the range of 4 to 8 mg 
(sublingual tablets) having been reported as safe in heroin dependent individuals, and are 
recommended for clinical use (Bickel and Amass 1995;'Ling 1999; Ling 1999). Importantly, 
the first dose of buprenorphine should not be administered whilst the patient is experiencing the 
effects of heroin use, and ideally should be delayed until the early stages of heroin withdrawal. 
This can be difficult to coordinate in outpatient clinical practice, but as a rule, the first dose of 
buprenorphine was delayed (or reduced) if the subject reported using heroin within the 
preceding 6 hours, or if the patient had no features of opiate withdrawal.
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The maximum buprenorphine dose available on day 1 was 8 mg, and 16 mg on days 2, 3 and 4. 
Subjects could return to the clinic on days 1 to 3 for an additional buprenorphine dose (if 
considered clinically appropriate by the reviewing medical officer). Only one dose was 
available on days 4 and 5. The day 5 dose was pre-determined as up to half of the dose 
administered on day 4. Buprenorphine doses were titrated on a daily basis by the study medical 
officers (Drs Lmtzeris and Dunlop) according to the following factors:
(i) severity o f withdrawal discomfort in preceding 24 hours: withdrawal features were 
monitored at each review (prior to dosing) using the Subjective and Objective Opiate 
Withdrawal Scales, and questions regarding sleep (not examined in the SOWS);
(ii) use o f heroin or other drugs: daily self-report of heroin and other drug use since last 
review, including subject’s stated reasons for use (for example, to relieve withdrawal, for 
intoxication, situational factors, routine). Urine drug screens were also conducted on days 
1, 5 and 7 or 8);
(iii) adverse events during the withdrawal episode’, subjects were asked to describe any side 
effects or atypical occurrences daily, and these were assessed by the study doctor;
(iv) subject perception o f dose adequacy. Subjects rated the adequacy of the previous day’s 
buprenorphine dose using a five point Likert scale (with the options of 1 = “much too low”; 
2 = “too low”; 3 = “about right”; 4 = “too high”; 5 = “much too high”).
The titration dosing schedule is shown in Table 3.1. A clinical example will help demonstrate 
the principles used in the titration of doses. The first four subjects were dosed with 4mg on the 
first day. All four subjects reported experiencing withdrawal symptoms later in the evening or 
by the following morning, and all four reported using heroin prior to their day 2 dose -  
suggesting that 4 mg had been an inadequate dose. This led to a change in prescribing practice 
whereby subjects were dosed either 6mg buprenorphine as their first dose; or else were dosed 4 
mg buprenorphine and asked to present to the clinic 3 to 4 hours later for a second dose of 2 or 
4 mg. Hence, the remaining 14 subjects received a total of 6 or 8 mg buprenorphine on the first 
day. A considerable proportion (up to 28%) of subjects reported side effects to buprenorphine 
during the first day of drowsiness, dizziness or sedation. The incidence of these side effects led 
to caution by the medical officers in prescribing 8 mg buprenorphine as a single dose on the 
first day, as there was no way of predicting which subjects were to experience these side 
effects.
The 2 mg sublingual tablet preparation of buprenorphine (Subutex®) was used, with all doses 
dispensed from the clinic pharmacy under supervision. All subjects received routine case
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management, supportive counselling, and written patient information as per standard practice at 
the clinic (Lintzeris, Dunlop et al. 1996). No other medications were routinely used.
Table 3.1. Buprenorphine outpatient titration dosing schedule
D ay o f  
program
First dose o f  buprenorphine 
(generally 9am to 12 noon)
A dditional dose o f  
buprenorphine >  
3hrs after first dose
Total
Possible
D ose
1 4m g or 6mg 2 or 4m g 4 to 8m g
2 Severe side effects =  Day 1 dose - 2 to 4m g  
N o heroin use, withdrawal or cravings = Maintain day 1 dose  
U ncom fortable withdrawal /  cravings = Day 1 dose +  2 to 4  m g
2 or 4m g 0 to 16mg
3 Severe side effects =  Day 2 dose - 2 to 4m g  
N o heroin use, withdrawal or cravings = Maintain day 2 dose  
U ncom fortable withdrawal / cravings = Day 2 dose +  2 to 4 m g
2 or 4m g
(to 16 m g m ax /day)
0 to lö m g
4 Severe side effects =  Day 3 dose - 2 to 4m g  
N o heroin use, withdrawal or cravings = Maintain day 3 dose  
U ncom fortable withdrawal /  cravings = Day 3 dose +  2 to 4 m g
0 to lö m g
5 Up to half o f  Day 4 dose - 0 to 8m g
6 to 8 N o  d ose - -
3.2.4 Data collection
In addition to the regular clinical monitoring of withdrawal severity, heroin use, adverse events 
and subject perception of dose adequacy (described in previous section), subjects underwent 
confidential research interviews on entry to the study (day 1) and on discharge (generally day 
8). At intake, data was collected regarding demographic characteristics, frequency of heroin 
and other drug use in the preceding month using the Drug Section of the Opiate Treatment 
Index (Darke, Hall et al. 1992); severity of dependence on heroin in the preceding week using 
the Leeds Dependence Questionnaire (Raistrick, Bradshaw et al. 1994); and expected severity 
of withdrawal using a (0 -  100) Visual Analogue Scale (as described in Table 2.5). Data 
collected at the discharge research interview was similar to procedures used in the Inpatient 
Titration Study, including measures of severity of heroin dependence (Leeds Dependence 
Questionnaire), severity of withdrawal symptoms experienced (0 - 100 Visual Analogue Scale); 
and measures of patient satisfaction with the medication and their dosing regime (including 
rankings of different withdrawal medications, semi-structured ‘good’ and ‘bad’ aspects 
associated with buprenorphine, and a global rating of adequacy of their buprenorphine dosing 
regime using a 5 point Likert scale (“much too low”; “too low”; “about right”; “too high”; 
“much too high”).
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3.3 Results
3.3.1 Subject characteristics at intake
Eighteen injecting heroin users were recruited to the study. Ten subjects (56%) were male, 89% 
were Caucasian, average age was 25.3 years (range 21 to 37, SD = 4.5), 50% were currently 
employed (either part or full time), and 78% were in receipt of some social security benefits. 
The mean duration of opioid dependence was 3.9 ± 4.6 years (median = 2.6, range < 1 to 19 
years), with a mean Leeds Dependence Questionnaire score of 23.2 ±3.9 (range 17 to 30 out of 
maximum possible score of 30) representing moderate to severe dependence (Raistrick, 
Bradshaw et al. 1994). The mean heroin OTI Q score was 2.9 ± 1.1 (range 1.5 to 4.5), which 
can be interpreted as subjects having injected heroin on average 2.9 times a day in the 
preceding month. 17 of the 18 subjects had had previous attempts at outpatient heroin 
withdrawal.
3.3.2 Treatment retention rates
Fifteen of the 18 subjects (83%) completed the 5-day buprenorphine dosing regime. Two 
subjects (a couple) failed to attend after the third day, and one subject terminated 
buprenorphine treatment on day 2, transferring to a methadone maintenance program. Of the 15 
subjects completing the 5-day dosing regime, one subject did not attend any further clinical or 
research appointments. Hence, 14 subjects (78%) completed at least 8 days of clinical follow­
up and completed the research interview at discharge.
3.3.3 Buprenorphine doses
Summary data regarding the doses of buprenorphine dispensed to the 15 subjects completing 
the dosing schedule are shown in Table 3.2. Doses dispensed for the three non-completers were 
within the same ranges on any given day.
Table 3.2. Mean, standard deviation and range o f daily buprenorphine doses (mg) dispensed.
Day 1 Day 2 Day 3 Day 4 Day 5 Total
Mean 6.1 9.6 10.1 8.9 4.1 38.9
St Dev 1.2 1.7 1.9 2.0 1.5 5.8
Range 4 -8 8- 14 8-14 6-  12 0 - 6 29 - 4 7
Chapter 3: Outpatient Dose Titration Study 106
Levels of subject satisfaction with dosing regime
11 of the 14 subjects (79%) completing this interview rated the adequacy of their 
buprenorphine doses at discharge interview as “about right”. The other three subjects (21%) 
rated their doses as “too low”. On closer examination of these three cases, their total 
buprenorphine doses were above the 50th percentile for total dose (39mg, 45 mg, and 46 mg); 
and their peak SOWS scores were indicative of mild withdrawal severity (18, 20 and 15), and 
were below the mean peak SOWS (20.7 ± 11.3) reported by the other 11 subjects completing 
the research interview. This highlights the diversity of patient expectations regarding the role of 
medications in withdrawal.
3.3.4 Drug use during the withdrawal episode
In total, 13 of a possible 36 urine drug tests over the withdrawal episode were negative for 
opiates (36%). Four subjects (22% of total sample) provided opiate negative urine results 
throughout the episode. Nine subjects had a negative urine drug screen for opiates at day 5 
(50% of total sample, 60% of those in treatment); 5 subjects had positive results, 3 were no 
longer attending, and results were ‘missing’ for one subject. Urine tests for opiates at day 7 or 8 
revealed 4 subjects had negative results (22% of total sample, 29% of those in treatment); 6 
subjects had positive results, 4 were no longer attending, and results were ‘missing’ for 4 
subjects.
Self reported heroin use during the 8-day withdrawal episode is shown in Table 3.3. Self-report 
data was generally consistent with results from urine drug screens.
Table 3.3. Levels o f heroin use reported by subjects during 8 day withdrawal period (n=18)
Number days used heroin during 8 day episode Number of subjects (% of total sample)
0 days 5(28)
1 day 5(28)
2 days 2(11)
3 or more days 3(17)
Subjects did not complete 3(17)
Subjects were asked by clinicians to describe the circumstances surrounding, and the reasons 
for any heroin use during the withdrawal episode. Several subjects reported heroin use in 
response to withdrawal discomfort prior to their day-2 dose (particularly early in the study 
when 4 mg doses were being used on day 1). Otherwise, all but one subject reported that their 
use of heroin was volitional (e.g. for intoxication, or wanting to recommence heroin use
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following several days of not using) or situational (e.g. partners or friends using around them), 
rather than to relieve severe withdrawal discomfort. Those subjects who used heroin during the 
dosing period all reported that buprenorphine considerably reduced the effects of heroin, 
serving as a barrier to further heroin use. There appeared to be no clear relationship between 
the use of heroin and dose of buprenorphine dispensed. The mean total dose for those subjects 
not using heroin (39.8 mg) was comparable to those using heroin on one or more occasions 
during the withdrawal episode (38.3 mg).
3.3.5 Withdrawal severity
Subjects generally reported minimal withdrawal discomfort throughout the withdrawal episode. 
The interpretation of withdrawal scores is difficult for those individuals who used heroin 
regularly, and consequently, Table 3.4 shows data regarding withdrawal severity for those 
subjects (n=13) reporting no or minimal heroin use (5 self-reported nil use and 5 reported using 
once over 8 days; one subject reported no heroin use prior to ‘dropping out’ after day 5; and 
two subjects used heroin on days 2 and 8 but completed the withdrawal scales on day 8 prior to 
their heroin use that day). Data for the remaining 5 subjects is omitted here, either due to 
missing data (n=3) and/or due to more regular heroin use (n=2).
Table 3.4. Subjective Opiate Withdrawal Scale scores during 8 day episode
Day 1 
(n—13)
Day 2 
(n—13)
Day 3 
(n—13)
Day 4 
(n-13)
Day 5 
(n=12)
Day 6 
(n—12)
Day 7 
(n=12)
Day 8 
(n=l 1)
Mean 15.5 14.4 7.8 7.5 7.3 9.5 9.8 9.6
St Dev 13.5 7.4 5.5 6.1 4.0 6.3 7.4 6.2
Median 11 15 7 8 7 9.5 7.5 10
Range 2-40 3-27 2-22 0-23 1 - 14 0-21 1 -26 0-21
The peak withdrawal severity was generally experienced as mild (mean peak SOWS score = 
20.2 ± 9.7), occurring during the first two days, with subsequent resolution of symptoms. There 
was minimal rebound withdrawal experienced: withdrawal scores generally remained low 
following the cessation of buprenorphine. Two subjects (out of 14 subjects for whom data was 
available till day 8, or 14%) reported peak withdrawal scores after day 5, although in both 
instances the peak SOWS scores were low (15 and 6). Six subjects (43% of subjects with data) 
described some mild and transient increase in withdrawal discomfort at some time during days 
6 to 8 compared to scores on days 3 to 5. Only one of the 9 subjects who recommenced heroin
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use after the cessation of buprenorphine stated that severity of withdrawal symptoms was the 
main factor in their relapse to heroin use.
Subjects rated the severity of withdrawal discomfort they expected to experience during this 
withdrawal episode at intake, and rated the severity of withdrawal discomfort that they had 
experienced on discharge, using a 100 mm Visual Analogue Scale (0 = no discomfort, and 100 
= most severe discomfort experienced). The mean expected withdrawal severity at intake 
(n=18) was 31 ± 17, whilst the mean experienced withdrawal severity (n=14) was 16 ± 12. A 
paired t-test indicated that subjects’ experience of discomfort was significantly less (p<0.05) 
than they had expected at the outset of the withdrawal (t(13) = 2.29, 95% Cl = -2 to -26).
3.3.6 Adverse events
Adverse events were recorded on a daily basis, with 16 of the 18 subjects (89%) reporting some 
adverse events, although it was not always easy to differentiate between buprenorphine side 
effects and withdrawal symptoms. All adverse events were anticipated, mild, and generally 
resolved within several days of buprenorphine treatment. The most common adverse events 
reported were headache (50% of all subjects), sedation (28%), nausea, constipation and anxiety 
(21% each), dizziness and ‘itching’ (17% each).
The most commonly reported adverse event was headache. The headaches were frequently 
described as constant, frontal headaches, usually commencing within one or two hours of a 
buprenorphine dose and reducing in severity by the following morning (before the next dose). 
Tolerance to headaches usually occurred within one or two days, with only 2 of the 9 subjects 
describing headaches continuing beyond the fourth day of buprenorphine treatment. Headache 
has been reported previously as a common adverse event with buprenorphine (for example, 
31% of subjects in a large, multicentre open label study of buprenorphine maintenance 
treatment (Ling, Charuvastra et al. 1998).
Sedation (28%) and dizziness (17%) were also commonly reported. Four of the five subjects 
reporting sedation did so in the first two days of treatment with buprenorphine, with sedation 
resolving by the third day, suggesting tolerance to this effect was rapidly established. 
‘Dizziness’ included various sensations such as impaired balance or difficulties judging 
distances. Again these were described as mild and transient.
3.3.7 Measures of patient satisfaction
Overall there were very high levels of patient satisfaction with buprenorphine as a withdrawal 
agent. Subjects ranked different medications for heroin withdrawal using a card sorting
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technique from ‘best’ (ranked as 1) to ‘worst’ at the discharge interview. Buprenorphine was 
considered the ‘best’ medication by 13 of the 14 respondents (mean ranking of 1.1); followed 
by a variety of opioid agonists, and then symptomatic medication regimes (see Table 3.5).
Subjects were asked to identify ‘good things’ and ‘bad things’ associated with the use of 
buprenorphine. Responses were open ended and written down by the research assistant for 
subsequent content analysis by the principal investigator (NL). The five most common positive 
responses were: (a) no, minimal or mild withdrawal symptoms experienced (79% of subjects); 
(b) felt ‘normal’ and could function in daily activities (57%); (c) reduced or no cravings for 
heroin use (36%); (d) blocks the effects of heroin use (36%); and (e) psychologically 
comfortable during withdrawal (29%). The most common negative aspects reported when 
prompted were (a) side effects (57% of subjects); inconvenience of daily dosing (7%); current 
dosing period too short (7%); and sleep disturbance (7%).
Table 3.5. Ranking of medications for the management o f heroin withdrawal (n=14)
Medication Ranking
(mean)
No. subjects 
experienced
Buprenorphine 1.1 14
d-propoxyphene preparation (Doloxene®) 2.7 10
Codeine (30mg) - paracetamol (500mg) (Panadeine forte®) 2.9 11
Short term methadone reduction 3.0 1
Benzodiazepines 3.2 13
Other symptomatic (eg NSAIDs, antiemetics) 4.1 8
Clonidine 5 2
3.3.8 Post withdrawal outcomes
The severity of dependence to heroin in the preceding week was assessed at intake and again on 
discharge using the Leeds Dependence Questionnaire (LDQ). The mean LDQ score at intake 
(n=18) was 23.2 ± 3.9. The mean LDQ score at discharge (n=14) was 9.0 ± 7.2. This represents 
a significant reduction (p<0.001) in scores for heroin dependence over the course of the 
withdrawal episode (t (13) = 8.72, 95% Cl = -11.2 to -17.9), although data for treatment non­
completers is not available for this analysis, as none completed the discharge interview.
Although follow up of subjects after the withdrawal episode was not systematic, data regarding 
subsequent outcomes and treatment uptake was available for 16 of the 18 subjects (collected 
either by the subjects remaining in contact with Turning Point, or through contact with 
acquaintances). One subject had discontinued their withdrawal episode during the study and 
transferred to a short-term methadone reduction regime, which in turn became a longer-term 
methadone maintenance program. Two subjects (11%) entered naltrexone treatment
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immediately following the completion of their buprenorphine withdrawal episode, but later 
ceased naltrexone and relapsed to heroin use within several weeks.
The most common outcome (n=13, 72%) was that subjects resumed regular heroin use soon 
after (within weeks of) the completion of the withdrawal episode. Eight of these subjects 
(44%) returned for further treatment at Turning Point within one month (five commenced 
methadone maintenance programs, and three subjects completed at least one further episode 
of outpatient withdrawal). Five subjects (28%) resumed heroin use soon after the study 
episode but it is unclear as to whether they entered treatment elsewhere.
3.4 Discussion
This was an exploratory study with two primary (and related) aims. Firstly, to examine the 
range of buprenorphine doses required for a comfortable withdrawal episode in an outpatient 
setting, with minimal heroin use or adverse events. The second broad aim was to gain 
experience with the use of buprenorphine for outpatient heroin withdrawal, exploring its 
impact upon commonly identified withdrawal outcomes such as the severity and profile of 
withdrawal symptoms (including the occurrence of rebound phenomena), heroin use and 
cravings, adverse events, completion rates, and patient perceptions regarding its use.
3.4.1 Outpatient buprenorphine dosing regime
The variation in the doses used by different subjects was not major, and a number of trends 
emerged during the study. The total buprenorphine dose dispensed on day 1 was usually 6 or 
8 mg. The first four subjects each received 4 mg on day 1 and reported inadequate relief of 
withdrawal symptoms and cravings over a 24-hour period. Doses higher than 8 mg were not 
available as part of the study protocol; however, I would caution against the use of higher 
initial doses in an outpatient setting due to the emergence of adverse events (such as sedation 
and dizziness) in over a quarter of subjects; and the risk of precipitated withdrawal associated 
with higher initial buprenorphine doses (Lintzeris, Clark et al. 2001).
Higher doses were generally used during the following 3 days. Most subjects received daily 
doses of between 8 and 12 mg per day during days 2 (94%), 3 (94%), and 4 (80%). Despite 
the reduction in dose on day 5, most subjects did not report any significant increase in 
withdrawal discomfort the following day. This is likely due to the slow dissociation of 
buprenorphine from opiate receptors, such that subjects continued to feel the effects of the 
higher doses administered on previous days.
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The majority of subjects (79%) reported at the completion of their episode that their doses of 
buprenorphine had been ‘about right’. The three subjects who reported that their doses had 
been ‘too low’ did not experience severe withdrawal symptoms and received higher than 
average doses of buprenorphine - suggesting the diversity of patient expectations as to the role 
of medication in withdrawal.
Although the titration dose ranging study design was considered most suited to the exploratory 
nature of this research, dose titration studies do not provide information regarding the efficacy 
of different dosing regimes. Ultimately, blinded randomised controlled trials, in which subjects 
are assigned to different buprenorphine doses (with comparison of between groups outcomes) 
are required in order to identify optimal dosing regimens. Nevertheless, when compared against 
a variety of outcome and process measures considered important for withdrawal services (as 
developed in Section 1.1.3), the findings of this study are generally satisfactory: few subjects 
reported using heroin to alleviate withdrawal discomfort; most individuals experienced 
minimal withdrawal discomfort over the course of their withdrawal episode; adverse events 
were mild and well tolerated; most subjects completed the withdrawal regime; and there were 
high levels of patient satisfaction. These findings would suggest that the range of 
buprenorphine doses used in this study are generally satisfactory, and it is possible to 
recommend a buprenorphine dosing regime for outpatient heroin withdrawal. The following 5- 
day regime is proposed.
Table 3.6. Recommended buprenorphine dosing regime for outpatient heroin withdrawal
Day of withdrawal regime Recommended dose of buprenorphine 
(sublingual tablets)
Day 1 6 mg
Day 2 8 to 10 mg
Day 3 8 to 12 mg
Day 4 6 to 10 mg
Day 5 4 mg
Total dose 32 to 42 mg
It must be emphasised that a certain degree of flexibility in withdrawal dosing regimes should 
be available for patients and clinicians to account for a variety of factors, such as individual 
variations in the effects and metabolism of buprenorphine, side effects to the medication, 
severity of underlying withdrawal syndrome, psychological factors (e.g. underlying anxiety 
conditions) and use of other drugs during the withdrawal episode. The previous Inpatient 
Titration Study identified that psychological state, gender, frequency of heroin use and severity
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of dependence at intake, significantly impact upon buprenorphine requirements during inpatient 
withdrawal, and similar factors may apply in outpatient settings. Furthermore, this regimen 
may not be suitable for heroin users with concomitant medical or psychiatric conditions, recent 
methadone treatment, or individuals undergoing withdrawal from multiple drugs, conditions 
that were excluded from the study.
How does the proposed dosing regime arising from this study compare with previous research? 
The buprenorphine doses used in the outpatient setting were considerably higher than the doses 
used for the management of inpatient withdrawal reported in Chapter 2 (Table 2.9). The two 
studies had almost identical selection criteria, recruited heroin users with similar demographic 
characteristics, levels of heroin use, severity and duration of dependence at intake; and had 
similar parameters regarding buprenorphine regimes available (up to 16 mg Subutex® per day 
for up to 5 days); enabling a valid comparison between the two studies. The mean daily and 
total doses used in the two studies are shown in the Table 3.7.
Table 3.1: Comparison o f buprenorphine doses used in inpatient and outpatient withdrawal
Day Inpatient withdrawal (n=21) 
Mean dose ± SD (mg)
Outpatient withdrawal (n=18) 
Mean dose ± SD (mg)
1 3.8 ±2.8 6.1 ± 1.2
2 5.8 ±3.2 9.6 ± 1.7
3 4.8 ±3.3 10.1 ± 1.9
4 2.3 ±2.6 8.9 ±2.0
5 0.8 ± 1.3 4.1 ± 1.5
Total 17.4 ±9.7 38.9 ±5.8
The general trend of these two regimes is similar, although mean daily doses utilised in the 
outpatient setting were approximately double the daily doses used during the first three days in 
an inpatient context, with even greater discrepancy on days 4 and 5. The differences can be 
understood by considering the different role and requirements of medication in each of the two 
treatment settings. In the inpatient setting, the role of medication is to primarily relieve the 
more severe discomfort of withdrawal, whilst the setting, with increased capacity for 
monitoring, supportive counselling and a drug-free environment facilitates the patient’s 
progress through the withdrawal episode. In contrast, the outpatient is exposed to regular cues 
and triggers for continued heroin use. Withdrawal medication must not only relieve withdrawal 
symptoms, the dose should also be adequate to significantly reduce cravings for heroin use, and 
to block the effects of any additional heroin use, thereby reducing the positive reinforcement of 
heroin use during the withdrawal attempt. In many cases the outpatient has to continue to
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function in their routine daily activities (such as employment, study, housework, child care, 
travel), and can not afford to be ‘unwell’ for extended periods of time, requiring the use of 
adequate doses to adequately alleviate withdrawal discomfort. Furthermore, medication in 
outpatient settings are generally dispensed once a day, hence, a higher dose of buprenorphine 
may be required to accomplish the goals of pharmacotherapy over a 24 hour period, compared 
to the inpatient context where multiple divided doses are available each day.
There have been only two descriptions of short-term buprenorphine regimens for the 
management of outpatient heroin withdrawal reported in the published literature (see Table 1.7 
Chapter 1). The first outpatient withdrawal regime was described by (O'Connor, Carroll et al. 
1997) in which 3 mg sublingual buprenorphine (preparation unspecified) was dispensed daily 
for 3 days prior to the initiation of naltrexone and a range of symptomatic medications 
(clonidine, oxazepam, ibuprofen, ketorolac, prochlorperazine) on day 4. There was no 
justification or rationale provided for the dosing regime used in the study, and the suitability of 
the regime is difficult to assess as certain key outcomes were either not reported (continued 
heroin use), or difficult to interpret (withdrawal severity, retention) due to the initiation of 
naltrexone early in the process.
Diamant, Fischer et al. (1998) reported generally positive outcomes in a short-term outpatient 
withdrawal regime. 0.2 mg sublingual buprenorphine tablets were clinically titrated up to a 
maximum of 4 mg per day (20 tablets), and then gradually reduced to zero over a 10-day 
period, with 70% of subjects completing the regime, and 48% had a negative urine test for 
opiates on day 10. The mean daily dose was reported as between 2 and 3 mg per day during the 
first 5 days, with a total mean dose of buprenorphine dispensed of approximately 15 to 20 mg, 
substantially lower than reported in this study. There were a number of differences between the 
studies worth noting: Diamant and colleagues used low dose (0.2 mg) sublingual tablets, the 
administration of buprenorphine tablets was not supervised and with multiple buprenorphine 
doses prescribed over the course of the day, additional symptomatic medication was used 
(prothipendyl and famotidine), and there was no follow up after the final day of buprenorphine 
dosing.
The different buprenorphine dosing regimes identified by the two outpatient studies using 
clinical dose titration methods (this study and the study reported by Diamant and colleagues) 
highlights the importance of conducting randomised trials to examine the efficacy of different 
dosing regimes. The findings from this study are consistent with the general trend of research 
literature (reviewed in Chapter 1) in which daily buprenorphine doses of 4 mg or more are 
more effective in reducing withdrawal discomfort, cravings and heroin use, than lower doses 
(Kosten, Schottenfeld et al. 1993; Seow, Quigley et al. 1986; Schottenfeld, Pakes et al. 1997;
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Johnson, Eissenberg et al. 1995; Schottenfeld, Pakes et al. 1993; Kosten and Kleber 1988; Ling, 
Charuvastra et al. 1998). Further research is required to compare the efficacy of high daily 
doses (as used in this study) and low doses (as described by Diamant and colleagues) in the 
management of short-term outpatient heroin withdrawal, with consistency on issues such as 
frequency of dosing, and the use of ancillary medication and psychosocial services.
3.4.2 Outpatient withdrawal outcomes
The second aim of the study was to more broadly explore issues in the use of buprenorphine, 
with particular emphasis upon its impact upon key withdrawal outcomes and process measures 
as developed in Section 1.1.3, such as withdrawal severity, impact upon heroin use, retention 
rates and patient satisfaction.
Buprenorphine was effective in reducing the severity of withdrawal without considerably 
prolonging the duration of symptoms. Most subjects reported minimal withdrawal discomfort 
over the course of the withdrawal: peak withdrawal discomfort generally occurred prior to the 
second dose of buprenorphine, and with substantial relief of symptoms thereafter. Importantly, 
there appeared to be only minor and brief rebound withdrawal experienced following the 
cessation of buprenorphine for most subjects. However, a degree of caution should be exercised 
in this claim, as a considerable proportion of subjects used heroin at least once after ceasing 
buprenorphine, and it is possible that this was in response to rebound withdrawal, despite the 
claims by most subjects that their heroin use was either volitional or situational, and not as an 
attempt to relieve withdrawal. An argument could also be made that there was an inadequate 
period of follow up and that subjects may have experienced rebound withdrawal symptoms 
more than 3 days after ceasing buprenorphine. This is unlikely, as the day 5 buprenorphine 
dose (3 to 6 mg in all cases) would not be expected to exert considerable effects for more 24 to 
48 hours (Walsh, Preston et al. 1994; Walsh, Preston et al. 1995), and one would expect the 
emergence of rebound withdrawal phenomena to occur within 72 hours of the last dose, given 
the short duration of the regime (see discussion in Section 1.4.3). These findings are consistent 
with the mild and transient rebound withdrawal described in the Inpatient Titration Study 
(Chapter 2).
Other short term outcomes during the withdrawal episode were generally favourable for an 
outpatient setting: there was good retention in withdrawal treatment - 83% of subjects 
completed the dosing regime, 78% were retained throughout the 8 day episode, and one subject 
(6%) transferred to a methadone maintenance program during the episode. Over a third (36%) 
of all possible urine drug screens were negative for opiates, approximately one quarter of 
subjects did not use heroin over the withdrawal episode (28% self report and 22% confirmed
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with urine tests), and a further 28% reported using heroin only once during this time. These 
findings compare favourably with outcomes for patients undergoing conventional outpatient 
heroin withdrawal at Turning Point Alcohol and Drug Centre (Clark, Dunlop et al. 1998). 
However, factors other than the utility of buprenorphine may have impacted upon the findings, 
including a Hawthorne effect associated with the use of a new experimental treatment, and the 
increased monitoring and enthusiasm by the treatment staff involved in a research project. The 
study had no control or comparison group with which to properly evaluate outcomes, and 
ultimately, a randomised controlled trial comparing buprenorphine to ‘gold standard’ outpatient 
treatment is required to assess the efficacy of buprenorphine as a withdrawal medication.
3.4.3 Conclusion
This study is the first to describe a short-term outpatient heroin withdrawal regime using the 
commercially available sublingual tablet preparation Subutex ®. The recommended outpatient 
regime uses higher doses than those reported in the earlier Inpatient Titration Study, and higher 
doses than those described in earlier short-term outpatient withdrawal regimes (Diamant, 
Fischer et al. 1998; O'Connor, Carroll et al. 1997). Nevertheless, the dosing regime used in this 
study resulted in generally favourable outcomes, and is consistent with the general trend in the 
clinical research literature in which single daily buprenorphine doses of greater than 4 mg per 
day are more effective in reducing withdrawal discomfort, cravings and heroin use.
The early promise in the research literature of buprenorphine being an effective and safe 
medication for the management of heroin withdrawal has been reinforced in this study. 
Buprenorphine comfortably alleviated the physical and psychological discomfort associated 
with heroin withdrawal; it diminished cravings for heroin; blocked the effects of additional 
heroin use thereby enhancing patient compliance with the objectives of withdrawal treatment; 
and there were minimal features of a rebound withdrawal syndrome on ceasing buprenorphine. 
The medication was easy to use and well tolerated by subjects - the majority were treated on a 
once a day dosing schedule, with no take home medications, and with minimal need for 
additional symptomatic medications. These factors enhance the safety aspects of buprenorphine 
in comparison to other withdrawal medications such as benzodiazepines or clonidine. There 
were high levels of patient satisfaction, with almost all subjects ranking buprenorphine as their 
preferred medication option for heroin withdrawal.
The limitations of the study design, most notably the lack of a control group, ultimately 
restricts the conclusions that can be made regarding the efficacy of buprenorphine, and this 
issue will be examined in the following study. Nevertheless, within the context of the broader
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research agenda, this exploratory study has provided sufficient basis for the development of an 
outpatient-dosing regime to be used in subsequent efficacy studies.
Chapter 3: Outpatient Dose Titration Study 117
Chapter 4: A Randomised Controlled Trial of 
Buprenorphine in the Management of Outpatient
Heroin Withdrawal
4.1 Study objectives and research questions
The aim of this study was to examine the clinical efficacy, safety and cost-effectiveness of 
buprenorphine compared to conventional pharmacotherapy for the management of short-term 
heroin withdrawal in outpatient specialist treatment settings. The key objectives, outcome and 
process measures for the evaluation of outpatient withdrawal services were examined in 
Section 1.1.3 (and summarised in Table 1.2), and form the framework for this study.
The principal research question for this study is: how does the use of buprenorphine compare to 
current ‘gold standard’ medication (clonidine plus other symptomatic medication) for the 
management of outpatient heroin withdrawal, with regard to each of the following outcomes:
• heroin (and other drug) use during and after withdrawal episode
• retention in treatment during the withdrawal episode and in the post-withdrawal period
• adverse events during the withdrawal episode and post-withdrawal period
• cost-effectiveness
• severity of opiate withdrawal symptoms during the withdrawal episode
• global measures of functioning, including severity of dependence on heroin, and measures 
of psychosocial functioning
• measures of patient satisfaction.
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4.2 Research Design & Methods
4.2.1 Overview of Research Design
The research design was an open label randomised controlled trial in which heroin dependent 
individuals presenting for an 8-day outpatient withdrawal program were randomly assigned to 
one of two withdrawal medication regimes. The two conditions were:
• Control Group: a regime of conventional symptomatic pharmacotherapy for heroin 
withdrawal, including clonidine, benzodiazepines and other symptomatic medications;
• Experimental Group', a buprenorphine regime, as developed in the Outpatient Titration 
Study (Chapter 3).
Upon completion of the 8-day withdrawal program, subjects were able to self-select from a 
range of post-withdrawal treatment options. These included substitution treatment (methadone 
for the Control group; methadone or buprenorphine for the Experimental group); naltrexone 
treatment; or counselling services without pharmacotherapy. Subjects were also able to re­
attempt (conventional) withdrawal services, or to seek treatment elsewhere (e.g. residential 
rehabilitation programs). Participation in post-withdrawal treatment services was monitored 
over a 4-week period following the initial withdrawal episode. Research interviews were 
conducted at the end of the withdrawal episode (day 8), and at the end of the 4-week follow-up 
period (day 35 after recruitment). All between group comparisons were conducted on an 
intention-to-treat basis. The design is shown in Figure 4.1.
The research was conducted across two sites: Turning Point Alcohol and Drug Centre in 
Fitzroy, Melbourne; and the Langton Centre in Surry Hills, Sydney. Both centres have 
established outpatient withdrawal programs with considerable experience in the conduct of 
clinical research projects.
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Figure 4.1. Research Design
4.2.1.1 Rationale for open-label study
Ideally, clinical research comparing different medication regimes should incorporate a double­
blind design, in which treatment staff, researchers collecting data and subjects, are blinded as to 
Control or Experimental group allocation. This is to minimise the impact of expectancy, which 
can be particularly relevant when using an investigational medication in addiction research 
(Blaine, Ling et al. 1994). Under these circumstances, it is likely that some participants may 
equate ‘new’ with ‘better’, and there may be unrealistically high expectations regarding the 
investigational medication, and/or unnecessarily low expectations regarding the conventional 
medication regimes. In circumstances where two active medication regimes are used, double­
dummy conditions should be employed (Blaine, Ling et al. 1994), which in this case would 
have required the Control subjects receiving active symptomatic medications and dummy 
buprenorphine tablets; whilst the Experiment subjects received active buprenorphine and 
dummy symptomatic medications.
However, the option of blinding research participants in this study was not feasible on two 
grounds. Firstly, the dosing regimes were markedly different. The Experimental group received 
one daily dose of buprenorphine under supervision at the clinic; whereas the Control group
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were provided with a number of different medications (up to 7) which they were to take in 
unsupervised divided doses over a 24-hour period. Even if ‘dummy’ tablets had been available, 
most subjects would have quickly determined whether they had dummy symptomatic or active 
symptomatic medication (simply by taking their tablets (e.g. benzodiazepines or placebo) and 
seeing if there was any effect). The other main reason for not attempting a blinded study was 
that the pharmacological actions of the two medication regimes are substantially different, and 
would be quite recognisable to most subjects. For example, buprenorphine is consistently 
identified as an opiate by heroin users (Jasinski, Fudala et al. 1989), whereas the effects of 
medications such as diazepam and clonidine are substantially different. In short, blinding 
research participants would have been preferable, but unrealistic. Indeed the only other 
outpatient, randomised trial comparing buprenorphine to other withdrawal medications 
attempted to blind subjects, however the authors concluded that blinding had not been achieved 
for most subjects (O'Connor, Carroll et al. 1997). The prospect of blinding the clinical staff and 
outcome assessors was likewise considered unfeasible, as the patients themselves were aware 
of their assigned treatment.
4.2.1.2 Selecting the ‘gold standard’ for comparison
Medications used in the management of heroin withdrawal were reviewed in Section 1.3. This 
review identified that both alpha-adrenergic agonists (e.g. clonidine and lofexidine) and 
methadone reductions have been demonstrated to be safe and effective medications for 
managing heroin withdrawal, and whilst there has been no direct comparison of these 
medications in properly controlled studies of outpatient heroin withdrawal, they each have their 
role. The role of antagonist-assisted withdrawal remains unclear at this stage, and cannot be 
considered ‘gold standard’. The decision to use symptomatic medication (principally clonidine) 
was due to the short time frame being considered for withdrawal services in this study. Brief 
methadone reduction regimes (e.g. 5 days) have not been systematically evaluated in the 
research literature, and as such could not be considered ‘best practice’ or ‘gold standard’. A 
comparison of buprenorphine and methadone reductions over a more gradual reduction period 
(e.g. 10 to 21 days or even longer) is research which is required, as there has been only one 
such study (Bickel, Stitzer et al. 1988) with small subject numbers; however a comparison of 
brief buprenorphine withdrawal regime with a longer methadone reduction regime would be 
difficult to interpret and was not considered appropriate.
Clonidine and other symptomatic medications are routinely used in short withdrawal episodes, 
and were therefore considered the appropriate ‘gold standard’ for this trial. Whilst lofexidine 
has some advantages over clonidine with regards to side effects, it has not been demonstrated
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to have better results for other outcomes over clonidine (Section 1.3.2). Furthermore, lofexidine 
is not registered in Australia, and it was considered somewhat inappropriate to compare two 
‘investigational’ and unregistered medications.
The decision to use a variety of other symptomatic medications, including benzodiazepines, 
and not restrict the Control Group to clonidine was due to the common practice within 
Australia (including the study sites) of using such combinations of medications for heroin 
withdrawal (NSW Health Department 1999; Frank and Pead 1995; Lintzeris, Murray et al. 
1997). To have excluded other symptomatic medications would have deterred many heroin 
users who have come to expect them, and may have led to criticisms of the study that ‘optimal’ 
medications had not been used for the Control group (although it should be noted that there is 
little research evidence regarding the value of many of these medications - see Section 1.3 for 
review).
4.2.1.3 Conducting a multi-site trial
There are advantages and disadvantages in single versus multi-site trials, and this study was 
conducted as a multi-site trial for several reasons. A practical consideration was the ability for 
faster rates of subject recruitment by incorporating two clinical sites, and therefore, a shorter 
duration for completing the research. Indeed, originally the study had been planned as a single 
site investigation, with projected time lines of approximately 12 to 18 months to complete the 
clinical component of the research. Instead, by conducting the research at two sites, the clinical 
component of the study was completed within 9 months at each site.
The other main reason was the greater capacity to generalise the findings of a multi-site trial. A 
limitation of conducting clinical research at only one site is that a number of unintended factors 
can impact upon the research, with the consequence that the research findings may not be able 
to be replicated elsewhere. For example, an unusual group of subjects may be recruited at a site 
due to promotional activities or ‘word of mouth’; or organisational issues (such as staff 
changes) can impact upon service delivery; or enthusiasm (or lack thereof) of a particular key 
staff member can impact upon the study findings. Conducting the research at two sites reduced 
the potential and impact of such factors. Less important from a research design perspective, but 
relevant in terms of enhancing the impact of the research, conducting the study at key clinics in 
the two main Australian cities, Melbourne and Sydney, was also viewed as important in the 
dissemination and acceptance of the research findings in the alcohol and drug treatment sector 
(Hall 1997).
The limitations of multi-site research were also considered, and steps taken to minimise 
potential problems. A potential difficulty is the delivery of substantially different treatment
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(and research procedures) at different sites. In this study, consistent treatment and research 
protocols were developed, training sessions were provided for clinical and research staff at both 
sites, and there was regular co-ordination of research activities across the two sites. The amount 
of clinician to subject contact was recorded to allow comparisons between the two sites. The 
principal investigator performed all data entry and analyses. Nevertheless, some discrepancies 
occurred with regards to baseline data collection at the two sites. Data regarding (a) 
demographic characteristics of current legal status, number of children (Section 4.3.1.1), and 
(b) reasons for exclusion of subjects was not collected at the Sydney site due to administrative 
errors.
Another potential problem in using sites from different cities is that there may be inherent 
differences in drug use patterns, such as the cost and strength of street heroin available, or 
routes of administration. Comparison of cost and strength of street heroin in Melbourne and 
Sydney during this period indicated very similar trends for the two cities (McKetin, Darke et al. 
2000) .
4.2.2 Subjects and recruitment
4.2.2.1 Selection criteria
The study recruited dependent heroin users presenting for outpatient heroin withdrawal, with 
no significant medical or psychiatric co-morbidity, or withdrawal from other drugs. Specific 
selection criteria for the study and their method of assessment are shown in Table 4.1. The 
same selection criteria were used in the two titration studies, and a more detailed rationale is 
provided in Table 2.1, Section 2.2.2.1. Details regarding the patients assessed and subjects 
enrolled are presented later in this chapter.
Regular cannabis use was not an exclusion criterion on the basis that large proportions of 
Australian heroin users also use cannabis regularly (McKetin, Darke et al. 2000), and to 
exclude them would significantly limit recruitment and the generalisability of the study 
findings. Furthermore, clinical experience suggests that most regular cannabis users continue to 
use cannabis during an outpatient heroin withdrawal episode, and therefore do not experience 
cannabis withdrawal symptoms; hence, cannabis use was considered unlikely to markedly 
hinder the interpretation of heroin withdrawal outcomes.
The selection criteria for subjects commencing naltrexone in the post-withdrawal phase as part 
of the study were (a) opiate negative urine drug results conducted on days 5 and 8 of the 
withdrawal episode (missing results were considered ‘positive’); and (b) an alanine transferase 
level (serum liver function test) less than three times greater than the normal laboratory range.
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The rationale for this arises from hepatotoxicity reported in a study of high-dose naltrexone in 
the treatment of obesity (Mitchell, Morley et al. 1987).
Table 4.1. Selection criteria
Selection criteria Operational criteria
1. Aged 18 years or more Proof of identification required.
2. Heroin dependent individuals Assessed clinically against DSM IV 304.0 criteria
3. Recent heroin use (within past 
48 hours)
Assessed by self report and positive urine test for opiates on 
assessment (using Accusign® diagnostic tests).
4. Not in methadone treatment 
within the past 8 weeks
Assessed by self report and confirmed with the relevant 
jurisdictional health authorities (Drugs and Poisons Unit in 
Victorian Department of Human Services; Pharmaceutical Services 
in NSW Health Department.
5. Not dependent upon or 
withdrawing from alcohol or 
benzodiazepines
Assessed by clinical history and examination, urine drug screen, 
and breath alcohol level where indicated.
6. Not pregnant or breastfeeding Pregnancy was assessed by a urine bHCG test.
7. Suitable social environment for 
outpatient withdrawal.
The key criterion here was that the patient had some form of 
accommodation (but not necessarily drug-free accommodation). 
The presence of ‘drug free’ support people was not a requirement.
8. No active or unstable medical 
or psychiatric condition
Assessed clinically by medical officer.
9. Able to meet attendance 
requirements for study
Requirement was that patient could attend the clinic daily over the 
8-dav withdrawal period, and could engage in the 4-week post­
withdrawal treatment period (e.g. no planned hospital admission, 
court appearance, or long term travel).
10. Able and willing to give 
informed consent
Participation in the study was voluntary. Capacity to give informed 
consent was assessed by the clinical team and research assistant.
4 .2 .2 .2  S u b jec t N um b ers
The sample size for the study was calculated using the primary outcome measure for which
greatest information was available before the trial - rates of completion of the withdrawal 
episode without heroin use. The sample size was determined using the following formula
(Pocock 1983):
n = p, x (100 - p,) + p2x(100-p2) x f (a,ß)
(Pi-P:)2
with: n = number in each group
p,= % successes (7 days with no heroin use) expected in Control group
p2 = % successes (7 days without heroin use) expected in Experimental group
a  = 0.05 (type I error); ß = 0.10 (type II error, 90% power); f (a,ß) = 10.5
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Various authors have estimated the successful completion rates for outpatient symptomatic 
heroin withdrawal to be approximately 20 per cent (see Chapter 1 for review). However, a 
review of computerised clinical records of outpatient withdrawal outcomes at Turning Point 
Clinical Services (1996-7) indicated a 20 - 25 per cent completion rate for attendance, although 
at least half of these patients used some heroin during their withdrawal episode. Using the 
criterion of one week with no heroin (or other opiate) use, a more realistic estimate of 
successful completion of outpatient heroin withdrawal using symptomatic medication is in the 
order of 5 to 10% of patients attending Turning Point Clinical Services. Similar estimates of 
heroin-free completion rates were independently estimated for outpatient withdrawal programs 
by experienced staff at the Langton Centre. The results from Outpatient Dose Titration Study 
(Chapter 3) conducted at Turning Point saw 28% of subjects reported completing 7 or 8 days 
with no heroin use. Using these estimates (p, = 5% completion; p2 = 28% completion):
n = 10 x (100 - 10) + 22 x (100 - 22) x 10.5 = 61 subjects 
( 10 - 22)2
From these calculations, it was estimated that 61 subjects were required in each group, and 
hence the proposed total number of subjects was 122. The study aimed to recruit equal numbers 
(approximately 60 subjects) at each site. The Turning Point site commenced and completed 
recruitment first, with 64 subjects randomised. Recruitment at Langton Centre was ceased after 
50 subjects had been randomised. Hence, in total 114 subjects were randomised into the study.
4.2.2.3 Recruitment procedures
Subjects were recruited from heroin dependent patients presenting for outpatient heroin 
withdrawal at Turning Point Clinical Services in Melbourne, and at the Langton Centre in 
Sydney. Recruitment to the study was voluntary with informed consent for the trial’s clinical 
and research activities. Patients not wishing to participate in the study had access to routine 
withdrawal and other clinical services at study sites. The emphasis was to recruit from patients 
presenting for outpatient withdrawal at these services, with no active advertising or promotion 
for the study. This was to minimise the potential for an ‘atypical’ group of heroin users 
presenting in order to try a ‘new medication’, with associated unrealistic expectations regarding 
the worth of the investigational medication.
The study recruitment procedures were different at each site. At Turning Point, all patients 
seeking outpatient withdrawal were screened for eligibility, and those considered broadly 
eligible were informed of the study, provided with written information regarding the study and 
the various treatment options available to them (including conventional withdrawal services). 
Interested patients then underwent further screening as relevant (urine testing, confirmation of
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prior methadone status), were given the opportunity to read the detailed Plain Language 
Statement (see Appendix 1) and to ask questions of the clinical staff. Eligible subjects then 
underwent a confidential (~30 to 60 minute) interview with the research assistant, during which 
they provided written informed consent, follow-up contact details, and baseline data. On the 
completion of the baseline research interview, subjects were randomised into one of the two 
study conditions (see next section), and then referred back to the treating clinician for initiation 
of the treatment regime.
Limited medical resources at the Langton Centre prevented the study being offered to all 
potentially eligible patients presenting for outpatient heroin withdrawal. Instead, there were a 
limited number of study vacancies during the course of each week (usually three per week), 
with a ‘first come, first served’ approach. Recruitment procedures similar to those described at 
the Turning Point site were followed, with randomisation occurring following clinical 
assessment, and written informed consent and data collection with the research assistant. Once 
the allotted number of research vacancies at the Langton site had been filled each week, 
subsequent patients presenting for withdrawal had the option of routine access to conventional 
withdrawal services (using symptomatic medication), or an appointment early in the following 
week when vacancies for the study would be available.
4.2.2,4 Randomisation procedures
Randomisation for the study was conducted by the Randomisation Service of the NHMRC 
Clinical Trials Centre, an independent organisation contracted to provide this service for the 
study. A computerised randomisation schedule was developed by this service using the 
technique of dynamic balanced randomisation (Signorini, Leung et al. 1993). This method 
balances treatment allocation within each site and across the study as a whole (with the aim of a 
1:1 ratio between Control and Experimental groups at each site). Dynamic balanced 
randomisation overcomes the potential for marked differences in subject allocation at different 
study sites, and reduces the potential for research participants to predict the group to which a 
particular subject may be allocated (as can occur with conventional block randomisation). 
Subject allocation is deterministic if certain pre-defined limits are exceeded, and random 
otherwise.
Upon completion of the informed consent procedures and baseline research interview, the 
research assistant telephoned the NHMRC Clinical Trials Centre, with summary subjects 
details (initials, date of birth, study site). The NHMRC Randomisation Service then provided 
the outcome of randomisation, initially by telephone, and with subsequent written 
confirmation.
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58 / 114 subjects (51%) were randomised to the Experimental Group, and 56 / 114 (49%) 
randomised to the Control Group. At the Turning Point site, 32 / 64 (50%) subjects were 
randomised to each group; while at the Langton Centre site, 26 / 50 (52%) were randomised to 
the Experimental group, and 24 / 50 (48%) to the Control group. Details regarding subject 
characteristics are provided later in this Chapter.
4.2.2.5 Enrolling couples in the study
One of the advantages of outpatient withdrawal programs is that they enable couples to attempt 
withdrawal together, which is generally prohibited by most Australian residential withdrawal 
services. However, it was considered inappropriate for partners to be randomised to different 
treatment groups in the study, and couples undergoing treatment together (entering withdrawal 
within the same week) were assigned to the same treatment condition. Consequently, only one 
partner of each couple was enrolled into the study as a subject for analysis purposes. The 
partner to be enrolled as the subject was selected as the patient who initially presented to the 
service, or in circumstances where the couple presented simultaneously, the partner to be 
enrolled was randomly selected (by the research assistant tossing a coin prior to the baseline 
research interview and subsequent random group assignment). Full data collection and 
treatment procedures were followed on both partners, so that the patients (and treatment staff) 
were unaware as to which member of the couple had been recruited to the study. Data for the 
non-randomised members of couples in the study is not included in any of the intention-to-treat 
data analyses.
4.2.2.6 Subjects enrolled
Table 4.2 displays the number of patients seeking outpatient heroin withdrawal, the number 
deemed as ineligible (including reasons for ineligibility among Turning Point patients), and the 
number of subjects enrolled into the study at each site. The reasons for ineligibility at the 
Langton Centre were not systematically recorded. Data regarding subject enrolment and follow 
up over the study is also presented in Figure 4.2 (Section 4.2.4.3).
Thirty-five patients were potentially eligible but did not participate in the study, either due to 
them declining to participate, or due to limited study treatment places at the Langton Centre 
site (see Section 4.2.2.3). More common reasons for eligible patients voluntarily declining to 
participate in the study included: unwilling to attend daily during the withdrawal episode; not 
wanting medications for withdrawal management; unwilling to participate in a research project; 
or seeking to enrol in another research study (in particular a number of heroin users were keen
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to enter naltrexone relapse prevention studies running at both clinic sites, and recruitment to the 
withdrawal study prevented enrolment in the naltrexone studies).
Table 4.2. Recruitment of subjects across the two sites
Subject Status Turning Point
n (%)
Langton Centre 
n (%)
Total 
n (%)
Total number of patients assessed 120(100) 152 (100) 272 (100)
Total ineligible 29 (24%) 56 (37%) 85 (31%)
Medical condition 3 n/a
Psychiatric condition 5 n/a
Concurrent dependence to other drug 4 n/a
Methadone treatment in prior 8 weeks 9 n/a
Attendance difficulties 4 n/a
Multiple reasons 4 n/a
Total eligible 91 (76%) 96 (63%) 187 (69%)
Chose not to participate in study and/or 11 35 46
no study places available at LC
Enrolled in study 80 (67%) 62 (41%) 142 (52%)
Randomised to study group 64 50 114
Non-randomised partner 16 12 28
Twenty-eight couples enrolled in the study, of which only one partner was included in data 
analysis (see previous discussion). Similar proportions of subjects enrolled as couples were 
randomised to each group, with 13 subjects randomised to the Control Group (comprising 23% 
of all Control subjects) and 15 randomised to the Experimental Group (26% of all 
Experimental subjects).
4.2.3 Treatment procedures
4.2.3.1 Withdrawal episode
The withdrawal episode required daily attendance of subjects over an 8-day period. Subjects 
were reviewed each day by a clinician prior to medication being dispensed. At each review, 
information was collected that would assist the appropriate titration of doses of medication, 
including (a) withdrawal severity using the Subjective and Objective Opiate Withdrawal 
Scales; (b) subject rating of the adequacy of the dose of the preceding day’s medication; (c) any 
drug use since last presentation and the surrounding circumstances; and (d) any adverse events.
Supportive counselling and case management activities were provided during the course of the 
withdrawal episode in line with standard practice for both sites. Areas addressed included: 
goals of treatment, organising social environment for withdrawal, strategies for coping with 
withdrawal symptoms, safer injecting and prevention of overdose information where
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appropriate, and linkages to post-withdrawal services. Subjects also received the written 
information book Getting Through Heroin Withdrawal (Lintzeris, Dunlop et al. 1996).
Urine drug screens were collected on days 5 and 8 of the withdrawal episode, with results 
available to clinicians and subjects. Subjects were reviewed at the completion of the 
withdrawal episode on day 8, with a discussion of the various treatment options available.
Subjects who did not attend or contact the clinic for two or more consecutive days were 
discharged from the study treatment procedures, although they could continue to access 
conventional treatment services, and were followed up for research interviews.
Medication regime for Experimental Group
The recommended dosing regime developed in the earlier Outpatient Dose Titration Study was 
used for the Experimental group (Table 3.6, Chapter 3). Sublingual buprenorphine tablets were 
dispensed once daily under supervision at the clinic pharmacy. The mean daily doses dispensed 
to the Experimental subjects are shown in Table 4.3.
Table 4.3 Buprenorphine doses (mg) dispensed during withdrawal episode
Day Buprenorphine dose administered (mg) 
mean ± SD
Day 1 6.0 ± 0.6
Day 2 9.3 ± 1.6
Day 3 9.6 ± 3.0
Day 4 8.8 ± 2.0
Day 5 3.6 ± 1.3
Total 37.2 ± 5.3
In order to minimise the risk of precipitated withdrawal with the first dose of buprenorphine, 
the first dose (usually 6 mg) was only administered to those subjects who reported using heroin 
at least 6 hours earlier, and who did not show any features of opioid intoxication. In some 
circumstances this required subjects to present later in the day for their first dose, or to have a 
reduced first dose (e.g. 4 mg) to avoid precipitated withdrawal.
The dose of buprenorphine dispensed on days 2 to 4 was titrated according to the subject’s 
experience of withdrawal severity, drug use, adverse events, and ratings of dose adequacy. The 
dosing regime allowed some flexibility to accommodate individual variation in medication 
requirements. For example, a subject describing uncomfortable withdrawal symptoms 
following day 1 without significant side effects was dispensed a 10 mg dose on day 2.
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Alternatively, subjects describing mild withdrawal symptoms since the first dose of 
buprenorphine, and/or those experiencing (tolerable) side effects were given an 8 mg dose.
In addition to buprenorphine, benzodiazepines were prescribed for 7 of the 58 subjects (12%) at 
a mean total (over the 8 day withdrawal episode) dose of 20 mg (± 9 mg) oral diazepam 
equivalent (maximum total dose prescribed = 30 mg). Clonidine was dispensed for one subject 
for the management of precipitated withdrawal following the first dose of buprenorphine (see 
section on Adverse Events). No other symptomatic medications were prescribed to the 
Experimental subjects during the withdrawal episode.
Medication regimes for Control Group
The Control Group had a range of different medications available to them over the course of 
the withdrawal episode (see Section 4.2.1.2 for rationale). Medications were dispensed daily 
from the clinic pharmacy, with clear verbal and written directions for their use. The main 
medication was clonidine, used in a dosing regime consistent with the published literature and 
usual practice for both study sites. Daily doses of clonidine dispensed over the withdrawal 
episode are shown in Table 4.4. Subjects were instructed to miss a dose of clonidine if they 
experienced features of postural hypotension (feel light-headed or like fainting), and to resume 
clonidine with resolution of these symptoms (usually within hours).
Table 4.4. Daily and total doses o f clonidine dispensed to Control Group
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Total
Mean ± SD 0.75 ± 0.74 + 0.90 ± 0.71 ± 0.61 ± 0.63 ± 0.51 ± 3.11±
(mg, oral) 0.24 0.19 0.83 0.20 0.25 0.26 0.23 1.51
Maximum 1.2 0.9 1.2 0.9 0.9 1.2 0.9 6.3
dose (mg)
Details regarding the total doses of other symptomatic medications dispensed over the 
withdrawal episode to Control subjects and approximate average daily doses are shown below.
Table 4.5 Doses o f other symptomatic withdrawal medications for Control group (n =42) a
Benzodiazepines 
(diazepam oral 
equivalent) (mg)
Metoclopramide
(mg)
Quinine
(mg)
Hyoscine
butylbromide
(mg)
Ibuprofen
(gm)
Total dose 
(Mean ± SD) 
(Range)
101 ±55 
20 to 250
117 ± 50 
30 to 210
2690± 1360 
900 to 6300
237± 125 
60 to 560
6.55 ±2.60 
2.4 to 10.8
Daily dose 14 ±8 17 ± 7 380 ± 190 34 ± 18 0.94 ±0.37
(Mean ± SD)
a  16 subjects did not receive any medication after the first day and are excluded from these results
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Clinician -  subject contact
The number and duration of contacts with all clinical staff was recorded prospectively for each 
subject during the 8-day withdrawal episode. Details of these contacts are shown in Table 4.6 
for those subjects who participated in treatment beyond day 1.
Table 4.6. Clinical contacts by randomised group for subjects engaged in treatment (> 1 day)
Experimental (n= 41) Control (n = 56)
Mean ± SD Mean ± SD
Medical staff
number of contacts 3.5 ±2.1 3.8 ± 1.9 NS
total time (min) 64 ±51 71 ±49 NS
Nursing staff
number of contacts 3.7 ±2.6 3.0 ±2.5 NS
total time (min) 64 ±57 49 ±46 NS
Pharmacists
number of contacts 3.2 ±2.1 3.8 ±2.5 NS
total time (min) 19 ± 15 37 ±28 p<0.01
(t(57)= 3.66)
All clinical staff
number of contacts 10.6 ±2.5 10.7 ±3.9 NS
There was a very similar pattem of clinician - patient contacts between the two groups, and the 
only statistically significant difference was that pharmacists spent more time preparing and 
dispensing medications for the Control group (due to daily dispensing of up to seven different 
medications).
4.2.3.2 Post withdrawal treatment procedures
Participation in post-withdrawal treatment services was voluntary, with subjects selecting their 
treatment modality. The study allowed for a number of treatment options, including naltrexone 
treatment, counselling (without medication), and substitution treatment. Participation in 
treatment services as part of the study protocol was conditional on the subjects meeting certain 
criteria. Subjects were informed of the post-withdrawal treatment options at the 
commencement of the withdrawal episode. The range of post-withdrawal treatment options 
available was reinforced for each subject on the final day of the withdrawal episode (day 8 of 
the study), and subjects provided with Plain Language Statements for post-withdrawal options 
(see Appendix). Those subjects who were ambivalent regarding their post withdrawal treatment 
options could delay their decision to enter treatment as part of the study until day 10.
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Subjects also had the capacity to engage in routine clinical services that were not part of the 
study. Subjects could attend treatment services at other agencies, or alternatively, subjects who 
discontinued treatment as part of the study could commence routine clinical services available 
at the study sites - for example, a subject who dropped out of buprenorphine treatment after 2 
weeks into the post-withdrawal period, could represent to the clinic and commence withdrawal 
or methadone maintenance treatment.
Buprenorphine substitution treatment
Treatment with buprenorphine was available only to subjects in the Experimental Group. To be 
eligible for buprenorphine treatment in the post-withdrawal phase, subjects had to have 
completed the withdrawal episode (satisfactory attendance record), and to have made the 
decision to enter buprenorphine treatment by day 10 of the study protocol. Subjects who chose 
not to enter buprenorphine treatment by day 10, and who presented at a later time (e.g. day 16) 
were ineligible to enter buprenorphine treatment (but could commence methadone or other 
treatment under conventional conditions).
Buprenorphine doses were generally prescribed according to maintenance treatment conditions 
(Lintzeris, Clark et al. 2001). Doses were individually titrated according to the needs of each 
subject. The starting dose was generally in the range of 4 to 8 mg, with the capacity for dose 
increases of up to 4 mg at a time, to a maximum daily dose of 16 mg. Buprenorphine was 
dispensed on a daily basis from the clinic sites, with no take home privileges allowed. Alternate 
day dosing with buprenorphine was not a routine option for subjects, although was 
accommodated in special cases of absence from the clinic (in lieu of take home doses). There 
were no dispensing fees for buprenorphine during the trial. Subjects were reviewed regularly by 
their assigned case-worker and medical staff, and had the option of more intensive counselling.
Not all subjects using buprenorphine chose to use it as a maintenance medication during the 
post-withdrawal phase, with a small number attempting a short course (for example, two 
weeks) of reducing doses of buprenorphine as another attempt at withdrawal.
Subjects who discontinued buprenorphine (missed 3 or more consecutive doses) during the 
post-withdrawal phase of treatment were not able to recommence buprenorphine treatment., but 
could enter conventional treatment options such as methadone treatment. Buprenorphine was 
not registered in Australia at the time the study was conducted, and as such, subjects could not 
access buprenorphine elsewhere. At the completion of the 4-week post-withdrawal study 
period, subjects on buprenorphine had the option of gradually reducing their dose and 
withdrawing off buprenorphine over a two to three week period, or alternatively transferring to
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methadone maintenance treatment. Continued long-term maintenance treatment with 
buprenorphine was not an option as part of the study.
Methadone substitution treatment
Methadone treatment was available to subjects in both the Control and Experimental groups. 
The study protocol allowed for free methadone dispensing!. Methadone was generally 
prescribed according to standard maintenance treatment conditions as specified in the 
appropriate jurisdictional guidelines (Department of Health and Community Services 1995; 
(New South Wales Health 1999). Starting doses were generally between 20 and 30 mg per day, 
and titrated upwards as required to a maximum possible dose of 100 mg. Methadone was 
dispensed on a daily basis under supervision from the clinic sites, with no routine take home 
privileges allowed during the first month of treatment. Subjects were reviewed regularly by 
their assigned case-worker and medical staff, and had the option of more intensive counselling.
As with buprenorphine treatment, not all subjects commencing methadone were necessarily 
intent on using it as a maintenance medication, with some subjects attempting a brief reduction 
regime using low doses as another attempt at withdrawal. Subjects who discontinued 
methadone (missed 3 or more consecutive doses) during the 4-week post withdrawal phase of 
treatment were able to recommence methadone treatment under conventional conditions. At the 
completion of the 4-week post withdrawal study period, subjects could continue methadone 
treatment under conventional conditions.
Naltrexone treatment
Naltrexone treatment was available under study conditions for subjects in both randomised 
groups, according to the selection criteria specified earlier. Doses were dispensed daily for the 
first 4 days, then weekly thereafter, with a minimum frequency of review with clinical staff of 
once a week. Naltrexone was provided free of charge to subjects under study conditions.
Control subjects who entered naltrexone as part of the study underwent a naloxone challenge 
test with 0.8 mg intravenous naloxone. Measures of opiate withdrawal (SOWS and OOWS) 
were recorded at baseline, and again at 10 and 20 minutes after the administration of naloxone.
1 Subjects who had not maintained regular attendance during the withdrawal episode or who 
chose not to enter methadone treatment by day 10 could commence methadone under 
conventional treatment conditions. The only difference between conventional and study 
protocol conditions for methadone treatment was that subjects at Turning Point had to pay 
a weekly dispensing fee of $25 per week for conventional methadone; whereas there were 
no dispensing fees as part of the study protocol. There were no fees at the Langton Centre, 
and therefore, no difference between study and conventional treatment.
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Subjects tolerating the naloxone challenge were then commenced on naltrexone, initially 
dispensed under supervision from the clinic for the first three days at 25 mg per day. The 
recommended dose thereafter was 50 mg per day, although some subjects reported side effects 
at this dose and maintained lower doses of 25 mg per day.
Induction onto naltrexone for Experimental subjects used a different procedure. Naloxone 
challenge tests are difficult to interpret in individuals treated with buprenorphine (Eissenberg, 
Greenwald et al. 1996), and as such were not used. The induction procedure used in the study 
entailed administering a 12.5 mg dose of naltrexone orally on day 8 (or later if so negotiated 
with the subject). The subject was then monitored (using SOWS and OOWS) in the clinic for 
up to three hours after the naltrexone dose, during which time any severe withdrawal response 
should have become apparent (Eissenberg, Greenwald et al. 1996). Subjects complaining of 
withdrawal discomfort had access to a range of symptomatic medications (see Table 4.7 
below). Subjects were allowed home after the period of monitoring (with symptomatic 
medications as required). The study doctor reviewed the subjects the following day. The 
naltrexone dose was maintained at 12.5 mg if the subject reported considerable withdrawal 
discomfort, or increased to 25 mg if the initial dose had been tolerated. The naltrexone dose 
was generally increased to 50 mg per day by the fourth day, although some subjects reported 
side effects at this dose and maintained lower doses of 25 mg per day.
A number of subjects were ineligible for naltrexone as part of the study protocol (due to heroin 
use during the withdrawal period), but nevertheless over the course of the 4-week post­
withdrawal period were able to complete opiate withdrawal and commence naltrexone 
treatment under conventional conditions (Bell, Kimber et al. 1999). Subjects had to pay the 
standard cost of the naltrexone medication (approximately $5 per 50 mg tablet) under these 
conditions.
Table 4.7. Medication available for Experimental Group subjects commencing naltrexone.
Medication Dose
Clonidine 100 meg 3 -4  hourly for subjects <65 kg body weight; 
150 meg 3 -4  hourly for subjects >65 kg body weight
Diazepam 5 mg 3 -4  hourly as required
Metoclopramide 10mg 6 hourly as required
Ibuprofen 400mg 4 to 6 hourly as required
Hyoscine butylromide 20 mg 6 hourly as required
Counselling services
Subjects could choose to enter counselling only services (without the use of substitution 
medications or naltrexone). The extent and content of counselling was determined by
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negotiation between the subject and counsellors in keeping with routine counselling services at 
each site. The content generally addressed relapse prevention, motivational interviewing and 
other post-withdrawal issues. Counselling sessions were usually scheduled as 60 minute 
appointments, one to two times per week over the 4-week period.
Withdrawal programs
A number of subjects had further attempts at withdrawal treatment during the 4-week follow-up 
period. Those subjects attempting withdrawal at the study sites were provided with 
conventional symptomatic medication regime similar to that described for the Control Group 
withdrawal. As described in the earlier section, a small number of subjects attempted to use 
short courses of reducing doses of buprenorphine or methadone as withdrawal medications.
Treatment at sites not involved in the study.
There were a number of cases (n = 16) where subjects engaged in treatment at agencies not 
involved in the study - 5 subjects entered conventional methadone programs elsewhere, 5 
entered withdrawal programs, 2 entered counselling, 3 entered naltrexone and 2 entered other 
forms of treatment). Limited data regarding these treatment episodes is available. For those 
subjects lost to follow up at day 35 (n=23), participation in methadone treatment was 
determined by contacting the relevant jurisdictional health departments to see if a permit had 
been issued for the ‘missing’ subjects during the 4-week follow-up period. There was no way 
of identifying participation in other treatment modalities (e.g. withdrawal, naltrexone) by 
subjects Tost’ to the day 35 research interview.
4.2.4 Outcomes, measures and data management.
4.2.4.1 Outcomes and measures
The framework for the evaluation of withdrawal services in this study was developed in 
Chapter 1.1. The primary outcomes and related measures for this outpatient study were:
1. Use o f heroin and other drugs during the withdrawal episode and in the post-withdrawal 
period. Data regarding heroin and other drug use in the preceding month was collected at 
baseline using the modified Drug Use Section of the Opiate Treatment Index (OTI) (Darke, 
Heather et al. 1991). The modifications included questions regarding the number of days 
used heroin in the preceding 28 days, and the average daily cost of heroin when used. Drug 
use during the withdrawal episode was measured by (a) self report to clinical staff, recalling 
any heroin use, amount and reasons for use; (b) self report at the day 8 research interview 
recalling the number of times and the number of days that the subject used heroin since
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commencing the withdrawal episode; and (c) urine drug screens collected on days 1,5, and 
8. Drug use in the post-withdrawal period was assessed using the modified Drug Use 
Section of the OTI at day 35.
2. Retention in withdrawal treatment. Retention in treatment was measured as the number of 
days each subject participated in withdrawal treatment. Subjects were deemed to have 
completed the withdrawal episode if they did not miss 2 or more consecutive days during 
the 8-day episode.
3. Participation in post-withdrawal treatment. This was measured as (a) the number of 
subjects entering post-withdrawal treatment options during the 4-week follow-up period; (b) 
the number of days subjects were enrolled in any treatment during the 4 week follow-up 
period; and (c) the number of subjects retained in post-withdrawal treatment (enrolled in 
some form of drug treatment at day 35).
4. Cost-effectiveness. Cost effectiveness was calculated by comparing the incremental costs of 
all health services utilised by subjects during the 8-day withdrawal episode, against various 
outcome measures. Incremental costs refer to costs that are inherently different between the 
two groups (such as staffing, medications, treatment of adverse events), without including 
costs considered to be essentially the same across subjects in the two groups, including 
‘overhead’ costs to the organisations providing the services (including heating, power, rent, 
clinic administration and support (e.g. receptionists, filing), and services standard to both 
(including pre-randomisation assessment and recruitment expenses, research costs not 
related to clinical activity). The cost of health services utilised by subjects during the 
withdrawal episode was calculated from clinic records (e.g. medication charts), prospective 
data collection by clinic staff of the duration of contacts with subjects, and self-report by 
subjects at the day 8 research interview of other health services and medications used in the 
preceding week. The two outcome measures for use in the economic evaluation were (a) the 
number of self-report heroin-free days during the withdrawal episode, and (b) the proportion 
of subjects completing the 8-day withdrawal episode without any heroin use on urinalysis.
The secondary outcomes and related measures for the study are:
1. Severity o f withdrawal features. Withdrawal severity was a secondary outcome for this 
study as it is difficult to interpret data regarding the severity of withdrawal symptoms during 
outpatient withdrawal where some subjects continue to use heroin. Subjects rated the 
severity of opiate withdrawal on a daily basis using the Subjective Opiate Withdrawal Scale, 
completed prior to dosing during days 1 to 8. Objective features of opiate withdrawal were 
assessed daily using the Objective Opiate Withdrawal Scale by trained clinicians prior to
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dosing during the withdrawal episode. At the day 8 research interview, subjects rated the 
global severity of withdrawal experienced during the withdrawal episode using a Visual 
Analogue Scale with 0 = “No withdrawal discomfort experienced” and 100 = “Most severe 
withdrawal discomfort experienced”.
2. Side effects and adverse events. Subjects were asked to record any adverse events that 
occurred during the first week of withdrawal treatment (daily reporting). The treating 
medical officer assessed any adverse events, with an interpretation of the extent to which the 
adverse event was related to the study medication.
3. Measures o f psycho-social functioning. Severity of dependence to heroin was measured 
using the Leeds Dependence Questionnaire (Raistrick, Bradshaw et al. 1994) at baseline, at 
day 8 and at day 35. The Leeds Dependence Questionnaire assesses physical, psychological 
and behavioural aspects of dependence within the past week, and is therefore well suited to 
detecting changes in the severity of dependence following short-term interventions such as 
withdrawal. Social functioning and psychological well-being were assessed at baseline, at 
day 8 and at day 35 using the BASIS-32 (Eisen, Dill et al. 1994). The BASIS-32 is a self- 
completed 32-item questionnaire assessing five parameters of psychosocial functioning 
within the past week, thereby making it suitable to detect any changes following a short 
withdrawal episode. An additional measure of psycho-social functioning examining a longer 
time frame (one month), the SF-36 (Ware, Snow et al. 1993) was used at baseline and day 
35.
4. Subject perceptions o f satisfaction with withdrawal medications and goal attainment. 
Subjects were asked at the day 8 research interview to rate their satisfaction with their 
withdrawal medication (using a Visual Analogue Scale with 0 = very unsatisfied to 100 = 
very satisfied); and to rate the adequacy of the doses used (using a 5 point Likert scale). 
Subjects were also asked open-ended questions to identify the “good” and “bad” aspects 
associated with the medication regime to which they had been randomised.
Subjects were asked at intake to rate the importance of various goals regarding their drug 
use and treatment (see Appendix) using Visual Analogue Scales (0 = not important to 100 = 
very important). The goals used in the questionnaire had been identified as key reasons for 
presentation for withdrawal in an earlier qualitative study of outpatient heroin withdrawal at 
Turning Point (Dunlop, Koutroulis et al. 1996). Subjects were then asked at the completion 
of the withdrawal episode (day 8) and at the day 35 follow up interview whether they 
achieved their goals for withdrawal treatment (using VAS with 0 = no goals achieved and 
100 = all goals achieved).
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Data was also collected at intake regarding the following variables:
• demographics (age, employment status, legal status, accommodation status, drug use status 
of partner, and drug use in place of accommodation);
• locater information to assist in tracking subjects for follow up research interviews;
• previous participation in drug treatment services.
• expected severity of heroin withdrawal. Subjects rated the severity of withdrawal they 
expected to experience using a Visual Analog Scale (0 mm = no withdrawal discomfort to 
100 mm = extreme withdrawal discomfort).
The interview schedules, questionnaires, Plain Language Statements and other Case Record 
Forms for this study are included in Appendix 1.
4.2.4.2 Data collection
Earlier sections have described the outcome measures and data collection procedures during the 
baseline, day 8 and day 35 research interviews, and as part of clinical service delivery during 
the initial assessment, withdrawal and post-withdrawal interventions. The schedule of data 
collection for each subject is shown in Table 4.8. Subjects were reimbursed (at $20 per 
interview) to cover the costs of participation in the research interviews on days 8 and 35.
4.2.4.3 Rates of follow-up of subjects for research interviews
A trial profile diagram is shown in Figure 4.2. 114 subjects were recruited to the study, with 58 
(51%) randomised to the Experimental Group, and 56 (49%) randomised to the Control Group.
101 of the 114 subjects recruited to the study (89%) completed the day 8 research interview 
with the research assistant, with similar follow up rates for the two groups: 91% (53 / 58) for 
the Experimental Group compared to the 86% (48 / 56) for the Control group.
91 of the 114 subjects (80%) completed the day 35 research interview, with comparable follow­
up rates for the two groups: 83% (43 / 58) of the Experimental group compared to the 77% (43 
/ 56) of the Control group.
It is generally considered that an acceptable loss to follow-up for an intention to treat analysis 
is in the order of up to 20 % of subjects - beyond this proportion, it is difficult to generalise and 
make conclusions from the available data (Sackett, Richardson et al. 1997). The follow up rates 
of 89% at day 8 and 80% at day 35 are adequate to enable between group comparisons on an 
intention-to-treat basis.
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Eligible Patients (n = 187)
Control Group (n=56)
(all commenced treatment)
Randomized subjects (N=l 14)
Experimental Group (n=58) 
(all commenced treatment)
Registered Patients (N = 272)
Ineligible due to selection criteria 
(n = 85) (31%)
Partners of couples enrolled in study 
(n = 28) (15%)
Chose not to participate (n=45) 
(24%)
Day 8 research interview 
(withdrawal outcomes) 
(n=48) (86%)
Day 35 research interview 
(post-withdrawal 
outcomes) (n=44) (79%)
Day 8 research interview 
(withdrawal outcomes) 
(n=53) (91%)
Day 35 research interview 
(post-withdrawal outcomes) 
(n=48) (83%)
Figure 4.2. Progress of subjects through trial
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4.2.4.4 Data handling and storage
Data collected by clinical staff as part of the delivery of study clinical services was subject to 
the clinic policies regarding confidentiality of clinical records. These identify that details 
regarding treatment and the contents of the clinical records are to remain confidential, with 
information provided to others only with the consent of the patient, or where there is a 
responsibility of duty of care (e.g. transferring treatment, management of severe adverse event). 
Data and information provided to research assistants was not available to clinical staff, except 
in one case where the research assistant had concerns regarding the safety of a subject who had 
expressed suicidal ideation during the baseline interview. The research assistant relayed this 
information to the treating staff (who assessed the patient as being at low risk of harm).
The principal investigator (NL) was involved in providing clinical services to subjects at the 
Turning Point site, and was responsible for all data entry and analysis. The potential for the 
principal investigator to have (inappropriate) access to confidential research data during the 
delivery of clinical services to subjects was minimised by: (a) a research assistant conducted all 
research interviews, (b) all information identifying the subject was removed from research 
files; and (c) data entry into computer data bases until the completion of treatment services.
All records of subject research data are securely stored and only available to study researchers. 
Information linking the subject to the research data (e.g. consent forms, follow-up forms) is 
securely stored separately from the remaining files, and only available to study researchers. The 
data will be retained for 15 years as required for studies under the Clinical Trials Notification 
scheme (Therapeutic Goods Administration 1991).
4.2.4.5 Data Monitoring
The project was independently monitored as part of the National Evaluation of 
Pharmacotherapies for Opioid Dependence coordinated by the National Drug and Alcohol 
Research Centre and the National Centre for Epidemiology and Population Health. Monitoring 
was conducted by Panacea Inc., which included an audit of all data collected for a random 
sample of 10 % of subjects, and confirmation of the existence of all clinical and research files.
4.2.4.6 Data Analysis
Data was entered into and analysed using SPSS for Windows 10.1 software package. Key 
outcomes were analysed for between-group differences on an intention-to-treat basis using 
Pearson chi-square tests for categorical data and Student t-tests for continuous data. Where 
significant differences were identified between groups for key outcomes, estimations of the 
effect size of the between-groups differences are presented using Numbers Needed to Treat 
(NNT) with 95% confidence intervals (95% Cl) for categorical outcomes, and 95% Cl for 
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difference of the means for continuous variables. Multiple regression analysis was conducted to 
examine for predictors of key withdrawal and post withdrawal outcomes.
4.3. Results
4.3.1 Baseline Data
This section presents baseline data for all subjects recruited, and by each randomised group to 
examine for differences in potential confounding variables.
4.3.1.1 Demographic characteristics of subjects
74 subjects (65%) were male, with similar proportions in each group (69% Experimental, 61% 
Control). Other demographic characteristics are shown in Table 4.9. There were no significant 
group differences with regards to these measures.
Table 4.9. Subject demographic characteristics
Experimental (n=58) Control (n=56) Total (N= 114)
n % n % n %
Country o f Birth
Australia 52 90 42 75 94 83
Oceania 1 2 4 7 5 4
Asia 2 3 3 5 5 4
Europe 3 5 7 13 10 9
Aboriginal
Yes 6 10 1 2 7 6
No 52 90 55 98 107 94
Highest Education Completed
Grades 1 - 6 2 3 1 2 3 3
Grades 7 -10 13 22 12 21 25 22
Grades 11-12 28 48 29 52 57 50
Completed tertiary 9 16 10 18 19 17
Missing 6 10 4 7 10 9
Marital status
Never married 36 62 33 59 69 61
Married / defacto 14 24 15 27 29 25
Divorced / separated 6 10 6 11 12 11
Missing 1 2 2 4 3 3
Employment status
Student 8 14 7 13 15 13
Employed (full / part 24 41 21 38 45 39
time, self employed)
Unemployed / pension 26 45 28 50 54 47
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Certain data was only available for the 64 subjects from the Turning Point site (see Section 
4.2.1.3). Thirteen subjects (20%) reported having any children, (7 Control (22 %) and 6 (19%) 
Experimental subjects), although only six subjects (9%) reported currently living with their 
children (2 Control and 4 Experimental subjects). Participation in the study was voluntary; 
nevertheless, three subjects (5%) had court sentences pending, and three subjects (5%) were 
serving non-custodial sentences; 56 of 64 (88%) subjects reported no current legal status, and 
data was missing for two subjects (3%).
4.3.1.2 History of drug use and participation in drug treatment services 
Significant ages regarding heroin use and study enrolment
The mean (± standard deviation) age of subjects at recruitment was 29.7 years ± 7.8 (range 18 
to 49). Subjects were asked to recall the age they first used heroin and the age of first regular 
heroin use (Table 4.10). On average, there was a two to three year delay between first and 
regular heroin use, and subjects enrolled in this study on average more than six years after 
commencing regular heroin use. There were no significant differences between the two groups 
on these measures.
Table 4.10. Significant ages regarding lifetime history o f heroin use
Experimental 
(mean± SD)
Control 
(mean ± SD)
Total
(mean ± SD)
Age first used heroin 21.5 ±5.6 20.4 ±5.7 21.0 ±5.7
Age first regular heroin use
(n = 5 5 ) 
23.6 ±6.3
(n=51) 
23.1 ±6.4
(n = 1 0 6 )
23.3 ±6.3
Age at study enrolment
(n=54) 
30.1 ±7.8
(n=51) 
29.3 ± 7.8
(n=105) 
29.7 ±7.8
(n= 58) (n = 5 6 ) (N =  114)
Lifetime treatment history
Subjects reported the number of times they had participated in various drug treatment 
modalities during their lifetime (Table 4.11). Most subjects (n=T00, 88%) had prior treatment 
experience, with no significant between group differences. Withdrawal episodes accounted for 
over 60% of all prior attempts. Sixty nine percent of all withdrawal attempts had been in 
outpatient settings, inpatient withdrawal accounted for 29%, and ‘rapid’ opiate withdrawal 
using opioid antagonists accounted for only 2% of all withdrawal attempts (reflecting its 
limited availability in Australia at the time of the study).
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Table 4.11. Lifetime history o f drug treatment participation by randomised group
Experimental
(n=58)
Control
(n=56)
Total 
(N=l 14)
All treatment modalities
Mean ± SD 7.0 ±8.8 6.8 ±8.5 6.9 ± 8 .6
Median 4 4 4
No prior attempt n = 9 (16%) n = 5 (9%) n =  14(12%)
Withdrawal services
Mean ± SD 4.4 ±6.1 4.4 ± 6.8 4.4 ± 6.4
Median 2 2 2
No prior attempt n =  16(28%) n = 9 (16%) n = 25 (22%)
Other treatment services
Mean ± SD 2.9 ±4.5 2.6 ±3.3 2.8 ± 3 .9
Median 1 2 1.5
No prior attempt n=19 (33%) n=16 (29%) n=35 (31%)
Details regarding lifetime participation in treatment services other than withdrawal are shown 
in Table 4.12. Although more subjects had participated in methadone maintenance than any 
other treatment modality, outpatient counselling accounted for 42% of all non-withdrawal 
treatment episodes, methadone maintenance for 34%, other (usually 12-step self help 
programs) 12%, residential rehabilitation 7%, and naltrexone 4%.
Table 4.12. Proportion o f subjects having ever participated in non-withdrawal treatment
Treatment modality Experimental (n=58) Control (n=56) Total (N= 114)
n (%) n % n %
Methadone maintenance 29 (50) 27 (49) 56 (49)
Buprenorphine maintenance a 3 (5) 0 (0) 3 (3)
Naltrexone treatment 7 (12) 6 (11) 13 ( I D
Outpatient counselling 24 (41) 22 (39) 46 (40)
Residential rehabilitation 10 (17) 6 (11) 16 (14)
Other (usually self help) 3 (5) 6 (11) 9 (8)
a 3 subjects had participated in a prior clinical research trial of buprenorphine maintenance in Sydney.
Treatment past 12 months
Most subjects (n=80, 70%) had participated in some form of treatment within the past 12 
months. Overall, subjects reported a mean of 2.6 (± 4.0) treatment attempts in the past year 
(Experimental Group = 2.7 ± 4.8, Control Group = 2.5 ± 2.8, with no significant between-group
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differences (t (112) = 0.37, p = 0.71). Most treatment attempts in the past year were for 
withdrawal (62%), outpatient counselling (17%) and methadone (10%).
Unassisted withdrawal attempts (‘cold turkey’)
Subjects were asked to estimate the number of times they had attempted ‘cold turkey’, defined 
as a withdrawal attempt without assistance or support from a health professional (Table 4.13). 
Most subjects (n=104, 91%) reported having attempted cold turkey before, with approximately 
two thirds (n=77, 68%) having done so within the past year.
Table 4.13 Previous attempts at unassisted withdrawal ( ‘cold turkey’)
Experimental 
n = 58
Control 
n = 56
Total 
n=  112
Lifetime
Mean ± SD 10.2 ± 16.9 a 6.1 ±8.7 8.1 ± 13.6
Median 3 3 3
Range 0-100 0-50 0-80
Past 12 months
Mean ± SD 2.9 ±5.1 b 1.9 ±2.5 2.4 ±4.0
Median 1 1 1
Range 0-50 0-12 0-30
a: 2 subjects (each reporting 100 attempts) are excluded from calculation o f the mean and SD (> 5 times SD) 
b- 3 subjects (reporting 40, 50 & 50 attempts) are excluded from calculation o f the mean & SD (> 5 times SD)
Several subjects reported numerous cold turkey attempts such that the distribution of the data is 
skewed, and the means are not representative of the majority of subjects (even with the 
exclusion of extreme (> 5 SD) ‘outliers’). Most subjects (70%) reported 5 or less attempts at 
cold turkey during their lifetime, and 69% of subjects reported 2 or less attempts at cold turkey 
within the past year. A square root transformation of the data was performed to accommodate 
for the skewed distribution and to facilitate comparison between the two groups. There was no 
significant difference between the groups for lifetime cold turkey attempts (t(92)=l.88, p> 
0.05) or for attempts within the past year (t(87)=1.69, p >0.05).
4.3.1.3 Measures of drug use at enrolment
Heroin Use
Measures describing heroin use at baseline are presented in Table 4.14. On average, subjects 
reported using heroin three to four times a day (OTI Q score) on most days in the past month, 
spending approximately $100 per day. There were no significant group differences.
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Table 4.14. Measures of heroin use at baseline by randomised group.
Experimental (n=58) 
mean ± SD
Control (n=56) 
mean ± SD
Total (N=l 14) 
mean ± SD
Frequency /  quantity measures
Q score (OTI) 3.51 ±2.34 3.20 ± 1.83 3.36 ± 2.10
# days used in past 28 26.3 ±2.9 25.3 ±4.5 25.8 ±3.8
Average daily cost of heroin ($) 95.90 ±71.80 100.60 ±74.20 98.20 ± 72.70
Measures o f dependence
DSM-IV criteria (out of 7) 6.3 ± 1.0 6.4 ± 0.9 6.4 ± 0.9
Leeds Dependence Questionnaire 20.2 ± 6.0 20.4 ±5.3 20.3 ±5.6
Comparison of injectors and non-injectors
103 / 114 (90%) subjects reported routinely injecting heroin, with 11 subjects (10%) describing 
non-injecting routes (smoking in 10 / 11 cases). Four of the non-injectors were randomised to 
the Experimental, and seven to the Control Group (x2(l) = 1-03, p = 0.31). The non-injectors 
were significantly younger (mean = 21.5 ± 4.2) than the injecting heroin users (mean = 30.6 ± 
7.5) (t (17.8) = 6.20, p < 0.001), reported significantly more frequent heroin use (mean OTI Q 
score = 6.80 ± 3.78) than injectors (mean = 3.0 ± 1.44) (t( 10.3) = 3.32, p < 0.01); however had 
similar average daily cost of heroin, LDQ scores and psychosocial functioning (BASIS-32).
Measures of other drug use
The proportion of subjects reporting the use drugs other than heroin in the preceding month is 
shown in Table 4.15. There were no significant differences between groups in mean OTI Q 
scores, or the proportions of subjects using any particular drug class. For those subjects 
reporting any use in the past month, the mean Q score (± SD) for alcohol use was 0.98 standard 
drinks (± 1.64); for cannabis 3.90 (± 5.39) at an average daily cost of $13.60 (± 16.20); and 1.44 
tablets (± 2.25) for benzodiazepines. The mean daily cigarette consumption was 20 (± 10).
Table 4.15. Proportion o f subjects reporting use of other drugs in the past month at intake
Experimental (n=56) 
n %
Control (n=58) 
n %
Total (N= 
n
114)
%
Other opiates 8 14 10 18 18 16
Alcohol 27 47 26 46 53 47
Cannabis 31 53 31 55 62 54
Benzodiazepines 22 38 22 39 44 39
Amphetamines 5 9 4 7 9 8
Cocaine 5 9 3 5 8 7
Hallucinogens 2 3 2 4 4 4
Tobacco 54 93 55 98 109 96
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4.3.1.4 Measures of psychosocial functioning
Details regarding employment status, marital status, and psychosocial measures of heroin 
dependence have been presented earlier (Section 4.3.1.1). Data was collected regarding drug 
use by the subject’s partner, and drug use in the subject’s place of accommodation, both 
variables thought to possibly impact upon outcomes for outpatient withdrawal (Table 4.16). 
There was no statistically significant difference between the groups with regard to partner’s 
drug use status (x^(2) = 5.20, p = 0.074), or for heroin use in the subject’s place of residence 
(X2(3) = 2.38, p = 0.97).
Table 4.16. Drug use status ofpartner and place o f residence
Experimental (n=58) Control (n=56) Total (N=•114)
n % n % n %
Partner ’s drug use
No current partner 32 55 19 34 51 45
Partner does not use heroin 9 16 13 23 22 19
Partner uses heroin 17 29 24 43 41 36
Heroin use in residence
Lives alone 7 12 6 11 13 11
Majority do not use heroin 30 52 28 50 58 51
Majority use heroin 21 36 21 37 42 37
Missing data 0 0 1 2 1 1
Psychosocial functioning in the week prior to enrolment was measured using the BASIS-32 
(Eisen, Dill et al. 1994). Data for each of the five subscales and Average BASIS-32 score are 
shown in Table 4.17. Each subscale has a maximum score of 4.0, with lower scores signifying 
better functioning. There were no significant differences between the two groups.
Table 4.17. BASIS-32 scores at intake
Experimental (n=58) 
mean ± SD
Control (n=56) 
mean ± SD
Total (N=l 14) 
mean ± SD
Relation to self / others 1.97 ±0.92 2.02 ± 0.90 1.99 ±0.91
Depression / anxiety 2.02 ± 0.97 1.96 ±0.87 1.99 ±0.92
Daily living / role functioning 2.16 ±0.93 2.14 ±0.87 2.14 ±0.90
Impulsive / addictive behaviour 1.29 ±0.81 1.15 ±0.66 1.22 ±0.74
Psychosis 0.70 ± 0.79 0.55 ±0.61 0.63 ±0.71
Average 1.68 ±0.72 1.61 ±0.62 1.64 ±0.67
Psychosocial functioning in the preceding month was measured using the SF-36 (Ware, Snow 
et al. 1993). Data for the two groups for each of the subscales is shown in Table 4.18. There 
were no significant between group differences. Included in this table is the percentile of the
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total study sample for each subscale compared to SF -36 scores for the general adult population 
in the United States (Ware, Kosinski et al. 1994). The study population were performing poorly 
in comparison - scoring below the 30th percentile for each subscale.
Table 4.18. SF-36 scores at intake (mean±SD)
Experimental (n=58) Control (n=56) Total (N=l 14) Percentile
Physical functioning 82.7 ± 17.4 78.6 ±21.3 80.7 ± 19.4 28%
Role - physical 32.3 ±38.9 32.6 ±37.5 32.5 ±38.1 16%
Bodily pain 52.9 ±26.3 53.5 ±23.8 53.2 ±25.0 20%
General health 49.4 ± 19.7 46.7 ± 20.3 48.1 ± 19.9 14%
Vitality 39.2 ±17.6 36.9 ± 15.9 38.1 ± 16.8 17%
Social functioning 40.1 ±23.4 47.1 ±22.5 44.0 ±23.1 12%
Role - emotional 35.1 ±43.0 34.5 ±40.7 34.8 ±41.7 18%
Mental Health 51.6 ± 20.1 52.1 ± 16.5 51.8 ± 18.3 13%
4.3.1.5 Goals and expectancy regarding withdrawal treatment
‘Expected withdrawal severity’ was rated by subjects at intake using a 0 to 100 mm Visual 
Analogue Scale (0 = “no withdrawal discomfort”, and 100 = “most severe withdrawal 
experienced”). The total sample had a mean score of 68 ± 22.7. The scores of the two groups 
were similar: the Control Group reported a mean of 66 ± 23, and the Experimental Group a 
mean of 70 ± 23 (t (112) = 0.83, p = 0.41).
Subjects rated the importance of a number of goals regarding their heroin use and treatment 
participation using Visual Analogue Scales with 0 = “not important” and 100 = “very 
important” (Table 4.19). Whilst not shown, the mean scores for the two randomised groups 
were similar for all measures, with no statistical differences between groups.
Almost all subjects identified that ceasing heroin use during withdrawal was a very important 
goal, and indeed the majority (88%) indicated that continued abstinence in the post-withdrawal 
period was very important for them (VAS score > 80 points). Interestingly, despite indicating 
abstinence as an important goal, most subjects also rated the goal of reducing their heroin use 
as just as important for them. A minority of subjects (28%) indicated that reducing (as opposed 
to stopping) their heroin use during the withdrawal episode was a low priority for them (VAS 
score < 40 points), and an even smaller proportion (21%) indicated that reduced heroin use in 
the post withdrawal period was a low priority. These results suggest that most subjects have 
multiple goals regarding their heroin use when approaching withdrawal services, with both 
abstinence and reduced use being considered important. Most subjects (81%) indicated that
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participation in treatment in the post withdrawal phase was important for them (VAS score > 
60).
Table 4.19. Subject ratings regarding treatment goals at intake
To cease heroin To reduce T o participate in To cease heroin T o reduce
L evel o f use throughout heroin use ongoing use for at least 1 heroin use for al
importance the withdrawal during the treatment after 8 m onth after least 1 m onth
(V A S Score) episode withdrawal day withdrawal withdrawal after withdrawal
(%) episode (%) ep isode (%) episode (%) ep isode (%)
0 - 2 0 0 27 5 5 19
2 1 - 4 0 0 1 2 0 2
41 - 6 0 3 5 12 4 3
61 - 8 0 4 5 7 3 7
81 - 100 93 61 7 4 88 6 9
M e a n  ±  S D 9 4  ± 9 71 ± 3 9 83 ± 2 5 8 9  ± 2 2 75  ± 3 7
4 . 3.1.6 Baseline data by study site
The data has been thus far presented according to Control and Experiment study groups. This 
section will briefly review the baseline characteristics of subjects enrolled at each of the study 
sites (Turning Point = TP; Langton Centre = LC). Overall, subjects recruited at the two sites 
were remarkably similar on most measures.
There were no significant differences between the two sites regarding subject demographic 
characteristics or measures of psychosocial functioning. The mean age (TP mean = 29.9 ± 8.0; 
LC mean = 29.5 ± 7.5) and sex (64% of TP subjects and 66% of LC subjects were male) at the 
two sites were very similar. There were no significant differences between the two sites 
regarding subject’s country of birth, highest educational level achieved, marital status or 
employment status. Subjects at each of the two sites had very similar measures of psychosocial 
functioning, with no significant differences regarding heroin-use status of their partner or place 
of residence, BASIS-32 or SF-36 scores.
One of the few areas in which there were differences between subjects at the two sites was their 
history of previous drug treatment. The mean number of total prior treatment episodes for 
subjects at the TP site was 8.0 ± 9.6, compared to 5.5 ± 7.1 times for subjects at the LC site. 
The TP group reported a significantly greater number of withdrawal episodes (mean = 5.7 ± 
7.6) compared to the LC group (mean = 2.8 ± 3.9); representing a greater number of outpatient 
withdrawal episodes among TP subjects (there was no difference in prior inpatient withdrawal 
participation). In contrast, although not statistically significant, the LC subjects had participated 
in more non-withdrawal episodes (mean = 3.1 ± 4.5) than TP subjects (mean = 2.5 ± 3.5), with
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more Langton Centre subjects having attempted methadone treatment (58%) and naltrexone 
treatment (16%) than at the TP site (42% and 8% respectively). A similar proportion of 
subjects (13 % at TP, 12% at LC) were presenting for their first ever treatment episode, and 
subjects at both sites reported a similar number of treatment attempts within the past year.
Measures of heroin use and dependence were also very similar for subjects at the two sites. TP 
subjects reported a mean Q score of 3.29 ± 1.74, had used heroin on average 26 days out of the 
past 28 at $98.52 ± 77.86 per day. LC subjects reported an average OTI Q score of 3.45 ± 2.50, 
using heroin on 26 of the previous 28 days at an average daily cost of $97.81 ± 66.15. Mean 
scores for the measures of dependence (DSM-IV and LDQ) were almost identical for subjects 
at the two sites. There were no significant differences regarding OTI Q scores for other drugs 
(alcohol, benzodiazepines, cannabis, psychostimulants) across the two sites.
The LC group had a higher mean score regarding expected severity of withdrawal (mean = 72 ± 
21) compared to the TP group (mean = 65 ± 24), although the difference was not statistically 
significant (t( 112) = 1.83, p = 0.07; 95% CI = -1 to 16). Subjects at the two sites had similar 
ratings regarding the importance of each of the various treatment goals.
4.3.1.7 Summary of baseline data
114 subjects were recruited at the two study sites, with 58 randomised to the Experimental 
condition and 56 to the Control condition. Two thirds of subjects were male, with an average 
age of approximately 30 years, and almost half reported no current employment or engagement 
in study. Most subjects (90%) were injecting heroin, spending on average approximately $100 
per day, and using heroin approximately 3 to 4 times a day. Subjects enrolled in the study 
approximately six years (on average) after commencing regular heroin use. The majority of 
subjects had sought treatment several times previously, with withdrawal the most common 
prior treatment modality, followed by outpatient counselling and methadone maintenance 
treatment. 70% had sought treatment in the previous 12 months. Approximately one third of 
subjects had a heroin-using partner, and over one third (37%) of subjects lived in a household 
where the majority of other residents used heroin. Almost all subjects identified that cessation 
of heroin use during and after the withdrawal episode were very important goals, however, 
three quarters of subjects also indicated that a reduction in heroin use during (and after) the 
withdrawal were also important goals for them. The similar scores on most measures at 
baseline suggests that the two study sites recruited very similar subjects.
Importantly, there were no significant differences at baseline between the two randomised 
groups for any of the key variables that may impact upon treatment outcomes (confounders). 
To this extent, the randomisation produced two similar groups of subjects, enabling
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comparisons between the randomised conditions without the concern of significant baseline 
differences.
4.3.2 Findings during withdrawal episode
4.3.2.1 Rates of retention in withdrawal services
Completion of the withdrawal episode was recorded for all subjects as a categorical measure, 
and refers to retention in treatment during the withdrawal episode, without incorporating any 
measure of heroin use. 50 of the 58 subjects (86%) in the Experimental group completed the 
withdrawal episode according to protocol, compared to 32 of 56 Control subjects (57%). A 
Pearson chi-square test indicates a significant difference between the two groups (x^(l) = 
11.92, p = 0.001). The relative risk (RR) regarding withdrawal retention is 1.5, and the Number 
Needed to Treat (NNT) for this outcome is 3.4 (rounded up to 4) (95% Cl for NNT = 2.2 to 7.5 
patients (rounded up to 3 to 8)).
Treatment retention was also recorded by the number of days that subjects remained in 
withdrawal treatment (Table 4.20 and Figure 4.3 on following page). This was calculated as the 
last day of attendance or contact with clinic staff. The Experimental group remained in 
withdrawal treatment for a mean of 7.3 ± 1.9 days, whereas the Control group participated for a 
mean of 5.6 ± 3.1 days. The differences in mean retention between the groups were statistically 
significant (t (91.4) = 3.59, p = 0.001, 95% Cl for difference of the means = 0.8 to 2.7 days). 
Kaplan Meier estimates of mean retention times were compared by the Mantel-Cox log rank 
test, indicating a significant difference between the groups (log rank= 12.25, p = 0.0005).
Table 4.20. Retention in withdrawal treatment
Days retained in withdrawal 
treatment
Experimental (n=58) Control (n=56)
n % n %
Day 1 58 100 56 100
Day 2 55 95 42 75
Day 3 53 91 41 73
Day 4 53 91 • 38 68
Day 5 53 91 35 63
Day 6 51 88 34 61
Day 7 51 88 34 61
Day 8 50 86 32 57
A limitation of the study was that the participants were not blinded to the treatment condition. 
Consequently, it is possible that a number of subjects (particularly from the Control group) 
were disenchanted with the outcome of the randomisation and ‘dropped out’ after being
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informed of their allocated treatment. Assuming this was relevant for subjects who did not 
attend after day 1 (and excluding their data), it is possible to recalculate the proportion of 
subjects completing the withdrawal episode. 42 Control subjects attended beyond day 1, with 
32 (76%) of these subjects completing the withdrawal episode. 55 subjects in the Experimental 
group attended beyond day 1, with 50 (91%) completing the withdrawal episode. A chi - square 
test indicates that the differences between the two groups remains statistically significant (%2 
(1) = 3.95, p < 0.05), indicating greater completion rates for subjects in the Experimental 
condition.
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Figure 4.3 Retention in withdrawal episode by randomised group
4.3.2.2 Drug Use During Withdrawal Episode
Heroin use during the withdrawal episode was measured by self-report (independently to 
clinicians during treatment and to the research assistant.at the day 8 interview), and by urine 
drug tests collected at day 5 and day 8.
Heroin use -  urine drug test results
Urine drug test results can be presented several ways. Data regarding opiate urine results for 
subjects participating in treatment are shown in Table 4.21. Pearson chi-square tests indicate 
significant differences between the two groups at both day 5 (%2 (1) = 11.53, p = 0.01) and at 
day 8 {j}  (1) = 4.73, p = 0.03). Significantly fewer Control subjects (2/32 or 6%) were retained
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in treatment and provided negative opiate urine results on both days 5 and 8; compared to 12/50 
(24%) of Experimental subjects (x2(l) = 4.34, p< 0.05).
Table 4.21. Opiate urine test results during withdrawal for subjects in treatment
Negative opiate urine result Experimental Control
Day 5 20 /53 (38%) 2 / 35 (6%)
Day 8 17/50 (34%) 4/32(13%)
All urines 37 / 103 (36%) 6 / 67 (9%)
As determined in the original study protocol, a ‘worse-case scenario’ approach for missing 
urine results was employed, with all missing urine specimens considered as ‘positive’ for 
opiates. Table 4.22 details the combined urine results for subjects using the ‘worse case 
scenario’ for missing data. The Experimental group had a significantly greater number of 
subjects remaining abstinent (day 5 and day 8 negative urines) during the withdrawal episode 
(X 2 ( 1) = 7.75, p = 0.005; NNT = 6; 95% Cl for NNT = 4 to 18). 25 Experimental subjects 
(43%) provided at least one negative urine result during the episode, compared to only 4 
Control subjects (7%) (x2(l) =19.4, p< 0.001, NNT = 3, 95% Cl for NNT= 2 to 5).
Table 4.22 Combined opiate urine drug test results
Urine opiate results Experimental (n=58) Control (n=56)
Both urine tests negative 12(21%) 2 (4%)
One urine test negative 13 (22%) 2 (4%)
No urine test negative 33 (57%) 52 (93%)
Heroin use- self report
Subjects were asked about their heroin use during the withdrawal episode at the day-8 research 
interview. Experimental subjects (n=53) reported using heroin on significantly fewer days 
(mean = 2.6 ± 2.5) compared to the 48 Control group subjects completing the interview (mean 
= 4.5 ± 2.3 days) (t(99) = 3.95, p < 0.001, 95% Cl = 1.0 to 2.5 days). From a clinical 
perspective, it is possible to categorise subjects’ reduction in heroin during the withdrawal 
episode as marked reduction (using heroin on 0, 1 or 2 days during the withdrawal episode), 
moderate reduction (using heroin on 3, 4 or 5 days), or minor / no reduction (using heroin on 6, 
7 or 8 days). Table 4.23 presents these findings. There is a statistically significant difference 
between the two randomised groups (x2(2) =13.0, p< 0.01). The relative risk for subjects 
having a marked reduction in heroin use between the two groups is 2.3, with a NNT of 2.84 (or 
3) (95% Cl for NNT = 2 to 6).
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Table 4.23. Patterns o f heroin use during the withdrawal episode
Experimental (n=53) Control (n=48)
n (%) n (%)
Marked reduction in heroin use 33 (62) 13 (27)
Moderate reduction in heroin use 11 (21) 16 (33)
Minor / no reduction in heroin use 9 (17) 19 (40)
A ‘worse case scenario’ approach was also used to account for the 13 cases not completing the 
day-8 research interview. This calculation incorporated data collected by clinical staff 
regarding heroin use during the withdrawal episode. The number of days used was calculated as 
[8 - (the number of ‘clean’ days reported to clinical staff during the withdrawal episode)]. For 
example, a subject attended the clinic for 5 days, reporting no heroin use on 2 days (but then 
had no further clinical or research contact); the number of heroin days = (8 - 2) = 6). Findings 
are shown in Table 4.24. There is a significant difference between groups (t (112) = 4.37, p 
<0.001, 95% Cl = 1.2 to 3.1).
Table 4.24. Self report number o f days used heroin during withdrawal episode
Experimental (n=58) Control (n=56)
n (%) n (%)
Number of days used heroin
0 13 (22) 2 (4)
1 6 (10) 3 (5)
2 14 (24) 8 (14)
3 7 (12) 8 (14)
4 4 (7) 4 (7)
5 2 (3) 4 (7)
6 3 (5) 2 (4)
7 4 (7) 10 (18)
8 5 (9) 15 (27)
Mean ± SD 2.9 ±2.6 5.0 ±2.6
Median 2.0 5.0
It should be noted that there was a discrepancy between the self-reported heroin use and 
findings from urine drug screens. 12 Experimental subjects had negative urine tests for opiates 
at day 5 and day 8, whilst 13 subjects reported no heroin use during the same period. The 
difference is accounted for by one subject who provided a day 5 urine test positive for 
amphetamines and morphine. On informing the subject of the positive urine result, he 
adamantly denied using heroin, but admitted to using ‘ecstasy’ early in the withdrawal episode. 
He brought samples of the ‘ecstasy’ tablets that he had used (4 different varieties) for drug
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analysis. Laboratory analysis indicated that all 4 varieties of ‘ecstasy’ contained heroin (and 
amphetamines), thereby accounting for the discrepancy between self-report and urine results.
Subjects also reported in the research interview the number of occasions (rather than number of 
days) they had used heroin during the withdrawal episode. Results are presented in Table 4.25, 
with data missing for 13 subjects. As for the other measures of heroin use, there was a 
significant difference between the two groups (t (99) = 2.66, p < 0.01, 95% Cl = 1.3 to 8.9).
Table 4.25. Number o f times used heroin during the withdrawal episode
Experimental (n = 53) Control (n = 48)
Mean ± SD 4.6 ±6.3 9.6 ± 12.3
Mode 0 and 2 2
Median 2 5
In order to compare the level of heroin use in the period prior to treatment (measured as an OTI 
Q score) and level of heroin use during the withdrawal period, data regarding number of times 
used during the withdrawal episode was transformed into a modified OTI Q score (modified Q 
score = number of times used heroin during withdrawal episode divided by 7, the number of 
days). Change in Q scores from baseline to day 8 was calculated as Q fay g - Q fay \- The 
Experimental group (n=53) had a mean change in Q score of -2.77 ± 2.33, compared to the 
Control group’s mean change of -1.76 ± 1.63 (n=48); this difference was highly significant (t 
(99) = 2.51, p = 0.01, 95%CI = -0.21 to -1.82).
Severity of dependence on heroin
Severity of heroin dependence in the preceding week was assessed at day-8 using the Leeds 
Dependence Questionnaire (LDQ). The Control subjects (n=48) reported a mean score of 14.8 
± 7.0, whereas the Experimental subjects (n=54) reported a significantly lower mean score of 
9.1 ± 6.8 (t (100)= 4.12, p <0.001, 95% Cl = 2.9 to 8.4).
Both groups had a significant reduction in their day-8 LDQ scores compared to baseline (paired 
t-test, pO.001); however the reduction in Experimental LDQ scores (mean = -11.1 ± 6.9) was 
significantly greater than the Control group reduction (mean = -5.9 ± 6.2) (t (100) = 3.94, p < 
0.001, 95% Cl for difference of means = 2.6 to 7.8).
Use of other drugs
Subjects were asked at the day-8 interview about the use of various drugs during the 
withdrawal episode - the more commonly reported drugs are shown in Table 4.26. The 
proportion of subjects reporting any use of these drugs is comparable to the baseline reports 
(see Table 4.15). Chi-square tests indicate no significant differences between the groups.
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Table 4.26. Proportion o f subjects reporting use o f other drugs during the episode
Experimental (n=54) Control (n=48)
n (%) n (%)
Cannabis 34 (63) 26 (54)
Alcohol 24 (44) 18(38)
Other opiates 7(13) 8(17)
The use of benzodiazepines is omitted from this table. All Control subjects were prescribed 
benzodiazepines, and 3 / 4 8  Control subjects (6%) also reported using additional 
benzodiazepines. In comparison, 7 Experimental subjects (12%) were prescribed 
benzodiazepines as part of the study (see Section 4.2.3.1). 17 / 54 Experimental subjects (31%) 
reported using (non-study) benzodiazepines during the withdrawal episode. The majority of 
these subjects reported using only small amounts of benzodiazepines: 5 subjects reported using 
only one tablet over the 8 day period, 5 reported using between 2 to 5 tablets, 3 reported using 
between 6 to 10 tablets, and 4 subjects reported using more than 10 tablets over the course of 
the withdrawal. Four of the 17 subjects reporting non-study benzodiazepines use were also 
prescribed benzodiazepines by the study doctors. Hence, in total, 20 Experimental subjects 
(34%) reported any benzodiazepine use during the episode (including study and non-study 
medications), with relatively low doses reported by most.
4.3.2.3 Withdrawal severity
The interpretation of withdrawal scores in an outpatient context is compromised by the use of 
heroin and other drugs by subjects during the withdrawal episode, and hence withdrawal 
severity was identified as a secondary outcome for this study. As described in Section 1.1.3, 
several approaches should be used to compare withdrawal severity between the two groups: 
daily withdrawal scores, total ‘area under the curve’ scores, and peak withdrawal scores.
Daily subjective withdrawal severity
There were too few Control subjects (n=2) reporting np heroin use to enable comparison of 
withdrawal data for ‘abstinent’ subjects in the two randomised groups. Hence, data was 
examined for subjects who described heroin use on 2 days or less (as such limited heroin use 
was less likely to dramatically alter the profile of withdrawal severity over the 8 day period). 
The mean daily SOWS scores (± SD) are shown in Table 4.27 for these 45 subjects (n = 12 
Control group, n = 33 Experimental group). Student t-tests indicate that Experimental subjects 
scored significantly less than the Control subjects on days 4 and 5, with non-significant trends
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on days 3 and 6 (which may be due to small numbers in the Control group (Type II error)). 
Figure 4.4 represents mean daily SOWS scores (± 95% Cl) by randomised group.
Table 4.27. Daily SOWS scores for subjects reporting heroin use on 2 or less days
Experimental Control
mean ± SD (n) mean ± SD (n)
Day 1 16.7 ± 10.2 (32) 13.9 ± 11.4 (12) NS
Day 2 17.5 ± 13.2 (33) 22.4 ± 11.3 (10) NS
Day 3 14.2 ± 12.5 (32) 24.0 ± 17.9 (10) p = 0.06, t(40) = 1.94
Day 4 10.1 ±8.1 (33) 27.5 ± 18.3 (10) p = 0.02, t( 10) = 2.93
Day 5 7.8 ±7.9 (31) 21.0 ±15.7 (8) p = 0.05, t(7.9) = 2.30
Day 6 8.5 ±7.4 (22) 19.5 ±15.0 (8) p = 0.08, t(8.3)= 1.99
Day 7 8.0 ±9.1 (25) 14.1 ±11.3 (7) NS
Day 8 8.7 ±8.0 (29) 11.4 ± 11.9 (7) NS
“  Control 
”  Experimental
Day of Withdrawal
Figure 4.4 Subjective withdrawal severity by randomised group for subjects using heroin on 
0,1 or 2 days during withdrawal episode (n=32 Experimental, n =  12 Control subjects).
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A repeated measures analysis for those subjects reporting minimal heroin use (< 2 days) was 
conducted for those subjects with minimal heroin use. SOWS scores for days with missing data 
were imputed as half way between the SOWS scores of the previous and subsequent days (for 
example, day 4 SOWS = 20, day 5 SOWS is missing, day 6 SOWS = 12, the day 5 SOWS 
score was assigned a value of 16 points). The Experimental group reported significantly less 
total withdrawal symptoms than the Control subjects (F = 9.17, p < 0.01).
Peak withdrawal severity
Another important measure of withdrawal severity is the peak withdrawal severity reported by 
subjects during the withdrawal episode. For this analysis, only subjects who reported 2 or more 
SOWS scores after baseline (day 1) were included. The mean peak SOWS score for the Control 
group (n=35) was 29.7 ± 15.0, whereas the mean peak score for the Experimental group (n=53) 
was 19.9 ± 11.7. The peak withdrawal score was significantly lower for the Experimental group 
(t (86) = 3.40, p = 0.001, 95% Cl = 4.0 to 15.4). The magnitude of the difference suggests this 
to be of clinical as well as statistical significance. The day at which peak withdrawal symptoms 
was reported (excluding baseline pre-treatment scores) is shown in Table 4.28, with the 
majority of subjects in both groups describing peak symptoms during the first 3 days of the 
withdrawal episode.
Table 4.28. Day of peak withdrawal severity
Experimental (n = 53) Control (n = 34)
Day 2 30 (57%) 10(30%)
Day 3 6(11%) 8 (24%)
Day 4 4 (8%) 7(21%)
Day 5 2 (4%) 4(12%)
Day 6 5 (9%) 1 (3%)
Day 7 5 (9%) 2 (6%)
Day 8 1 (2%) 2 (6%)
Mean ± SD 3.3 ± 1.9 days 3.8 ±1.8 days
Rebound withdrawal in Experimental subjects
11 of 53 subjects (21%) in the Experimental group reported a peak SOWS score on days 6,7 or 
8. This is after the cessation of buprenorphine and possibly indicates a degree of rebound 
withdrawal. The data is difficult to interpret for two subjects who used heroin on at least half of 
the days during the treatment episode and therefore the profile of the withdrawal syndrome for 
these subjects will have been altered considerably. The remaining 9 subjects (17%) reported 
using heroin on three days or less, and therefore the possibility of rebound withdrawal must be 
considered. Of these 9 cases, 5 subjects (9%) had mild rebound withdrawal severity (<5 point
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increase in SOWS score compared to scores from days 2 to 5) and/or transient withdrawal 
(resolution of peak severity by day 8). In four cases (of 53 subjects, or 8%) moderate rebound 
withdrawal was experienced (increase in SOWS >5 points compared to day 2 to day 5 scores), 
or SOWS scores remained elevated at day 8.
Global subject ratings of withdrawal severity
Another approach in estimating withdrawal seventy employed a more global measure at the 
day-8 research interview in order to include the experience of those individuals who continued 
to use heroin. Subjects rated the general withdrawal discomfort experienced using a 0 to 100 
VAS, with 0 = no withdrawal discomfort, and 100 = most severe withdrawal discomfort ever 
experienced. The Control group (n=44) reported a mean score of 63 ± 26, significantly higher 
than the Experimental (n=54) mean of 32 ± 28, (t(96)= 5.65, p < 0.001, 95% Cl = 20 to 42).
4.3.2.4 Adverse events
Adverse events (Table 4.29) were reported daily by subjects during the withdrawal episode, and 
assessed by the treating clinician. Excluded from the Table are symptoms that were assessed as 
clearly being part of the underlying withdrawal syndrome (for example, withdrawal symptoms 
considered by the subject as being usual or typical for them in both severity and onset), or 
adverse events considered to be definitely unrelated to the medication or the condition being 
treated. Data was missing for 13 Control and 3 Experimental subjects who did not attend 
clinical appointments beyond the first day.
Table 4.29. Adverse events during withdrawal episode
Adverse event Experimental
(n=55)
Control
(n=43)
Headache 15 (27%) 2 (5%)
Precipitated withdrawal symptoms 7(13%) -
Nausea 5 (9%) -
Sweating 5 (9%) -
Drowsiness 4 (7%) 6 (14%)
Vomiting 3 (5%) -
Lethargy / tiredness 3 (5%) 12 (28%)
Paraesthesia / sensory disturbances 3 (5%) -
Dry mouth 2 (4%) 7(16%)
Significant rebound withdrawal on ceasing medication 2 (4%) -
Constipation 2 (4%) -
Significant mood disturbance (agitation, dysphoria) 2 (4%) 3 (7%)
Light-headed / dizziness / hypotension 1 (2%) 15 (35%)
Sleep disturbance - 3 (7%)
Other (each reported by one subject only) 6(11%) 2 (5%)
None reported 16(29%) 13 (30%)
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Similar proportions of subjects in each group reported no adverse events. The profile of adverse 
events reported in each group is consistent with previous reports for these medications: the 
Control subjects predominantly complained of anticipated side effects to clonidine (lethargy, 
light headedness, dry mouth, drowsiness) (Washton and Resnick 1981). The subjects receiving 
buprenorphine predominantly complained of headache, nausea, sweating and drowsiness, 
typically following the first few doses of buprenorphine, and subsiding thereafter.
Seven Experimental subjects (13%) reported some degree of precipitated withdrawal upon 
commencement of buprenorphine. This was despite efforts to ensure that subjects were not 
given a dose of buprenorphine within 6 hours of recent heroin use (see Section 2.3.1). In most 
cases the precipitated withdrawal was mild in severity, and of short duration (up to six hours). 
Only one case of precipitated withdrawal was of sufficient severity to warrant management 
with ancillary medications (clonidine, metoclopramide and diazepam). One subject continued 
to use heroin throughout the withdrawal episode and continued to experience a degree of 
precipitated withdrawal following each buprenorphine dose, resulting in the subject refusing 
buprenorphine doses on days 4 and 5. Two subjects who experienced precipitated withdrawal 
were subsequently administered split doses of buprenorphine on the following day as a 
precaution (i.e., a small dose was administered in the morning and the subject presented four 
hours later for the remainder of the day’s dose).
4.3.2.5 Measures of psychosocial functioning
The BASIS-32 was administered at day 8 to assess various aspects of psychosocial functioning 
during the course of the one-week withdrawal episode (Table 4.30). Whereas subjects from the 
two groups reported similar BASIS-32 scores at baseline, the subjects in the Experimental 
group reported a significantly higher level of psychosocial functioning (lower scores) during 
the withdrawal episode for the combined Average score, and for all subscales with the 
exception of the Psychosis subscale.
Table 4.30. BASIS-32 scores at day-8 by randomised group
Experimental 
(n=53) 
mean ± SD
Control 
(n=48) 
mean ± SD
Relation to self / others 1.21 ±0.81 1.76 ±0.88 p=0.001, t(100)=3.28, 95%CI =0.22 to 0.8
Depression / anxiety 1.15 ±0.72 1.89 ±0.92 pcO.001, t(89)=4.50, 95%CI = 0.41 to 1.0'
Daily living / role functioning 1.32 ±0.81 1.92 ±0.95 p=0.001, t(100)=3.44, 95%CI= 0.25 to 0.9
Impulsive / addictive behaviour 0.65 ±0.59 0.94 ±0.55 p< 0.05, t(100)=2.54, 95%CI = 0.06 to 0.5
Psychosis 0.31 ±0.45 0.45 ±0.51 NS
Average 0.96 ±0.56 1.45 ±0.66 p O .0 0 1 , t(100)=3.98, 95%CI= 0 .24 to 0.7
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Within-subject change in BASIS-32 scores was assessed for the Average and the five subscales 
(BASIS score day g - BASIS score fay j). The Experimental group had a significantly greater 
reduction in BASIS Average score, Depression, Addiction and Daily Living subscales 
(p<0.01), and Relationship and Psychosis subscales (p<0.05), compared to the Control group.
4.3.2.6 Measures of patient satisfaction
The adequacy of medication dosing regimes can influence treatment outcomes. To examine for 
this potential confounder, subjects were asked at the day-8 research interview to rate the 
adequacy of the doses of medication prescribed during the withdrawal regime using a 1 to 5 
Likert scale (see Appendix 1). Findings are presented in Table 4.31. Most subjects in both 
groups indicated that their doses had been ‘about right’, although approximately one quarter of 
subjects indicated that their dose had been inadequate. There were no significant differences 
between groups on this measure.
Table 4.31. Ratings of dose adequacy o f withdrawal medications.
Experimental (n=53) 
n (%)
Control (n=44) 
n (%)
Much too low = 1 4(8) 3(7)
Too low = 2 10(19) 9(20)
About right = 3 38 (72) 31 (70)
Too high = 4 1(2) 1(2)
Much too high = 5 0 0
General satisfaction with the withdrawal medication was elicited at the day-8 research 
interview using a Visual Analogue Scale, with 0 = ‘not satisfied’ and 100 = ‘very satisfied’. 
The mean score for the Control group (n=46) was 36 ± 31, whereas the mean score for the 
Experimental Group (n=54) was 81 ±24,  representing a statistically significant difference 
between the groups (t (98) = 8.26, p < 0.001, 95% Cl = 34 to 56).
Subjects were asked in an open-ended question to identify the ‘good’ or ‘positive’ aspects and 
the ‘bad’ or ‘negative’ aspects associated with their prescribed medication. Common positives 
regarding buprenorphine included: the alleviation of withdrawal discomfort (reported by 91% 
of subjects), reduction of cravings (51%), enabling subjects to function with normal daily 
activities (28%), improved sleep (19%) and the ability to remain ‘clear headed’ during the 
withdrawal (13%). Less common positives included the ‘blocking’ of the effects of heroin use 
(6%) and the convenience of the dosing regime (6%). The more common negative aspects 
included: side effects (25%) and taste of the medication (13%), whilst only a small proportion 
reported that buprenorphine did not adequately relieve withdrawal discomfort (6%),
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precipitated withdrawal (4%) or described significant rebound withdrawal following its 
cessation (9% - a similar proportion as identified earlier in Section 4.3.2.3).
Positive aspects reported by subjects using symptomatic medication included: reduction in 
withdrawal discomfort (57%), improved sleep (20%), reduction in cravings (13%), heavy 
sedation (as a positive - 9%), and the avoidance of a prolonged withdrawal (7%). Negative 
aspects regarding symptomatic medication included: heavy sedation (56%), other side effects 
(43%), inadequate relief of withdrawal symptoms (28%); and poor daily functioning (15%).
21 of 48 Control subjects (44%) indicated that they would use symptomatic medication again if 
required for heroin withdrawal, 15 (31%) indicated they would not, and 12 (25%) were 
undecided. In comparison, 52 of the 54 Experimental subjects (96%) indicated that they would 
use buprenorphine again, one subject (2%) responded negatively, and one (2%) was undecided. 
There was a significantly different distribution of responses between the two groups (%2(2) = 
34.49, p<  0.001).
Another measure of treatment satisfaction included subjects rating the extent to which they had 
achieved the goals they had identified at the outset of the withdrawal episode. Experimental 
subjects (n=54) reported a significantly higher degree of goal attainment (mean = 66 ± 28) than 
Control subjects (n = 47, mean = 41 ± 29) (t (99) = 4.47, p < 0.001, 95% Cl = 14 to 36).
4.3.2.7 Cost effectiveness of withdrawal interventions
Cost effectiveness was determined by comparing the incremental cost of all health services 
utilised during the withdrawal episode, against measures of withdrawal outcome, on an 
intention-to-treat basis.
Calculation of incremental health costs during the withdrawal episode
The cost of all health services utilised during the withdrawal episode includes services related 
and unrelated to the withdrawal episode. These were calculated as follows:
Costs related to withdrawal episode = Trial staffing costs + Trial medication costs + 
Cost of other health services (related to withdrawal) + Cost of other medications 
(related to withdrawal)
Costs unrelated to withdrawal = Cost of other services (not related to withdrawal) + 
Cost of other medications (not related to withdrawal)
A prospective record was maintained of all contacts (following randomisation and recruitment 
to the study) between trial clinicians and subjects during the withdrawal episode. A comparison 
of the mean number of clinical contacts and total contact time with each profession is presented
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m the Table 4.322. Subjects in the Experimental group had a significantly greater number of 
overall clinical contacts, and in particular nursing contacts, however utilised less pharmacist 
time than the Control group subjects.
Trial staff costs were calculated for each subject according to the following formula:
[Total contact hours medical staff x average hourly cost medical staff] + [Total contact 
hours nursing staff x average hourly cost nursing staff] + [Total contact hours 
pharmacists x average hourly cost pharmacists] + [Total contact hours other staff x 
average hourly cost other staff]
Oncosts were estimated at approximately 16% of salaries. The mean hourly rate for each 
professional group at the two sites is provided in Appendix 2.
Table 4.32. Clinical contacts by randomised group for all subjects
Experimental Control
(n = 58) (n = 56)
Mean ± SD Mean ± SD
Medical staff
number of contacts 3.5 ±2.1 3.0 ±2.0 NS
total time (min) 62 ±51 56 ±50 NS
Nursing staff
number of contacts 3.6 ±2.7 2.4 ±2.3 p < 0.05 (t(85.5) = 2.54)
total time (min) 62 ±57 40 ±42 p < 0.05 (t (105.1) = 2.43)
Pharmacists
number of contacts 3.1 ±2.1 3.1 ±2.5 NS
total time (min) 19 ± 15 29 ±27 p < 0.05 (t(85.5) = 2.54)
Other staff
number of contacts 2.0 ±0 1.0 ±0 NS
total time (min) 50 ± 10 28 ±8 NS
(n = 2) (n=4)
All clinical staff
number of contacts 10.3 ±2.9 8.6 ±4.9 p < 0.05 (t(88.3) = 2.29) 
95% Cl = 0.2 to 3.2
Details regarding trial medications administered during the withdrawal episode were collected 
from clinical records and were presented in Section 4.2.3.1. Costs for all medications were 
assigned at pharmacy wholesale prices as at April 1999 (Schedule of Pharmaceutical Benefits, 
April 1999), with the exception of buprenorphine, which was not registered at the time of the
2 Note: Table 4.32 describes contacts for all subjects enrolled in the study for calculating total 
costs. This is in contrast to Table 4.6, which only included data for those subjects who 
attended 2 or more days during the withdrawal episode (n = 97).
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study. The wholesale price of buprenorphine (2 mg Subutex®) in Australia was provided by 
Reckitt & Benkiser at $1.54 per 2 mg tablet (personal communication, August 2000).
Details regarding the utilisation of health services and medications from other service providers 
(not from study sites) were ascertained at the day-8 research interview, including whether 
services were related or unrelated to the withdrawal episode (from subject’s perspective). Data 
was available for 100 subjects (46 in Control group, 54 in Experimental group). The majority 
of subjects did not utilise medications or services outside of the study (see Table 4.33). The 
health services related to the withdrawal episode were consultations with general practitioners 
(5 subjects), counsellors (2 subjects) and other health professionals (acupuncture, masseuse) by 
3 subjects. There were no significant differences between groups in the number of subjects 
utilising external services.
Medications used outside of the study were costed in the same manner as described for trial 
medications. The Centre for Economic Health Evaluation provided estimates for the cost of 
health services utilised outside of the study (see Appendix 2 for details).
Table 4.33. Utilisation o f external health services during the withdrawal period
Experimental (n=54) 
n (%)
Control (n= 46) 
n (%)
Related to withdrawal episode
Number subjects using other health services 3(6) 7(15)
Number subjects using other medications 7(13) 4(9)
Not related to withdrawal episode
Number subjects using other health services 4(7) 3(7)
Number subjects using other medications 4(7) 5(11)
The costs of health services incurred during the withdrawal episode are shown in Table 4.34 for 
the two randomised groups. There were no significant differences between the two randomised 
groups with regards to the cost of health services related to the withdrawal episode, nor for the 
total cost of all health services utilised during the withdrawal episode. The only item which was 
significantly different between the two randomised groups was the cost of the trial withdrawal 
medications, with the Experimental group having a significantly greater cost than the Control 
group (t(l 12) = 8.52, p < 0.001).
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Table 4.34. Cost o f all health services utilised during the withdrawal episode.
Experimental Group Control Group
(mean ± SD) (mean ± SD)
Costs related to withdrawal episode
Trial staffing costs a $75.55 ±33.32 $66.99 ±41.71
Trial medication costs a $26.85 ±9.80 $11.94 ±8.84
Other medications $0.59 ±3.37 $0.13 ±0.83
Other health services $4.82 ±26.51 $13.75 ±60.55
Total related costs $110.48 ±47.07 $101.36 ±76.25
Costs not related to withdrawal episode
Other medications $0.26 ± 1.25 $0.90 ±3.40
Other health services $3.96 ± 16.78 $7.07 ± 26.26
Total unrelated costs $4.22 ±16.77 $7.97 ±26.71
Total cost o f health services provided $114.70 ±48.78 $109.33 ±83.70
during withdrawal episode
a data available for all 114 subjects. Data on other variables are restricted to those subjects (n=100, 88%)
completing day-8 research interview
Cost effectiveness
Two outcomes for outpatient withdrawal services were considered to be most relevant for a 
cost effectiveness analysis:
(i) The number heroin-free o f days achieved during the withdrawal episode, in which cost 
effectiveness for the withdrawal episode was calculated for each subject using the equation:
Cost effectiveness = total (incremental) cost of health services / number heroin free days^
Using this equation, the mean incremental cost for subjects to achieve one heroin-free day for 
the Experimental group (n=53) was $30.03 ± 32.14, and for the Control group (n=46) was 
$52.47 ± 72.14, which can be interpreted as the Experimental condition achieves on average, 
1.75 times more heroin free days for the same cost. Statistical comparison between the two 
groups indicates this to be a non-significant trend (t(58.4) = 1.84, p = 0.07, 95% Cl = -$1.98 to 
$46.85). Given that this data is not distributed normally, the non-parametric tests comparing the 
two groups indicates a non-significant difference (Mann Whitney U = 992, p = 0.11).
3 Subjects reporting no heroin-free days during the withdrawal episode were assigned a value 
of 1 heroin-free day in order to avoid zero as a denominator.
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(ii) The proportion o f subjects completing the withdrawal episode with no heroin use. Cost 
effectiveness with this outcome was calculated as:
Cost effectiveness per group = total (incremental) cost of health services for all subjects in 
group / proportion completing the withdrawal episode with no heroin use
With this outcome measure, the cost to achieve one completed withdrawal episode without 
heroin use was $554.10 for the Experimental condition, and $3,036.94 for the Control 
condition, representing a incremental cost effectiveness ratio of 5.48 (Experimental) to 1 
(Control).
4.3.2.8 Predictors of withdrawal outcomes
Multiple regression analysis was conducted to examine which subject variables at baseline 
were independently related to the two primary short-term withdrawal outcomes: days used 
heroin during withdrawal episode, and number of days retained in withdrawal treatment. Given 
the significant impact of the randomised treatment condition upon the withdrawal outcomes, 
regression analysis was conducted separately for the Experimental group and Control groups. 
The baseline characteristics initially entered into the univariate regression analysis were: sex 
(dummy variable); age; years since commenced regular heroin use; number of prior treatment 
attempts; partner’s heroin use (dummy variable); route of administration (dummy variable); 
average daily cost of heroin in past 4 weeks; number of days used heroin in past 4 weeks; 
heroin OTI Q score; Leeds Dependence Questionnaire; BASIS Average score; alcohol Q score; 
cannabis Q score; tranquilliser Q score; expectancy regarding severity of withdrawal; and 
treatment goals at intake. Stepwise backwards regression was employed, with non-significant 
variables removed sequentially from the equation until the removal of variables considerably 
reduced R^.
Three intake variables were significant predictors of the number of days heroin was used during 
the withdrawal episode by the Experimental subjects (R^ = 0.36): age at entry to study (F = 
7.41, p< 0.01), average daily cost of heroin use in preceding 4 weeks (F = 6.02, p < 0.05), and 
having a heroin-using partner (F = 4.95, p < 0.05). The only significant predictors of heroin use 
during withdrawal for the Control subjects (R^ = 0.44) were average daily cost of heroin use in 
preceding 4 weeks (F = 6.95, p < 0.05), and severity of dependence on heroin (F = 6.37, p < 
0.05).
Regression analysis was also conducted with the number of days retained in withdrawal 
treatment as the dependent variable. Increased severity of dependence on heroin (LDQ) at 
baseline (F=7.63, p < 0.01) and general psychosocial dysfunction (BASIS-32 Average) (F =
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4.58, p < 0.05) were significant predictors of increased duration in withdrawal treatment for the 
Experimental subjects (R- = 0.33). Intake OTI heroin Q score was the only significant variable 
(F = 5.10, p < 0.05) for the Control group (R- = 0.35).
4.3.2.9 Comparison of withdrawal outcomes by site
A similar pattern of withdrawal outcomes was replicated at each of the two study sites. There 
was a significant difference between the two sites in that a greater proportion of all Turning 
Point subjects completed the withdrawal regime (51 / 64 or 80%) than at the Langton Centre 
(31/50 or 62%) (x^ (1) = 4.35, p < 0.05). The Experimental group had a significantly (p<0.05) 
greater rate of completion than the Control group at each site.
Levels of heroin use during the withdrawal episode were very similar across the two sites, with 
no significant differences between sites. A significantly greater proportion of Experimental 
subjects had an opiate negative urine test than Control subjects within each site, and the 
Experimental group reported using heroin on significantly fewer days than the Control group (p 
< 0.01). A similar pattem was seen regarding other treatment outcomes, with the Experimental 
group at each site reporting significantly lower seventy of dependence (p < 0.05), lower global 
withdrawal symptom severity (p<0.01), and higher subject-rated global medication satisfaction 
scores (pO.Ol).
4.3.2.10 Summary of findings during withdrawal episode
Subjects from both randomised groups described significant reductions in their heroin use 
during the withdrawal episode. Whereas subjects reported using heroin (on average) 3 to 4 
times a day prior to enrolment, the mean level of heroin use during the withdrawal episode was 
approximately once a day. Similarly, subjects reported significant improvements in measures 
of dependence and psychosocial functioning during the withdrawal episode compared to 
baseline.
The primary short-term outcomes for outpatient withdrawal services (reduction in heroin use 
and retention in withdrawal treatment) were significantly enhanced for the Experimental 
subjects compared to the Control subjects. The extent of the difference between the groups was 
considerable, with small Numbers Needed to Treat, suggesting a clinical as well as a statistical 
advantage in using buprenorphine during withdrawal.
The study examined incremental cost effectiveness (and did not include overhead expenses 
similar to both groups). The cost of delivering health services for subjects during the 
withdrawal episode was similar for both groups. When considering heroin-free days during the 
withdrawal episode as the primary treatment outcome, the Experimental condition achieved
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1.75 times more heroin-free days for the same cost as the Control condition, although this was 
not statistically significant (p = 0.07, 95% Cl for difference of means = -$1.98 to $46.85). The 
incremental cost-effectiveness ratio for the outcome of ‘completing withdrawal without heroin 
use’ was 5.5 to 1.
Secondary short-term outcomes were also enhanced for the Experimental group. Despite the 
difficulties in interpreting withdrawal severity scores during outpatient withdrawal, the 
available data suggests that Experimental subjects experienced less severe withdrawal 
symptoms than Control subjects. The peak withdrawal severity for subjects in both groups was 
generally described early in the withdrawal episode (prior to the day 3 dose for most subjects). 
A minority of Experimental subjects described peak withdrawal symptoms in the days 
following the cessation of buprenorphine: five subjects (9%) had mild and transient rebound 
withdrawal symptoms, and four subjects (8%) described moderate or persistent rebound 
withdrawal.
Measures of psychosocial functioning (BASIS-32 and severity of dependence) indicated 
significantly better levels of functioning during the withdrawal episode among the 
Experimental group. There were significantly higher levels of satisfaction with the withdrawal 
medication reported by the Experimental subjects. Adverse events were generally anticipated 
for the study medications. A similar proportion of subjects from both groups reported no 
adverse events, with no severe adverse events during the withdrawal episodes.
4.3.3 Post-Withdrawal Outcomes
4.3.3.1 Participation in post withdrawal treatment services
The principal outcome in the post-withdrawal period was the extent to which subjects 
participated in treatment services, serving as a measure of the capacity for withdrawal services 
to facilitate linkages to ongoing treatment. The number of subjects entering and being retained 
in post-withdrawal treatment at day 35 for the two groups is shown in Table 4.35. There was a 
significant difference in the distribution of subjects .from the two groups (x^(2)= 6.10, 
p<0.05)4.
4 22 subjects (10 Experimental, 12 Control) did not complete day 35 research interviews and hence complete data 
regarding post-withdrawal treatment is missing. Clinic records and jurisidictional records regarding state-wide 
methadone treatment were reviewed for these subjects and evidence o f ongoing treatment is included in this table; 
however, it is possible that some subjects entered other forms of treatment elsewhere. The data presented has used a 
‘worse case scenario’ and assigned ‘missing data’ as having not participated in treatment.
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Table 4.35: Summary o f post-withdrawal treatment participation by randomised group.
Experimental (n=58) Control (n-56) Total (N= 114)
Subject did not enter any treatment 11 (19%) 19 (34%) 30 (26%)
Subject entered treatment but not 11 (19%) 15 (27%) 26 (23%)
retained in treatment at day 35
Subject in treatment at day 35 36 (62%) 22 (39%) 58 (51%)
A high proportion of subjects from both groups participated in some form of treatment in the 
post withdrawal period (66% of Control and 81% of Experimental group, x^O) = 2.80, p= 
0.09). A significantly higher proportion of Experimental subjects were retained in some form of 
treatment at day 35 compared to Control subjects (x^(l) = 5.50, p <0.05, NNT = 4.4 or 5, 95% 
Cl for NNT = 3 to 25).
The Experimental subjects participated in treatment for significantly more days in the 28-day 
post-withdrawal interval (mean = 19.0 ± 11.2) compared to the Control group (11.0 ± 11.0) (t 
(112) = 3.83, p < 0.001, 95% Cl = 3.8 to 12.1).
Table 4.36 examines the patterns of participation in different treatment modalities during the 
post-withdrawal period. Approximately a third of the Control subjects (36%) attempted another 
withdrawal episode during the 4-week follow up period. These were predominantly outpatient 
withdrawal or ‘cold turkey’ attempts, although two subjects did report attempting rapid opioid 
withdrawal with naltrexone at a private clinic. Few Experimental subjects (3%) attempted 
another withdrawal episode.
Table 4.36 Participation in treatment modalities in the post-withdrawal period
Experimental (n=58) Control (n=56)
Entered In treatment Entered In treatment
at day 35 at day 35
Withdrawal treatment 2 (3%) 0 20 (36%) 3 (5%)
Outpatient 1 0 11 2
Residential 0 0 3 0
‘Cold turkey’ 2 0 8 1
Substitution treatment 39 (67%) 30 (52%) 20 (36%) 15 (27%)
Methadone 5 5 20 15
Buprenorphine 34 25 N/A N/A
Naltrexone treatment 9(16%) 3 (5%) 7(13%) 5 (9%)
Outpatient counselling 5 (9%) 5 (9%) 2 (4%) 0
Other 0 0 1 (2%) 0
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Significantly more Experimental subjects entered substitution treatment in the post-withdrawal 
period (x^(l) = 11.3, p < 0.005) and significantly more were in substitution treatment at day 35 
(X^(l) = 7.42, p < 0.01) compared to Control subjects. The high proportion of Experimental 
subjects who continued with buprenorphine treatment may be related to the high levels of 
patient satisfaction with buprenorphine as a medication, but may also be related to the limited 
availability of buprenorphine outside of the study. The rate of retention in substitution 
treatment at day 35 was similar in both groups (75% of Control and 77 % of Experimental 
subjects who entered substitution treatment were still in treatment at day 35). Retention rates 
were similar for subjects entering methadone (20/25, 80%) and buprenorphine (25/34, 74%).
Similar proportions attempted naltrexone treatment (13% of Control subjects, 16% of 
Experimental subjects). 5 /7  (71%) Control subjects who commenced naltrexone were still in 
treatment at day 35, compared 3 / 9  (33%) of Experimental subjects (statistically not 
significant). The Experimental subjects generally commenced naltrexone earlier in the follow 
up period: 7 Experimental subjects and only 2 Control subjects initiated naltrexone treatment 
under trial conditions by day 11 of the study, which may account for the different proportions 
in naltrexone treatment at day 35.
4.3.3.2 Post-withdrawal outcomes by randomised group (intention to treat)
The various post-withdrawal outcome measures are reported and analysed in this section for the 
total sample and by randomised group on an intention-to-treat basis. It should be emphasised 
that participation in treatment in the post-withdrawal period was self-selected by subjects, and 
the outcomes at day 35 may be related to a range of factors in the post-withdrawal period (such 
as the efficacy of any treatment program in which the subject is engaged in), and cannot be 
entirely attributed to the impact of the withdrawal episode.
Heroin Use
Measures of heroin use (modified OTI and Leeds Dependence Questionnaire) at the day-35 
interview are shown in Table 4.37. There was considerable individual variation in heroin use, 
and hence the data regarding frequency of use is presented in categories to assist interpretation.
Overall, subjects from the Experimental group reported significantly less heroin use in the past 
month than Control subjects as measured by the OTI Q score (t (89) = 2.48, p < 0.02, 95% Cl = 
0.11 to 0.96), and the number of days used heroin (t (89) = 2.94, p < 0.01, 95%CI = 1.8 to 9.4 
days). There was a non-significant trend for severity of dependence (LDQ) (t(90) = 1.95, p= 
0.054, 95% Cl = -0.1 to 6.4).
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Table 4.37. Measures o f heroin use in post-withdrawal period by randomised group
Experimental (n=58) 
n (%)
Control (n =56) 
n (%)
Total (n=l 14) 
n (%)
Q score for heroin (OTI)
0 5(9) 1(2) 6(5)
0.04 (used once only) 4(7) 3(5) 7(6)
0.05 - 0.14 (< than weekly) 11(19) 4(7) 15(13)
0.15 - 0.99 (less than daily) 15 (26) 13 (23) 28 (25)
1.0 or more (daily) 14 (24) 23 (41) 37 (35)
Missing 9(16) 12(21) 21(18)
Mean ± SD a> h 0.68 ±0.92 1.21 ± 1.13 0.93 ±1.05
Median Q score a 0.38 1.0 0.50
# days used in past 28 days
0 5(9) 1(2) 6(5)
1 -7 22 (38) 13 (23) 35 (31)
8- 14 8(14) 8(14) 16(14)
14-21 8(14) 9(16) 17(15)
21 -28 4(7) 12(21) 16(14)
Missing 9(16) 12(21) 21 (18)
Mean ± SD a 9.0 ±8.2 14.6 ±10.0 11.6 ±9.5
Average daily cost of heroin 50.91 ±41.77 53.21 ±66.18 52.03 ± 54.74
mean ± SD ($)a
Mean LDQ score ± SD a 9.6 ±7.4 12.8 ±8.1 11.1 ±7.8
a Mean and median scores for 93 subjects with complete data (49 Experimental and 44 Control group)
b Two outliers are excluded from this analysis: (1 Control, Q = 10.0) & (1 Experimental, Q = 20.0)
Within-subject changes in heroin use between day 35 and day 8 were examined for both heroin 
OTI Q (Q day 35 “ Q day8) and LDQ scores (LDQ day 35 - LDQ day 8)- These findings 
indicate that the main reductions in OTI Q and LDQ scores had occurred in the initial 
withdrawal period for most subjects, and these changes had generally been sustained over the 
follow up period. Overall there was little change in Heroin Q scores from day 8 to day 35 for 
either group (Experimental mean = -0.01 ± 0.88; Control mean = 0.10 ± 1.13), with no 
significant between group differences, although some subjects made considerable changes as 
suggested by the large standard deviations Similarly, there was minimal within-subject change 
in severity of dependence from day 8 to 35 (Experimental mean = 0.8 ± 6.9; Control mean = -.9 
± 8.1), with no significant between group differences.
The average daily cost of heroin for those subjects reporting heroin use in the follow up period 
was compared to their reported average cost at baseline. There was a significant reduction in
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the average daily cost of heroin use (paired t-test, t (84) = 6.83, p <0.001), with similar 
reductions reported by subjects in both groups.
Other Drug Use
The proportion of subjects reporting use of other drugs in the preceding 4 weeks (as measured 
at the day 35 interview with the OTI), are shown in Table 4.38. Data was missing for 22 
subjects.
Table 4.38. Use of other drugs in the post-withdrawal period
Experimental (n=48) Control (n=44) Total (n=92)
n (%) n (%) I n (%)
Other opiates 4 (8) 5 (11) 9 (10)
Alcohol 32 (67) 22 (50) 54 (59)
Cannabis 32 (67) 26 (59) 58 (63)
Benzodiazepines 12 (25) 13 (30) 25 (27 )
Amphetamines 0 (0) 3 (7) 3 (3)
Cocaine 4 (8) 2 (5) 6 (7)
Hallucinogens 6 (13) 4 (9) 10 ( I D
Tobacco 43 (90) 42 (95) 85 (92)
There were no significant between-group differences in the OTI Q scores, nor in the proportion 
of subjects using these drugs. Cannabis consumption remained high, with 63% of individuals 
reporting some use in the preceding month, compared to 54% at baseline. There was 
considerable variation in the Q scores for cannabis, with several subjects reporting scores of 
greater than 10. The mean Q score for those individuals using cannabis was 4.35 ±7.18 
(median = 1.63, maximum = 40).
A similar proportion (59%) reported some alcohol use in the preceding month, although most 
individuals using alcohol reported moderate consumption levels (mean =1.1 standard drinks ± 
1.8, median = 0.4, maximum = 11). At baseline, 47% of subjects had reported any alcohol use 
in the preceding month (see section 4.3.1.3, Table 4.15). Fewer subjects reported using 
benzodiazepines (27%) compared to baseline (39%). Benzodiazepine users reported a mean 
OTI Q score of 1.0 ± 1.2 (median = 0.5, maximum = 4). Tobacco use remained high, with 92% 
smoking at the mean rate of 17 ± 10 cigarettes per day.
Paired t-tests compared OTI Q scores for alcohol, cannabis and tranquillisers at day 35 with 
baseline (day 1) scores. The Experimental group reported a statistically significant increase in 
alcohol Q scores (t(47)=2.90, p < 0.01), but no significant changes in cannabis or tranquilliser 
scores. However, the extent of the increased mean Q score for alcohol consumption over this
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time corresponds to 0.27 standards drinks of alcohol per day, and is unlikely to be of major 
clinical significance. The Control group reported no significant changes in Q scores for these 
drug classes over the study period.
Measures of Psychosocial Functioning
Psychosocial functioning was measured using the BASIS-32 (preceding week) and SF-36 
(preceding month) at day 35. Results are shown in following Tables.
Table 4.39. BASIS scores at day 35 by randomised group
Experimental (n=48) 
mean ± SD
Control (n=44) 
mean ± SD
Relation to self / others 1.23 ±0.78 1.35 ±0.90
Depression / anxiety 1.11 ± 0.82 1.36 ± 0.83
Daily living / role functioning 1.24 ±0.84 1.44 ± 0.92
Impulsive / addictive behaviour 0.73 ±0.56 0.73 ± 0.58
Psychosis 0.32 ±0.41 0.31 ±0.42
Total Average 0.96 ±0.59 1.08 ± 0.66
Although the Experimental group had lower mean scores (signifying better functioning) for 
most subscales and for the global Average score, the differences between the two groups were 
not significant for any of the measures. Examination of wi thin-subject changes in BASIS scores 
from day 8 (Table 4.30) to day 35 revealed that the Control group made significant 
improvements (p<0.05) in the Average score and most subscales (all except for Psychosis) 
during the post-withdrawal period. In contrast, the BASIS scores for the Experimental subjects 
did not differ significantly during this time. Hence, the main improvements for Experimental 
subjects had occurred during the withdrawal episode, and these were generally sustained 
thereafter, whereas the Control subjects had made fewer initial improvements during the 
withdrawal episode, but made considerable advances by the fifth week.
SF-36 scores indicated that there were significant differences in favour of the Experimental 
group at day 35 on the subscales of Bodily Pain (t (90) = 3.40, 95% CI= 6.5 to 24.5), Vitality (t 
(90) = 2.40, 95% CI= 1.6 to 16.4), Social Functioning (t (90) =3.19, 95% Cl = 5.6 to 24.1) and 
Mental Health (t (90) = 2.11,.95% Cl = 0.5 to 15.6). Paired student t-tests from baseline (Table 
4.18) to day 35 for subjects from both groups (n=92) indicated a statistically significant 
improvement (p<0.05) for all subscales with the exception of Physical Functioning. However, 
subjects continued to perform poorly on these subscales compared to scores for adults from the 
general population. For example, the subjects in the Experimental group (who generally were 
performing better than the Control subjects) were between the 18th and 35th percentile for the
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various subscales (Ware, Kosinski et al. 1994). By comparison, subjects at baseline tended to 
be between the 12th and 28th percentile for the various subscales (Table 4.18).
Table 4.40. SF-36 scores at day 35 by randomised group.
Experimental (n=48) 
mean ± SD
Control (n=44) 
mean ± SD
Percentile*
Physical functioning 85.5 ±18.0 83.3 ± 19.5 NS 35%
Role - physical 51.0 ±40.3 40.9 ±38.5 NS 21%
Bodily pain 67.3 ± 20.8 51.8 ±22.7 p<0.02 33%
General health 53.4 ±22.6 54.7 ±25.9 NS 18%
Vitality 50.9 ± 18.6 41.9 ± 17.0 p<0.02 32%
Social functioning 67.7 ± 22.5 52.8 ± 22.2 p<0.01 25%
Role - emotional 43.8 ±41.3 41.7 ±40.1 NS 18%
Mental Health 63.9 ± 19.1 55.9 ± 17.2 p<0.05 26%
* refers to percentile for Experimental subjects at day 35 compared to US adult general population data
Goal Attainment
Subjects were asked the extent to which they had attained their treatment goals using a 0 (no 
goals attained) to 100 (all goals attained) Visual Analogue Scale. The Control subjects reported 
a significantly lower mean score (50 ± 31), compared to the Experimental mean score of 63 ± 
31 (t (90) = 2.12, p < 0.05, 95% CI = 1 to 26).
4.3.3.3 Outcomes by post-withdrawal treatment status
This section examines the various outcome measures according to the treatment status of 
subjects in the post-withdrawal period, in order to examine the impact of post-withdrawal 
treatment upon key outcomes. Data is analysed according to whether subjects entered and/or 
were retained in post withdrawal treatment, and not by the (randomly allocated) group status, 
as in the previous section.
Heroin and other drug use
Measures of heroin use are presented according to the treatment status of subjects at day 35 in 
Table 4.41. Data is available for only 93 subjects (82%).
As a group, subjects-in-treatment at day 35 reported significantly less heroin use on all 
measures compared to those subjects not in treatment at day 35: Q score: (t (49.8) = 5.03, p < 
0.001, 95% Cl = 0.64 to 1.50); days used heroin: (t (69.9) = 4.17, p < 0.001, 95% Cl = 4.1 to 
11.7); average daily cost of heroin (t (42.0) = 2.93, p <0.01, 95% Cl = $11.21 to 60.63); and 
LDQ score (t (70.9) = 4.94, p < 0.001, 95% Cl = 4.5 to 10.5).
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Table 4.41. Heroin use by treatment status at day 35
In treatment at day 35 
(n=52)
Not in treatment at day 35 
(n=41)
Q score
0 4 (8%) 2 (5%)
0.04 (used once only) 4 (8%) 3 (7%)
0.05 - 0.14 (< than weekly) 14 (27%) 1 (2%)
0.15 - 0.99 (less than daily) 21 (40%) 7(17%)
1.0 or more (daily) 9(17%) 28 (68%)
Mean ± SD a 0.47 ±0.56 1.54 ± 1.24
Median Q score 0.22 1.33
Number of days used in past 28 days 8.1 ±7.5 16.1 ± 10.0
(mean ± SD)
Average daily cost of heroin ($AUS) 35.74 ± 18.71 71.67 ±74.54
(mean ± SD)
LDQ score (mean ± SD) 7.9 ±6.1 15.3 ±7.9
a The mean score excludes n= 2 outliers (neither in treatment at day 35) with Q score = 10.0 and 20.0
On examining the Q scores more closely, it is apparent that a similar proportion of subjects in 
both groups reported no heroin use or use on only one occasion (12% in the ‘not in treatment’ 
group, 16% in the ‘treatment’ group). The main difference between the two groups appears to 
be that the majority of subjects (68%) in the ‘not in treatment’ group had relapsed to regular 
heroin use (Q scores > 1.0), with only a small proportion (19%) sustaining irregular heroin use 
(Q score between 0.05 and 0.99). In contrast, only a minority (17%) of those in treatment had 
relapsed to regular use (Q score > 1.0), whereas the majority (67%) sustained irregular heroin 
use (Q score between 0.05 and 0.99). The difference in average daily cost of heroin for those 
describing heroin use between the two groups is further evidence of the treatment group being 
better able to limit or control their use of heroin.
Within-subject changes in heroin use were examined according to treatment status. The ‘in 
treatment’ subjects (n=52) reported an overall reduction in the heroin Q score from day 8 to 35 
(mean = - 0.21 ± 0.83), whereas the ‘not in treatment’ group (n=41) reported an increase in 
their Q score (mean = 0.39 ± 1.12); representing a significant difference between groups (t 
(62.5) = 2.76, p < 0.01, 95% Cl = 0.17 to 1.04).
Use of other drugs did not appear related to day 35 treatment status, with no significant group 
differences for the more commonly used drugs (alcohol, cannabis, benzodiazepines, other 
opiates).
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The data indicates that the group of subjects who were retained in treatment at day 35 were 
using less heroin, and were less dependent on heroin than the group of subjects not retained in 
treatment. Interestingly, a considerable proportion of subjects (n = 26 or 23% of the total 
sample) entered some form of treatment in the post-withdrawal period, but were not retained in 
treatment at day 35. A separate senes of analyses (one way ANOVA) was conducted 
examining heroin use outcomes for three groups of subjects (Table 4.42):
• subjects retained in treatment at day 35 (data available for 52 / 58 subjects (90%));
• subjects who entered, but dropped out of post withdrawal treatment (data available for 25 / 
26 subjects (96%)); and
• subjects not entering any post-withdrawal treatment (data available for 16 / 30 subjects 
(53%)).
The three groups differed significantly across all measures of heroin use. Tukey’s post-hoc 
analyses indicate that the enhanced outcomes were seen in those individuals who were retained 
in treatment at day 35. With regards to OTI Q score, the ‘in-treatment’ group used significantly 
less heroin than the ‘treatment drop out’ group (p < 0.001, 95 % Cl = 0.50 to 1.56), and 
significantly less than the ‘no treatment’ group (p < 0.001, 95% Cl = 0.48 to 1.80). The Q 
scores for the treatment drop out and no treatment groups were not significantly different (p = 
0.93)
Table 4.42. Heroin use in post withdrawal period by treatment status
In treatment at Post-withdrawal No post w/d
day 35 treatment drop treatment
(n=52) out (n = 25) (n= 16)
OTI Q score
mean ± SD 0.47 ±0.56 1.50 ± 1.34 1.61a ± 1.06 F (2, 90)= 15.23
median 0.25 1.33 1.41 p< 0.001
Days used heroin in past 28
mean ± SD 8.1 ±7.5 14.2 ±9.6 18.8 ± 10.3 F (2, 90)= 10.89
p< 0.001
Ave daily cost of heroin (SAUS)
mean ± SD $35.74 ± 18.71 $62.17 ±51.94 $85.31 ±98.90 F (2, 85) = 6.08
median $30 $50 $50 p< 0.005
LDQ score (mean ± SD) 7.9 ±6.1 15.6 ±8.0 14.9 ±8.2 F (2, 91)= 12.98
p< 0.001
a The data for 2 subjects who were outliers (Q = 20.0 and 10.0) were excluded from the analysis of Q scores.
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Post-hoc analyses indicate that subjects in treatment at day 35 used heroin on significantly 
fewer days than subjects who dropped out of treatment (p < 0.05, 95% Cl = 1.0 to 11.1 days), 
and subjects who did not enter treatment (p < 0.001, 95% Cl = 4.8 to 16.5 days). The ‘no 
treatment’ and ‘treatment drop out’ groups were not significantly different on this measure.
Similar findings were seen with regard to severity of dependence on heroin as measured by the 
LDQ. The ‘in-treatment’ group had significantly lower scores than the ‘treatment drop out’ 
group (p < 0.001, 95% Cl = 3.7 to 11.9) and the ‘no treatment’ group (p < 0.01, 95% Cl = 2.3 
to 11.8). There was no statistically significant difference between the ‘no treatment’ and 
‘treatment drop out’ groups.
Subjects in treatment reported spending significantly less on heroin when they did use, 
compared to subjects in the ‘no treatment’ group (p < 0.01, 95% Cl = $13.83 to $85.30); and 
there was a non-significant trend compared to the ‘treatment drop out’ subjects (p= 0.12, 95 % 
Cl = -$5.00 to $57.85). The ‘no treatment’ and ‘treatment drop out’ groups were not 
significantly different on this measure.
Finally, data regarding heroin use is presented in Table 4.43 for those subjects who remained in 
treatment at day 35 according to their treatment modality (buprenorphine, methadone, 
naltrexone or counselling). Statistical comparisons have not been made given the small 
numbers and the similarity of scores for heroin use measures across the four treatment 
modalities. The exception is the naltrexone group, who reported very low levels of heroin use, 
although data is missing on many (38%) of these subjects, limiting the capacity to draw 
conclusions.
Table 4.43. Measures of heroin use at day 35 by treatment modality
Treatment modality # subjects with data / 
# subjects in 
treatment (%)
OTI Q score 
(mean ± SD)
Days heroin use 
in past month 
(mean ± SD)
LDQ score 
(mean± SD)
Substitution treatment 39/45 (87%) 0.44 ±0.51 8.1 ±7.0 8.1 ±6.1
Buprenorphine 25/25 (100%) 0.34 ± 0.47 6.3 ± 6.3 7.4 ± 6.4
Methadone 14 / 20 (70%) 0.63 ±0.53 11.2 ±7.2 9.5 ±5.6
Naltrexone 5 / 8 (63%) 0.03 ±0.05 0.4 ±0.6 1.8 ±2.4
Counselling 4 / 5 (80%) 0.44 ± 0.32 11.7 ± 10.4 10.0 ±6.9
Psychosocial measures
One possible explanation for some subjects not seeking treatment is that they were functioning 
quite well (regardless of their heroin use) and were not in need of ongoing treatment. To
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examine for this possibility, BASIS-32 data is presented in Table 4.44 according to whether 
subjects were enrolled in treatment at day 35.
Table 4.44. Day 35 BASIS-32 data according to post-withdrawal treatment status
In treatment (n=52) Not in treatment (n=40)
mean ± SD mean ± SD
Relation to self / others 0.98 ±0.63 1.69 ±0.90 p <  0 .0 0 1  ( t ( 6 6 .5 )  =  4 .2 0 )
Depression / anxiety 0.87 ±0.65 1.69 ±0.82 p <  0 .0 0 1  ( t ( 9 0 )  =  5 .3 7 )
Daily living / role functioning 0.96 ± 0.64 1.82 ±0.91 p <  0 .0 0 1  ( t ( 6 6 .5 )  =  5 .0 7 )
Impulsive / addictive behaviour 0.55 ±0.41 0.96 ±0.65 p <  0 .0 0 1  ( t ( 6 2 .3 )  =  3 .4 7 )
Psychosis 0.22 ± 0.34 0.44 ± 0.48 p < 0 .0 1  ( t ( 6 7 .4 )  =  2 .4 4 )
Total Average 0.75 ± 0.44 1.37 ±0.65 p <  0 .0 0 1  ( t ( 6 5 .7 )  =  5 .2 2 )
The group of subjects not in treatment at day 35 had significantly higher psychosocial 
dysfunction on all subscales and for the mean Average score. Within-subject changes in BASIS 
scores for the post-withdrawal period indicates that overall, both groups reported marginal 
improvements at day 35 compared to day 8 on all subscales, although there was considerable 
variation among subjects and no significant between group differences.
There were marked differences on most of the SF-36 subscales for those subjects in treatment 
at day 35 compared to those not engaged in treatment (see Table 4.45). Despite the subjects in 
treatment reporting significantly better outcomes on most subscales, they continued to rate 
poorly in comparison to general population data (Ware, Kosinski et al. 1994), scoring in the 
18th to 35th percentiles for the different subscales.
Table 4.45. SF-36 scores at day 35 according to post withdrawal treatment status
In treatment 
(n=52)
Percentile* Not in treatment 
(n=40)
Physical functioning 86.2 ± 18.1 35% 82.3 ± 19.4 NS
Role - physical 53.4 ±39.0 21% 36.9 ±38.8 p<0.05
Bodily pain 66.5 ± 20.8 33% 51.2 ± 23.1 p<0.01
General health 62.9 ±18.5 29% 42.4 ±25.8 p<0.01
Vitality 52.2 ± 18.9 32% 39.4 ± 14.9 p<0.01
Social functioning 67.5 ±21.6 25% ‘ 51.6 ±22.9 p<0.01
Role - emotional 46.8 ±41.4 18% 37.5 ±39.4 NS
Mental Health 67.2 ± 16.4 28% 50.8 ± 17.1 p<0.01
*  refers to percentile compared to US adult general population data
Goal attainment
The subjects in treatment at day 35 indicated (on a Visual Analogue Scale) that they had 
achieved a greater proportion of their treatment goals (mean = 68 ± 28) compared to those
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subjects not in treatment at day 35 (mean = 43 ± 30). The difference between the two groups 
was statistically significant (t (90) = 4.20, p <0.001, 95% Cl = 13 to 37).
4.3.3.4 Predictors of post-withdrawal outcomes
Multiple regression analysis was conducted to examine the impact of a number of variables at 
baseline and during the withdrawal episode upon the two primary outcomes in the post 
withdrawal period: participation in post-withdrawal treatment and heroin use (number of days 
used in past 28). Separate analyses were conducted for the Control and Experimental Groups, 
given the importance of Group upon both dependent variables. Independent variables included 
baseline characteristics (identical to those described for earlier regression analysis in Section 
3.2.8); and withdrawal episode variables, including: number of times used heroin during 
withdrawal episode; number of days used heroin in withdrawal episode; abstinence from heroin 
during withdrawal (dummy variable); day 8 LDQ score; withdrawal severity experienced 
(global VAS score); number of days retained in treatment during withdrawal episode; day 8 
BASIS-32 Average score; satisfaction with withdrawal medication (VAS score); goal 
attainment in withdrawal (VAS score).
With regards to days attended in post withdrawal treatment, the significant variables for the 
Experimental group (R^ = 0.40) were average daily cost of heroin at intake (F = 9.94, p < 0.01) 
and number of days participated in the initial withdrawal episode (F = 9.24, p < 0.01). Two 
variables were significant for the Control group (R^ = 0.40): average daily cost of heroin at 
intake (F = 6.90, p < 0.05) and importance of reduced heroin use in the post withdrawal period 
treatment as a treatment goal at baseline (F = 7.19, p < 0.05). Interestingly, amount of heroin 
use in the withdrawal episode was not predictive of post-withdrawal treatment participation for 
either group of subjects.
Variables which were predictive of the number of days of heroin use in the post-withdrawal 
period for the Experimental group (R^ = 0.52) were: average daily cost of heroin use at intake 
(F=13.7, p < 0.01), number of days used heroin in withdrawal episode (F = 6.0, p < 0.05), 
number of previous treatment attempts in the past year. (F = 7.4, p < 0.05), and number of 
lifetime attempts at non-withdrawal treatment modalities (F = 7.5, p < 0.01). For the Control 
group, number of days in which heroin was used during the withdrawal episode (F = 6.3, p < 
0.05) was the only significant predictor of days heroin use in the post withdrawal period (R^ = 
0.42).
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4.3.3.5 Induction onto naltrexone following buprenorphine treatment
This section examines the experience of induction onto naltrexone soon after a short 
buprenorphine withdrawal. Nine subjects who underwent buprenorphine assisted withdrawal 
commenced treatment with naltrexone during the 4 week post-withdrawal period. Of these, 4 
subjects commenced on day 8 (three days after their last dose of buprenorphine (4 mg) on day 
5); two subjects commenced on day 10; and one on day 11. The remaining 2 subjects 
commenced naltrexone at least 7 days after the last dose of buprenorphine, and they will not be 
further considered in this section as they underwent a conventional induction onto naltrexone. 
Furthermore, one subject (commencing at day 10) initiated naltrexone at home without clinical 
monitoring, and without clinical review for three days. Data for this subject is therefore 
unavailable and cannot be included in this description. Hence, data is presented on six subjects 
initiating naltrexone treatment following buprenorphine-assisted withdrawal.
The procedures for induction onto naltrexone following buprenorphine withdrawal were 
described in Section 4.2.3.2 in detail. Recapping, subjects were administered an initial 12.5 mg 
oral dose of naltrexone, 25 mg the following day, and if tolerated, 50 mg daily thereafter. 
Subjects were monitored using the Subjective and Objective Withdrawal Scales at baseline 
(prior to the initial naltrexone dose), for 3 hours after the initial dose (where possible), and on 
subsequent days (immediately prior to dosing). Symptomatic medications were available to 
subjects. The Subjective Opiate Withdrawal Scales for the four subjects who commenced 
naltrexone on day 8 are shown in Figure 4.5.
Figure 4.5: SOWS scores following naltrexone induction
The SOWS data presents only a limited picture of the response to naltrexone due to the brief 
period of monitoring of withdrawal after the initial naltrexone dose. Consequently, a short
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clinical summary is presented for each of these subjects, and for the two subjects inducted on 
days 10 and 11.
Subject AA. 26 year old woman. AA described no withdrawal discomfort at baseline (SOWS 
= 1, OOWS =1).  She described mild withdrawal symptoms during the clinical observation 
period, peaking in severity at 2 hours after the naltrexone dose (SOWS = 5, OOWS = 3). The 
predominant withdrawal symptoms reported during this time were sweating, hot / cold 
flushes, yawning, lacrimation and muscle and bone aches. She felt somewhat better at three 
hours than at two, and subsequently left the clinic confident that she had been ‘over the 
worst’. The following day on review she described a very difficult night - complaining of 
considerable anxiety, muscle and bone aches, sweating, disturbed sleep, and generally 
feeling ‘wired’. She described taking 5 mg diazepam orally at around 3 am, and slept for 
approximately 5 to 6 hours. By the morning (day 9) she had improved considerably, and 
reported minimal discomfort (SOWS = 4, OOWS = 0). She took a 25 mg dose of naltrexone 
on day 2. On review the following day she described no withdrawal discomfort over the 
preceding 24 hour period, scoring 0 for both the SOWS and OOWS. Subject AA remained 
on naltrexone for the 4 week post withdrawal period.
Subject BB. 31 year old man with a history of several episodes of successful completion of 
outpatient withdrawal followed by very rapid relapses to heroin use. BB described a mild 
degree of withdrawal at baseline (SOWS = 8, OOWS = 3), scoring predominantly on 
symptoms of anxiety and cravings. BB complained of only a minor increase in withdrawal 
features over the subsequent 3 hour review period, peaking on the SOWS (11) one hour after 
the naltrexone dose; and peaking on the OOWS (6) at 2 -3 hours. Main withdrawal features 
during this observation period were: perspiration, yawning, rhinorrhoea, lacrimation, flushes, 
aches and nausea. By the evening, BB described that many of the early symptoms had 
diminished, but was experiencing anxiety, restlessness, muscle and bone aches, and 
abdominal cramps. The subject stated that 150 mcgm clonidine and 10 mg diazepam eased 
these symptoms for several hours. By the following day, most of the withdrawal discomfort 
had eased, reporting SOWS = 6, and OOWS = 2. No significant increase in withdrawal 
discomfort was reported after the second naltrexone dose. Subject BB discontinued 
naltrexone treatment after day 12 (4 days of naltrexone treatment), and relapsed into heroin 
use 2 days later. He re-presented to the clinic after several weeks and attempted withdrawal 
using symptomatic medication (buprenorphine was not available as per study protocol - see 
methods).
Subject CC. This 43 year old woman had previously experienced naltrexone treatment 
several years earlier, and entered withdrawal with the aim of re-commencing naltrexone. She
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had described herself as being very fearful of withdrawal discomfort, and had been 
pleasantly surprised at the ease of her recent withdrawal using buprenorphine. At baseline 
she had some mild withdrawal discomfort (SOWS = 5, OOWS = 5). Approximately 2 hours 
after her initial naltrexone dose she described considerable withdrawal discomfort (SOWS = 
26, OOWS = 5), complaining predominantly of anxiety, muscle and abdominal cramps, 
sweating, and restlessness. On returning home, she took the prescribed symptomatic 
medication (150 mcgm of clonidine and 10 mg diazepam) and went to bed. She awoke in the 
early hours of the morning still complaining of general withdrawal discomfort, took another 
10 mg diazepam, but could not sleep again. The following morning she was experiencing 
mild withdrawal discomfort (SOWS = 12, OOWS = 3), but was reticent to take naltrexone 
on days 9 or 10. CC recommenced naltrexone on day 11, and remained in treatment for 
several months.
Subject DD. 46 year old woman had completed withdrawal with very minor discomfort, and 
commenced naltrexone on day 8. She reported minimal withdrawal at baseline (SOWS = 2, 
OOWS = 1), but within 2 hours experienced the onset of anxiety and a cluster of autonomic 
withdrawal features (SOWS = 7; OOWS = 5). On review the following day, DD described a 
very uncomfortable evening, complaining of worsening anxiety, restlessness, body aches, 
muscle and abdominal cramps, and several episodes of vomiting. Symptoms had peaked 
approximately six to ten hours after the naltrexone dose, and the withdrawal features had 
predominantly resolved by the following morning (SOWS = 9, OOWS = 0). She consented 
to taking only 12.5 mg naltrexone on day 9, but increased this to 25 mg on day 10. DD did 
not stabilise on naltrexone, complaining of persistent lethargy and dysphoria (recognised 
side effects to naltrexone), and ceased it after two weeks. She described not using heroin 
during the follow up period.
Subject EE: This 25 year old man commenced naltrexone on day 10. He reported no 
withdrawal discomfort either immediately prior or after his initial 12.5 mg dose of 
naltrexone. EE increased his dose on successive days, remaining in naltrexone treatment for 
the duration of the follow up period.
Subject FF. A 23 year old man who completed withdrawal on day 8 without heroin use, but 
had a busy work schedule for several days, and deferred naltrexone induction until day 11. 
FF described no withdrawal discomfort immediately before or following his initial 
naltrexone dose (SOWS at baseline = 5; at 2 hours = 4). He described no noticeable increase 
in withdrawal discomfort that evening, and continued in naltrexone treatment as per protocol 
for three weeks, prior to discontinuing naltrexone treatment.
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In summary, five of the six subjects (83%) and three of the four ‘day 8’ subjects were inducted 
onto naltrexone (as evidenced by remaining in naltrexone treatment for at least one week), 
although only 3 subjects (50%) remained in naltrexone treatment for the 4 week follow up. All 
four subjects inducted on day 8 described a similar withdrawal response to naltrexone. They 
reported mild withdrawal features commencing one to two hours after the initial 12.5 mg dose, 
describing initially autonomic features of sweating, piloerection, runny nose and eyes. The 
severity of the withdrawal features progressed rapidly over subsequent hours, with patients 
principally complaining of anxiety, restlessness, skeletal muscle cramps, sweating, and 
backache. These peaked in severity within a period approximately 6 to 12 hours after the initial 
naltrexone dose, and were generally subsiding by the following day (12 to 18 hours later). 
Three of the 6 subjects described symptoms, most notably lethargy and fatigue, during the 
subsequent few days on naltrexone. These may have been persistent withdrawal features 
following naltrexone induction or side effects of naltrexone (Resnick 1977; San, Pomarol et al. 
1991; Judson and Goldstein 1982).
The two subjects who commenced naltrexone on days 10 and 11 reported no withdrawal 
discomfort, nor any other difficulties during their naltrexone induction.
These findings suggest that induction onto naltrexone is possible at day 8, and generally 
tolerated by patients on an outpatient basis with minimal additional medication. However, 
delaying the naltrexone induction by a further two days may be preferable if the patient does 
not wish to experience withdrawal discomfort and is confident of not using heroin in the 
interval.
4.3.3.6 Comparison of outcomes in post withdrawal period by study site
Similar proportions of subjects at each site entered treatment in the post withdrawal period, and 
similar proportions were in treatment at day 35. There were no significant differences between 
the two sites regarding rates of participation in the different treatment modalities.
The various measures of heroin and other drug use, and psychosocial functioning were similar 
for subjects at the two sites. The only significant difference between the two sites was that the 
Sydney (Langton) subjects reported higher rates of benzodiazepine use in the post-withdrawal 
period compared to Melbourne (Turning Point) subjects (t (67) = 2.59, p < 0.05, 95% Cl = 0.07 
to 0.57), although the small difference in means between the two groups (approximately a 
quarter of a benzodiazepine tablet per day) is likely to not be clinically significant.
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4.3.3.7 Summary of findings in post withdrawal period
The key findings from the post-withdrawal period were examined by randomised group and by 
post-withdrawal treatment status. There were high levels of ongoing participation in drug 
treatment by subjects in both randomised groups, although significantly more Experimental 
subjects entered and were retained in post-withdrawal treatment. Substitution treatment 
(methadone and buprenorphine) was the most widely used of the treatment modalities, 
accounting for over three quarters of subjects in treatment at day 35.
Overall, the general improvements that had occurred during the withdrawal episode on most 
measures of heroin use and psychosocial functioning were maintained over the post-withdrawal 
period. Subjects from the Experimental group reported significantly lower levels of heroin use 
as measured by the OTI and number of days used, and higher levels of psychosocial 
functioning over the month as measured by the SF-36. However, the Control group made 
substantial improvements in measures of psychosocial functioning by the end of the follow-up 
period, and there were no significant differences between groups on psychosocial functioning 
in the final week of follow up on the BASIS-32.
Importantly, subjects who were retained in treatment over the post-withdrawal period were 
performing better on almost all outcome measures compared to those subjects who had not 
entered, or had dropped out of post withdrawal treatment. Indeed, those in treatment continued 
to show improvements on most measures oveT the follow-up period, whereas as those not in 
treatment at day 35 were generally deteriorating in most measures. Interestingly, there were 
similar proportions of subjects who had remained abstinent from heroin over this time, 
however, most subjects in treatment had been able to sustain irregular heroin use, whereas most 
subjects who were not in treatment at day 35 had returned to daily heroin use by the end of the 
follow up period. Nevertheless, even those subjects not in treatment were still performing 
considerably better than they had been at baseline.
Multiple regression analysis indicated that the main predictors of levels of heroin use in the 
post withdrawal period were measures of heroin use at baseline and frequency of heroin use 
during the withdrawal episode. Predictors of participation in treatment during the post­
withdrawal period were measures of heroin use at baseline (in particular average daily cost) for 
both Experimental and Control groups, retention in withdrawal treatment for the Experimental 
group, and the importance of reduced heroin use in the post-withdrawal period as a treatment 
goal for the Control group. Levels of heroin use during the withdrawal episode were not 
predictive of ongoing participation in drug treatment.
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4.4. Discussion
This is the first randomised controlled study to demonstrate that buprenorphine has greater 
efficacy than clonidine and other symptomatic withdrawal medications for the outcomes most 
relevant to outpatient withdrawal services: reduction in heroin use during withdrawal, and 
enhanced treatment retention during the withdrawal and post-withdrawal periods. Subjects 
receiving buprenorphine also reported greater improvements with regard to severity of 
dependence and psychosocial functioning. Consistent with previous studies (Nigam, Ray et al. 
1993; Cheskin, Fudala et al. 1994; O'Connor, Carroll et al. 1997), subjects randomised to 
buprenorphine also reported significantly less severe withdrawal symptoms. Importantly, the 
effect sizes on key outcome measures between the two groups were considerable, with 
Numbers Needed to Treat of generally less than 5 to 10 patients for most outcomes, 
demonstrating a considerable advantage in using buprenorphine over combination symptomatic 
medication. There were also considerable benefits with regard to incremental cost effectiveness 
over symptomatic medication in achieving heroin-free days during the withdrawal episode 
(ratio of 1.7 to 1), and in achieving heroin-free withdrawal episodes (ratio of 5.5 to 1). Given 
the large number of outpatient heroin withdrawal episodes attempted each year within 
Australia, the widespread use of buprenorphine should result in considerable improvements in 
the efficiency of withdrawal services.
4.4.1 Limitations of the study
Prior to considering the broader implications of the research, a number of limitations of the 
study need to be addressed. The most significant limitation of the study was that participants 
were not blinded to the medication regimes. The open label design may have biased the 
outcomes for the study, given the tendency for some subjects to assume that ‘new’ or 
‘investigational’ medications are likely to be ‘better’ medications. This may have resulted in a 
number of subjects randomised to the Control Group becoming disillusioned with their 
treatment allocation, resulting in poorer treatment outcomes. Alternatively, it may have biased 
reporting on subjective outcome measures, such as levels of satisfaction with medication or 
global ratings of withdrawal discomfort. Attempts were made to limit the impact of expectancy, 
such as the recruitment of subjects from patients presenting for routine withdrawal services, 
with no advertising or promotion of the study; and the provision of information regarding the 
different withdrawal medications to subjects in a neutral manner so as to not favour either 
medication regime. Nevertheless, an element of bias is inevitable in open label studies.
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Other limitations of the study were possibly less important. There was good follow up of 
subjects, with approximately 89% of all randomised subjects being followed up at day 8, and 
80% being followed up at day 35. Drug use measures in the post withdrawal period were 
limited to self-report, without corroboration of objective urine drug screens. However, self- 
report data is usually considered reliable under the conditions in which the data was collected 
(Darke 1998): by research assistants not involved in clinical service delivery, and with no 
punitive consequences for subjects reporting continued heroin use during the post-withdrawal 
period. Self-reported heroin use during the withdrawal episode was consistent with the findings 
of urine drug tests during this period.
Attempts to generalise from these findings to broader populations of heroin users and treatment 
settings must take into consideration that heroin users with significant medical or psychiatric 
conditions, recent methadone treatment, or concomitant alcohol or benzodiazepine dependence 
were excluded from the study; and that the study was conducted in specialist treatment settings. 
Nevertheless, the almost identical findings for all the principal outcomes at two clinical sites in 
different cities enhances the degree of confidence that the results can be generalised to similar 
populations of heroin users attending specialist treatment settings. Finally, a longer period of 
post-withdrawal follow up would have been preferred in order to examine the broader impact 
of withdrawal and post-withdrawal services, but was not possible within the available 
resources.
The treatment protocol for the Control group appeared (at face value) to have been adequate 
with regard to the medication regime and intensity of ancillary services. Doses for clonidine in 
this study were comparable to previously reported outpatient regimes, there was general patient 
satisfaction with the adequacy of dosing levels, and the addition of ancillary medication 
particularly suited to the withdrawal symptoms least relieved by clonidine (benzodiazepines, 
anti-emetics, anti-spasmodic, and anti-inflammatory medications) should have intuitively 
resulted in enhanced outcomes compared to clonidine-only regimes. There was a relatively 
high level of contact between service providers and subjects, with an average of approximately 
10 staff - patient contacts over the 8-day withdrawal episode. Yet despite what appeared to be 
‘adequate’ treatment, the rate of abstinence from heroin during the withdrawal episode among 
the Control group in this study was quite low (4%), whereas most earlier studies of outpatient 
heroin withdrawal using clonidine report ‘successful completion’ rates in the range of 20 to 
30% (Gowing, Ali et al. 2000; Lipton and Maranda 1983). However, as identified in Chapter 1, 
there are numerous difficulties in directly comparing findings across studies that employ 
different recruitment methods, subject populations, treatment protocols and outcome measures.
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There are a number of factors that relate to this study that may explain the low ‘abstinence’ rate
during the withdrawal episode seen in the Control group:
• Many subjects in the study were chronic and heavy heroin users, had multiple prior 
treatment attempts, few ‘positive’ social supports, and most (90%) were injecting heroin. In 
contrast, several previous withdrawal studies have recruited heroin users with less severe 
dependence, shorter duration of heroin use and better psychosocial functioning, for whom 
better outcomes may be expected (Blaine, Ling et al. 1994).
• Many previous outpatient withdrawal studies of clonidine have examined patients 
withdrawing from methadone maintenance treatment, not active heroin users. Patients 
attempting outpatient withdrawal from dependent heroin use may be more likely to continue 
heroin use during a withdrawal episode than patients withdrawing from methadone 
maintenance treatment with no recent history of heroin use (Gowing, Ali et al. 2000).
• This was a study of subjects presenting for withdrawal services, with the option of entering 
post-withdrawal treatment afterwards. Several prior studies (for example, Gerra, Marcato et 
al. 1995) have reported outcomes relating to the withdrawal episode for subjects enrolling in 
longer term, abstinence based treatment modalities (such as naltrexone maintenance 
treatment or therapeutic communities). It is likely that subjects enrolling in such long-term 
treatment programs will have higher rates of heroin cessation compared to a more general 
population of heroin users seeking withdrawal.
• The study generally inducted subjects and commenced treatment on the day of initial 
presentation to the clinics. This is in contrast to studies in which withdrawal treatment is 
commenced several days after the initial assessment of patients (potentially allowing less 
motivated patients to drop out prior to the withdrawal episode commencing); or 
alternatively, studies in which the withdrawal regime commences following a period of 
stabilisation on prescribed morphine or methadone (for example, Washton and Resnick 
1981). Stabilisation for several days on methadone (or morphine) potentially allows for the 
interruption of daily behavioural patterns of heroin use in a manner that is not routinely seen 
in clinical withdrawal programs using symptomatic medication.
• As identified earlier, subjects were not blinded to their medication regime, and it is likely 
that a number of subjects were disappointed following randomisation to the Control group, 
with poor treatment outcomes as a consequence. Indeed, a quarter of Control subjects did 
not continue treatment beyond the first day, although treatment drop out soon after 
enrolment is not an uncommon event (for example, 9% of Experimental subjects did not
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attend beyond the second day), and the majority of Control subjects were retained in 
withdrawal treatment.
• The availability and accessibility of heroin in the environment is likely to impact upon 
outcomes for individuals enrolled in outpatient treatment. At the time in which the study 
was conducted, heroin was widely available, inexpensive, and of high concentration in both 
Sydney and Melbourne (McKetin, Darke et al. 2000). The environmental context 
(availability and accessibility of heroin) in which earlier outpatient withdrawal studies have 
been conducted may have been different, thereby complicating comparisons with earlier 
research.
• Differences in how withdrawal outcomes are operationalised in studies have a considerable 
impact upon the reporting of findings. This study defined abstinence during withdrawal as 
negative urine tests for opiates on both days 5 and 8. Self-report data was available for 86% 
of Control subjects, and missing urine test results were assigned ‘positive’, according to 
protocol. In contrast, many previously reported studies have had considerably different end 
points and ways of reporting findings. For example, some studies (e.g. Nigam, Ray et al. 
1993) disregard treatment drop-outs, and only report a survival analysis rather than an 
intention-to-treat analysis, thereby generally inflating ‘success rates’. Other studies have not 
reported heroin use during outpatient withdrawal (e.g. O'Connor, Carroll et al. 1997), and 
use treatment protocol completion or antagonist challenges as their end points. However, a 
‘negative’ naloxone challenge can be achieved after only several days without opiate use, 
and is therefore not necessarily a comparable outcome measure to urine results throughout 
an 8-day withdrawal episode. To highlight these points, had this study discounted treatment 
drop-outs from the final analysis, and had it used a negative opiate urine drug screen at day 
8 as an operational measure of withdrawal success (as many, if not most, patients with a 
negative opiate urine at day 8 following minimal heroin use early in a withdrawal episode, 
can tolerate a dose of an opioid antagonist on day 8), then 13% of Control subjects (4 out of 
32), and 34% of Experimental subjects (17 out of 50) ‘successfully completed withdrawal’. 
This places the outcomes for the Control group in this study more broadly within the range 
reported in earlier outpatient clonidine studies of heroin withdrawal.
Although the abstinence rate of 4% seen in this trial appears low in comparison to earlier 
reported studies, this did not appear uncharacteristically low to experienced clinicians working 
at the study sites. Prior to commencing the study, clinicians at both sites estimated that between 
5 and 10% of patients would not use heroin for at least one week during their initial attempt at 
symptomatic withdrawal (see Section 4.2.2.2).
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4.4.2 The impact of outpatient withdrawal services for heroin users
In addition to comparisons between the two medication regimes, this study also provides an 
opportunity to consider the broader impact of outpatient withdrawal services for dependent 
heroin users. The general outcome for most subjects in the study was that they reduced (but did 
not cease) their heroin use, reduced their dependence on heroin, and improved their level of 
psychosocial functioning during the withdrawal episode. These improvements were generally 
maintained in the post-withdrawal period, with most subjects performing considerably better 
one month after withdrawal than prior to treatment entry. Whilst outcomes were enhanced for 
those subjects who were retained in some form of post withdrawal treatment, even those 
subjects who did not participate in further treatment beyond the withdrawal episode reported 
less heroin use and better levels of functioning four weeks later than at treatment entry.
4.2.2.1 Heroin use during withdrawal episode
The reduction in heroin use during the withdrawal episode was considerable - the average 
frequency of heroin use fell from three to four times a day in the week prior to treatment, to 
less than daily during the withdrawal episode. The majority of subjects in the Experimental 
Group and almost a quarter of Control subjects reported no heroin use or minimal heroin use 
(on 1 or 2 days) during the 8-day withdrawal episode. Most patients and clinicians would 
generally consider such a marked reduction in heroin use as a relatively successful attempt at 
outpatient heroin withdrawal. Most subjects (particularly those randomised to the Experimental 
condition) reported minimal discomfort during the withdrawal episode in association with these 
reductions in heroin use.
Despite the initial high degree of patient interest in ceasing heroin use during the withdrawal 
episode, only a minority of subjects (12% in the Experiment and 4% in the Control group) 
achieved this goal. Complete cessation of heroin use (as measured by urine testing) is a clearly 
defined, objective measure well-suited to research trials. However, abstinence during 
withdrawal is not the only clinically relevant outcome, and indeed, the broader benefits that 
were experienced by most subjects during and after the withdrawal episode occurred in a 
context of a reduction, not necessarily a cessation, in heroin use during the withdrawal episode. 
Furthermore, abstinence during withdrawal was not found to be predictive of performance in 
the post-withdrawal period. Multiple regression analysis indicated that the continuous measure 
of frequency of heroin use during the withdrawal episode was more predictive of post­
withdrawal heroin use than the categorical measure of abstinence during withdrawal. Whilst 
not discounting abstinence as an important outcome measure, it should be seen as one end of a 
continuum. In this regard, parallels can be drawn with maintenance substitution treatment, in
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which the accepted framework for evaluating treatment efficacy involves the primary outcomes 
of reduction in heroin use, retention in treatment, and reduction in drug-related morbidity and 
mortality.
4.4.2.2 Impact upon post-withdrawal outcomes
Importantly, the improvements in heroin use, severity of dependence and psychosocial 
functioning were generally maintained during the four-week follow up period. Most subjects 
reported using considerably less heroin in the month after withdrawal, than in the month prior 
to withdrawal treatment. Although only a small proportion reported complete abstinence during 
the 4-week post-withdrawal period (10% of the Experimental and 2% of the Control group), a 
considerable proportion used heroin infrequently during this time (for example, 21 / 49 or 43% 
of Experimental group and 10 / 44 or 23% of Control group reported using heroin on average 
less than once a week). Furthermore, subjects reported using less heroin on the occasions that 
they did use: the average daily cost of heroin at intake was $98 ± 73, whereas the average daily 
cost during the post-withdrawal period was $52 ± 55.
Approximately half of all subjects (62% of the Experimental Group and 39% of the Control 
group) were retained in drug treatment at day 35. Over three quarters of these subjects were 
enrolled in maintenance substitution treatment, reflecting its broad appeal to heroin users and 
its high rate of treatment retention (76% of those commencing substitution treatment were still 
in treatment at day 35). Considerably smaller numbers were retained in naltrexone treatment 
(14% of all subjects in treatment at day 35, with 50% of subjects commencing naltrexone being 
retained at day 35) or counselling only at day 35 (9% of all subjects). The high uptake and 
retention rate for substitution maintenance treatment and the lower rates for naltrexone 
treatment seen in this study are consistent with previous reports for these treatment modalities.
Subjects who were retained in post-withdrawal treatment had significantly better outcomes than 
those who did not enter, or those who dropped out of post-withdrawal treatment. This 
difference is most clearly highlighted by comparing measures of heroin use. On average, 
subjects retained in treatment reported using on half as many days in the preceding 4 weeks (8 
compared to 16), and reported spending half as much money on those days compared to 
subjects not retained in post-withdrawal treatment. It is tempting to (intuitively) attribute the 
better outcomes as being a result of treatment in the post-withdrawal period. However, caution 
is needed in interpreting these findings and causality can not be assumed: an alternative case 
can be made that those subjects who were more likely to perform better (for whatever reason) 
were also more likely to remain in treatment. Nevertheless, the findings suggest that patients 
should be strongly encouraged to continue in longer-term drug treatment following withdrawal.
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The high level of retention in post-withdrawal treatment and the improved outcomes for those 
retained in post withdrawal treatment in the study highlight the importance of having a range of 
post-withdrawal treatment choices available (to account for individual patient preferences and 
circumstances), and the importance of withdrawal services actively facilitating linkages to 
ongoing treatment. The high uptake of maintenance substitution treatment is particularly 
noteworthy, emphasising the need for flexible treatment pathways within withdrawal services 
that can accommodate those patients whose initial attempts at withdrawal prove ‘unsuccessful’. 
It should be remembered that maintenance substitution treatment was available, but initially 
rejected, by all subjects at the time of enrolment in study. However, approximately 40% of all 
subjects (and over half of the Experimental group) were engaged in maintenance treatment at 
the end of the follow up period.
The longer-term impact of withdrawal upon heroin use and related outcomes is not addressed in 
this study. The subjects who were retained in post-withdrawal treatment (maintenance 
substitution, counselling or naltrexone treatment) could be expected to have longer term 
outcomes routinely associated with each of these treatment modalities, as the outcomes 
observed at day 35 would suggest. However, the longer-term outcomes for subjects who were 
not retained in post-withdrawal treatment are unknown. Most of these subjects continued to be 
better placed at day 35 compared to baseline on a range of measures for heroin use and 
psychosocial functioning. What remains unclear is how long such improvements last. At four 
weeks after the withdrawal episode, the outcomes for subjects no longer in treatment were 
deteriorating compared to day 8 measures for frequency of heroin use and severity of 
dependence on heroin. Two thirds of subjects not in treatment had resumed regular heroin use 
(OTI Q scores greater than 1.0), and a very real concern is that heroin use and related 
psychosocial parameters would further deteriorate with time. Longer term follow up of such 
subjects is required to ascertain the extent to which an isolated episode of withdrawal treatment 
can substantially alleviate heavy heroin use and related harms over time.
4.4.3 Using buprenorphine for managing heroin withdrawal
This section will examine particular issues specific to the use of buprenorphine for heroin 
withdrawal arising from this research. The study findings confirm earlier research which 
identified that buprenorphine has many of the properties required of a withdrawal medication 
(see Section 1.4.1 for review). Buprenorphine was easy to administer on a once-a-day 
supervised dosing regime without substantially disrupting work or other daily activities for 
most patients, and dispensing was linked to regular clinical reviews in the clinic settings. There 
were high levels of satisfaction among subjects with buprenorphine as a withdrawal
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medication; and approximately three quarters of subjects identified the adequacy of 
buprenorphine regime as satisfactory, 19% indicated the doses were ‘too low’, and 8% 
indicated the doses had been ‘much too low’.
This study compared short-term withdrawal using buprenorphine to a conventional 
symptomatic medication regime. As identified in Chapter 1, short withdrawal episodes 
predominate within the Australian treatment context, and gradual withdrawal services spanning 
weeks to months using substitution medications such as methadone have hitherto been 
uncommon. Nevertheless, longer withdrawal treatment episodes may have certain advantages 
for some patients, and further consideration should be given to comparing the efficacy of short 
versus gradual reduction regimes of buprenorphine. This has not been systematically examined 
in previous buprenorphine research for heroin withdrawal, and indeed, even the evidence 
regarding the optimal duration of methadone regimes for heroin withdrawal remains unclear 
despite over two decades of methadone-assisted withdrawal studies (see Chapter 1 for reviews). 
Related to this issue, further research is required which directly compares buprenorphine and 
methadone in gradual reduction regimes over several weeks, as the only previous comparative 
study was inconclusive (see Section 1.4.2 for review). Issues regarding the selection of 
different treatment approaches for withdrawal management are explored in the final Chapter.
4.4.3.1 Adverse events
Most side effects experienced with buprenorphine were generally mild, well tolerated and 
transient, typically occurring during the first few days of treatment. Most side effects to 
buprenorphine are characteristic of opioids and have been previously reported in similar 
proportions in the earlier Outpatient Dose Titration Study (Section 3.3.5), and in maintenance 
buprenorphine treatment (Ling, Charuvastra et al. 1998; Lange, Fudala et al. 1990). Headache, 
nausea and vomiting, drowsiness, sweating, and lethargy were reported by more than 5% of 
subjects.
An adverse event not characteristically seen with other opioid medications is that of 
precipitated withdrawal, reported by 13% of subjects receiving buprenorphine in this study. In 
most cases the features of precipitated withdrawal were mild, lasted for several hours, and 
occurred only after the first buprenorphine dose. However, there were two cases (3%) in which 
symptoms persisted beyond the first day (both in the context of continued regular heroin use 
during withdrawal), with patients complaining of moderate to severe features of precipitated 
withdrawal. Although this side effect can theoretically be avoided by delaying the first 
buprenorphine dose until the patient is experiencing withdrawal, in practice this is not always 
feasible - doses can not always be delayed in outpatient treatment due to closing times of
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clinics or pharmacies, not all dispensing pharmacists are adequately trained to identify opiate 
withdrawal, and indeed many of the early features of opiate withdrawal are subjective rather 
than objective, relying on self-report of patients (which can be unreliable in a clinical context). 
Considerable emphasis needs to be given to training clinical staff and educating patients in the 
underlying mechanisms and potential risks of precipitated withdrawal (see discussion regarding 
the implementation of buprenorphine treatment in Chapter 5).
Mild and transient rebound withdrawal symptoms after the cessation of buprenorphine was 
experienced by approximately 9% of subjects; and a further 8% experienced rebound 
symptoms that were of moderate severity and/or had not subsided by day 8. This emphasises 
the need for continued monitoring and support of patients attempting withdrawal beyond the 
cessation of medication.
The emergence of withdrawal features following naltrexone induction suggests that complete 
reversal of tolerance had not occurred in these subjects by day 8, even though the last dose of 
buprenorphine had been 3 days earlier. Although rebound withdrawal symptoms were typically 
most pronounced in the 24 to 48 hours after the last dose of buprenorphine, the response to 
naltrexone on day 8 would suggest that the physiological withdrawal process (neuroadaptation 
reversal) had not been completed by this time, and that some withdrawal symptoms would 
persist, although it should be emphasised that subjective withdrawal symptoms persisting into 
the second week, particularly cravings, sleep and mood disturbances, following all forms of 
heroin withdrawal are common. All patients undergoing a brief buprenorphine withdrawal 
regime who do not commence naltrexone or substitution treatment should be warned of the 
potential persistence of low level withdrawal symptoms for some time after the discontinuation 
of buprenorphine, and should be encouraged to continue to participate in withdrawal services 
for several days beyond the cessation of buprenorphine.
4.4.3.2 Levels of functioning and participation in counselling during withdrawal
One of the benefits described by many subjects in this study was the ability of buprenorphine to 
relieve physical and psychological withdrawal symptoms (cravings, agitation, dysphoria and 
other mood disturbances), without causing the degree of sedation or drowsiness commonly 
associated with the use of clonidine and benzodiazepines (and as described by the majority of 
Control subjects in the study). This potentially reduces the risk of sedative overdose during 
buprenorphine-assisted heroin withdrawal. Furthermore, this allowed subjects using 
buprenorphine a better degree of day-to-day functioning during the withdrawal episode, and 
indeed many subjects continued their routine daily activities (e.g. work, study), a relatively 
uncommon event when using symptomatic medications. The capacity for buprenorphine to
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adequately relieve withdrawal discomfort and mood disturbances without significant sedation, 
also enabled subjects to more effectively engage in counselling during the withdrawal period. 
As discussed in the introduction, counselling interventions during withdrawal are usually 
limited to maintaining motivation, providing support and assistance in coping with withdrawal 
symptoms and high-risk situations, and examining post-withdrawal treatment options. 
Although staff - patient contact time between the two study groups was comparable, a common 
impression among treatment staff was that subjects using buprenorphine generally required less 
time during appointments addressing issues such as day to day symptom relief, allowing more 
time to examine broader issues such as goal setting and post-withdrawal linkages.
4.4.3.3 Post-withdrawal treatment options
There are a wide variety of post-withdrawal treatment options available following 
buprenorphine assisted heroin withdrawal. The potential advantage of buprenorphine over other 
withdrawal medications in facilitating links to a broader range of post-withdrawal treatment 
modalities will be explored in greater detail in the final chapter.
Most subjects chose to continue buprenorphine, or commenced methadone treatment during the 
post-withdrawal period. The uptake of substitution treatment highlights the broad appeal of this 
treatment modality, being equally applicable to patients who wish to cease heroin use, and to 
those who are aiming to merely bring their heroin use under control.
As identified in Chapter 1.4.3, clinical procedures for induction onto naltrexone following 
buprenorphine treatment remain poorly understood, and as such, the experience from this study 
warrants closer examination. Induction onto naltrexone following buprenorphine treatment was 
attempted in 6 subjects during days 8 to 11 as per study protocol. Five of the six subjects 
remained on naltrexone for more than one week, with only one subject discontinuing 
naltrexone treatment after 4 days. The four subjects who commenced naltrexone on day 8 all 
experienced moderate to severe withdrawal discomfort within 2 to 4 hours after the first 
naltrexone dose and persisting for up to 12 to 18 hours. The early withdrawal features were 
predominately ‘autonomic’ in nature (sweating, piloerection, lacrimation and rhinorrhoea). 
These were subsequently replaced by: agitation, sleeplessness, sweating, hot and cold flushes, 
and abdominal cramps. Symptoms were somewhat relieved by symptomatic medication 
(clonidine and diazepam), and all cases were successfully managed at home under supervision 
of a friend or relative. The second dose of naltrexone resulted in less pronounced withdrawal 
discomfort, although most subjects continued to report side effects to naltrexone (particularly 
dysphoria and mild withdrawal) for several days. Interestingly, the 2 subjects who initiated 
naltrexone on days 10 and 11 (5 and 6 days after the last buprenorphine dose respectively)
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described no withdrawal discomfort following naltrexone induction. Although these are small 
numbers, the findings suggest that wherever possible, the initiation of naltrexone should be 
delayed until more than 3 days after the last buprenorphine dose; however, in circumstances 
where the patient is concerned about relapse to heroin use, earlier induction onto naltrexone can 
be achieved as an outpatient, albeit with temporary features of moderate withdrawal severity 
requiring supervision and ancillary medications.
The commencement of naltrexone before day 8 was restricted by the study protocol. Umbricht 
and colleagues described a similar approach of initiating naltrexone on day 8 (after a 4 day 
buprenorphine regime) (Umbricht, Montoya et al. 1999), and these authors also noted an 
increase in withdrawal features following the initial (50mg) dose of naltrexone. Alternative 
strategies have been described in the research literature for earlier induction onto naltrexone 
(Umbricht, Montoya et al. 1999; O'Connor, Carroll et al. 1997). Low naltrexone doses can be 
administered during the period of buprenorphine dosing, with a gradual increase in naltrexone 
doses as buprenorphine doses taper off over several days (Umbricht, Montoya et al. 1999). 
There are potential advantages and disadvantages with each approach. The early naltrexone 
induction regime requires a shorter period of abstinence from heroin (e.g. less than 48 hours) 
prior to commencing naltrexone, which is likely to result in a greater proportion of heroin users 
being able to commence naltrexone treatment. However, this may not always be an advantage, 
as naltrexone treatment is not well suited to many heroin users (as evidenced by poor retention 
rates), and better longer term outcomes may be achieved by directing some patients towards 
maintenance substitution treatment. The early naltrexone induction regime has the advantage of 
an earlier resolution of withdrawal discomfort, whereas the late induction regime will result in 
peak withdrawal discomfort late in the withdrawal episode, often when patient motivation is 
waning. These are somewhat theoretical suppositions, and further research in this area is 
required.
4.4.4 Summary and conclusion
This open label randomised controlled trial compared the efficacy and cost effectiveness of a 
short term buprenorphine regime compared to clonidine, benzodiazepines and other 
symptomatic medications in the management of outpatient heroin withdrawal in specialist 
treatment settings. The outcomes seen in both groups suggest that withdrawal services are 
associated with a range of benefits for heroin users during, and in the immediate post­
withdrawal period, such as reduced heroin use, reduced severity of dependence, and improved 
psychosocial functioning, although cessation of heroin use and continued abstinence was an 
uncommon outcome. There were high rates of retention in treatment 4 weeks after the
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withdrawal episode, with substitution treatment as the main post-withdrawal treatment 
modality selected. In general, subjects who remained in treatment reported considerably better 
outcomes than those who had discontinued treatment by day 35.
The study demonstrated the enhanced efficacy and cost effectiveness of buprenorphine 
compared to the symptomatic medication regime. In general, buprenorphine-assisted heroin 
withdrawal achieved higher treatment retention rates, lower levels of heroin use and better 
symptom relief. Specifically, subjects randomised to the buprenorphine assisted withdrawal 
group:
• had significantly lower levels of heroin use and significantly lower severity of dependence 
on heroin during the outpatient withdrawal episode
• had significantly greater rates of treatment retention in the withdrawal episode
• reported significantly less severe opiate withdrawal symptoms
• reported significantly better levels of psychosocial functioning during the withdrawal 
episode
• reported higher levels of satisfaction with their medication and withdrawal treatment
Incremental cost effectiveness ratios indicate considerable advantages in using buprenorphine 
over symptomatic medications in achieving heroin-free days during the withdrawal episode 
(ratio of 1.7 to 1), and in achieving abstinence from heroin during the withdrawal episode (ratio 
of 5.5 to 1). There was a similar proportion of subjects reporting adverse events, and the profile 
of side effects reported in the study were anticipated for each of the medication regimes. There 
were no severe adverse events reported during the withdrawal episode. The use of other drugs 
was not significantly impacted upon during withdrawal in either group. The similar findings at 
each of the two study sites enhance the confidence with which the findings of this study can be 
generalised to other specialist treatment settings.
Principal findings during the four-week post withdrawal period included: (a) significantly more 
subjects in the Experimental group entered and remained in drug treatment; (b) subjects in the 
Experimental group reported significantly less heroin use than Control subjects; and (c) 
subjects in the Experimental group reported significantly higher levels of psychosocial 
functioning over the 4 week follow up period (SF-36 scores), although these differences were 
not significant on comparing levels of functioning by the final week of follow up (using the 
BASIS - 32).
Importantly, the effect sizes for differences between the two groups on the key outcome and 
process measures were considerable. Together with the enhanced cost-effectiveness of
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buprenorphine, its widespread use for heroin withdrawal should lead to substantial 
improvements in the delivery and efficiency of withdrawal services for heroin users. The 
following (and final) chapter will examine issues regarding the uptake of buprenorphine within 
the drug treatment system, including the development of clinical guidelines for the use of 
buprenorphine in managing heroin withdrawal.
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Chapter  5: The role of Buprenorphine  in the  
Management of Heroin  W ithdraw al
This final chapter examines some key issues in the implementation and uptake of 
buprenrophine in the management of heroin withdrawal, including the application of principles 
of evidence-based medicine in clinical-decision making for individual patients undergoing 
heroin withdrawal; and an examination of broader systemic issues likely to impact upon the 
uptake of this new approach to withdrawal management within the drug treatment system in 
Australia. To this end, the chapter concludes with a brief description of the process for the 
development of national clinical guidelines for the use of buprenorphine for heroin withdrawal 
in Australia.
5.1 Overview of research studies
5.1.1 Evidence based practice in the management of heroin 
withdrawal: identifying gaps in the evidence regarding buprenorphine
There is an increasing recognition of the importance of evidence-based practice in clinical 
medicine, integrating individual clinical expertise with the best available external evidence 
from systematic research (Sackett, Richardson et al. 1997). The application of the principles of 
evidence-based medicine to the management of heroin withdrawal is long overdue. As 
identified in the review of the literature in Chapter 1, there continue to be many unanswered 
(and in some cases, even unaddressed) questions regarding the safety, efficacy and cost- 
effectiveness of different withdrawal approaches. Two examples highlight this point. Firstly, 
although clonidine and methadone are among the two most widely used (and researched) 
medications for heroin withdrawal of the past two decades, there has been no randomised 
controlled trial directly comparing these two medications in the management of outpatient 
heroin withdrawal, the setting in which many (if not most) heroin users undergo withdrawal. 
Secondly, in the area of methadone-assisted heroin withdrawal, the ‘optimal’ duration of 
methadone reductions (that is, should we encourage 10 day, 10 week or six month reduction 
regimes) has not been systematically addressed in the research literature, and the evidence 
remains equivocal.
Whilst research has failed to address a number of important outstanding questions confronting 
clinicians and patients in this field, many historical and contemporary practices in the clinical 
management of heroin withdrawal are not based upon external evidence regarding safety,
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efficacy or cost effectiveness. Exponents of evidence-based medicine have identified that, until 
recently, much of clinical medicine has considered it sufficient to understand the 
pathophysiological process of a disorder, and to prescribe treatments that had been shown to 
interrupt or otherwise modify this process (Sackett, Richardson et al. 1997). Hence in recent 
times, the dissemination and promotion of ultra-rapid opiate withdrawal has occurred despite a 
lack of evidence about the efficacy of such procedures. A significant task for the alcohol and 
drug field is to bridge this gap between research evidence and clinical practice in the area of 
withdrawal management.
This thesis has attempted to address some of the outstanding questions regarding the use of 
buprenorphine for the management of heroin withdrawal. A review of the research (Section 
1.4) identified that: (i) buprenorphine has many of the desired pharmacological properties to 
treat heroin withdrawal - its use was consistent with the ‘pathophysiological processes of the 
disorder’; and (ii) buprenorphine has been shown in three (of three) randomised trials to be 
more effective than clonidine in suppressing the severity of withdrawal symptoms. However, 
there were still considerable gaps identified in the available evidence. Most importantly:
(a) There remained uncertainty regarding the efficacy of buprenorphine in achieving clinical 
outcomes for heroin withdrawal other than the reduction of withdrawal symptoms. On using the 
evaluation framework for withdrawal services developed in Section 1.1.3, it was apparent that 
no previous study had demonstrated significantly greater rates of withdrawal completion for 
buprenorphine-assisted withdrawal compared to conventional approaches, no studies had 
demonstrated a greater reduction in heroin use during outpatient withdrawal compared to 
conventional approaches, and no study had examined post-withdrawal outcomes beyond 
induction onto one or two doses of naltrexone. This lack of demonstrated efficacy of 
buprenorphine across a broad range of withdrawal outcomes was due to the limited number of 
studies in this area (and in particular randomised trials), limited numbers of subjects in (most) 
studies, and due to evaluation frameworks which have focussed upon symptom relief in 
inpatient settings and/or studies with naltrexone induction as their end points. Whilst not 
discounting these as important outcomes, an understanding of broader withdrawal outcomes is 
critical in order to better understand the role of buprenorphine in the management of heroin 
withdrawal.
(b) There is considerable uncertainty as to how buprenorphine should be used for heroin 
withdrawal, due to the limited research examining many of the key issues confronting clinical 
decision-making (such as how much and for how long buprenorphine should be prescribed). 
This has been compounded by the fact that most earlier withdrawal studies have used different 
buprenorphine preparations (often with different bioequivalencies) to the commercially
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available product (Subutex®). For example, there have been only two previous descriptions in 
the published literature of short outpatient buprenorphine withdrawal regimes (Diamant, 
Fischer et al. 1998; O'Connor, Carroll et al. 1997), neither of which used the sublingual 
Subutex® tablets commercially available in Australia.
5.1.2 Addressing the gaps in the evidence
The research studies in this thesis have attempted to address some of these gaps in the available 
evidence. The main study has been the randomised controlled trial of outpatient heroin 
withdrawal comparing buprenorphine and symptomatic medication regimes in 114 heroin 
dependent subjects. The framework for this evaluation was established in the Chapter One, 
identifying a number of key objectives for withdrawal services, with corresponding outcomes 
and process measures, from which to assess withdrawal services. The study demonstrated the 
significantly enhanced efficacy of buprenorphine over symptomatic medications in achieving 
key withdrawal outcomes for outpatient withdrawal, particularly
• the reduction in heroin use during and after withdrawal episode,
• higher rates of retention in withdrawal and post-withdrawal treatment,
• better relief of withdrawal symptoms during the withdrawal episode,
• better general psychosocial functioning and lower severity of dependence on heroin,
• higher levels of patient satisfaction with buprenorphine,
• greater cost-effectiveness
The findings of the randomised trial are the first demonstration of the enhanced efficacy of 
buprenorphine for most withdrawal outcomes, and will contribute to the evidence base upon 
which clinical practice draws from.
Questions concerning how buprenorphine should be used were examined in the first two studies 
of the thesis - Chapter Two examining dosing regimes in inpatient settings, and Chapter Three 
addressing dosing regimes for outpatient settings. These studies aimed to establish the range of 
doses of Subutex® required by Australian heroin users, important questions due to the 
considerable variation of buprenorphine doses and preparations reported in the published 
literature (ranging from regimes using maximum doses of less than 1 mg per day (Nigam, Ray 
et al. 1993), to regimes using doses of 12 mg per day (Umbricht, Montoya et al. 1999)). The 
investigations undertaken were dose titration studies, not randomised trials comparing the 
efficacy of different dosing regimes, and as such these studies do not claim to have identified 
the ‘optimal’ dosing regimes for withdrawal. Nevertheless, these studies provide a sense of the 
types of doses required by heroin users undergoing withdrawal in different settings, and 
provide a basis upon which clinicians can tailor doses according to individual circumstances.
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Furthermore, the inpatient dose titration study examined, for the first time in the published 
literature, which patient factors impact upon dosing requirements of individual patients. This 
knowledge should further assist clinicians in determining dosing regimes for individual 
patients.
The studies have also provided some insight into, although not necessarily ‘resolved’, other 
outstanding questions regarding the use buprenorphine. The randomised trial has provided 
further evidence regarding the experience of outpatient induction onto naltrexone following 
short buprenorphine regimes, indicating that induction onto naltrexone can be accomplished 
soon after the cessation of buprenorphine dosing in an outpatient setting. The research has also 
provided a better understanding of the adverse events experienced during short buprenorphine 
withdrawal regimes, which had not previously been addressed in the published literature (see 
Gowing, Ali et al. 2000).
5.2. Tailoring withdrawal approaches for individual patients
As emphasised by exponents of evidence based medicine (Sackett, Richardson et al. 1997), the 
application of evidence based medicine is not about identifying from systematic reviews or 
meta-analyses which is the ‘best’ medication approach for treating all patients with a particular 
condition, nor is it about the development of ‘cook book’ recipes of medication regimes. 
Rather, the application of the principles of evidence-based practice in clinical decision-making 
regarding the management of heroin withdrawal must take into consideration a number of 
factors routinely confronted in clinical scenarios by service providers and individual patients. 
These include:
1. The evidence regarding the safety and efficacy of different withdrawal regimes.
2. The resources available for withdrawal, including treatment settings, the level of staff 
expertise, the extent of supervision, monitoring and support available during withdrawal, 
and the time frame in which withdrawal is to be conducted.
3. The preferences and consent of informed patients. •
4. The post-withdrawal treatment options being considered by each patient.
This section profiles the different withdrawal approaches reviewed in Chapter 1 against each of 
these four factors, with particular attention to buprenorphine. A number of clinical scenarios 
highlight the importance of each of these factors:
• a heroin user who must continue to function in their daily routine (e.g. work) without 
having the capacity to take ‘time out’ may have difficulties attempting antagonist-
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accelerated or symptomatic withdrawal due to the severity of withdrawal and the sedating 
effects of the medication regimes; and should perhaps consider a gradual reduction regime 
using methadone or buprenorphine, thereby postponing severe withdrawal features until 
respite from work or child care is organised.
• a patient who is very keen to commence long term naltrexone treatment should generally 
avoid methadone-assisted withdrawal, as the use of a long-acting opiate agonist will delay 
and complicate induction onto naltrexone.
• alternatively, the heroin user who is not interested in long term naltrexone treatment for 
relapse prevention should probably not be subjected to the expense and risks associated 
with antagonist-accelerated withdrawal.
• a heroin user who does not wish to use any opiate medication during withdrawal should 
avoid the use of methadone or buprenorphine.
5.2.1 Research evidence regarding safety and efficacy
Issues regarding the safety and efficacy of the four main medication approaches to heroin 
withdrawal were reviewed in detail in Sections 1.3 and 1.4. To this body of work can be added 
the findings from the research conducted as part of this thesis. The general trends of the 
comparative randomised trials of the different withdrawal medications are summarised in Table 
5.1. The research evidence regarding the safety and efficacy of the different medications, and 
buprenorphine in particular, is accumulating, yet it appears that buprenorphine generally has 
better outcomes than adrenergic agonists. Further work comparing buprenorphine and 
methadone withdrawal is a high research priority, given the widespread use of methadone 
reductions in withdrawal programs internationally.
The available research evidence is however not limited to the findings of comparative 
randomised controlled trials. Chapter 1 reviewed the evidence regarding the relative merits and 
disadvantages of buprenorphine, methadone, adrenergic agonists, and naltrexone for the 
management of heroin withdrawal. Table 5.2 attempts to summarise the evidence regarding key 
issues in the use of each of the four different medication approaches against the main objectives 
and process measures for withdrawal services, incorporating the findings from the studies 
conducted in this body of research.
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5.2.2 Resource availability and accessibility
An important feature of withdrawal services is that they should be readily accessible to 
patients, and withdrawal approaches which are simple to deliver and relatively inexpensive will 
offer advantages over resource intensive and expensive services (such as antagonist-accelerated 
withdrawal approaches). The experience of using buprenorphine in these research studies was 
that it is a relatively easy medication to use (in specialist agencies), amenable to both short 
inpatient and outpatient withdrawal settings, without requiring intensive resources from the 
patient or service. The incremental cost of delivering outpatient withdrawal services with 
buprenorphine was comparable to using symptomatic medications, and buprenorphine was 
found to be considerably more cost-effective than conventional symptomatic medication in an 
outpatient setting. The once-a-day outpatient dosing regimes did not significantly interfere with 
patient lifestyle, although this may be difficult to co-ordinate in rural or remote treatment 
settings. Issues regarding the uptake of buprenorphine treatment by service providers and its 
accessibility as a treatment option will be considered further in Section 5.3.
5.2.3 Patient preference
The vast majority of subjects in the three studies expressed high rates of satisfaction with 
buprenorphine, and it is likely that buprenorphine will become a popular medication for 
withdrawal among heroin users. However, these findings were among a group of heroin users 
who were prepared to participate in these studies, and may not reflect the preferences of all 
heroin users. There will be a proportion of heroin users who are reticent to use an opioid 
medication for withdrawal; there will be others who prefer the use of a full opioid agonist such 
as methadone; and a proportion of heroin users will be attracted to the idea of an 
‘anaesthetised’ withdrawal using ultra-rapid accelerated withdrawal procedures.
5.2.4 Post-withdrawal treatment options
In order to optimise retention in post-withdrawal treatment, withdrawal regimes should be 
initiated which are matched to the post-withdrawal treatment options best suited to each 
patient. As described earlier, the use of methadone for withdrawal complicates induction into 
abstinence oriented post-withdrawal treatment (such as naltrexone or residential rehabilitation 
programs), however facilitates entry into methadone maintenance treatment; whereas the use of 
naltrexone for withdrawal is not appropriate for the large numbers of heroin users who are not 
prepared or suited to continue in long term naltrexone treatment. Ideally, these issues should be 
identified at the commencement of treatment.
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Unfortunately, the optimal post-withdrawal treatment modality can often be difficult to identify 
at initial presentation and clinical assessment, for a number of reasons. One important issue is 
that most heroin users identify long term abstinence as a treatment goal, yet only a (small) 
proportion achieve this outcome even in the short term^, so that linking patients into 
abstinence-based post-withdrawal treatment modalities (such as naltrexone) at the outset of 
withdrawal attempts may not always be appropriate, despite the initial wishes of patients (and 
their families). Another difficulty in matching patients to post-withdrawal treatment at the 
commencement of a withdrawal episode is that many heroin users presenting for withdrawal 
services may have unrealistic expectations of the need for longer term treatment, and/or may be 
unfamiliar with, or ambivalent about, longer term treatment options. In some circumstances, 
the capacity for long-term treatment planning at the initial assessment is limited due to 
inadequate assessment time, staff expertise, or due to the patient presenting in crisis, with crisis 
management becoming the focus of the initial interventions.
A potential advantage of using buprenorphine for withdrawal is the greater variety of post­
withdrawal treatment options available compared to the other withdrawal medication 
approaches. Rather than attempting to identify appropriate post-withdrawal treatment options at 
the initial presentation, the patient can be stabilised on buprenorphine for several days, with 
minimal withdrawal discomfort, sedation or inconvenience. During this time, the patient and 
clinicians have the opportunity to examine longer-term treatment needs and explore available 
options. Patients who are keen to commence naltrexone treatment can be inducted onto 
naltrexone either while the patient is taking buprenorphine, or after a brief interlude of several 
days. For the majority of patients, continued use of buprenorphine for a longer period of time 
may be preferable, either as a gradual reduction withdrawal regime, or as a long-term 
maintenance medication. Transfer to methadone can also be an option, particularly for those 
individuals who have difficulties stabilising on buprenorphine (for example, those continuing 
to use heroin). Alternatively, patients wishing to discontinue all medication can do so, with 
minimal rebound withdrawal. The use of buprenorphine for heroin withdrawal can be 
considered as a ‘gateway’ for heroin users entering treatment, linking withdrawal with post­
withdrawal services. The gateway model of treatment is schematised below. A similar model 
has been developed for the use of buprenorphine as a maintenance medication (Ling 1998), 
emphasising the versatility of buprenorphine in treatment planning.
5 Note, that this is not necessarily a reflection of poor withdrawal treatment, nor of 
unmotivated patients - patients usually desire the best possible treatment outcomes in most 
areas of clinical medicine - for example, if patients undergoing surgery for cancer were 
asked “how important is a complete cure of your cancer”, the vast majority could be 
expected to respond: “very important”.
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Figure 5.1. Gateway model of withdrawal management with buprenorphine
The combination of these four factors -  safety, efficacy and cost effectiveness, ease of service 
delivery and accessibility, high levels of patient satisfaction, and greater flexibility with regards 
to post withdrawal treatment options - all suggest that buprenorphine provide a significant 
development in the management of heroin withdrawal for individual patients. The next section 
will explore issues regarding the dissemination of buprenorphine for this purpose.
5.3 The uptake of buprenorphine for withdrawal in treatment 
systems
5.3.1 Factors impacting upon the uptake of treatment innovations
The previous section examined issues regarding the choice of medication regimes for 
individual patients, assuming these options are readily available in the treatment system. 
However, it would be incorrect to assume that drug treatment systems will automatically 
embrace buprenorphine as a maintenance or withdrawal medication. There are historical 
examples of treatment systems not widely incorporating pharmacotherapies that have been 
shown to be safe, effective and cost efficient treatment approaches. Most notably has been the
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limited uptake of LAAM, which despite the favourable available evidence regarding its safety 
and efficacy, it remained under-utilised throughout the 1990’s in most countries in which it had 
been registered (Rawson, Hasson et al. 1998).
This process can be understood by recognising that the uptake of a new treatment innovation in 
the health sector is influenced by a number of factors. Barriers to improving clinical 
effectiveness may include inadequate dissemination of information on effective interventions, 
failure of clinicians to act on information received, disincentives to change (such as financial 
considerations), or public perceptions of the appropriateness of new interventions which conflict 
with the best available evidence. In considering how clinical interventions can be made more 
effective, (Haines, Freemantle et al. 1996) identified five characteristics of treatment 
innovations that influence their uptake by the health sector. The characteristics of 
buprenorphine-assisted heroin withdrawal are considered for each:
1. Relative advantage: how much better is the new intervention than available interventions 
Previous research, and the findings of the randomised trial suggest that buprenorphine- 
assisted withdrawal is associated with considerably better outcomes than combined 
symptomatic medications. Most importantly, the effect sizes for key outcomes in this study 
were considerable, indicating that few patients need to undergo buprenorphine-assisted 
withdrawal in order for clinicians and patients to see advantages on a range of outcomes 
(NNT on most key withdrawal outcomes were less than 10).
2. Compatibility: the extent to which the intervention is compatible with existing 
understandings, values and systems. The principle of using substitution medication for 
managing withdrawal is well established (nicotine replacement therapy, benzodiazepine 
reductions, methadone-assisted heroin withdrawal). Although buprenorphine has a number 
of pharmacological properties than differ from methadone, the fundamental principles of its 
use are not dissimilar. Buprenorphine can be successfully used in short courses, in order to 
be compatible with the model of brief withdrawal episodes (particularly inpatient services), 
which predominate in Australia (or can be used in more protracted reduction regimes, as is 
more common in Europe and the USA).
3. Complexity: is the new intervention too difficult to learn or do. The general experience 
from these studies was that buprenorphine-assisted heroin withdrawal is not difficult to 
deliver within specialist treatment settings. The extent to which these findings can be 
replicated in general practice settings is currently being examined in a randomised trial in 
Sydney comparing buprenorphine withdrawal (and a three month post-withdrawal treatment 
phase) in a specialist outpatient drug clinic and general practitioner settings (personal
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communication, James Bell, Nov 2000). The uptake of buprenorphine by service providers 
will be facilitated by the development and dissemination of clinical guidelines, training 
programs, and relevant patient literature. These resources have been prepared for use in 
Australia, and are discussed in the following section.
4. Trialability: the capacity for service providers and patients to ‘give it a go ’ without too 
much long-term commitment or investment. In addition to having access to clinical 
guidelines and training programs, service providers must be able to trial buprenorphine 
without too much commitment or investment. On this point, buprenorphine has certain 
advantages over antagonist-accelerated withdrawal procedures (particularly ultra-rapid 
opiate withdrawal), which require considerable initial resource allocation and investment in 
training. However, the main issue regarding the ‘trialability’ of buprenorphine relates to its 
regulatory controls. Buprenorphine is an opioid medication, and will therefore be subject to 
certain regulatory restrictions in most countries. For example in Australia, restrictions 
regarding its use are being introduced which are generally similar to those in place for 
methadone treatment: in which only medical practitioners who have undergone approved 
training will be authorised to prescribe buprenorphine, with authorised pharmacies 
dispensing buprenorphine under supervision. The rationale for these restrictions is to 
enhance the quality (safety and effectiveness) of service provision (Allsop, Bell et al. 1997), 
and to limit the extent of diversion and abuse of medication. However, this approach is 
likely to result in a restriction of the accessibility of treatment with buprenorphine, as only a 
small proportion of Australia’s medical practitioners are authorised to prescribe medications 
such as methadone. For example, a review of the Victorian community based methadone 
program indicated that less than 5% of registered general practitioners are authorised to 
prescribe methadone (Lintzeris, Koutroulis et al. 1996). It is unclear as to how the small 
number of authorised prescribes will meet the additional demand for heroin withdrawal 
services using buprenorphine. Patient demand may result in an substantial increase in the 
number of doctors prepared to become an authorised prescriber of substitution 
pharmacotherapies; or the small number of authorised service providers may result in the 
limited availability of buprenorphine as a withdrawal medication.
Several countries have proceeded with a more liberal approach to the availability of 
buprenorphine treatment than the system proposed for Australia. In particular, France has 
allowed buprenorphine to be widely prescribed by any medical practitioner, without 
conditions of supervised dispensing. Whilst this has resulted in widespread availability of 
buprenorphine treatment, with approximately 50,000 heroin users being prescribed 
buprenorphine (Auriacombe, Franques et al. 2001), this has not been without certain
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problems. Individual patient outcomes may be compromised by unsupervised dispensing 
and by inadequately skilled service providers, and there must be some concerns regarding 
the safety of buprenorphine when diverted to non-treatment populations (Reynaud, Petit et 
al. 1998; Obadia, Perrin et al. 2001; Tracqui, Kintz et al. 1998). Interestingly, despite the 
absence of restrictions for medical practitioners to prescribe buprenorphine in France, a 
similar trend has been observed where only a minority of medical practitioners become 
involved in treating heroin users, and indeed the majority of heroin users are treated by a 
very small proportion of doctors (Moatti, Souville et al. 1998).
5. Observability: do the clinician & patient get positive outcomes. There were highly 
favourable responses to buprenorphine from patients and clinicians.
Based on the factors identified by Haines and colleagues, the uptake of buprenorphine within 
the Australian treatment system appears promising, although not without potential barriers. 
Clearly, many of the decisions made by governments and the pharmaceutical industry will 
substantially impact upon the uptake of buprenorphine in Australia (and elsewhere). These 
include: which doctors and pharmacists are allowed to prescribe and dispense buprenorphine; 
the availability of clinical guidelines and training programs for service providers; the 
regulations regarding supervised versus unsupervised dispensing; and mechanisms for funding 
buprenorphine treatment. Buprenorphine is a relatively expensive medication in comparison to 
methadone or clonidine, and although the cost of buprenorphine for short withdrawal regimes is 
not prohibitive, many patients will not be able to afford gradual reductions regimes (over weeks 
or months), or the benefits of post-withdrawal buprenorphine maintenance treatment without 
some form of subsidisation.
5.3.2 Clinical guidelines for the use of buprenorphine in managing 
heroin withdrawal
The previous discussion identified several key issues in the uptake of buprenorphine by the 
Australian treatment system, such as having sufficient numbers of service providers authorised 
to deliver buprenorphine treatment, the dissemination of knowledge and expertise regarding its 
use (particularly clinical guidelines and training programs), and the extent of government 
subsidisation of the cost of the medication. This section examines the development of clinical 
guidelines and procedures regarding the use of buprenorphine for the management of heroin 
withdrawal.
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Developing clinical guidelines
Clinical guidelines have been defined as “systematically developed statements to assist 
practitioner and patient decisions about appropriate health care for specific clinical conditions” 
(Institute of Medicine 1992). Clinical procedures refer to the processes involved in the delivery 
of treatment. Guidelines and procedures are aimed at ensuring efficiency, effectiveness and 
appropriateness of healthcare intervention (Miles and Lugon 1996).
There is considerable literature regarding the development of guidelines for clinical practice, 
which is beyond the scope of this thesis. Contemporary approaches (Grimshaw and Russell 
1993; Grimshaw, Freemantle et al. 1995; Eccles, Clapp et al. 1996; National Health and 
Medical Research Council 1998) emphasise that central factors in the validity and integrity of 
clinical guidelines are:
• A systematic review of available evidence. A systematic review requires the application of 
definitive search strategies and inclusion criteria for studies. This is in preference to 
methods utilising consensus of expert opinion (which may perpetuate the biases or traditions 
of practice of those involved), or unsystematic review of the literature.
• Linking guidelines to available evidence. Guidelines should link the recommendations with 
the quality of the supporting evidence.
• Inclusion of all relevant disciplines in the process of guideline development.
The evidence considered by most systematic reviews of an area of clinical practice is often 
limited to findings from randomised controlled trials (Sacket 1986)). However, there is also 
recognition by many commentators that there are considerable ‘grey zones’ of clinical practice 
where the evidence in relation to competing clinical options is incomplete or contradictory 
(Naylor 1995; Polychronis, Miles et al. 1996; Lomas, Anderson et al. 1988). In such 
circumstances consensus approaches for developing guidelines are required, in order to avert 
was has been termed by one author as “paralytic indecision” on the behalf of clinicians. In 
practice, most clinical guidelines utilise a combination of evidence based and consensus based 
recommendations, preferably with an indication as to the quality of the evidence supporting 
each recommendation.
Another factor to be taken into consideration in the development of guidelines is the extent to 
which recommended practices are realistic and practical for the given clinical situation 
(Fowkes 1982). Clinicians are less likely to adhere to guidelines or take up recommendations if 
they are not compatible with existing understandings, values or systems of service delivery 
(Haines, Freemantle et al. 1996).
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The development of national clinical guidelines for buprenorphine-assisted heroin 
withdrawal
The need for the development of clinical guidelines for the use of buprenorphine for managing 
heroin withdrawal and for maintenance treatment was identified by the National Expert 
Advisory Committee for Illicit Drugs (NEACID), pending the registration and introduction of 
buprenorphine into Australia for the management of heroin dependence. A similar process has 
led to the development of guidelines for the use of naltrexone for the management of opioid 
dependence (Bell, Kimber et al. 1999). A national consensus panel of senior clinicians, 
researchers and consumer representatives were brought together under the auspices of NEACID 
to develop national clinical guidelines, with the final report becoming the National Clinical 
Guidelines and Procedures for the use of Buprenorphine in the Treatment of Heroin 
Dependence (Lintzeris, Clark et al. 2001), of which a chapter is dedicated to the use if 
buprenorphine in managing heroin withdrawal. A copy of the published guidelines is included 
as Appendix 3.
Whilst these guidelines are the product of a consensus panel, I was the principle author of these 
guidelines, and in particular, the section on heroin withdrawal draws heavily from research 
undertaken as part of this thesis. The systematic review of buprenorphine in heroin withdrawal 
has been conducted as part of this thesis (Section 1.4) and a separate systematic Cochrane 
review process was completed contemporaneously (Gowing, Ali et al. 2000). The findings of 
the inpatient and outpatient dose titration studies, and experiences with naltrexone induction 
have informed the development of the recommendations regarding dosing regimes contained in 
the national guidelines, although it is recognised that further research is required on these 
topics. These guidelines will need to be updated as more experience with buprenorphine- 
assisted withdrawal accumulates, and as better evidence becomes available.
It should also be noted that the recommended dosing regimes for inpatient and outpatient 
heroin withdrawal using buprenorphine developed in this research have also been adopted by 
the pharmaceutical company Reckitt Benckiser in Australian (and international) product labels 
for Subutex® (see Appendix 4).
In addition to the development of clinical guidelines, a Subutex® National Training Package 
for Health Professionals (Lintzeris, Connolly et al. 2001) has been published by the 
pharmaceutical company Reckitt Benckiser, to assist in the dissemination of clinical expertise 
among service providers. Again, the module on heroin withdrawal in this training package is 
based upon the work of this thesis, and is consistent with the national clinical guidelines. This
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training package has formed the basis for training of medical practitioners and pharmacists 
across Australia since the registration of Subutex®.
5.4 Conclusion
This research has examined a number of issues relating to the use of buprenorphine in 
managing heroin withdrawal. Having established a framework for evaluating withdrawal 
services, a review of the literature identified several areas requiring further investigation, which 
were then investigated in three separate research trials. The first trial identified suitable dosing 
regimes for inpatient heroin withdrawal using the commercially available preparation 
(Subutex®), including an examination of the impact of patient characteristics upon dosing 
requirements. The second study developed a suitable brief, outpatient dosing regime for heroin 
withdrawal, which was subsequently examined in the third and largest study - a randomised 
controlled trial of buprenorphine compared to symptomatic medication (including clonidine 
and benzodiazepine). This study demonstrated buprenorphine to be superior to conventional 
symptomatic withdrawal mediations on most outcomes. This study was the first trial to 
demonstrate enhanced outcomes of retention in withdrawal and post-withdrawal treatment, 
reduction in heroin use during withdrawal episode, enhanced psychosocial outcomes, and 
greater cost-effectiveness for buprenorphine compared to symptomatic medication. From this 
research, the ‘gateway model’ of using buprenorphine as the primary medication option for 
heroin users entering withdrawal services has been developed, allowing greater flexibility in 
post-withdrawal treatment matching. The findings of this research have subsequently been 
incorporated into national clinical guidelines and training programs for health professionals in 
the management of heroin withdrawal with buprenorphine.
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• Patient Information Sheets for Post-withdrawal Treatment Options 
(F160INF2.DOC)
• Patient Consent Form (F154CONS.DOC)
• Opiate Antagonist Challenge Withdrawal Rating Form (F164CHAL.DOC)
• Summary of Adverse Events (F165ADEV.DOC)
Day 8 - Research Assessment
• Weekly Drug Use Diary (F157DIRY.DOC)
• Medication History (F155MDHX.DOC)
• Utilisation of Other Health Services (F162SERV.DOC)
• LEEDS Dependence Questionnaire (F18LEEDS.DOC)
• BASIS-32 (F17BASIS.DOC)
• Client Ratings of Withdrawal (F158RATG.DOC)
• Attainment of Client Goals - day 8 (F159GA.DOC)
• Client Satisfaction with Medication (F161SATS.DOC)
Day 1 -35 - Termination from the Study: Medical Assessment
• Summary of Adverse Events (F165ADEV.DOC)
• Termination From the Study (F168TERM.DOC)
Day 35 - Research Assessment (Follow-up)
• Opiate Treatment Index (OTI) - Section 2 (F190TI2.DOC)
• Basis -3 2  (F17BASIS.DOC)
• LEEDS Dependence Questionnaire (F18LEEDS.DOC)
• Health Status Profile (SF-36) (F55SF36.DOC)
• Attainment of Client Goals - day 35 (F166GA2.DOC)
• Previous Drug Treatments - day 35 (F167TMT2.DOC)
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
T.A.W. CHECKLIST
Office Use only
Client Name
Itudv Code I I f f | Staff initials I I I Date f I i h I I I I 1 1 i i
day month year
V. POTENTIAL ELIGIBILITY CRITERIA
Is the client aged between 1 8 - 65  years? 1[ ] Yes 0[ ] No**
Is the client is heroin dependant? 1[ ] Yes 0[ ] No**
Is the client dependant on alcohol, benzodiazepines or other 
psychostimulants?
1[ ] Yes** 0[ 3 No
Is the client seeking outpatient treatment at Turning Point and is 
geographically appropriate?
1[ ] Yes 0[ 3 No**
Does the client have any major medical or psychiatric problems? 1[ I Yes** 0[ 3 No
Has the client been in any form of methadone treatment in the last 2 
months?
1[ ] Yes** 0[ 3 No
Is the client pregnant or breastfeeding? 1[ ] Yes** 0[ 3 No
ANY TICK IN SECTION MARKED WITH A ' * * '  RESULTS IN INELIGIBILITY FOR HWBR
I. DOES THE CLIENT HAVE A CURRENT PARTNER WHO IS ALSO CONSIDERING 
OUTPATIENT HEROIN WITHDRAWAL AT TURNING POINT? 1[ ] Yes 0[ ] No
OUTCOME OF TELEPHONE ASSESSMENT / TRIAGE OR OTHER COMMENTS
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Randomised Trial of Outpatient Heroin Withdrawal 
Background Information for Clients
Overview of the research
Turning Point is conducting a study looking at different medications for treating heroin withdrawal. 
The aim of the study is to see how a new medication, buprenorphine, compares to current medications 
used for treating heroin withdrawal. It is a randomised trial, which means that the withdrawal 
medication that a client gets is determined by chance (randomly). This is the only way to really know 
which medication works better for most people in withdrawal. There are two stages to the research:
Withdrawal treatment.
This is an 8 day outpatient withdrawal program at Turning Point Services include counselling and 
support during withdrawal, and the use of one of two medication regimes.
• Symptomatic medication for heroin withdrawal: this includes doses of clonidine (Catapress®), 
diazepam (Valium®), ibuprofen (Brufen®), metoclopramide (Maxolon®), Lomotil ®, quinine and 
Buscopan® tablets. Medications are available for the first 6 days, with higher doses during the first 
3 days when symptoms are usually more severe. All medication is dispensed daily from the 
Turning Point pharmacy.
• Buprenorphine: this is an opiate type medication that is only available for treating heroin use in 
Australia as part of research. Buprenorphine is available for 5 days as part of the withdrawal, with 
tablets being dispensed daily from the Turning Point pharmacy.
Clients who volunteer for the study do not choose which type of medication they get: that is done 
randomly by a computer, with every client having a 50% chance of getting either the symptomatic 
withdrawal or buprenorphine medication for their withdrawal . Counselling and support will be the 
same for clients in both groups.
Post withdrawal treatment
Following the withdrawal period (8 days), all clients have the option of continuing in some form of 
treatment at Turning Point (although continued treatment is not mandatory). The choice of post 
withdrawal treatment must be made during the first 3 days after the withdrawal episode has finished 
(days 8, 9 or 10). There are 3 types of treatment to choose from:
• Counselling only: individual counselling with a counsellor is available, with up to 2 counselling 
sessions per week. Counselling usually focuses on reducing the risk of relapse to heroin use
• Naltrexone treatment: clients who have not used heroin during their withdrawal (with ‘clean’ 
urines on days 5 and 8 of the detox) may choose to start naltrexone treatment. Naltrexone is a 
medication that ‘blocks’ the effects of heroin use, and many people find it useful in preventing 
relapse to heroin. However, before commencing naltrexone, clients must have a Narcan challenge 
test done, to make sure that they do not go into major withdrawal after starting naltrexone. 
Naltrexone tablets should be taken once every day. Naltrexone is dispensed daily at Turning Point 
for the first three days, then weekly.
• Maintenance treatment: clients may choose to enter maintenance treatment with an opiate 
medication. Clients in the buprenorphine group may choose to enter buprenorphine or methadone 
treatment, while clients from the symptomatic medication group may choose to enter methadone 
treatment. This requires daily dosing at Turning Point for both groups.
Clients do not have to make a decision about post withdrawal treatment until day 8, 9 or 10. However, 
it is important that if clients are interested in naltrexone treatment, then they should not use heroin 
during the withdrawal episode.
The post withdrawal treatments are available as part of the study for four weeks. If clients wish to 
continue counselling, methadone or naltrexone treatment after this time, they can do this as part of 
standard treatment. Unfortunately, long term treatment with buprenorphine is not available. As such, 
clients still on buprenorphine at the end of the four week period will have the option of withdrawing 
off their buprenorphine over a two week period, or transferring to methadone maintenance treatment.
• Maintenance treatment: clients may choose to enter maintenance treatment with an op 
medication. Clients in the buprenorphine group may choose to enter buprenorphine 
methadone treatment, while clients from the standard medication group may choose to e: 
methadone maintenance treatment. This requires daily dosing at Turning Point for both grouf
You do not have to make a decision about your post withdrawal treatment until day 8, 9 or 10, 
more information will be given to you towards the end of the withdrawal episode about wha 
involved in each of the treatment options. However, it is important to remember that if you 
interested in naltrexone treatment, then you should not use heroin during the withdrawal episode.
The post withdrawal treatments are available as part of the study for four weeks, during wl 
clients do not have to pay for their treatment or for their medication. If clients wish to conti 
methadone or naltrexone treatment after this time, they can do this as part of standard treatment, 
clients must pay the usual fees for their treatment ($ 25 to 30 per week for methadone, 
approximately $35 per week for naltrexone treatment). Unfortunately, long term treatment v 
buprenorphine is not available. As such, clients still on buprenorphine at the end of the four w 
period will have the option of withdrawing off their buprenorphine over a two week period, 
transferring to methadone maintenance treatment. Ongoing counselling at Turning Point can 
organised with your case worker.
The research project is summarised in the following diagram
Enter study 
Day 1
Randomised
End o f Study
•IIP
medi'6ali0'n •
Day 1
Study ends, but 
clients can 
continue 
methadone, 
naltrexone or 
counselling under 
‘standard’ 
conditions.
Day 8
counselling only "
■............ ............M
. Day 35
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What’s involved in participating in the research project?
The following is a summary of what is involved for people who choose to enter the research:
1. Admission procedures. This includes a clinical assessment and an interview with the researcher. 
This takes about 3 hours in total.
2. An 8 day outpatient withdrawal program at Turning Point. This involves daily attendance and 
contact with a worker at Turning Point for counselling, support and monitoring of how things are 
going in withdrawal. The types of medication used for each client is randomly chosen. Medication 
is dispensed daily.
3. A research interview on day 8. This takes about 45 minutes and clients are reimbursed $20 for 
their time.
4. The option o f entering a number offorms of ongoing treatment after withdrawal. These include:
0  naltrexone treatment
0  maintenance treatment with methadone or buprenorphine 
0  counselling without any medication.
0  Clients do not have to enter ongoing treatment if they do not want to.
Treatment is continued as part of the research for 4 weeks. Clients get to choose to enter one of 
these treatments within the first 3 days of finishing the withdrawal program (days 8, 9 or 10). Even 
if you continue to use heroin or do not every day during the withdrawal episode (the first week), 
you can still enter these forms of ongoing treatment. Clients who miss 2 or more consecutive days 
during the withdrawal episode can not be guaranteed post withdrawal treatment options.
5. A research interview after 5 weeks (day 35). This again takes about 45 minutes and clients get 
reimbursed $20 for their time. We want to talk to all clients who enter the research at this time, not 
just the ones who stay in treatment. The involvement in research finishes for clients at this time.
6. Ongoing treatment. Even though the research study for clients finishes after 5 weeks, ongoing 
treatment will be provided for clients. Clients can stay on naltrexone or on methadone, and clients 
can continue counselling. Clients on buprenorphine however can not continue long term 
buprenorphine treatment. At this point in time, clients can choose to swap over to methadone 
treatment, or else can withdraw off buprenorphine over a two week period. Clients must commence 
paying for their methadone or naltrexone at this point in time.
Participation in the study is voluntary, and clients can decide to cease their involvement in the study 
at any point in time. This also means stopping the study medications, although routine treatment 
services will be available for you at Turning Point.
Who can enter the study?
The research is looking at the treatment of people going through outpatient heroin withdrawal. 
However the treatment programs that have been designed may not suitable for everyone wanting to 
do heroin withdrawal, in particular, other forms of treatment or medication may be better for some 
people who:
• require other medications during withdrawal due to regular use of other drugs (such as alcohol, 
benzodiazepines, methadone);
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• have particular medical (eg chronic pain) or psychiatric (eg anxiety, depression) treatment ne
• are homeless and would be better off with an inpatient detox
• have had side effects to the medications being used in the withdrawal
• are pregnant or breast feeding
In order to determine if you are eligible for the study, we need to do the following:
0  a routine clinical assessment by an alcohol and drug worker and then by a medical office 
Turning Point. This takes about 60 to 90 minutes in total, and will include questions about 
treatment you are interested in, your recent and past drug use, previous treatment, medical 
psychiatric history, current social circumstances, and a medical examination.
0  check proof of your identity (photo ED is preferable)
0  urine test looking at recent drug use and to exclude pregnancy (where relevant)
0  check with the Victorian Department of Human Services about any recent methadone treatme 
0  any investigations considered important by your medical officer
If all this is OK, then the client may volunteer to enter the research study. This involves a 30 to 
minute interview with a researcher who will:
0  get written informed consent to enter the study
0  collect some more information (eg about your drug use, previous experience of withdraw 
psychological well being)
0  do the randomisation as to which type of withdrawal treatment you can get 
0  organise details about follow up research interviews in one week and five weeks time
People who do not meet the criteria to enter the research will have normal treatment services 
Turning Point available to them.
Entry into the research study is entirely voluntary. If you choose to not enter research study, tl 
standard withdrawal treatment and other treatment services will be available for you.
Withdrawal treatment as part of the research
Most of the withdrawal services in the research are similar to normal services at Turning Point. T 
involves:
0  Counselling and support during withdrawal: counselling is kept fairly low key, mainly look: 
at things such as coping with withdrawal symptoms and cravings, drug use during withdraw 
side effects, and future treatment options.
0  Information: knowing what is going on and having information about getting through heri 
withdrawal is important. You will be given a booklet that outlines alot of this information.
0  Daily attendance for medication: the research requires that you attend daily for medication 
Turning Point. We normally recommend this for most clients doing withdrawal at Turning Po 
0  Urine drug screens: this is not part of normal withdrawal treatment at Turning Point, but is p 
of the research. We want to get urine drug screens at days 5 and 8 of the withdrawal. This 
particularly important for people thinking about doing naltrexone treatment afterwards.
0  Medication. The medication used during withdrawal is determined by chance (randomisation 
this is part of the research study and not part of usual practice at Turning Point. There are b 
types of medication being used: standard medications and buprenorphine. Each is describ 
below.
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Withdrawal with symptomatic medication
The medications that are used for ‘symptomatic’ heroin withdrawal at Turning Point are:
Diazepam. This is a sedative that can help with anxiety during withdrawal and with sleep problems. 
The usual doses are up to 5 mg (one tablet) four times a day over the first 3 days then reducing 
doses (by one tablet per day) over the next 3 days. This medication is commonly known as 
Valium® or Ducene®.
Clonidine. This is a medication that is usually used for treating high blood pressure, but is also a 
very useful medication for treating the symptoms of opiate withdrawal and also has a sedating 
effect. International research suggests that it is the most effective medication routinely available for 
opiate withdrawal. However, it can cause problems of lowering blood pressure, which may make 
some people feel giddy, or light headed, particularly when standing up from a sitting or lying 
position. This should not be a problem at the doses we prescribe, but please tell the staff if you are 
having such symptoms, and we will usually take your blood pressure while you are taking it. The 
clonidine is prescribed for up to 6 days. This medication is commonly known as Catapress®.
Metoclopramide. This is a medication that can help reduce feelings of nausea and vomiting. It is 
commonly known as Maxolon®.
Ibuprofen. This is a medication related to aspirin, that is usually used for treating arthritis, and can 
be useful for helping relieve the joint aches common in heroin withdrawal. It should be taken with 
food, as it can sometimes cause stomach irritation on an empty stomach. The dose we usually 
prescribe is one tablet (400 mg) four times a day for three days then one tablet three times a day for 
3 days. This medication is commonly known as Brufen®.
Lomotil ®. This is medication for relieving diarrhoea. Taken as one or two tablets up to twice a day 
as needed.
Quinine. This is a medication that is sometimes useful for relieving muscle cramps, particularly at 
night time.
Buscopan®. This medication can help relieve abdominal cramps. Taken as one tablet three or four 
times a day as needed.
All these medications are dispensed daily from the Turning Point pharmacy. Maximum doses of the 
medications are set as part of the research. Medications such as codeine (eg Panadeine forte®) 
propoxyphene (eg Doloxene®) or methadone are not available as part of the study.
Buprenorphine assisted withdrawal
Buprenorphine is an opioid drug that has similar properties and effects to other opiates. 
Buprenorphine is only available for treating heroin use in Australia as a research medication, 
although it is available for the treatment of heroin dependence in France.
Buprenorphine relieves symptoms of heroin withdrawal, reduces cravings for heroin use and 
reduces the effects of any additional heroin use. Unlike other opiates (such as methadone or 
morphine), buprenorphine does not appear to prolong the duration of opiate withdrawal symptoms 
when given for short periods of time (less than one week). These factors make it a promising 
medication in the treatment of heroin withdrawal.
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Buprenorphine is manufactured as thin white oval tablets. These tablets are placed under the ton 
and take about 2 to 3 minutes to dissolve (on average). They should not be swallowed or chewe< 
this will considerably lessen their effect. It is important that you take the medication as directed 
the clinic staff. No additional tablets will be given to you if they are taken incorrectly.
As with other opiates, buprenorphine may have a number of side effects. These are most commoi 
constipation, tiredness, sleepiness, dizziness, nausea and headaches. Side effects are usually m 
short lasting and cease on stopping the medication.
The doses of buprenorphine used in the study are as follows:
Day o f  withdrawal Dose o f  buprenorphine 
(sublingual tablets)
Day 1 6 mg
Day 2 10 mg +/- 2mg
Day 3 10 mg +/- 2mg
Day 4 8mg +/- 2mg
Day 5 4 mg
Total dose 38 mg +/- 6mg
These doses were found to be effective in an earlier study of heroin withdrawal conducted 
Turning Point in 1998. There is the capacity to alter doses on days 2,3 and 4 of the withdrawal 
2mg (up or down) according to how severe the withdrawal is and any side effects experienc 
Buprenorphine is not available after day 5 as part of the withdrawal program. Other medication 
the management of heroin withdrawal (eg sleeping tablets) will not be routinely available for peo 
on the buprenorphine.
Caution about using other drugs during withdrawal
The use of other sedative drugs in combination with buprenorphine, diazepam or clonidine c 
be dangerous and may lead to overdose and death. This includes drugs such as alcohol, sleepi 
tablets or tranquillisers (eg Valium, Serepax, Mogadon, temazepam, Rohypnol), antidepressa 
or other opiates. Furthermore, the effects of these medications can last for several days after \ 
last dose. This means that you should not use other sedative drugs for several days after your l 
dose o f withdrawal medication without checking with your doctor.
Medications will not be dispensed if a client presents intoxicated. Clients can refuse a dose 
medication at any time.
Post withdrawal treatments
The option of entering ongoing treatment after withdrawal is open to all clients who enter 1 
research. The three main types of treatment options are:
• Counselling: individual counselling with a counsellor is available, with up to 2 counselli 
sessions per week. Counselling usually focuses on reducing the risk of relapse to heroin use
• Naltrexone treatment: clients who have not used heroin during their withdrawal (with ‘cles 
urines on days 5 and 8 of the detox) may choose to start naltrexone treatment. Naltrexone ii 
medication that ‘blocks’ the effects of heroin use, and many people find it useful in preventi 
relapse to heroin. However, before commencing naltrexone, clients must have a challenge t< 
done with either Narcan or naltrexone, to make sure that they do not go into severe withdraw
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after starting full doses of naltrexone. Naltrexone tablets should be taken once every day 
Naltrexone is dispensed daily at Turning Point for the first week, then weekly.
• Maintenance treatment: clients may choose to enter maintenance treatment with an opiate 
medication. Clients in the buprenorphine group may choose to enter buprenorphine 01 
methadone treatment, while clients from the standard medication group may choose to entei 
methadone maintenance treatment. This requires daily dosing at Turning Point for both groups.
You do not have to make a decision about your post withdrawal treatment until day 8, 9 or 10, and 
more information will be given to you at the end of the withdrawal episode about what is involved 
in each of the treatment options. However, it is important to remember that if you are interested in 
naltrexone treatment, then you should not use heroin during the withdrawal episode.
If you are particularly interested in getting more information about these treatment options before 
the end of the withdrawal, then talk to you doctor or case worker.
Other business....
• Participation in the study will require you to comply with the normal procedures and rules of 
Turning Point, and with any scheduled counselling sessions.
• If you join the study, we will also request that you consent to allowing the medical staff to access 
information from the Drugs of Dependence Unit of the Victorian Department of Human Services 
(who keep records of who is in methadone treatment in Victoria). This is only for the purpose of 
being certain that you have not been treated with methadone or other opiates in the preceding 2 
months. This involves a separate consent form (Consent Form B).
• Information you provide to the research staff will be held as confidential and not made available 
to the clinical staff. The exception to this is where the research staff have grave concerns 
regarding your immediate safety or the safety of others. In such circumstances, the research staff 
will inform you of their concerns (if possible) prior to notifying the clinical staff. This can not be 
guaranteed however in the (unlikely) event of a court subpoena specifically requesting access to 
your research records.
• All medical records will be held as confidential, and not be made available to staff not directly 
involved in your care or in the research study. This can not be guaranteed however in the event 
of a court subpoena specifically requesting access to your medical records.
• The results of the study may be published or discussed, but no individual participating in the study 
will be identified in any way.
• We cannot guarantee that you will find buprenorphine to be a satisfactory medication in 
withdrawal, and we do not hold out that you will receive any benefits from participating in this 
study.
And finally....
The study is being run by researchers from Turning Point, St.Vincent’s Hospital, The National 
Centre for Epidemiology and Population Health at the Australian National University in Canberra, 
Melbourne University, and The Langton Centre in Sydney. The project is principally funded by the
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Victorian government’s Turning The Tide initiatives. The buprenorphine medication is bei 
provided by the pharmaceutical company Reckitt & Colman.
Compensation
The sponsor of this study, Turning Point, has undertaken to adhere to guidelines for compensation 
to patients whose health is affected by taking part in the study. A copy of these Australian 
Pharmaceutical Manufacturers Association guidelines is available for you to peruse. If an injury 
occurs to you as a result of participation in this study as a result of the study medication, clinical 
intervention or procedure provided for by the protocol, you have the right to seek compensation, 
either through the procedure outlined in the guidelines or by normal legal channels.
2. Advice on Avoiding Pregnancy
You should avoid becoming pregnant during the course of this trial if you are taking the 
investigational medications buprenorphine or naltrexone. If you become pregnant you will have to 
withdraw from the trial and you will be medically followed up carefully until delivery. These 
precautions are necessary because the information on the effects on the unborn or newborn baby o 
drugs like buprenorphine or naltrexone is still very limited.
3. Information and / or complaints
Turning Point and St Vincent’s Hospital requires all investigators to carry out their investigations 
under guidelines issued by the World Health Organisation, The National Health and Medical 
Research Council and the Therapeutic Goods Administration of the Commonwealth Department o 
Health and Family Services. These guidelines have been drawn up to protect the interests of peoph 
who agree to take part in medical research.
If you require further information concerning the project in which you are involved, you should 
contact the principal investigator responsible for this project:
Dr Nicholas Lintzeris 
Turning Point Alcohol and Drug Centre 
54 Gertrude Street, Fitzroy, VIC 3065 
Telephone (03) 9254 8061
If you have any complaints about any aspects of the study or the way in which it is being conducte< 
then you should contact
Professor Margaret Hamilton 
Director of Turning Point Alcohol and Drug Centre 
54 Gertrude Street, Fitzroy, VIC 3065 
Telephone (03) 9254 8061
You will be given a copy of this form to keep.
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
BRIEF SCREENING FORM
Research Use Only
Research No. | f I I I Date I f ,  f . 1 1 1.1 1 1 1
Studv Code I H I WI 8  I R I Site Code I T \ P 1 Client Initials | f 1 Staff initials 1 1 1
INSTRUCTIONS: This form is to be completed jointly by the withdrawal worker and medical officer, aftei 
during the clinical assessment.
A. INCLUSION CRITERIA
1. Between 18-65 years of age (inclusive)? i [ ] Yes o [ ] No
2. DSM-IV diagnosis of current heroin dependence? i [ ] Yes o [ ] No
3. Heroin use within the past 48 hours? (client self report) i [ ] Yes 0 [ ] No
4. Able to meet attendance requirements for study? i [ ] Yes 0 [ ] No
5. Able to give informed consent? i [ ] Yes o f ] No
If NO to any (1 - 5) do not proceed with enrolment — client is not eligible for the trial. Complete the Study 
Rejection Form.
B. EXCLUSION CRITERIA
6. In methadone or other opioid treatment in the last two months? (client self-report) i [ ] Yes o f ] No
7. Dependent upon, intoxicated or withdrawing from aicohol, BZDs or other drugs? i [ ] Yes O f ] No
8. Pregnant, or breastfeeding? (client self-report) Vi ] Yes o f ] No
9. Active or unstable medical conditions? i [ ] Yes 0 [ ] No
10. Active or unstable psychiatric conditions? i f . ] Yes 0 [ ] No
11. Known hypersensitivity / side effects with buprenorphine? i [ ] Yes O f ] No
12. Currently receiving buprenorphine from another source? i [ ] Yes O f ] No
13. Currently enrolled in another clinical trial? i [ ] Yes O f ] No
If YES to any (6-13) do not proceed with enrolment -  client is not eligible for the trial. Complete the 
Study Rejection Form.
C. OTHER
1. Does the client meet the initial screening criteria? i [ ] Yes O f ] No
2. Has the client seen and read a copy of the Patient Information Sheets? i [ ] Yes O f ] No
3. Is the client still interested in participating in this study? i [ ] Yes 0 [ ] No
If NO to any question (1-3) do not proceed with enrolment -  inform research assistant of unsuccessful 
screening. Make alternate arrangements for client withdrawal. Complete the Study Rejection Form.
[If the client meets the initial eligibility criteria please contact the research assistant to arrange client enrolment.]
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
STUDY REJECTION FORM
Research Use Only
Research No. I J___ I___ I
Study Code I H I K I 8 I %  I Site Code I T \  P
Date I___ L J .|___ I I I
Client Initials I I I Staff Initials 1____ |___ J
INSTRUCTIONS: This form is to be completed by a member of clinical staff and forwarded to the Research Assistant once 
completed.
A. REASONS FOR REJECTION
THE CLIENT WAS NOT ELIGIBLE i t ] Yes 0[ ] No
The client was between the ages 18-65 years i [ ] Yes o[ ] No
The client met DSM-IV diagnosis of current heroin dependence. i [ ] Yes 0[ ] No
The client was dependant or withdrawing from alcohol, BZDs 
or other drugs. Please specify
i t ] Yes ° [ ] No
Had the client used heroin within the past 48 hours i t ] Yes 0[ ] No
* UDS [ ]
* Self report [ ]
Was the client able to commit to attendance requirements i t ] Yes 0[ ] No
of the study, (ie, daily attendance for first 8 days).
Was the client to give informed consent? ] Yes 0[ ] No
Has the client been in a methadone program in the last 2 months. i [ ] Yes 0[ ] No
Is the client pregnant or breastfeeding. i [ ] Yes 0[ ] No
UDS
Self report
[ ] 
[ ]
• Does the client have any active or unstable medical / psychiatric conditions. 
Please specify
1[ ] Yes 0[ ] No
• Other. Please specify i [ ] Yes 0[ ] No
2. THE CLIENT WAS ELIGIBLE, BUT DECLINED PARTICIPA TION i [ ] Yes 0[ ] No
B. ALTERNATIVE MANAGEMENT
Please indicate the alternative treatment management in place for the client.
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Outpatient Heroin Withdrawal Using 
Buprenorphine
Randomised Control Trial
Medical Assessment
(intake)
• Medical History Summary
• Physical Examination
• Medication History
• Birth Control Assessment
• DSM-IV Assessment for Opiate
Dependence
• Consent for DPU
• DPU Permit Application
• Client Eligibility Validation
1999
CLIENT NAME UR NUMBER I I I I I
CLIENT MEDICAL HISTORY SUMMARY
Research Use Only Clinic & Research Use Only
Research No. f 1  I I I
Study Code 1 H i hi I B I R I Site Code I P t
I___ I . L___ I___ I . LDate I.
Client Initials I I l  Staff Initials [
.L
J___ I
TO BE COMPLETED BY A MEDICAL OFFICER ONLY AFTER ASSESSMENT
A. MEDICAL HISTORY
1. Has the client had any significant abnormalities diseases or disorders of the following:
1 = YES 
0= NO IF YES, BRIEFLY DESCRIBE THE PROBLEM & ACTION TAKEN
Head, eyes, ears, nose, 
throat
Cardiovascular
Respiratory
Gastrointestinal
Genito-urinary
Musculo-skeletal
Neurological
Endocrinological
Allergies
Skin
Psychiatric
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CLIENT NAME __________________________________________  UR NUMBER [___ l l l____[
CLIENT MEDICAL HISTORY SUMMARY CONTINUED...
A. MEDICAL HISTORY CONTINUED
1(Cont.). Has the client had any significant abnormalities diseases or disorders of the following:
1 = YES 
0 = NO IF YES, BRIEFLY DESCRIBE THE PROBLEM
Hepatitis B
Hepatitis C
HIV
Other (please specify)
B. MEDICAL STATUS - MEDICAL ISSUES IN NEED OF ATTENTION
1. Does the client has any current or ongoing medicaf problems other than drug addiction? 1 [ ] Yes 
If  YES, list these problems below 0[ }  No
Nature of the problem
Duration of 
problem 
(days, mths, yrs)
Current
Severity
(1)
Current 
Action Taken
m
C
Oi
A.
B.
C.
D.
(n SEVERITY codes
1 = Müd
2 = Moderate
3 = Severe
All ACTION TAKEN codes
0 = None
1 = Outpatient treatment
2 = tn-patient treatment
(HI) OUTCOME codes
1 = Resolved, no sequelae
2 r  Continuing, not yet resolved
3 = Resulted in chronic or prolonged condition, severe &
permanent disability
4 = Unknown
This medical history was completed by 
(please print name & date)
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C LIE N T  N A M E UR NUMBER I I i i i __ i
CLIENT PHYSICAL EXAMINATION
Research Use Only Clinic & Research Use Only
Research No. I I I I I Data I t  l . l  I M  I I I
Studv Code I H I hi B  I &  I Site Code I T  [ P  f Client Initials I f I Staff Initials I I I
A. VITAL SIGNS (may be completed by MEDICAL OFFICER or NURSE » please fill In your name below) 
NAME: DATE:
1. Height (cm) - (shoes off & to nearest cm) |____ l l I cm
2. Weight (kg) - (outer clothing off & to nearest kg) |____ |____ |____ | kg
3. Temperature (°C) (please S)
4. Blood pressure - sitting (mmHg)
• use LEFT arm
• Client must have rested for 5 min
•  Measure to nearest 5mmHg
5. Pulse rate - resting (beats/min)
6. Respiration - resting (breaths/min)
[ ] Afebrile
SYSTOLIC
I___ I___I___ I
I___ I___ I
[ ]Febrile |____|____ | . |____ | °C
DIASTOLIC
7. Blood Alcohol Concentration (%) I___I • I___ I___ I___ I %
8. Pupil Size (please circle) 1mm* 2m m # 3mm 4mm 5mm 6mm (or more)
9. Are the pupils reactive? (please circle) Yes / No Are both pupils equal? (please circle) Yes /  No
10. Is there evidence of injecting drug use (ie, injection marks on arms)? (please circle) Yes / No
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CLIENT NAME ________________________________________ UR NUMBER l l I l l
CLIENT PHYSICAL EXAMINATION
B. PHYSICAL EXAMINATION (to be completed by a MEDICAL OFFICER only - please M  in your name below)
NAME : 
DATE:
0 = Not checked
1 = N.A.D
2 = Abnormal
Describe any abnormality
10. Head, eyes, ears, nose, 
throat
11. Nutrition / Hydration
12. Heart
13. Lungs
14. Abdomen
15. Extremities
a injection sites
b available veins
16. Skin
17. Lymph Nodes
18. Other Physical Findings 
(please specify)
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CLIENT N AM E______________________________________ UR NUMBER |________ |___ I l i___ l
CLIENT PHYSICAL EXAMINATION
Research Use Only Clinic & Research Use Only
Research No. | f I t I Date i I t . I I i . l  I 1 i
Studv Code t H  I M  I £ >  I R  I Site Code l T \ P  t Qient Initiats I I l Staff Initials 1 1 1••• ' ...... • • • .... .. . ..
C. MENTAL STATE EXAMINATION (to be completed by a MEDICAL OFFICER only - please M  in your name below)
NAME: 
DATE :
0 = Not checked
1 = N.A.D
2 = Abnormal
Describe any abnormality
19. Appearance
20. Consciousness
21. Speech
22. Mood
23. Affect
24. Thought
a. Stream
b. Content
25. Perception
26. Orientation (T, P,P)
27. Memory
28. Insight
29. Judgement
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CLIENT NAME ___________________________________ ___ UR NUMBER |___ |___ i i i
CLIENT PHYSICAL EXAMINATION
D. OTHER (To be completed by a MEDICAL OFFICER only > (please fill in your name below)
27. Global Assessment of Functioning GAF Score :
28. Is the client intoxicated? (please circle) 1 2 3— — 4 - 5
not moderately severely
intoxicated intoxicated intoxicated
29. Is the client in withdrawal? (please circle) 1 2 3------- - 4— 5
not moderate severe
withdrawing withdrawal withdrawal
30. Is the client able to give Informed Consent? (please s  ) 1 [ ] Yes of ] N o
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CLIENT NAME ____________________________________ _ UR NUMBER |___ l I i i i
CLIENT PHYSICAL EXAMINATION
Research Use Only Clinic & Research Use Only
Research No. | f 1 1 1 Date 1 1 f . 1 1 k l  1 1 1
Study Code | H f W  | ß  | R  1 Site Code l"T *  \ R  f Client Initials 1 1 t Staff Initials 1 1 1
E. INVESTIGATIONS QRDEREDffo be completed by a MEDICAL OFFICER only - please fill in your name befow)
NAME: 
DATE : Ordered 1 = Yes 0 = No
Date Ordered Specimen Collected 
(Date & By whom)
Pregnancy Test
Urine Drug Screen
Full Blood Examination
Liver Function Test
Urea & Electrolytes
Serology Screen
Urinalysis
Other
Other
Other
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CLIENT NAME _____________________________________ __  UR NUMBER |___ i i i i___ L
BIRTH CONTROL ASSESSMENT
Research Use Only Clinic & Research Use Only
Research No. I I I I I Date I I U  I 1.1 I I I
Studv Code t H  t  N  I ß  I £  I Site Code I T" f P \ Client Initials I t I Staff Initials I I I
This form is to be completed by a MEDICAL OFFICER during the assessment of female participants.
1. Is the patient o f child-bearing potential? i [ ]  Yes
0[ ] No Go to question 1b
1 b. If NO, specify the reason 1[ ]  Hysterectomy Go to question 1c
2 [ ] Tubal ligation Go to question 1c
3 [ ] Post menopausal Go to question 1c
4 [ ] Other (Please specify
Go to question 1c
1c. If patient answered question 1b, give date of surgery or
completion o f menopause I ] - [  ] " [  ] 1 [ 3 Surgery
(Signed Release o f information Form Required) Da}f Month Year 2 [ ] M enopai
2. Is the patient nursing an infant? ' I ] Yes NOT ELIGIBLE FOR NPP TRIAL
0 [ ] No
3. W hat method of birth control is the patient using? 0 [ ] None
1[ ] Oral Contraceptive
2[ ] IUD
3[ ] Bam'er Methods (Condom / Diaphragm)
4 [ ] Rhythm Method
5[ ]  Abstinence from heterosexual sex
6[ ]  Deproprovera
n ] Other (p le a s e  S D ec ifv  )
8[ ] Not aDDlicable (w h v  )
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CLIENT NAME UR NUMBER |___ |___ i
DSM-IV CRITERIA FOR OPIATE DEPENDENCE
Research Use Only Clinic Use
Research No. [_ .1___ L Date I I 1-1___ L I . L
Study Code l H  l l* S  I &  I R  I Site Code I T  ( P \ Client initials I____ [____ \ Staff Initials L
INSTRUCTIONS: This form is to be completed by jointly by the assessment worker and medical officer after assessment
A. SUBSTANCE DEPENDENCE - CRITERIA
A. A maladaptive pattern of substance use, leading to clinically significant impairment or distress, as manifested 
by THREE (or more) of the following, occurring at anytime in the same 12-month period
1. Tolerance, as defined by either of the following: 1[ ] Yes 0 [ ] No
a. A need for markedly increased amounts of the substances to achieve 
intoxication or the desired effect
b. Markedly diminished effect with continued use of the same amount of the 
substance
2. Withdrawal as manifested by either of the following:
a. The characteristic withdrawal syndrome of the substance 
(see Withdrawal criteria)
b. The same (or closely related) substance is taken to relieve or avoid 
withdrawal symptoms
3. The substance is often taken in larger amounts or over a longer period than 
was intended
4. There is a persistent desire or unsuccessful efforts to cut down or control 
substance use
5. A great deal of time is spent in activities necessary to obtain the substance 
(eg. visiting multiple doctors or driving long distances), using the substance
(eg. chain smoking), or recover from its effects
6. Important social, occupational or recreational activities are given up or reduced 
because of substance use
7. The substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been caused 
or exacerbated by the substance (eg. current cocaine use despite recognition 
of cocaine induced depression, of continued drinking despite recognition that 
an ulcer was made worse by alcohol consumption) (DSM IV)
1[ ] Yes
1[ ] Yes
1[ ] Yes
1[ ] Yes
1[ ] Yes
1[ ] Yes
0 [ ] No
0 [ ] No 
0 [ ] No
0[ ] No
0[ ] No
0[ ] No
8. Total number of DEPENDENCE criteria met (total no. of ‘Yes’ responses) = |___| (max 7)
9. Does the participant satisfy the criteria of opiate dependence? =>3 met i [  ]Y es  0[ ] No
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CONSENT FOR DPU INFORMATION (CONSENT FORM B)
Research Use Only
Study Code l H  1 N  1 8  1 R 1 Site Code 1 T “ f P |
Oats {
Client Initials ]_
l t I i M  1 1 1
1 i Staff Initials 1 1 1
I , ............................................................ . born on the i i i / 1 i i / 1__ i i i i
day month year
ailow an officer from the Drugs and Poisons Unit of the Victorian Department of Human
Services to provide information to D r............................................. regarding whether I have
had a permit for methadone or other opiate medications in the preceding eight week period.
Dated: i i i / 1__ i__ i / 1 i i i i
Signed: .........................................................
Witness: .........................................................
DPU USE ONLY
Active Permit within the Last Eight Weeks 1[ ]Yes 0[ ] No 
Date of Last Dose i__ i__ j / i i i / 1 i i i i
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT ELIGIBILITY VALIDATION
Research Use Only
Research No. I I I I I Date I I I .1 1 ... I . t  1 1
StudvCode I H  \ N  I 3 \  R \  SiteCode fT " | P | Client Initials 1 f l  Staff Initials 1 . ... 1
INSTRUCTIONS: This form is to be completed by the medical officer and withdrawal worker prior to cl 
enrolment in buprenorphine study. PLEASE TICK THE APPROPRIATE BOX FOR EACH QUESTION.
A. CRITERIA
1. Between 18-65 years of age (inclusive). 1[ ] Yes 0[ ] No
* What evidence of proof of age and identity have been recorded on file?
U ] Drivers licence
2 [ ] Passport
3 [ I Health care card
4 [ ] Medicare card
5 [ ] Other (Please specify
6 [ ] None***
2. DSM-IV diagnosis of current heroin dependence. 1[ ] Yes G[ j No
3. Confirmation that the client is not dependant or withdrawing from alcohol,
BZDs or other drugs ( from clinical assessment) 1[ ] Yes 0[ ] No
4. Confirmation of heroin use within the past 48 hours (UDS). 1[ ] Yes 0[ ] No
* Was an instant urine drug screen conducted?
1 [ ] Yes
2 [ ] No***
* Instant urine drug screen result:
1 [ ] Positive opiates
2 [ ] Negative***
5. Confirmation that the client is not pregnant or breastfeeding.
* Was a urine sample collected for pregnancy testing? (females only)
1 [ ] Yes
2 [ ] No***
* Has the client received pre-pregnancy test counselling?
1 [ ] Yes
2 [ ] No***
* Urine pregnancy test result:
1 [ ] Positive***
2 [ ] Negative
6. Confirmation that the client has no major medical or psychiatric 
conditions (from medical assessment)
1[ ] Yes 0[ ] No
1[ ] Yes 0[ ] No
F156VALD.DOC 16/3/99 3:43 PM Tuminq Point Alcohol & Data Centre Inc. Daae 1 c
HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT ELIGIBILITY VALIDATION
CONTINUED
7. Were other blood investigations ordered?
(Please specify_________
Do the other blood test results warrants client exclusion?
1 [ ] Yes*
2 [ ] No
8. Confirmation from DPU. Has the client been in a 
methadone program in the last 2 months?
* Client consent for DPU release of information signed?
1 [ ] Yes
2 [
9. The client has read the patient information sheets and been given the 
opportunity to ask questions and have them answered.
10. Attendance requirements have been explained and client able to meet 
the study’s requirements?
11. Social circumstances suitable for an outpatient withdrawal program? 
(ie. client is not homeless)
12. The client is willing and able to give informed consent?
1[ ] Yes 0[ ]
1[ ] Yes' 0[ ] li
1[ ] Yes 0[ ]N
1[ ] Yes 0[ ]IS 
1[ ] Yes 0[ ]N
1[ ] Yes 0[ ]N
An answer of YES must be obtained to all the BOLD typefaced questions (excluding q.8) before 
the client can be enrolled in the study.
If a response has been recorded for responses marked *** the client is not eligible -  do not proceed v 
enrolment Complete Study Rejection Form.
B. CLIENT STUDY / TRIAL ENROLMENT STATUS
1. Individual’s enrolment status? 1[ ] Ineligible
2[ ] Eligible & to be enrolled
3[ ] Eligible but declines
IF ENROLLED IN THIS STUDY/TRIAL:
2. Date client was enrolled in the study/trial? Day [ ] Month [ ] Year [
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HEROIN WITHDRAWAL USING BUPRENORPHINE
PATIENT DECLARATION /  CONSENT
Research Use Only
Date ] r.r i i . t i i
Studv Code I H I N I 3  I £ f Site Code f T  \ P I Client Initials I l  Staff Initials I 1 1
ST VINCENTS HOSPITAL
CONSENT OF PATIENT TO PARTICIPATE IN RESEARCH STUDY
PROTOCOL NO. (SVH) : 1 I I I / 1___ |___| 1 I [ 1 (Office use only)
NAME OF PATIENT:
U.R. NO:
NAME OF INVESTIGATORS:
Dr Nicholas Lintzeris,
Dr Gabriele Bammer,
Professor Greg Whelan,
Dr James Bell,
Alison Ritter,
Damian Jolley
STUDY TITLE:
“Random ised Controlled Trial of Outpatient Heroin W ithdrawal using Buprenorphine”
I _____________________________________________have had the purpose and nature of this research
study explained to me by a member of Clinical Staff at Turning Point Alcohol & Drug Centre. The methods 
and procedures of this study, and the risks and discomfort that may be associated with my participation have 
also been explained to me. I have been given a copy of the Patient Information Sheets and have read and 
understood them.
I am willing to take part in this study and I consent to all of the procedures with their associated risks as has 
been explained to me. I understand that I am free to withdraw from this study at any time without cost to 
myself and without jeopardising the management of my condition and the future care and attention that I will 
receive. I have read/had translated to me the above explanation and understand it.
Signed: ____________________________________
(Patient / Guardian / Next Friend)
Witness__________________________________
Date I I I / 1 i I / I I I I I
day month year
F154CONS.DOC 12/3/99 2:34 PM Turning Point Alcohol & Dnjg Centre Inc. page 1 of 1
WmSB
TREATMENT WITH DRUGS OF ADDICTION
S E R V I C
DRUGS, PO ISO N S AND CONTROLLED SUBSTANCES ACT 1981
(Notice o f and application for permit to administer, prescribe or supply.)
PART A: (THIS SECTION SHOULD BE COMPLETED IN ALL CASES) S e x . M /F
N am e of P a tie n t:  Date 0f ß jrth :
(Block Letters)
P rivate  A ddress o f P a tien t:
Postcode:
N am e a n d  A ddress o f M edical P ractitioner:
Postcode:
T e lephone  No. o f M edical P ractitioner:
N am e a n d  A ddress of H ospital W here the  P atien t Is U ndergoing Treatm ent: (If A pplicable)
Clinical D iagnosis:
PART B: (THIS SECTION SHOULD BE COMPLETED IF THE PATIENT REQUIRES CONTINUING TREATMENT)
D rug(s) o f A ddiction fo r Which P erm it Is Requested:
(Name and Form of Drug)
Dose:
F requency  of A dm in istra tion :
D uration  fo r  W hich Such D ru g /D ru g s  Have Been Used:
D etails o f O th e r T rea tm en t: (if app licab le)
I h a v e /h a v e  n o t p rev iously  ap p lied  fo r a  perm it to ad m in iste r, prescribe or supply a d rug  of addiction for this p a tien t. 
If yes, p lea se  ind icate  n a m e  o f d ru g  an d  ap p ro x im a te  da te  o f application.
PART C: (THIS SECTION IS A NOTICE TO THE EFFECT THAT DRUGS OF ADDICTION HAVE BEEN MADE AVAILABLE TO 
THE PATIENT NAMED IN PART A HEREOF, BUT ARE NO LONGER BEING PRESCRIBED)
D ru g /D ru g s  Used:
D uration  o f T rea tm en t:
S ig n a tu re  of M edical P rac titioner:
Da t e : " ~
OFFICE USE ONLY
(Please see over)
EXPLANATORY NOTES
TREATMENT WITH DRUGS OF ADDICTION
Under the terms of the Drugs, Poisons and Controlled Substances Regulations 1985, a medical practitioner shot 
not administer, prescribe or supply the following drugs of addiction—amphetamines, dextromoramide, methad 
or methylphenidate, unless he first holds a permit from the Department of Health and Community Services to c 
For all other drugs of addiction, an initial period of four weeks of treatment is allowed, after which a permit is 
required.
A medical practitioner should not administer, prescribe or supply a drug of addiction for a patient believed to t 
drug dependent unless he First holds a permit to do so.
Also, please note that this form should not be used for application for a permit to treat an opiate dependent pai 
with methadone syrup for which purpose Form DP 41 is available.
Any further information required may be obtained from:
Drugs and Poisons Unit 
Health and Community Services 
Phone: 412 7928/7958 or 7969
All correspondence should addressed to:
Chief Drugs and Poisons Officer 
Drugs and Poisons Unit 
P.O. Box 4057 
Melbourne 3001
Outpatient Heroin Withdrawal Using 
Buprenorphine 
Randomised Control Trial
Research Assessment 
Intake Data Collection
• Research Consent Form (St. V’s ethics)
• Follow-up Locator Form
• Previous Drug Treatment & Additional 
Demographics Form
• Opiate Treatment Index - section 2
• LEEDS Dependence Questionnaire
• BASIS-32
• Health Status Profile (SF - 36)
• AQOL
• Goals Of Treatment (V.A.S.)
• Withdrawal Expectancy (V.A.S.)
1999
FOLLOW-UP LOCATER INFORMATION
Research Use Only
Studv Code 1 H 1 N 1 3  I R 1 Site Code 1 T  I P I
Date i 1 t .T  1 1.1 1 f 1
Client Initials | | f Staff Initials 1 1 1
Participant’s full nam e:_______________________________________________________________________________
Participant’s aliases or nicknames:_____________________________________________________________________
MAILING ADDRESS IF DIFFERENT FROM RESIDENTIAL ADDRESS (AS SPECIFIED ON CLIENT REGISTRATION FORM)
MAILING ADDRESS
I I I I I I I I I I I I I I I I I I I I I I I I I
I I I I I I I____ I I I I I I I I I I I I I I I
SUBURB/TOWN
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
POSTCODE 
1 1 1 1
STATE
1 1 1 1 1
TELEPHONE BUSINESS HOURS 
1 1 1 1 1 1 1 1 1 1
MOBILE PHONE
I I I  1 1 1 1 1 1 1 1 1 1 1 1 1
TELEPHONE AFTER HOURS
I I I I I I I I I I I I I
SECOND CONTACT PERSON (eg. parent, close relative)
CONTACT NAME RELATIONSHIP TO YOU
1 1 1 1 1 1 1 1 1 1 1 1 1 1 . 1 1  1
ADDRESS
1 1 1 1 1 1 1 1 1 1 1 1 _l 1 1 1
SUBURB/TOWN
1 1 1 1 1 1 1 1 1 1 1 1 1 l
POSTCODE
I I  l l 1 l 1
STATE
1 1 1 1
TELEPHONE BUSINESS HOURS MOBILE PHONE
I I I I____I I I I I I I I I I I I I I I_____I____I____ I I I I I
TELEPHONE AFTER HOURS
I I I I I I I I I____ I I I I
NAMES AND PHONE NUMBERS OF TWO PEOPLE WHO WOULD KNOW YOUR ADDRESS OR PHONE NUMBER IF YOU MOVED 
DURING THE COURSE OF THE STUDY
PERSON 1
I I I I I I I I I I I I I I I II I I I I I I I I I I
TELEPHONE BUSINESS HOURS MOBILE PHONE
I__ I___1 I I I I I I I I I I I I I I I I I I I I I I___I
TELEPHONE AFTER HOURS
I I I I I I I I I I I____ I____ I
PERSON 2
I I I I I I I I___ I I I I I I I II I I I I I I I I I I
TELEPHONE BUSINESS HOURS MOBILE PHONE
I____ I_____I I____ I_____I_____I_____I I____ I I I I I____ I I
TELEPHONE AFTER HOURS
I I I I I I I I I I I I I
F 5 1 F U P .D O C  1 2 /1 0 /9 8  10 :0 8  A M T u rn in g  P o in t A lc o h o l & D ru g  C en tre  Inc. p a g e  2  o f  2
FOLLOW-UP LOCATER INFORMATION- CONSENT
Research Use Only
Date I f t . | | l . l
1
...........■■■■:*
I f :
Studv Code f H t H  l ß 1 R 1 Site Code | T  f P f Client Initials 1 1 f Staff Initials 1
1
t  1 1
• • •----------------------------------------------------------------------------- — ------ -----  -
I......................................................................................................................... . (full name of trial participant)
agree to providing additional details about my addresses and contacts on page two of this form.
I understand that this information will be used only if the researcher is unable to contact me for appointments 
follow-up interviews.
I understand that when the researcher makes contact with the people nominated on page 2, that he/she will n< 
mention my drug or alcohol use history or status, or that I am participating in a project about drug treatment, o 
the researcher is calling from Turning Point Alcohol & Drug Centre, and that the researcher will not in any othe 
way disclose that the research project is related to drug use.
Signed:
(participant)
Date: /
Researcher: Date:_____ / ______/
Turning Point Alcohol & Drug Centre Inc.F51FUP.DOC 12/10/98 10:08 AM page 1 oi
OUTPATIENT HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
PREVIOUS DRUG TREATMENTS & ADDITIONAL DEMOGRAPHICS
Research Use Only____________________________ _ ___
Research No. t I I____|____ | Date \ I 1. 1 I 1.1  1 I
Study Code I H  I I V  I ß  I f t  1 Site Code f T *  i P  \ Client Initials { {____ [ Staff Initials I 1 1
INSTRUCTIONS - Ask the client to self-report the number of times they have participated (a) ever ANC 
(b) in the past 12 months, in the following forms of treatment.
A. Previous Drug Treatment
HOW MANY TIMES HAVE YOU PARTICIPATED IN: Ever In past 12 
months
1. Outpatient withdrawal with or without medication
(including attempts with GP, A&D Agency, Home Based 
Withdrawal etc.)
2. Inpatient withdrawal with or without medication
3. Rapid Opiate withdrawal using Naltrexone
4. Cold Turkey (unassisted withdrawal) with or without 
medication
5. Methadone Maintenance
6. Naltrexone Maintenance treatment
7. Maintenance Treatment with other substitution 
pharmacotherapy (eg. Buprenorphine, LAAM)
8. Outpatient counselling not as part of other listed treatment
9. Residential Rehabilitation (eg. Therapeutic Community)
lO.Other
(Please specify
F148TMNT.DOC 12/3/99 11:59 AM Turning Point Alcohol & Drug Centre page 1 of 2
OUTPATIENT HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
PREVIOUS DRUG TREATMENT & ADDITIONAL DEMOGRAPHICS
B. Drug use status of your current partner__________________________
11. What is the current drug use status of your partner (please tick s  one box only)
(a) Don’t have a current partner [ ]
(b) Current partner is a non-heroin user [ ]
(c) Current partner is a dependant heroin user [ ]
(d) Current partner is a non-dependant heroin user [ ]
C. Drug use status of your current place of accommodation._______________________
12. How many adults live in your current place of accommodation? |____ |____ |____ |
13. What is the current drug use status of your place of accommodation (please tick s  one box only)
(a) Don’t have a current accommodation [ ]
(b) I live alone [ ]
(c) Majority of adults are non-heroin users [ ]
(d) Majority of adults are dependant heroin users [ ]
(e) Majority of adults are non-dependant heroin [ ]
users
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R esearch  U s e  O n ly
Research No. I I I | | Date I I I . I I I . I I I I
Studv C ode I H I N  I ß I R I Site Code I T I P I Client Initials |_____ I I Staff Initials I I I
SECTION II
NB: For all categories, if  the subject responds that their last use of the drug was more than a month ago, score 
zero for that category. Do not include use on the day of interview.
Day this form was completed (circle)
MON TUE WED THUR FRI SAT SUN
HEROIN
Now I’m going to ask you some questions about heroin (smack, hammer, horse, scag).
1. On what day did you last use heroin? ________________
2. How many hits/smokes/snorts did you have on that day? ________________
3. On which day before that did you use heroin? ________________
4. And how many hits/smokes/snorts did you have on that day? ________________
5. And when was the day before that? ________________
5a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _______________
5b. On how many days in the past four weeks have you
used any heroin? ___________ days
q1 = , q2 = , t1 = , t2 = Q
POLY-DRUG USE 
Other Opiates
These questions are about your use of opiates other than heroin (eg. street methadone/done, morphine, pethidine 
codeine).
6. On what day did you last use opiates other than heroin? (do not include
legally obtained methadone) ________________
7. How many pills, doses etc. did you have on that day? ________________
8. On which day before that did you use opiates other than heroin? ________________
9. And how many pills, doses etc. did you have on that day? ________________
10. And when was the day before that? ________________
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10a. What was the average cost of a typical day’s use (or estimated cost if not purchased) $ 
NOTE: Include only cost of other opiods obtained illicitly - not on prescription.
q1 = , q2 = , t1 = , t2 = Q
Alcohol
These questions are about your use of alcohol.
11. On what day did you last drink alcohol? _
12. How much alcohol did you drink on that day? _
Wine Spirits Beer Fortified Wine
Wine Gl. 
(120 ml)
Nips 
(30 ml)
Glasses 
(200 ml)
Port Gl. 
(60 ml)
Bottles 
(750 ml)
Doubles 
(60 ml)
Pots 
(285 ml)
Bottles 
(750 ml)
Flagons 
(1.5 It)
Bottles 
(750 ml)
Cans/Stubbies 
(375 ml)
Flagons 
(1.5 It)
Casks 
(___ lit.)
No. Standard 
Drinks
Total Standard Drinks
13. On which day before that did you drink alcohol?
14. And how much did you drink on that day?
Wine Spirits Beer Fortified Wine
Wine Gl. 
(120 ml)
Nips 
(30 ml)
Glasses 
(200 ml)
Port Gl. 
(60 ml)
Bottles 
(750 ml)
Doubles 
(60 ml)
Pots 
(285 ml)
Bottles 
(750 ml)
Flagons 
(1.5 It)
Bottles 
(750 ml)
Cans/Stubbies 
(375 ml)
Flagons 
(1.5 It)
Casks 
(___ lit.)
No. Standard 
Drinks
Total Standard Drinks
15. And when was the day before that?
q1 = , q2 = , t1 = , t2 = Q
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Cannabis
These questions ask you about your use of marijuana (dope, grass, hash. pot).
16. On what day did you last use marijuana? __
17. How many joints, bongs, etc. did you have on that day? __
18. On which day before that did you use marijuana? __
19. And how many joints, bongs etc. did you have on that day? __
20. And when was the day before that? __
20a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _
q1 = , q2 = , t1 = , t2 = Q
Amphetamines
These questions ask you about your use of amphetamines (speed).
21. On what day did you last use amphetamines? __
22. How many tablets/snorts/hits did you have on that day? ___
23. On which day before that did you use amphetamines? __
24. And how many tablets/snorts/hits did you have on that day? __
25. And when was the day before that? __
25a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _
q1 = , q2 = , t1 = , t2 = Q
Cocaine
These questions ask you about your use of cocaine (coke, snow, crack)
26. On what day did you last use cocaine? ___
27. How many snorts/hits/smokes etc. did you have on that day? ___
28. On which day before that did you use cocaine? ___
29. And how many snorts/hits/smokes etc. did you have on that day? ___
30. And when was the day before that? ___
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30a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _______________
q1 = , q2 = , t1 = , t2 = Q
Tranquillisers (Benzodiazepines)
These questions ask you about your use of tranquillisers (eg. Serepax, Valium, Rohypnol, Mogadon)
31. On what day did you last use tranquillisers? _______________
32. How many pills did you have on that day? _______________
33. On which day before that did you use tranquillisers? _______________
34. And how many pills did you have on that day? _______________
35. And when was the day before that? ______________
q1 = , q2 = , t1 = , t2 = Q
Hallucinogens
These questions ask you about your use of hallucinogens (eg. LSD/acid, ecstasy, magic mushrooms)
36. On what day did you last use hallucinogens? _______________
37. How many tabs/pills etc. did you have on that day? _______________
38. On which day before that did you use hallucinogens? _______________
39. And how many tabs/pills etc. did you have on that day? _______________
40. And when was the day before that? _______________
40a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _____________
qi = , q2 = , t1 = , t2 = Q
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Inhalants
These questions ask you about your use of inhalants (eg. amyl nitrate/rush, giue, laughing gas, aerosol: 
petrol)
41. On what day did you last use inhalants? _______________
42. How many sniffs did you have on that day? _______________
43. On which day before that did you use inhalants? _______________
44. And how many sniffs did you have on that day? _______________
45. And when was the day before that? _______________
q1 = , q2 = , t1 = , t2 = Q
Tobacco
46. Finally, if you smoke cigarettes, how many do 
you usually smoke each day?
DRUG USE SUMMARY
Heroin Use Total Poly-drug use total
DRUG USE
Heroin Cocaine
Other Opiates Tranquillisers
Alcohol Hallucinogens
Cannabis Inhalants
Amphetamines Tobacco
General Comments on Drug Use
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LEEDS DEPENDENCE QUESTIONNAIRE
R esearch  U se O nly
Research No. 1 1 1 | | Date 1 1 \ . \  1 l . l  1 1 1
Studv Code 1 H 1 N 1 ß 1 R 1 Site Code 1 TfP | Client Initials | { f Staff Initials 1 1 1
In answering this questionnaire:
* think about the last week
think specifically about your heroin use 
tick the answer most appropriate to you
B. LEEDS DEPENDENCE QUESTIONNAIRE_____________________________ (^Appropriate Box )
No. Question
0=
Never
|  1 -  i  
Some­
times
2=
Often
3
Nes
Alw
1 Do you find yourself thinking about when you will next be able to 
take Heroin?
2 Is taking heroin more important than anything else you might do 
during the day?
3 Do you feel that your need for heroin is too strong to control?
4 Do you plan your day around taking heroin?
5 Do you take heroin in a particular way in order to increase the effect 
it gives you?
6 Do you take heroin morning, afternoon & evening?
7 Do you feel that you have to carry on taking heroin once you have 
started?
8 Is getting the effect you want more important than the heroin you 
use?
9 Do you want to take more heroin when the effect starts to wear off?
1 0 Do you find it difficult to cope with life without heroin?
(O ffice  use only)
SCORE FOR EACH COLUMN 
TOTAL SCORE
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R e s e a rc h  U se  O n ly
Research  No. 1 1 1 1 1 Date I f |
I I  t .  I Ö  iO  T *  f )
.1 1 1 .1  f 1 1
Studv C ode 1 H  1 K \H  D  1 K 1 Site Code 1 1 | r  | Client Initials 1 1 f Staff Initials 1 1 1
A. BEHAVIOUR & SYMPTOM IDENTIFICATION SCALE (BASIS - 32) INSTRUCTIONS
Below is a list of problems and areas of life functioning in which some people experience difficulties. Using the 
scale below, WRITE IN THE BOX THE NUMBER THAT BEST DESCRIBES THE DEGREE OF DIFFICULTY Y 
HAVE BEEN EXPERIENCING IN EACH AREA IN THE PAST WEEK.
0 no difficulty
1 a little difficulty
2 moderate difficulty
3 quite a bit of difficulty
4 extreme difficulty
Please respond to each item. Do not leave any blank. If there is an area you consider to be inapplicable, indical 
that there is NO DIFFICULTY (IE. ‘0’)
ExamDle v
Tn what extent are you experiencinq difficulty in the area of FRIENDSHIPS
B. THE BEHAVIOUR &  SYMPTOM IDENTIFICATION SCALE (BASIS -  32)
[ 2  ]
TO WHAT EXTENT ARE YOU EXPERIENCING DIFFICULTY IN THE AREA OF :
1. MANAGING DAY-TO-DAY LIFE (Eg. getting to places on time, 
handling money, making everyday decisions) [ 1
2. HOUSEHOLD RESPONSIBILITIES (Eg. shopping, cooking, 
keeping room clean, other chores) [ ]
3. WORK (Eg. completing tasks, performance level, finding/ 
keeping a job) [ ]
4. SCHOOL (Eg. academic performance, completing assignments, 
attendance) [ ]
5. LEISURE TIME OR RECREATIONAL ACTIVITIES [ ]
6. ADJUSTING TO MAJOR LIFE STRESSES (Eg. separation, 
divorce, moving, new job /  school, a death) [ ]
7. RELATIONSHIPS WITH FAMILY MEMBERS [ ]
8. GETTING ALONG WITH PEOPLE OUTSIDE OF THE FAMILY [ ]
9. ISOLATION OR FEELINGS OF LONELINESS [ 1
10. BEING ABLE TO FEEL CLOSE TO OTHERS [ I
1 1 . BEING REALISTIC ABOUT YOURSELF OR OTHERS [ 1
12. RECOGNISING AND EXPRESSING EMOTIONS APPROPRIATELY [ ]
... c o n tin u e d  n e x t p a g e  ...
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WRITE IN THE BOX THE NUMBER THAT BEST DESCRIBES THE DEGREE OF DIFFICULTY YOU HAVE 
BEEN EXPERIENCING IN EACH AREA IN THE PAST WEEK.
0 no difficulty
1 a little difficulty
2 moderate difficulty
3 quite a bit of difficulty
4 extreme difficulty
Please respond to each item. Do not leave any blank. If there is an area you consider to be inapplicable, indk 
that there is NO DIFFICULTY (IE. *0')
A. BASIS - 32 CONTINUED ...
13. DEVELOPING INDEPENDENCE, AUTONOMY
14. GOALS OR DIRECTIONS IN LIFE
15. LACK OF SELF-CONFIDENCE, FEELING BAD ABOUT YOURSELF
16. APATHY, LACK OF INTEREST IN THINGS
17. DEPRESSION, HOPELESSNESS
18. SUICIDAL FEELINGS OR BEHAVIOUR
19. PHYSICAL SYMPTOMS (Eg. headaches, aches & pains, sleep 
disturbances, stomach aches, dizziness)
20. CONFUSION, CONCENTRATION & MEMORY
21. FEAR, ANXIETY OR PANIC
22. DISTURBING OR UNREAL THOUGHTS OR BELIEFS
23. HEARING VOICES, SEEING THINGS
24. MANIC, BIZARRE BEHAVIOUR
25. MOOD SWINGS, UNSTABLE MOODS
26. UNCONTROLLABLE, COMPULSIVE BEHAVIOUR (Eg. eating disorder, hand
washing, hurting yourself) Please specify_______________________________
27. SEXUAL ACTIVITY OR PREOCCUPATION
28. DRINKING ALCOHOLIC BEVERAGES
29. TAKING ILLEGAL DRUGS, MISUSING DRUGS
30. CONTROLLING TEMPER (Eg. outbursts of anger or violence)
31. IMPULSIVE, ILLEGAL OR RECKLESS BEHAVIOUR
32. FEELING SATISFACTION WITH YOUR LIFE
[ ] 
[ ] 
[ 1 
[ ] 
[ ] 
[ ] 
[ ]
[ ] 
[  ] 
[  ] 
[  ] 
[ ] 
[ ] 
[ ]
[ 1 
[ ]
[ ]
[ ]
[ ]
[ ]
Office use only
TOTAL SCORE |___ ]___ |___ |
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HEALTH STATUS PROFILE (SF - 36)
Research Use Only
Research No. 1 | 1 | I Data L_ f K l ! 1.1 t 1 1
Studv Code I H I W I ß I R I Site Code 1 T [ P  | Client Initials 1 ¥ i Staff initials 1 1 1
Instructions: This survey asks for your views about your health. This information will help keep track o f how you feel and 
how well you are able to do your usual activities.
Answer every question by selecting the appropriate answer. I f  you are unsure about how to answer a question, please give 
the best answer you can.
1. In general, would you say your health is:
(circle one)
Excellent........................................................................... 1
Very good.........................................................................2
Good................................................................................. 3
Fair.....................................................................................4
Poor...................................................................................5
2. Compared to one year ago, how would you rate your health in general now?
(circle one)
Much better than 1 year ago ...........................................1
Somewhat better now than 1 year ago.............................2
About the same as 1 year ago..........................................3
Somewhat worse now than 1 year ago...........................4
Much worse now than 1 year ago................ ................... 5
3. The following items are about activities you might do during a typical day.
Does your health now limit you in these activities? If so, how much?
circle one number in each row
Yes
Limited Alot
Yes
Limited a little
No, not 
Limited at
a. Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports
1 2 3
b. Moderate activities, such as moving a table, pushing a vacuum 
cleaner, bowling or playing golf
‘ 1 2 3
c. Lifting or carrying groceries 1 2 3
d. Climbing several flights of stairs 1 2 3
e. Climbing one flight of stairs 1 2 3
f. Bending, kneeling, or stooping 1 2 3
g- Walking more than a kilometre 1 2 3
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continued from page 1
h. Walking several blocks 1 2 3
i. Walking one block 1 2 3
j- Bathing or dressing yourself 1 2 3
4. During the past four weeks, have you had any of the following problems with your work or other regular dail] 
activities as a result o f your physical health?
YES NO
a. Cut down on the am ount o f tim e you spent on work or other activities 1 2
b. Accom plished less than you would like 1 2
c. Were limited in the kind of work or other activities 1 2
d. Had difficulty performing the work or other activities (for example, it 
took extra effort)
1 2
5. During the past four weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of anv emotional problems (such as feeling depressed or anxious)?
(circle one number on each line)
YES NO
a. Cut down on the am ount o f time you spent on work or other activities 1 2
b. Accom plished less than you would like 1 2
c. Didn’t do work or other activities as carefully as usual 1 2
6. During the past four weeks, to what extent has your physical health or emotional problems interfered with your 
normal social activities with family, friends, neighbours, or groups?
(circle one)
Not at a ll.............................................................................. 1
Slightly................................................................................2
Moderately...........................................................................3
Quite a b it............................................................................4
Extremely............................................................................5
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7. How much bodily pain have you had during the past 4 weeks?
(circle one)
None.................................................................................... 1
Very mild............................................................................ 2
M ild.....................................................   3
Moderate............................................................................. 4
Severe..................................................................................5
Very severe......................................................................... 6
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the 
home and housework)?
(circle one)
Not at all..............................................................................1
Slightly................................................................................2
Moderately.......................................................................... 3
Quite a bit........................................................................... 4
Extremely........................................................................... 5
9. These questions are about how you feel and how things have been with you during the past 4 weeks. For each
question, please give the one answer that comes closest to the way you have been feeling. How much of the time 
during the past 4 weeks -
(circle one number on each line)
All o f M ost o f A  good Som e A little N oi
the the bit o f o f the o f the o f  tl
time time the time time tim e tim
a. Did you feel full of pep? (energy) 1 2 3 4 5 6
b. Have you been a very nervous person? 1 2 3 4 5 6
c. Have you felt so down in the dumps that nothing 1 2 3 4 5 6
could cheer you up?
d. Have you felt calm and peaceful? 1 2 3 4 5 6
e. Did you have a lot of energy? 1 2 3 4 5 6
f. Have you felt downhearted and blue? 1 2 3 4 5
6
g- Did you feel worn out? 1 2 3 4 5 6
h. Have you been a happy person? 1 2 3 4 5 6
i. Did you feel tired? 1 2 3 4 5 6
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10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered witl 
social activities (like visiting with friends, relatives, etc.)?
(circle one)
All of the time......................................................................1
Most of the time.................................................................. 2
Some of the time................................................................. 3
A little of the time.............................................................. 4
None of the time................................................................. 5
11. How TRUE or FALSE is each of the following statements for you?
Definitely
True
M ostly
True
D on ’t
K now
M ostly
False
Defini
Fals
a. I seem to get sick a little easier than 
other people
1 2 3 4 5
b. I am as healthy as anybody I know 1 2 3 4 5
c. I expect my health to get worse 1 2 3 4 5
d. My health is excellent 1 2 3 4 5
Reproduced with permission from Medical Outcomes Trust (Quality Metric Inc)
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Rsssareh Um  Only
WiwrUMo. I 1 I I I I I
Study Cods I I I I I «sCods 1 1 1
I I I . I I I - 1 I I I I
ADVICE FOR RESPONDENT PROVIDED BY AN INTERVIEWER 
RELATION TO ADMINISTERING THE ASSESSMENT OF QUAL! 
OF LIFE (AQOL) INSTRUMENT
Ql refers to prescribed medicines. These are medicir 
prescribed for the client by a doctor. This DOES NOT Inch 
the study medications: METHADONE, LAA
BUPRENORPHINE or NALTREXONE.
It should include any other regular medication prescribed b; 
doctor (for example, benzodiazepines, pain kiile 
antidepressants, asthma drugs, contraceptives etc).
Q2 If the client uses a medication obtained from sources otfi 
than a doctor’s prescription (for example over the coun 
drugs or benzodiazepines bought from the streets) that shoi 
be recorded here.
Q3 Covers the need for regular medical treatment. The treatme 
provided within the current study (i.e. an initial assessme 
provision of the study medication or attending group sessio 
as a part of Naltrexone trial) SHOULD NOT BE RECORD! 
HERE. However if the same C
(methadone/LAAM/Buprenorphine prescriber) also provides 
REGULAR treatment for a medical condition, that should I 
recorded here.
Th« Assessment of Quality of Life (AQOL) index
IN STRUCTIO NS: Please circle the alternative that best describes you during the lest week.
1 Concerning the use of prescribed medicines:
A. I do not or rarely use any medicines at all
B. I use one or two medicinal drugs regularly
C. I need to use three or four medicinal drugs regularly
D. I use five or more medicinal drugs regularly
2 To what extent do I rely on medicines or a medical aid? (NOT glasses or a hearing a 
(For example: walking frame, wheelchair, prosthesis etc.)
A. I do not use any medicines and/or medical aids
B. I occasionally use medicines and/or medical aids
C. I regularly use medicines and/or medical aids
D. I have to constantly take medicines or use a medical aid
3 Do I need regular medical treatment from a doctor or other health professional?
A. I do not need regular medical treatment
B. Although, I have some regular medical treatment I am not dependent on this
C. I am dependent on having regular medical treatment
D. My life is dependant upon regular medical treatment
4 Do I need any help looking after myself7
A. I need no help at all
B. Occasionally I need some help with personal care tasks.
C. I need help with the more difficult personal care tasks
D. I need daily help with most or all personal care tasks *•
5 When doing household tasks: (For example, preparing food, gardening, using the via 
recorder, radio, telephone or washing the car)
A. I need no help at all
B. Occasionally I need help with household tasks
C. I need help with the more difficult household tasks
D. I need daily help with most or all household tasks
6 Thinking about how easily I can get around my home and community:
A. I get around my home and community by myself without any difficulty
B. I find it difficult to get around my home and community by myself
C. I cannot get around the community by myself, but I can get around my home with some 
difficulty
D. I cannot get around either the community or my home by myself
7 Because of my health, my relationships (for example: with my friends, partner or pare 
generally:
A. Are very close and warm
B. Are sometimes close and warm
C. Are seldom close and warm
D. I have no dose and warm relationships
8 Thinking about my relationships with other people:
A. I have plenty of friends, and am never lonely
B. Although I have friends, I am occasionally lonely
C. I have some friends, but am often lonely for company
D. I am socially isolated and feel lonely
P
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0 Thinking about my health and my relationship wittrmy family:  ̂ 1
A. My role in the family Is unaffected by my health 
8. There are some parts of my family role I cannot carry out
C. There are many parts of my family role I cannot carry out
D. I cannot carry out any part of my family role
10 Thinking about my vision, including when using my glasses or contact lenses if ne 
I see normally
I have some difficulty focusing on things, or I do not see them sharply. For example: sm 
print, a newspaper, or seeing objects in the distance
i have a lot of difficulty seeing things. My vision is blurred. For example I can see just e 
to get by with
I only see general shapes or I am blind. For example: I need a guide to move around
Thinking about my hearing, including using my hearing aid, if  needed:
I hear normally
I have some difficulty hearing or I do not hear dearly. For example: I ask people to spes 
or turn up the TV or radio volume
I have difficulty hearing things dearly. For example I do not understand what is said. I uj 
do not take part in conversations because I cannot hear what is said 
I hear very little indeed. For example: I cannot fully understand loud voices speaking din 
me
When I communicate with others; (for example: by talking, listeningt writing or sign
I have no trouble speaking to them or understanding what they are saying 
I have some difficulty being understood by people who know me well. I have great troub 
understanding what others are saying to me
I am only understood by people who know me weil. I have great trouble understanding v 
others are saying to me 
I cannot adequately communicate with others
If  I think about how I sleep: 
l am able to sleep without difficulty most of the time
My sleep is interrupted some of the time, but I am usually able to go back to sleep withou
I sleep in short bursts only. I am awake most of the night
14 Thinking about how I generally feel:
A. I do not feel anxious, worried or depressed
B. I am slightly anxious, worried or depressed
C. I feel moderately anxious, worried or depressed
D. I am extremely anxious, worried or depressed
15 How much pain or discomfort do I experience?
A. None at all
B. I have moderate pain
C. I suffer from severe pain
D. I suffer unbearable pain
My sleep is interrupted most nights, but I am usually able to go back to sleep without drffi<
Now that you have finished, please go back and check 
you have answered all the questions.
THANK YOU
OUTPATIENT HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
GOALS OF TREATMENT
Research Use Only_______________________________
Research No. I 1 I I___J  Date I I 1. 1 I 1. 1 T 1
Study Code I H I W I 6  | R 1 Site Code i T t P | Client Initials I i I Staff Initials |_____I I
INSTRUCTIONS - Identify your (the client) current treatment goals by indicating on the following visua 
analogue scales where feel best represents your view. Please mark a VERTICAL SLASH through the lin 
(for ALL of the presented treatment goals) to indicate the level of importance to you, for this treatment 
episode.
0 = Achieving this goal is of no importance 
100 = Achieving this goal is of great importance
“GOAL 1 - To cease heroin use throughout the withdrawal episode (8 days)’
0 100
Not
Important
Very
Important
“GOAL 2 - To reduce heroin use during the 8 day withdrawal episode”
0 100
Not
Important
Very
Important
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GOALS OF TREATMENT
“GOAL 3 - To get heroin use ‘under control’ by the end of the 8 day withdrawal period”
0 100
Not
Important
Very
Important
“GOAL 4 - To participate in ongoing treatment after the 8 day withdrawal”
o 100
Not
Important
Very
Important
“GOAL 5 - To cease heroin use for at least one month after completing the 8 day withdraw
period”
0 100
Not
Important
Very
Important
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OUTPATIENT HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
GOALS OF TREATMENT
Research Use Only
Research No. I I I [ I Date I f 1.1 I l . t  I f
Studv Code I H I W I B  I d  I Site Code I T l P I Client Initials j f | Staff Initials I ! I
“GOAL 6 - To reduce heroin use for at least one month after completing the 8 day withdrawa
period”
0 100
Not
Important
Very
Important
“GOAL 7 - To get heroin use under control for at least one month after completing the 8 day
withdrawal period”
0 100
Not
Important
Very
Important
Research Use Only
GOAL# Total mm GOAL# Total mm
Goall I \ f  I Goal 5 t i l l
Goal 2 t  l  i l Goal 6 I  1 1 1
'
Goal 3 i  t  f  i Goal 7 I  f  1 1
Goal 4 l  l I l
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OUTPATIENT HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
WITHDRAWAL EXPECTANCY V.A.S
Research Use Only
Research No. f t I I I Date 1 1 1.1 1 1.1 i  1
Study Code f I I I I Site Code I 1 I Client Initials 1 t t Staff Initials 1 1 1
A. EXPECTANCY REGARDING THIS WITHDRAWAL
“How severe do you think this withdrawal episode will be?”
Please indicate on the following scale by marking a slash through the line as to where you think best represent 
how much discomfort you expect to experience during this withdrawal episode.
0 = predict no discomfort will be experienced this heroin withdrawal and,
100 = predict the most severe withdrawal symptoms ever experienced.
1____________________________1
1
0 100
No Most Severe
Discomfort Discomfort Will Be
Will Be Experienced
Experienced
Research Use Only
Total mm |___ i i i
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NHMRC Clinical Trials Centro 
Randomisation Service: Instruction Sheet 
NEPOD06: A randomised controlled trial of outpatient heroin withdrawal
using Buprenorphine
The NHMRC Clinical Trials Centre (CTC) randomisation service is staffed on a 
roster basis by about 30 individuals. The service is currently provided to over 40 trials 
from 6.00 am to 8.00 pm. When you telephone the randomisation line the first 
questions you will be asked will focus on identifying the specific trial to which you 
want to randomise.
1. Make sure you have all the information required for randomisation in front of you 
BEFORE you telephone the randomisation service.
a) It is recommended that the Randomisation Form provided (or similar) be used.
2. Telephone the randomisation line on 1800 027 928
3. State specifically that you want to randomise to the NEPOD06 trial.
4. You will then be asked for the following information (in this order).
a) Surname: if you do not want to provide the patient's Surname, you may record 
the subject number or the initial
b) First name: if you do not want to provide the patient’s First name, you may 
record the subject number or the initial
c) ID/MRN: the subject number
d) Date of birth: in dd/mm/yy form. If you do not want to provide a data of birth 
you may give the dummy date of birth 01/01/99.
e) Hospital code / site code. This is a 3 digit code. The first digit indicates the 
city the site is based in. The remaining 2 digits identify the specific site.
i) There are the following choices:
101, Langton Clinic, Sydney 
201, Turning Point, Melbourne 
301, Peel St Clinic, Brisbane 
601, Palm Beach Clinic, Gold Coast
ii) You must provide this number.
f) Strata: the choices are: Methadone (1) or Heroin (2). All subjects on this trial 
should be in the Heroin strata.
5. When data collection is complete the computer will then perform the 
randomisation. There may be a short delay.
6. The data manager will then read out:
• a randomisation number
• the result of the randomisation (ie Sublingual Buprenorphine or 
Symptomatic withdrawal medication)
a) You should write this information down.
b) You will then be asked to repeat the information back to the data manager.
7. The randomisation is then complete.
8. A confirmation," of randomisation form will then be faxed to you.
X X ’ >s x
Randomisation Form: NEPOD 06
1. Surname (or initial):_________________________________
2. First name (or initial):_____________ _________________
3. ID/MRN (or subject code):___________________________
4. Date of birth: ____________________________________ _
5. Hospital code
□ 101 (Langton Clinic)
□ 201 (Turning Point)
□ 301 (Peel St Clinic)
□ 601 (Palm Beach Clinic)
6. Strata
□ 1 (Methadone)
□ 2 (Heroin)
Telephone the randomisation line on 1800 027 928
Randomisation result
Randomisation number: __________________________ ___
Randomised to:
□  Experimental Arm: 5 day withdrawal regime of
Sublingual Buprenorphine
O  Control Arm:
Symptomatic withdrawal medication
Date:
TGT
Outpatient Heroin Withdrawal Using 
Buprenorphine
Randomised Control Trial
Data collection during episode 
of withdrawal treatment
• Contact Record Form
• Client Report Form
• Clinician Report Form
• Review Form
1999
3  0«n
= 11
CO c
CLIENT NAME
Research Use Only
Research No. |___
Study Code |___
UR NUMBER l [ 1 I l i
CLIENT REPORT FORM
Site Code I I I
Clinic & Research Use Only 
Date I t I . L
Client Initials |____|____ I
___ I____ I • L_
Staff Initials L
INSTRUCTIONS : Please score each of the 15 items below according to how you feel NOW. Place a ticl 
(✓ ) in the appropriate column. Only one tick per question. Use the scoring values as provided. Obtain th 
total score by adding the score given for each item. Please answer all items.
A. TIME OF FORM COMPLETION |___ |___ j : I I I AM / PM
B. SUBJECTIVE OPIATE WITHDRAWAL SCALE
ITEM o.Not at alt
1
A Little
2
Moderate
3
Quite a Bit
4
Extreme
I fee l a n x io u s
I fee l like  ya w n in g
I am  p e rsp ir in g
M y e ye s  a re  te a ry
M y n o se  is ru n n in g
I have  g o o s e b u m p s
I am  sh a k in g
I have  h o t flu sh e s
I have  co ld  flu sh e s
M y b o n e s  & m u sc le s  ache
I fee l re s tle ss
I fee l n a u se o u s
I fee l like  vo m itin g
M y m u sc le s  tw itch
I have  s to m a ch  c ram ps
I fee l like  us ing  n o w
Column Scores
Total Score
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CLIENT NAME ______________________________________ UR NUMBER |___ I___ I___ I___ i
CLIENT REPORT FORM
B. WHICH TREATMENT MEDICATION ARE YOU CURRENTLY RECEIVING? (Please circle)
Buprenorphine Naltrexone Clonidine Methadone LAAM
C. COMMENTS ON MEDICATION RECEIVED_____________________________________________
Only complete this section befow once per day (morning)
How would you rate yesterday’s total dose? (please ✓  tick)
1 = much too low I___ I
2 = too low I___ I
3 = about right I___ I
4 = too high I___ I
5 = much too high I___ I
Please rate how you slept last night in comparison to how you normally sleep. Place a circle around the cor 
response.
1 2 3 4 5
Much Slightly No Slightly Much
Better Better Different Worse Worse
Please list any side effects to the treatment medication that you experienced.
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CLIENT N A M E __________________________________________ UR NUMBER I i i i i_________ i
CLINICIAN REPORT FORM
Research Use Only__________________________________ __________Clinic & Research Use Only
Research No. | 1 1 1 Date 1 f M 1 1 . 1 1 1
Study Code J . -L... 1 1 1 Site Code 1 ___ I Client Initials I 1 1 Staff Initials 1 ____ 1
Staff Name & Signature : _________________________________________________________
Time : I I I I L
A. PHYSICAL OBSERVATIONS
P l i p i l  S i z e  ( m m )  (please circle) 1mm« 2mm•  3m m ™  4mm ™  5 m m ™  6mm (or me
BP(mmHg) |___ l I l /  I l l
Respiratory rate (b/min) I___ I
Pulse rate (b/min)
BAL reading (%)
I___ L
. I I
Level of Consciousness 0 = drowsy, no response to verbal stimuli
(please «'tick) 1 = drowsy but responds (alert) to stimuli
2 = alert (normal) [ l
3 = agitated [ ]
Speech 0 = slurred [ ] Gait 1 = normal [ ]
(pi«»« «'tick) 1 = normal
t ] (pleas* «'tick) 0 = impaired [ ]
2 = pressured [ ]
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C L IE N T  N AM E U R  N U M B E R  I I ! I I
CLINICIAN REPORT FORM 3
4
B. OBJECTIVE OPIATE WITHDRAWAL SCALE
INSTRUCTIONS : This form is to be completed by a member of clinical staff. Give a 
score for each of the observations (No.s 1-13) according to the scoring values for 
each given observation and how the client appears within a 5-10 MINUTE OBSERVATION 
PEROID. Add up the total score for all of the observations to get the overall withdrawal score.
Observations Scoring Score
1. Y aw n ing 0 = no yaw ns 1 = > 1 yaw ns
2. E xcess ive  nasal d ischarge 0 = <3 sn iffs 1 = >3 sn iffs
3. G oose  flesh  (obse rve  arm ) 0 = absen t 1 = presen t
4. P ersp ira tion 0 = absen t 1 = presen t
5. W a te ry  eyes 0 = absent 1 = p resen t
6. T re m o r 0 = absen t 1 = present
7. Pupil d ila tion 0 = absen t 1 = ^  3m m
8. H ot and C old  F lushes 0 = absen t 1 = shivering / huddling for warmth
9. R es tlessness 0 = absen t 1 = frequen t sh ifts  o f pos ition
10. V om iting 0 = absent 1 = presen t
11. M usc le  tw itches 0 = absen t 1 = p resen t-
12. A bdom ina l cram ps 0 = absen t 1 = H old ing s tom ach
13. A nx ie ty 0 = absent 1 = m ild - seve re
TOTAL SCORE
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CLIENT NAME UR NUMBER |___|___ i 1 I___ i
REVIEW FORM
Research Use Only Clinic Use
Research No. [ i r i I Date | I U :  1 1.1 1 1 1
Studv Code I H i W f  B  | R  | Site Code lT *  l  P i Client Initials 1__ 1 1 Staff Initials 1 I 1
INSTRUCTIONS This form is to be comDleted bv the Clinician followina each client consultation.
Staff Name & Signature : __________________________________________
Staff Designation : _________________________________  Time: [
A. SELF REPORT DRUG USE BY CLIENT SINCE LAST REVIEW
Drug used
.
Amount used r.o.a When used Reason for drug use
[Reasons for use may be: to avoid withdrawal discomfort (severe symptoms / cravings); for intoxication; 
situational factors, other]
B. SELF REPORT USE OF STUDY MEDICATIONS - Please include the number of tablets (administered from 
T/P Pharmacy) taken since the last review. Answer for each of the listed medications.
• Valium *----- 1 1 • Clonidine 1 ^ 1
• Brufen 1----- 1----- 1 • Buscopan
• Maxalon • Quinine *----- *----- *
• Lomotil 1 1 1
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CLIENT NAME ________________________________________  UR NUMBER |___ |___ |___ j___ L
REVIEW FORM
B. WHAT TREATMENT MEDICATION IS THE CLIENT RECEIVING?
C. STAFF ASSESSMENT OF DOSE ADEQUACY.
Please rate the adequacy of preceding day’s total dose:
1 = much too low
2 = too low
3 = about right SCORE [
4 = too high
5 = much too high
N/A = did not present, dose withheld
D. CLINICIAN ASSESSMENT OF ADVERSE EVENTS.
Description of adverse event reported by client / observed by clinician. Include description, onset, other potent 
causes, examination findings, management, outcome, likely relationship to the study medication (highly unlike 
unlikely / possible / probable/ likely / highly likely)
D. OTHER ISSUES DISCUSSED IN CONSULTATION / PLAN FOR NEXT CONSULTATION
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Outpatient Heroin Withdrawal Using 
Buprenorphine
Randomised Control Trial
Medical Assessment
(day 8)
• Post-withdrawal Eligibility Checklist
• Patient Information Sheets (Post­
withdrawal Treatment Options)
• Consent Form for post-withdrawal
treatment
• Opioid Antagonist Challenge Withdrawal
Rating Form
• Summary of Adverse Events
1999
HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
POST-WITHDRAWAL ELIGIBILITY CHECKLIST
Resaarch Usa Only
R esearch No, I 1 I | | Date L f 1 .1  £ 1.1 1 t
Studv Code l H  1 W | ß ! R  | site Code I T  f P  1 Client Initials I r J  Staff Initials 1 1
A. WHAT TREATMENT MEDICATION DID THE CLIENT RECEIVE? BUPRENORPHINE [
(please tick O CLONIDINE
B. POST-WITHDRAWAL ELIGIBILITY CRITERIA
Attendence Issues:
• Did the client meet the attendence requirements for the 8 day withdrawal 
period? (ie, did not miss 2 or more consecutive days)
Opiate Use during 8 day withdrawal episode:
• Self - report of opiate use
• Urine Drug Screen
Day 5 [ ] positive * [ ] negative [ ] results not confirmed **
Day 8 [ ] positive * [ ] negative [ ] results not confirmed **
• Instant Urine Drug Screen (Accusign) - day 8
Liver Function Test
• Is the ALT > 3 times normal range 
Information & Consent:
• Has the client been given a copy of the Patient Information Sheets
• Has the client given informed consent
If response is marked with a *  or** do NOT commence post-withdrawal treatment with Naltrexone. Client is ineligible.
C. POST - WITHDRAWAL TREATMENT
Post - Withdrawal Options Eligible for Treatment Treatment Entered
• Counselling Only [ ] yes [ ] no [ ] yes [ ] r
• Naltrexone Treatment [ ] yes [ ] no [ ] yes [ ] r
• Buprenorphine Treatment [ ] yes [ ] no [ ] yes [ ] r
• Methadone Treatment [ ] yes [ ] no [ ] yes [ ] r
• Complete Symptomatic Withdrawal [ ] yes [ ] no [ ] yes [ ] r
• Undecided n/a [ ] yes [ ] r
D. DAY 10 OUTCOME
What post-withdrawal treatment did the client enter? 
Comments _______________________________
] yes* [ ] no
] yes* [ ] no
[ ] specimen not provided*
[ ] specimen not provided*
] positive * [ ] negative
] yes* [ ] no
] yes [ ] no*
] yes [ ] no*
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Randomised Trial of Outpatient Heroin Withdrawal using
Buprenorphine
Information for Clients
POST WITHDRAWAL TREATMENT OPTIONS
After withdrawal, the study offers a range of treatment options. These services are available as part 
of the study for 4 weeks. After this time, you may continue the treatment independent of the study, 
as part of ‘routine’ treatment (with the exception of buprenorphine). Each treatment is described 
below.
Treatment as part of the research is free of charge during the first 4 weeks. A fee for medication 
applies after this time.
You do not have to enter any ongoing treatment. However, you must make a decision about entering 
these treatment options during the first three days after the withdrawal has finished - on days 8, 9 or 
10. Naltrexone, methadone or buprenorphine treatment are not routinely available at Turning Point, 
so you can only enter these treatments during this three day period.
You can not change the type of treatment you are in during the four week period (eg, you can not 
start on naltrexone and then change to methadone after 2 weeks).
You can cease treatment at any time. However, if you cease treatment, you will not be able to enter 
treatment again as part of the study. Other treatment plans can be considered with your doctor and 
case worker.
if you miss more than 3 consecutive days of treatment with naltrexone, methadone or 
buprenorphine then your treatment program as part of the research will be ceased. Alternative 
treatment plans can be considered.
If you are interested in other forms of treatment (eg residential rehabilitation), this may be organised 
with your doctor and case worker
Counselling
Individual counselling is available with one of the workers at Turning Point (generally your 
withdrawal worker). In general, 2 counselling sessions per week are available for four weeks, 
although this can be negotiated with your counsellor. The general aim of counselling will be to 
assist you to meet your goals around drug use or other issues. Counselling can assist you with 
strategies aimed at preventing relapse into regular heroin, or dealing with problems related to your 
drug use.
Naltrexone Treatment
Naltrexone is a medication that is used to reduce relapse to regular heroin use in people who have 
already gone through withdrawal. Naltrexone has been used in the treatment of heroin use in the 
USA and other countries for over 10 years, but it is not registered for use in Australia yet. It is 
therefore not widely available in Australia.
Previous studies have shown that naltrexone reduces relapse to regular heroin use and reduces 
cravings for heroin. Studies also indicate that naltrexone works best for those people who are
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motivated to remain abstinent from heroin use, and where ongoing counselling and support are pai 
of treatment.
Naltrexone is an opioid antagonist - it works to block the effects of opiates by binding to opiate 
receptors in the brain and preventing other opiates from working. This means that the ‘high’ from 
any heroin use is greatly reduced. Most people finding that heroin use is not worthwhile while 
taking naltrexone. Naltrexone has this effect for up to 3 days, so it takes up to 3 days before people 
can feel stoned from heroin.
Getting started on naltrexone
Taking naltrexone after recent opiate use will send you into severe opiate withdrawal. Therefore, 
before you start naltrexone, you must not have used heroin or other opiates for at least 7 days. 
Naltrexone is only available for people who have not used heroin during the withdrawal episode, 
and this must be confirmed by urine tests on days 5 and 8 of the withdrawal. Also, a naloxone 
challenge test is conducted for those people who used symptomatic medication for withdrawal. Th 
is to make sure that you do not get severe withdrawal discomfort when starting naltrexone. This is 
done by giving you an injection of naloxone (Narcan) and observing if there is a withdrawal 
reaction within the next 15 minutes. If this is OK, then you can commence naltrexone immediately 
If you do have a severe reaction to the naloxone challenge test, then we recommend you wait 
another 24 hours before having another challenge test.
For those people who used buprenorphine for withdrawal, a test dose of naltrexone is used. This is 
low dose of naltrexone (12.5 mg), and clients are asked to stay at the clinic for 3 hours after the doi 
to make sure they do not have any withdrawal reaction.
The routine with naltrexone
Naltrexone is dispensed daily for the first week at Turning Point, initially at 25 mg per day (half a 
tablet) for the first three days, increasing to 50 mg per day (a full tablet). After a week, naltrexone i 
dispensed weekly, but you should keep taking a tablet once a day.
Part of naltrexone treatment involves regular (weekly) contact with your doctor, and with your 
counsellor. Naltrexone is available for the first 4 weeks for free. After this time (after the research 
has finished), you will have to commence payments for naltrexone treatment - it usually costs abou 
$5 per dose per day (~$150 per month).
Side effects
Mild side effects have been reported with naltrexone in about 5 to 15% of people taking it. The 
most common symptoms reported by more than 10% of people are opiate withdrawal symptoms 
during the first week on naltrexone, such as sleep problems, anxiety, abdominal cramps, nausea, 
diarrhoea, joint and muscle aches, headache. These usually settle down within the first week of 
treatment with naltrexone.
Less common side effects include: feeling down or flat, irritability, skin rash and sexual difficulties 
Most of these symptoms are usually mild and short lasting. Overall, naltrexone is considered to be ; 
safe medication. Please tell your treatment team if you have any side effects. One concern however 
is the effects upon people with severe liver disease, and therefore all people thinking of starting 
naltrexone must have liver function tests first.
A possible, but rare side effect of the naloxone (Narcan®) challenge test is the onset of pulmonary 
oedema (fluid in the lungs). This can be severe and needs treatment in hospital.
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Pregnancy and breast feeding
The safety of naltrexone in pregnancy has not been proven, therefore we recommend that pregnant 
or breast feeding women do not take naltrexone. Women taking naltrexone should avoid becoming 
pregnant during the course of this trial - this often means using a reliable form of contraception. If a 
woman taking naltrexone becomes pregnant, they must stop taking naltrexone immediately and 
consider other forms of treatment.
Overdose risk
It is important to remember that after a period of withdrawal, and particularly after being on 
naltrexone, your tolerance for opiates will be very much reduced. This means that if you stop taking 
naltrexone, even small amounts of heroin will get you very stoned, and may cause overdose.
Buprenorphine Treatment
Buprenorphine is an opioid drug that has similar properties and effects to other opiates. 
Buprenorphine is only available in Australia as a research medication, although it is available for 
the treatment of heroin dependence in France.
Buprenorphine relieves or prevents symptoms of heroin withdrawal, reduces cravings for heroin use 
and reduces the effects of any additional heroin use. Buprenorphine also is reported to have much 
milder withdrawal symptoms on stopping it compared to other opiates such as morphine, heroin or 
methadone.
Buprenorphine is manufactured as thin white oval tablets. These tablets are placed under the tongue 
and take about 2 to 3 minutes to dissolve (on average). They should not be swallowed or chewed as 
this will considerably lessen their effect. It is important that you take the medication as directed by 
the clinic staff. No additional tablets will be given to you if they are taken incorrectly.
Doses of buprenorphine are usually commenced around 4 to 8 mg per day and increased over the 
next few days until the client is comfortable. Most people find that daily doses of between 8 and 16 
mg per day are adequate. Buprenorphine is dispensed once a day. No take aways are available as 
part of the study.
Side effects
As with other opiates, buprenorphine may have a number of side effects. These are most commonly: 
constipation, tiredness, sleepiness, dizziness, nausea and headaches. Side effects are usually mild, 
short lasting and cease on stopping the medication.
Pregnancy and breast feeding
The safety of buprenorphine in pregnancy or breastfeeding has not been proven and therefore we 
recommend that pregnant or breast feeding women do not take buprenorphine. It is recommended 
that women taking buprenorphine should use reliable contraception, which you can discuss with 
your doctor or other health care workers. If a woman taking buprenorphine becomes pregnant, they 
must stop taking buprenorphine immediately and consider other forms of treatment such as 
methadone.
Caution about using other drugs with buprenorphine
The use o f other sedative drugs in combination with buprenorphine can be dangerous and may 
lead to overdose and death. This includes drugs such as alcohol, sleeping tablets or tranquillisers 
(eg Valium, Serepax, Mogadon, temazepam, Rohypnol), antidepressants or other opiates. 
Furthermore, the effects of buprenorphine can last for several days after the last dose. This
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means that you should not use other sedative drugs for several days after your last dose 
buprenorphine without checking with your doctor.
Medications will not be dispensed if a client presents intoxicated. Clients can refuse a dose 
medication at any time.
Availability of buprenorphine after the research
Unfortunately, long term treatment with buprenorphine is not an option in this study. At the end c 
the research (after 4 weeks of buprenorphine treatment), clients on buprenorphine have one of tw< 
options -
• to transfer to methadone maintenance treatment and continue long term treatment on 
methadone; or
• to withdraw off buprenorphine. This can take up to 2 weeks, so in total, the maximum duratio: 
of buprenorphine treatment available after withdrawal is 6 weeks.
Methadone Treatment
Methadone is an opioid drug that is widely used around Australia for the treatment of heroin 
dependence. It is a substitution medication - that is, it reduces or prevents features of heroin 
withdrawal, cravings for heroin, and at high doses also reduces the effects of additional heroin use 
It has been shown to be a safe and effective treatment approach in numerous studies around the 
world. Detailed description of methadone treatment is available in the client handbook “ Methado 
treatment in Victoria” which will be given to you.
As methadone is an opiate, it has side effects common with other opiates. These include sedation, 
drowsiness, constipation, sweating, nausea, vomiting, reduced libido, fluid retention, skin rashes. 
Many of these side effects are mild and short lasting, while others persist (eg constipation). Other 
less common side effects are described in the booklet on methadone. One of the concerns often 
described with methadone is difficulties in coming off methadone, with prolonged withdrawal 
discomfort.
Methadone is dispensed as a syrup which you drink. Doses are dispensed daily from the Turning 
Point pharmacy. Clients can receive take aways for methadone (one per week) after 3 months in 
treatment - but this does not apply for the 4 week study. Doses are adjusted according to any 
symptoms of heroin withdrawal, cravings, side effects or additional drug use that you may be 
experiencing.
Methadone treatment during the research study (first 4 weeks) will be provided free of charge at 
Turning Point pharmacy. If you wish to stay in methadone treatment after the study has finished, 
then you will have to commence paying usual methadone dispensing fees (~$25 to 30 per week). 
You can transfer to a community based pharmacy at this time.
Pregnancy and breast feeding
Methadone is relatively safe in pregnancy and for breast feeding, and is the recommended form of 
treatment for pregnant heroin users in Australia. Some babies are bom with features of opiate 
withdrawal, but this is usually mild and short lasting, and does not appear to be related to the dose 
of methadone that the mother was taking.
Caution about using other drugs with methadone
The use of other sedative drugs in combination with methadone can be dangerous and may lei 
to overdose and death. This includes drugs such as alcohol, sleeping tablets or tranquillisers 0 
Valium, Serepax, Mogadon, temazepam, Rohypnol), antidepressants or other opiate
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Furthermore, the effects o f  methadone can last fo r  several days after the last dose. This means 
that you should not use other sedative drugs for several days after your last dose o f  methadone. 
Medications will not be dispensed if a client presents intoxicated. Clients can refuse a dose of 
medication at any time.
Other Business
1. Compensation
The sponsor of this study, Turning Point, has undertaken to adhere to guidelines for compensation 
to patients whose health is affected by taking part in the study. A copy of these Australian 
Pharmaceutical Manufacturers Association guidelines is available for you to peruse. If an injury 
occurs to you as a result of participation in this study as a result of the study medication, clinical 
intervention or procedure provided for by the protocol, you have the right to seek compensation, 
either through the procedure outlined in the guidelines or by normal legal channels.
2. Advice on Avoiding Pregnancy
You should avoid becoming pregnant during the course of this trial if you are taking the 
investigational medications buprenorphine or naltrexone. If you become pregnant you will have to 
withdraw from the trial and you will be medically followed up carefully until delivery. These 
precautions are necessary because the information on the effects on the unborn or newborn baby of 
drugs like buprenorphine or naltrexone is still very limited.
3. Information and / or complaints
Turning Point and St Vincent’s Hospital requires all investigators to carry out their investigations 
under guidelines issued by the World Health Organisation, The National Health and Medical 
Research Council and the Therapeutic Goods Administration of the Commonwealth Department of 
Health and Family Services. These guidelines have been drawn up to protect the interests of people 
who agree to take part in medical research.
If you require further information concerning the project in which you are involved, you should 
contact the principal investigator responsible for this project:
Dr Nicholas Lintzeris 
Turning Point Alcohol and Drug Centre 
54 Gertrude Street, Fitzroy, VIC 3065 
Telephone (03) 9254 8061
If you have any complaints about any aspects of the study or the way in which it is being conducted 
then you should contact
Professor Margaret Hamilton 
Director of Turning Point Alcohol and Drug Centre 
54 Gertrude Street, Fitzroy, VIC 3065 
Telephone (03) 9254 8061
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HEROIN WITHDRAWAL USING BUPRENORPHINE
PATIENT DECLARATION / CONSENT
Research Use Only
Date 1 f 1.1 1 1.1 f 1 I
Study Code f. H  f W  1 B l R  I Site Code f T  1 P  l Client Initials | f \ Staff Initials 1 1 f
ST VINCENT’S HOSPITAL
CONSENT OF PATIENT TO PARTICIPATE IN RESEARCH STUDY
PROTOCOL NO. (SVH) : 1 I I I / 1 I J [ 1 1 1  (Office use only)
CONSENT FOR: WITHDRAWAL TREATMENT [ ]
(please tick ✓ ) POST-WITHDRAWAL TREATMENT [ ]
NAME OF INVESTIGATORS:
Dr Nicholas Lintzeris,
Dr Gabriele Bammer,
Professor Greg Whelan,
Dr James Bell,
Alison Ritter,
Damian Jolley
STUDY TITLE:
“Random ised Controlled Trial of Outpatient Heroin W ithdrawal using Buprenorphine”
I ____________________________________________ have had the purpose and nature of this research
study explained to me by a member of Clinical Staff at Turning Point Alcohol & Drug Centre. The methods 
and procedures of this study, and the risks and discomfort that may be associated with my participation have 
also been explained to me. I have been given a copy of the Patient Information Sheets and have read and 
understood them.
I am willing to take part in this study and I consent to all of the procedures with their associated risks as has 
been explained to me. I understand that I am free to withdraw from this study at any time without cost to 
myself and without jeopardising the management of my condition and the future care and attention that I will 
receive. I have read/had translated to me the above explanation and understand it.
Signed:
(Patient / Guardian / Next Friend)
Witness
Date / I
month year
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CLIENT NAME UR NUMBER |___ |___ I i i i___ |
OPIOID ANTAGONIST CHALLENGE
WITHDRAWAL RATING FORM
Research Use Only_____________________________________  Clinic & Research Use Only
Research Na f f I I I Date f 1.1 I 1.1 I I T
Studv Code I H I W  I 6  I fs  I Site Code t T J_P I Client initials I I f Staff Initials ! I I
This form is to be completed by the medical officer during the Naloxone or Naltrexone Challenge Test. 
SECTION A
This section is to be completed by the medical officer five minutes after the naloxone injection or 3 
hours after naltrexone is administered, and involves making a global observation of the patient 
Please rate the presence and seventy of the patient’s withdrawal symptoms by placing a tick next to 
your response._____________________________________
1. Is the patient displaying signs of withdrawal from 1 [ ] Yes
opioids?
0 [ ] No
2. If you answered ‘yes’ to Question 1, please indicate 1 [ ] Mild
with a tick the severity of the signs the patient is
displaying. 2 [ ] Moderate
3 [ ] Severe
SECTION B
The medical officer should tell the participant that any symptoms they are experiencing are likely to 
continue if they are inducted to naltrexone today. Please indicate the participant’s response with a tick.
1. Are the symptoms you are experiencing tolerable? 1 [ ] Yes (without symptomatic medication)
2 [ ] Yes (with symptomatic medication)
0 [ ] No
2. Do you want to begin taking naltrexone today? 1 [ ] Yes
0 [ ] No
SECTION C__________________________________________________________________
1. Individual’s dosing status? 1 [ ] Ineligible
2 [ ] Eligible and prescription written
3 [ ] Eligible but declines
page 1 of 1F164CHAL.DOC 22/3/99 1:42 PM Turning Point Alcohol & Drug Centre Inc.
SUMMARY OF ADVERSE EVENTS
(B a s e d  o n  VA / NIDA Fo r m )
Research Use Only
Research No. .1___ L
Study Code f H  i Vsi 1 I R  I Site Code ( I  }
Date L
Client Initials I
[___ L •f___ l___ I___ L
J  Staff Initials |_
A. PERIOD OF REVIEW :
From Date |___ |___ | . I I___ | . I l I___ |___ | To Date I___ |___ | . |___ |___ | . I l i___ [
B. WHAT TREATMENT MEDICATION DID THE CLIENT RECEIVE?
(please tick S)
BUPRENORPHINE [ ]
CLONIDINE [ ]
C. ADVERSE EVENTS
Date of 
Onset
Nature of Illness, Event or Abnormal Lab 
Value
1.
Type
of
Report
IL
Relatedness
in.
Level of 
severity
IV.
Action
Taken
V.
Outcome Date
Resolv
1.
2.
3.
4.
5.
6.
7.
8.
1. II. II. IV. V.
Type of report Relatedness Severity Action Taken Outcome
1 = A ntic ipa ted  adverse 1 -  Definite ly s tudy drug 1 = Müd 1 = None required 1 = Resolved
event re la ted 2 -  Moderate 2 = Prescription drug therapy 2 -  Unresolved
2 = Unanticipated adverse 2  = Probably study drug 3 = Severe” 3 = In-patient hosprtaOsation 3 -  R esulted in chronic
event related 4 = Prescription drug therapy & condition o r severe/
3 = Concom itant illness 3 -  Possibly study drug hospitalisation perm anent
4 = Developm ent o f  c lin ica lly related 6 -  Medical specialty d isab ility**
significant abnonna i lab 4 = Unrelated to study consultation required 4 -  D eceased”
value drug 7 = Randomisation code broken 5 = Unknown
5 = Serious adverse event 8 = Other (please specify)
* *  Complete Serious Adverse Events Form (F1 OSAdv.Doc)
Continued Next P a g e ....
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SUMMARY OF ADVERSE EVENTS
(Based on VA / NIDA Form)
C. Is a Serious Adverse Events form required? 1[ ] Yes o[ ] No
Adverse Event 
Number (from table 
overleaf)
Date Serious Adverse Event form completed.
I I I/I I I/I I I I I
I I I / I I I /I I I I I
I I I/I I I/I I I I I
I I I/I I I/I I I I I
INFORM PRINCIPLE INVESTIGATOR WITHIN 12 HOURS OF SERIOUS ADVERSE EVENT
D. Comments:
*  PLEASE FORWARD THIS FORM TO THE PRINCIPLE INVESTIGATOR A T TURNING POINT A.S.A.P.
Principle Investigator’s Signature and Date
___________________________________________________ I___ I___ l / l I I / I  I___ I I I
Principle Investigator’s Comments :
F165ADEV.DOC 22/3/99 2:02 PM Turning Point Alcohol & Dmg Centre Inc. Page 2 c
Outpatient Heroin Withdrawal Using 
Buprenorphine
Randomised Control Trial
Research Assessment 
Day 8 Data Collection
• Weekly Drug Use Diary
• Medication History
• Utilisation of Other Health Services
• Leeds Dependence Questionnaire
• BASIS-32
• Client Ratings of Withdrawal
• Attainment of Client Goals - day 8
• Client Satisfaction with Medication
1999
HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
W EEKLY DRUG USE DIARY
Research Use Only
Research No. | I I I I Date I I 1 .1  1 U  1 1 1
Studv Code i H f W  i f t  i ß  I Site Code i T  I P  I Client initials 1 1 1 Staff Initials 1 1 1
DATES OF REVIEW
FROM I I i . I i I . I I I I I TO 1 1 1.1 1 1.1 1 1 1 1
day month year day month year
Please answer every question honestly. Ask for help if you do not know what to do.
Drug Class
Have you used this 
drug since 
commencing this 
withdrawal program? 
(p lease tick S)
If YES. how man v times have 
you used it since 
commencing this withdrawal 
program?
How manv hits, snorts, drir 
did you have since 
commencing this withdraw 
program?
Heroin 1 [ ] YES
2 [ ] NO
Street Methadone 1 [ ] YES
2 [ ] NO
Other opiates ( eg. 
pethidine, codeine, 
mersyndol)
1 [ ] YES
2 [ ) NO
Stimulants (eg
cocaine,
amphetamines)
1 [ ] YES
2 [ ] NO
Hallucinogens(eg. 
ecstasy, trips)
1 [ ] YES
2 [ ] NO
Benzodiazepines 
(eg. rohypnol, 
valium) - excluding 
study medications
1 [ ] YES
2 [ ] NO
Alcohol 1 [ ] YES
2 [ ] NO
Cannabis 1 [ ] YES
2 [ ] NO
Other (please 
specify)
1 [ ] YES
2 [ ] NO
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
UTILISATION OF OTHER HEALTH SERVICES
Research Use Only
Research No. I I I I I
Study Code I H I H I ß I ^ I Site Code fT I ’P I
Date | 1 | . f r i . i f i  1
Client Initials I 1 1 Staff Initials | _ 1 1
DATES OF REVIEW
FROM I___ 1___ I . I I I . I I I I I TO I___ I___ I . I I I . I I I___ I___ I
day month year day month year
Service
Have you used this 
service since 
commencing this 
withdrawal program? 
(please tide
If YES. how many times have 
you used this service since 
commencing this withdrawal 
program?
Was your visit to this sen 
related to th is withdraw 
episode?
(please tick S)
Other Medical 
Practitioner (eg. GP) 
Please specify
1 [ ] YES
2 [ ] NO
1 [ ] Y E S
2 [ ] NO
Other Health 
Professional (eg. 
dentist, counsellor) 
Please specify
1 [ ] YES
2 [ ] NO
1 [ ] Y E S
2 [ ] NO
Hospital 1 [ ] YES
2 [ ] NO
1 [ ] Y E S
2 [ ] NO
Natural Therapies 
(eg. herbal remedies, 
acupuncture, yoga) 
Please specify
1 [ ] YES
2 [ ] NO
1 [ ] Y E S
2 [ ] NO
Masseuse 1 [ ] YES
2 [ ] NO
1 [ ] Y E S
2 [ ] NO
Other
Please specify
1 [ ] YES
2 [ ] NO
1 [ ] Y E S
2 [ ] NO
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LEEDS DEPENDENCE QUESTIONNAIRE
Research Use Only
Research No. I f ! | | Date ! t \ . \  I I . I f I I
Studv Code I H  | N  | ß  | ß , | Site Code l T *  f P  I Client initials I f f Staff initials I I I
In answering this questionnaire:
* think about the last week
think specifically about your heroin use 
tick the answer most appropriate to you
B. LEEDS DEPENDENCE QUESTIONNAIRE___________________________________(^Appropriate Box )
No. Question
0=
Never
1 =
Some­
times
2=
Often
3=
Near
Aiwa
1 Do you find yourself thinking about when you will next be able to 
take Heroin?
2 Is taking heroin more important than anything else you might do 
during the day?
3 Do you feel that your need for heroin is too strong to control?
4 Do you plan your day around taking heroin?
5 Do you take heroin in a particular way in order to increase the effect 
it gives you?
6 Do you take heroin morning, afternoon & evening?
7 Do you feel that you have to carry on taking heroin once you have 
started?
8 Is getting the effect you want more important than the heroin you 
use?
9 Do you want to take more heroin when the effect starts to wear off?
10 Do you find it difficult to cope with life without heroin?
(Office use only)
SCORE FOR EACH COLUMN 
TOTAL SCORE
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BASIS - 32
Research Use Only____________________________________________________
Research No. I I 1 I I
Study Code I H I H \ & \ R | Site Code iT
Date
Client Initials
i I f . l I I . {____L  t f
I____t____I Staff Initials I I I
A. BEHAVIOUR & SYMPTOM IDENTIFICATION SCALE (BASIS - 32) INSTRUCTIONS__________________
Below is a list of problems and areas of life functioning in which some people experience difficulties. Using the 
scale below, WRITE IN THE BOX THE NUMBER THAT BEST DESCRIBES THE DEGREE OF DIFFICULTY YC 
HAVE BEEN EXPERIENCING IN EACH AREA IN THE PAST WEEK.
0 no difficulty
1 a little difficulty
2 moderate difficulty
3 quite a bit of difficulty
4 extreme difficulty
Please respond to each item. Do not leave any blank. If there is an area you consider to be inapplicable, indicati 
that there is NO DIFFICULTY (IE. ‘0’)
Example
To what extent are you experiencing difficulty in the area of FRIENDSHIPS [ 2
B. THE BEHAVIOUR & SYMPTOM IDENTIFICATION SCALE (BASIS - 32)
TO WHAT EXTENT ARE YOU EXPERIENCING DIFFICULTY IN THE AREA OF :
1. MANAGING DAY-TO-DAY LIFE (Eg. getting to places on time, 
handling money, making everyday decisions)
2. HOUSEHOLD RESPONSIBILITIES (Eg. shopping, cooking, 
keeping room clean, other chores)
3. WORK (Eg. completing tasks, performance level, finding/ 
keeping a job)
4. SCHOOL (Eg. academic performance, completing assignments, 
attendance)
5. LEISURE TIME OR RECREATIONAL ACTIVITIES
6. ADJUSTING TO MAJOR LIFE STRESSES (Eg. separation, 
divorce, moving, new job / school, a death)
7. RELATIONSHIPS WITH FAMILY MEMBERS
8. GETTING ALONG WITH PEOPLE OUTSIDE OF THE FAMILY
9. ISOLATION OR FEELINGS OF LONELINESS
10. BEING ABLE TO FEEL CLOSE TO OTHERS
11. BEING REALISTIC ABOUT YOURSELF OR OTHERS
12. RECOGNISING AND EXPRESSING EMOTIONS APPROPRIATELY
... continued next page ... 
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BASIS - 32
WRITE IN THE BOX THE NUMBER THAT BEST DESCRIBES THE DEGREE OF DIFFICULTY YOU HAVE 
BEEN EXPERIENCING IN EACH AREA IN THE PAST WEEK.
0 no difficulty
1 a little difficulty
2 moderate difficulty
3 quite a bit of difficulty
4 extreme difficulty
Please respond to each item. Do not leave any blank. If there is an area you consider to be inapplicable, indi 
that there is NO DIFFICULTY (IE. ‘0’)___________________________________________________________
A. BASIS - 32 CONTINUED ...________________________________________________________________
13. DEVELOPING INDEPENDENCE, AUTONOMY [ J
14. GOALS OR DIRECTIONS IN LIFE [ ]
15. LACK OF SELF-CONFIDENCE, FEELING BAD ABOUT YOURSELF [ ]
16. APATHY, LACK OF INTEREST IN THINGS [ J
17. DEPRESSION, HOPELESSNESS [ ]
18. SUICIDAL FEELINGS OR BEHAVIOUR [ ]
19. PHYSICAL SYMPTOMS (Eg. headaches, aches & pains, sleep 
disturbances, stomach aches, dizziness)
20. CONFUSION, CONCENTRATION & MEMORY [ ]
21. FEAR, ANXIETY OR PANIC [ ]
22. DISTURBING OR UNREAL THOUGHTS OR BELIEFS [ ]
23. HEARING VOICES, SEEING THINGS [ ]
24. MANIC, BIZARRE BEHAVIOUR [ ]
25. MOOD SWINGS, UNSTABLE MOODS [ ]
26. UNCONTROLLABLE, COMPULSIVE BEHAVIOUR (Eg. eating disorder, hand [ j
washing, hurting yourself) Please specify_______________________________
27. SEXUAL ACTIVITY OR PREOCCUPATION [ ]
28. DRINKING ALCOHOLIC BEVERAGES [ ]
29. TAKING ILLEGAL DRUGS, MISUSING DRUGS [ ]
30. CONTROLLING TEMPER (Eg. outbursts of anger or violence)
31. IMPULSIVE, ILLEGAL OR RECKLESS BEHAVIOUR [ ]
32. FEELING SATISFACTION WITH YOUR LIFE [ ]
Office use only_____________________________
TOTAL SCORE [___ l I I
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT RATINGS OF WITHDRAWAL
Research Use Only
Research No. | | | | I Date I t  f . I  I l . t  1 1
Studv Code I H I N | ß | R i Site Code f T t P I Client Initials I f f Staff Initials 1 1 1
A. WHAT TREATMENT MEDICATION DID THE CLIENT RECEIVE? (please tick ✓ )
BUPRENORPHINE [ ] CLONIDINE [ ]
B. SEVERITY OF WITHDRAWAL EXPERIENCED DURING THIS EPISODE.___________________
“How  severe  w ould  you rate your discom fort you experienced during this w ithdraw;
episode?”
Please indicate on the following line by marking a slash through the line where you feel besi 
represents the discomfort you experienced during this heroin withdrawal.
0 = no discomfort was experienced and 
100 = the most severe discomfort you have ever experienced.
0
No
Discomfort
Experienced
100
Most Severe 
Discomfort 
Experienced
Research Purposes Only
Total mm !
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT RATINGS OF WITHDRAWAL
C. SATISFACTION WITH WITHDRAWAL PHARMACOTHERAPY
“O verall, how  satisfied w ere you with your w ithdraw al m edication? ”
Please indicate on the following line by marking a slash through the line where you feel b 
representstour staisfaction with the withdrawal medication you received.
0 = very unsatisfied 
100 = very satisfied.
0 100
Very
Unsatisfied
Very
Satisfied
Research Purposes Only
Total mm
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
ATTAINMENT OF CLIENT GOALS - day 8
Research Use Only
Research No. | | | | | Date | | I . I I I . I I I I
Study Code \H \H  I ß l ß  I Site Code I T~ I P I Client Initials I I I Staff Initials I i____ I
A. ATTAINMENT OF GOALS FOR THIS WITHDRAWAL EPISODE._________________________
“To what extent have you achieved your goals for this withdrawal episode?”
Please indicate on the following line by marking a slash through the line where you feel best 
represents the attainment of your goals for this heroin withdrawal episode.
0 = no goals were attained 
100 = all goals were attained.
0 100
No goals were 
attained
All goals were 
attained
Total mm |__ |__ |__ |
B. What treatment option do they intend to pursue following the withdrawal? (please tick ✓ )
(a) Methadone treatm ent i [ ] Yes 0 [ ] No
(b) Naltrexone treatment i [ ] Yes 0 [ ] No
(c) Buprenorphine treatment i t ] Yes 0 [ ] No
(d) Counselling i [ ] Yes 0[ ] No
(e) Self-help group (eg, NA) i t ] Yes 0 [ ] No
(0 Unsure i t ] Yes 0 [ ] No
(g) No ongoing treatment i t ] Yes 0[ ] No
(h) O ther i t ] Yes 0 [ ] No
(please specify )
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT SATISFACTION WITH MEDICATION
Research Use Only________________________ ___ _ _
Research No. 1 I I I 1 Date I I I . I I I . I I I I
Study Code I M  I N  I R \  R  I Site Code 1 T"l P I Client Initials I I I Staff Initials |____ 1____ |
A. WHAT TREATMENT MEDICATION DID THE CLIENT RECEIVE? (please tick S)
BUPRENORPHINE [ ] CLONIDINE [ ]
B. RANKING OF AVAILABLE HEROIN WITHDRAWAL OPTIONS.
According to patient experience, rank the following heroin withdrawal options from best (1) to worst (8) using the 
card sorting technique. With the cards (each card containing the different treatment options listed below) ask the 
client to place in order, their experience of each treatment from best to worst. Transcribe this order into the 
boxes below. If the client has never attempted such withdrawal or does not know the answer mark with a ‘O’.
Client Rank
• Combination Symptomatic - excluding Doloxene® / Panadeine forte® 
(eg. Brufen®, Maxalon®, Valium® etc) c
• Panadeine forte® or Doloxene®
• Short Term Methadone (less than 2 weeks )
• Benzodiazepines (only)
• Other medications (Please specify )
• Buprenorphine
• Clonidine (Catapress®) - only
• Rapid opiate withdrawal using naltrexone
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT SATISFACTION WITH MEDICATION
C. From your experience, what were the good things about using________________________ for
heroin withdrawal?
D. From your experience, what were the bad things about using____________________for heroin
withdrawal?
F161SATS.DOC 22/3/99 10:12 AM Turning Point Alcohol & Drug Centre page 2 of
HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
CLIENT SATISFACTION WITH MEDICATION
Research Use Only
Research No» 1 t 1 1 1 Date 1 t I A  I I .  I f 1 1
Study Code i H l ß  iW 1 Rl Site Code iT lP 1 Client Initials 1 l  1 Staff Initials 1 1 1
E. If it was available, would you choose______________________  again for attempting Heroin
withdrawal in the future?
No[ ]0 Yes [ ]1 Maybe [ ]2
(please ^ appropriate section)
List 3 main reasons for this view
F. ADEQUACY OF DOSES OF WITHDRAWAL MEDICATION.
“Overall, how adequate do you think your doses of the withdrawal medication were?
Please indicate on the following scale by circling the appropriate indicator.
1 = much too low,
3 = about right,
5 = much too high
1 2 3 4 5
Much About Mu
Too Low Right Too I
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Outpatient Heroin Withdrawal Using 
Buprenorphine
Randomised Control Trial
Research Assessment 
Day 35 Data Collection
• Opiate Treatment Index
• Leeds Dependence Questionnaire
• BASIS - 32
• Health Status Profile (SF-36)
• Attainment of Client Goals - day 35
• Previous Drug Treatments - day 35
•  M0U
OPIATE TREATMENT INDEX
R esearch  U se O nly
R esearch  No. | | | | | Date I I I . I I I .  r I i 1
Studv C ode I H I W I ß I R I Site Code I T  I P I Client Initials 1 i 1 Staff Initials 1 1 1
SECTION II
NB: For all categories, if  the subject responds that their last use of the drug was more than a month ago, score 
zero for that category. Do not include use on the day of interview.
Day this form was completed (circle)
MON TUE WED THUR FRI SAT SUN
HEROIN
Now I’m going to ask you some questions about heroin (smack, hammer, horse, scag).
1. On what day did you last use heroin? _______________
2. How many hits/smokes/snorts did you have on that day? _______________
3. On which day before that did you use heroin? _______________
4. And how many hits/smokes/snorts did you have on that day? _______________
5. And when was the day before that? _______________
5a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ ______________
5b. On how many days in the past four weeks have you
used any heroin? ___________days
q1 = , q2 = , t1 = , t2 = Q
POLY-DRUG USE 
Other Opiates
These questions are about your use of opiates other than heroin (eg. street methadone/done, morphine, pethidir 
codeine).
6. On what day did you last use opiates other than heroin? (do not include
legally obtained methadone) _______________
7. How many pills, doses etc. did you have on that day? _______________
8. On which day before that did you use opiates other than heroin? _______________
9. And how many pills, doses etc. did you have on that day? _______________
10. And when was the day before that? _______________
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OPIATE TREATMENT INDEX
10a. What was the average cost of a typical day’s use (or estimated cost if not purchased) $ 
NOTE: Include only cost of other opiods obtained illicitly - not on prescription.
q1 = , q2 = , t1 = , t2 = Q
Alcohol
These questions are about your use of alcohol.
11. On what day did you last drink alcohol? _
12. How much alcohol did you drink on that day? _
Wine Spirits Beer Fortified Wine
Wine Gl. 
(120 ml)
Nips 
(30 ml)
Glasses 
(200 ml)
Port Gl. 
(60 ml)
Bottles 
(750 ml)
Doubles 
(60 ml)
Pots 
(285 ml)
Bottles 
(750 ml)
Flagons 
(1.5 It)
Bottles 
(750 ml)
Cans/Stubbies 
(375 ml)
Flagons 
(1.5 It)
Casks 
(___lit.)
No. Standard 
Drinks
Total Standard Drinks
13. On which day before that did you drink alcohol?
14. And how much did you drink on that day?
Wine Spirits Beer Fortified Wine
Wine Gl. 
(120 ml)
Nips 
(30 ml)
Glasses 
(200 ml)
Port GL 
(60 ml)
Bottles 
(750 ml)
Doubles 
(60 ml)
Pots 
(285 ml)
Bottles 
(750 ml)
Flagons 
(1.5 It)
Bottles 
(750 ml)
Cans/Stubbies 
(375 ml)
Flagons 
(1.5 It)
Casks 
(___lit.)
No. Standard 
Drinks
Total Standard Drinks
15. And when was the day before that?
q1 = , q2 = , t1 = , t2 = Q
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OPIATE TREATMENT INDEX
Cannabis
These questions ask you about your use of marijuana (dope, grass, hash. pot).
16. On what day did you last use marijuana? __
17. How many joints, bongs, etc. did you have on that day? __
18. On which day before that did you use marijuana? __
19. And how many joints, bongs etc. did you have on that day? __
20. And when was the day before that? __
20a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _
q1 = , q2 = , t1 = , t2 = Q
Amphetamines
These questions ask you about your use of amphetamines (speed).
21. On what day did you last use amphetamines? __
22. How many tablets/snorts/hits did you have on that day? ___
23. On which day before that did you use amphetamines? __
24. And how many tablets/snorts/hits did you have on that day? __
25. And when was the day before that? __
25a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _
q1 = , q2 = , t1 = , t 2= Q
Cocaine
These questions ask you about your use of cocaine (coke, snow, crack)
26. On what day did you last use cocaine? ___
27. How many snorts/hits/smokes etc. did you have on that day? ___
28. On which day before that did you use cocaine? ___
29. And how many snorts/hits/smokes etc. did you have on that day? ___
30. And when was the day before that? ___
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30a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _______________
q1 = , q2 = , t1 = , t2 = Q
Tranquillisers (Benzodiazepines)
These questions ask you about your use of tranquillisers (eg. Serepax, Valium, Rohypnol, Mogadon)
31. On what day did you last use tranquillisers? _______________
32. How many pills did you have on that day? _______________
33. On which day before that did you use tranquillisers? _______________
34. And how many pills did you have on that day? _______________
35. And when was the day before that? _______________
q1 = . q2 = , t1 = , t2 = Q
Hallucinogens
These questions ask you about your use of hallucinogens (eg. LSD/acid, ecstasy, magic mushrooms)
36. On what day did you last use hallucinogens? _______________
37. How many tabs/pills etc. did you have on that day? _______________
38. On which day before that did you use hallucinogens? _______________
39. And how many tabs/pills etc. did you have on that day? _______________
40. And when was the day before that? _______________
40a. What was the average cost of a typical day’s use
(or estimated cost if not purchased) $ _____________
q1 = , q2 = , t1 = , t2 = Q
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Inhalants
These questions ask you about your use of inhalants (eg. amyl nitrate/rush, glue, laughing gas, aerosols 
petrol)
41. On what day did you last use inhalants? ________________
42. How many sniffs did you have on that day? ________________
43. On which day before that did you use inhalants? ________________
44. And how many sniffs did you have on that day? ________________
45. And when was the day before that? ________________
q1 = , q2 = , t1 = , t2 = Q
Tobacco
46. Finally, if you smoke cigarettes, how many do 
you usually smoke each day?
DRUG USE SUMMARY
Heroin Use Total Poly-drug use total
DRUG USE
Heroin Cocaine
Other Opiates Tranquillisers
Alcohol Hallucinogens
Cannabis Inhalants
Amphetamines Tobacco
General Comments on Drug Use
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LEEDS DEPENDENCE QUESTIONNAIRE
Research Use Only
Research No. I 1 1 1 1 Date \ 1 1 A  1 1.1 1 1 1
Studv Code 1 H 1N \ ß 1 R 1 Site Code 1 T  1 P 1 Client Initials I f 1 Staff Initials 1 1 1
In answering this questionnaire:
* think about the last week
think specifically about your heroin use 
tick the answer most appropriate to you
B. LEEDS DEPENDENCE QUESTIONNAIRE___________________________________ (^Appropriate Box)
No. Question
°~
Never
1=;
Some­
times
: 2= 
Often
3=
Nee
Alwi
1 Do you find yourself thinking about when you wili next be able to 
take Heroin?
2 Is taking heroin more important than anything else you might do 
during the day?
3 Do you feel that your need for heroin is too strong to control?
4 Do you plan your day around taking heroin?
5 Do you take heroin in a particular way in order to increase the effect 
it gives you?
6 Do you take heroin morning, afternoon & evening?
7 Do you feel that you have to carry on taking heroin once you have 
started? ‘
8 Is getting the effect you want more important than the heroin you 
use?
9 Do you want to take more heroin when the effect starts to wear off?
10 Do you find it difficult to cope with life without heroin?
(Office use only)
SCORE FOR EACH COLUMN 
TOTAL SCORE
; it
it Mg! . it ■ i
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Research Use Only
Research No. I 1 I I I Date 1 f 1 .1  1 l . f  1 1 1
Studv Code I H | K l  | B | R ! Site Code I T f P | ' . • : ;  . : : V:' ‘ . \ ; / ' '  . ■ /Client Initials | | „ f Staff Initials 1 1
A. BEHAVIOUR & SYMPTOM IDENTIFICATION SCALE (BASIS - 32) INSTRUCTIONS___________________
Below is a list of problems and areas of life functioning in which some people experience difficulties. Using the 
scale below, WRITE IN THE BOX THE NUMBER THAT BEST DESCRIBES THE DEGREE OF DIFFICULTY YC 
HAVE BEEN EXPERIENCING IN EACH AREA IN THE PAST WEEK.
0 no difficulty
1 a little difficulty
2 moderate difficulty
3 quite a bit of difficulty
4 extreme difficulty
Please respond to each item. Do not leave any blank. If there is an area you consider to be inapplicable, indicate 
that there is NO DIFFICULTY (IE. ‘0’)
Example
To what extent are you experiencing difficulty in the area of FRIENDSHIPS [ 2
B. THE BEHAVIOUR & SYMPTOM IDENTIFICATION SCALE (BASIS - 32)
TO WHAT EXTENT ARE YOU EXPERIENCING DIFFICULTY IN THE AREA OF :
1. MANAGING DAY-TO-DAY LIFE (Eg. getting to places on time, 
handling money, making everyday decisions)
2. HOUSEHOLD RESPONSIBILITIES (Eg. shopping, cooking, 
keeping room clean, other chores)
3. WORK (Eg. completing tasks, performance level, finding/ 
keeping a job)
4. SCHOOL (Eg. academic performance, completing assignments, 
attendance)
5. LEISURE TIME OR RECREATIONAL ACTIVITIES
6. ADJUSTING TO MAJOR LIFE STRESSES (Eg. separation, 
divorce, moving, new job / school, a death)
7. RELATIONSHIPS WITH FAMILY MEMBERS
8. GETTING ALONG WITH PEOPLE OUTSIDE OF THE FAMILY
9. ISOLATION OR FEELINGS OF LONELINESS
10. BEING ABLE TO FEEL CLOSE TO OTHERS
11. BEING REALISTIC ABOUT YOURSELF OR OTHERS
[ 1
[ ]
[ ]
[ ]
[ ]
[ ]
[ 1 
[ 1 
[ ] 
[ l 
[ ]
12. RECOGNISING AND EXPRESSING EMOTIONS APPROPRIATELY [ ]
... continued next page  ...
F17BASIS.DOC 1/04/99 Turning Point Alcohol & Drug Centre Inc. Page 1 o f 2
BASIS - 32
WRITE IN THE BOX THE NUMBER THAT BEST DESCRIBES THE DEGREE OF DIFFICULTY YOU HAVE 
BEEN EXPERIENCING IN EACH AREA IN THE PAST WEEK.
0 no difficulty
1 a little difficulty
2 moderate difficulty
3 quite a bit of difficulty
4 extreme difficulty
Please respond to each item. Do not leave any blank. If there is an area you consider to be inapplicable, ind 
that there is NO DIFFICULTY (IE. ‘0’)___________________________________________________________
A. BASIS - 32 CONTINUED ...
13. DEVELOPING INDEPENDENCE, AUTONOMY [ ]
14. GOALS OR DIRECTIONS IN LIFE [ J
15. LACK OF SELF-CONFIDENCE, FEELING BAD ABOUT YOURSELF [ ]
16. APATHY, LACK OF INTEREST IN THINGS [ ]
17. DEPRESSION, HOPELESSNESS [ j
18. SUICIDAL FEELINGS OR BEHAVIOUR [ ]
19. PHYSICAL SYMPTOMS (Eg. headaches, aches & pains, sleep J ]
disturbances, stomach aches, dizziness)
20. CONFUSION, CONCENTRATION & MEMORY [ ]
21. FEAR, ANXIETY OR PANIC [ }
22. DISTURBING OR UNREAL THOUGHTS OR BELIEFS [ ]
23. HEARING VOICES, SEEING THINGS [ ]
24. MANIC, BIZARRE BEHAVIOUR [ ]
25. MOOD SWINGS, UNSTABLE MOODS [ ]
26. UNCONTROLLABLE, COMPULSIVE BEHAVIOUR (Eg. eating disorder, hand [ ]
washing, hurting yourself) Please specify_______________________________
27. SEXUAL ACTIVITY OR PREOCCUPATION [ ]
28. DRINKING ALCOHOLIC BEVERAGES [ ]
29. TAKING ILLEGAL DRUGS, MISUSING DRUGS [ ]
30. CONTROLLING TEMPER (Eg. outbursts of anger or violence)
31. IMPULSIVE, ILLEGAL OR RECKLESS BEHAVIOUR [ ]
32. FEELING SATISFACTION WITH YOUR LIFE [ ]
Office use only_____________________________
TOTAL SCORE l I I I
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HEALTH STATUS PROFILE (SF - 36)
Research Use Only_________________________________________________________________________________________
Research No. I \ I I I Date j____[ 1 . 1 I U  I I
Study Code I H  I N  I ß  I fis | Site Code tT ] P l Client Initials i I I Staff Initials |____|____ |
_L
Instructions: This survey asks for your views about your health. This information will help keep track o f how you feel and 
how well you are able to do your usual activities.
Answer every question by selecting the appropriate answer. I f  you are unsure about how to answer a question, please give 
the best answer you can.
1. In general, would you say your health is:
(circle one)
Excellent............................................................................ 1
Very good..........................................................................2
Good..................................................................................3
Fair..................................................................................... 4
Poor................................................................................... 5
2. Compared to one vear ago, how would you rate your health in general now?
(circle one)
Much better than 1 year ago ........................................... 1
Somewhat better now than 1 year ago............................. 2
About the same as 1 year ago.......................................... 3
Somewhat worse now than 1 year ago............................4
Much worse now than 1 year ago....................................5
3. The following items are about activities you might do during a typical day.
Does your health now limit you in these activities? If so, how much?
circle one number in each row
Yes
Limited Alot
Yes
Limited a little
No, not 
Limited at
a. Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports
1 2 3
b. Moderate activities, such as moving a table, pushing a vacuum 
cleaner, bowling or playing golf
' 1 2 3
c. Lifting or carrying groceries 1 2 3
d. Climbing several flights of stairs 1 2 3
e. Climbing one flight of stairs 1 2 3
f. Bending, kneeling, or stooping 1 2 3
g- Walking more than a kilometre 1 2 3
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continued from page 1
h. Walking several blocks 1 2 3
i. Walking one block 1 2 3
j- Bathing or dressing yourself 1 2 3
4. During the past four weeks, have you had any of the following problems with your work or other regular dai 
activities as a result of your physical health?
YES NC
a. Cut down on the amount of time you spent on work or other activities 1 2
b. Accomplished less than you would like 1 2
c. Were limited in the kind of work or other activities 1 2
d. Had difficulty performing the work or other activities (for example, it 
took extra effort)
1 2
5. During the past four weeks, have you had any of the following problems with your work or other regular dailj 
activities as a result of anv emotional problems (such as feeling depressed or anxious)?
(circle one number on each line)
YES NC
a. Cut down on the amount of time you spent on work or other activities 1 2
b. Accomplished less than you would like 1 2
c. Didn’t do work or other activities as carefully as usual 1 2
6. During the past four weeks, to what extent has your physical health or emotional problems interfered with you 
normal social activities with family, friends, neighbours, or groups?
(circle one)
Not at a ll..............................................................................1
Slightly................................................................................2
Moderately.......................................................................... 3
Quite a bit........................................................................... 4
Extremely............................................................................5
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7. How much bodily pain have you had during the past 4 weeks?
(circle one)
None.....................................................................................I
Very mild.............................................................................2
Mild..................................................................................... 3
Moderate..............................................................................4
Severe.................................................................................. 5
Very severe..........................................................................6
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the 
home and housework)?
(circle one)
Not at a ll.............................................................................. 1
Slightly................................................................................ 2
Moderately...........................................................................3
Quite a b it............................................................................ 4
Extremely............................................................................ 5
9. These questions are about how you feel and how things have been with you during the past 4 weeks. For each
question, please give the one answer that comes closest to the way you have been feeling. How much of the time 
during the past 4 weeks -
(circle one number on each line)
A ll o f M o s t  o f A  g o o d S o m e A  lit t le N o n
th e th e b it  o f o f  th e o f  th e o f  th
t im e t im e th e  t im e t im e t im e tim i
a. Did you feel full of pep? (energy) 1 2 3 4 5 6
b. Have you been a very nervous person? 1 2 3 4 5 6
c. Have you felt so down in the dumps that nothing 1 2 3 4 5 6
could cheer you up?
d. Have you felt calm and peaceful? 1 1 3 4 5 6
e. Did you have a lot of energy? 1 2 3 4 5 6
f. Have you felt downhearted and blue? 1 2 3 4 5 6
g- Did you feel worn out? 1 2 3 4 5 6
h. Have you been a happy person? 1 2 3 4 5 6
i. Did you feel tired? 1 2 3 4 5 6
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10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with 
social activities (like visiting with friends, relatives, etc.)?
(circle one)
All of the time......................................................................1
Most of the time.................................................................. 2
Some of the time................................................................. 3
A little of the time............................................................... 4
None of the time................................................................. 5
11. How TRUE or FALSE is each of the following statements for you?
D efinitely
True
M ostly
True
D on’t
K now
M ostly
False
Definit
Fals<
a. I seem to get sick a little easier than 
other people
1 2 3 4 5
b. I am as healthy as anybody I know 1 2 3 4 5
c. I expect my health to get worse 1 2 3 4 5
d. My health is excellent 1 2 3 4 5
Reproduced with permission from Medical Outcomes Trust (Quality Metric Inc)
F55SF36.DOC 24/2/99 12:09 PM Turning Point Alcohol & Drug Centre Inc. page 4
HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
ATTAINMENT OF CLIENT GOALS - day 35
Research Use Only
Research No. I I | I | Date t  1 1.1 ] 1.1 1 1 1
Studv Code I H  I W 1 ß  1 R. 1 Site Code 1 T  | P | Client Initials 1 I ( Staff Initials 1 1 1
A. ATTAINMENT OF GOALS FOR THIS WITHDRAWAL EPISODE.___________________________
“To w hat extent have you achieved your goals for this w ithdraw al ep isode?”
Please indicate on the following line by marking a slash through the line where you feel best 
represents the attainment of your goals for this heroin withdrawal episode.
0 = no goals were attained 
100 = all goals were attained.
0 100
No goals were 
attained
All goals were 
attained
Research use only
Total mm |___i
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OUTPATIENT HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
PREVIOUS DRUG TREATMENTS - DAY 35
Research Use Only___________________________________________________________________________________________
Research No. I I I I I Data I 1 I . f t 1. 1 f I
Study Code I H IN I ß I Rl Site Code I T  | P | Client Initials I t 1 Staff Initials I I I
INSTRUCTIONS - Ask the client to self-report the number of times since they enrolled in this study, 
they have participated in the following forms of treatment.
A. Previous Drug Treatment
TREATMENT OPTIONS : Have you Was the treatment Are you
; received this at T/P or another currently in
treatment? service? treatmenl
1. Outpatient withdrawal with or without 1[ ] Y e s 1 ( ] Y e s 1 [ 3 Ye
medication ( in c lu d in g  a t te m p ts  w ith  G P ,  A & D  
A g e n c y ,  H o m e  B a s e d  W ith d r a w a l  e tc .)
2 [ ] N o 2  [ ] N o 2  [ 3 Nc
2. Inpatient withdrawal w ith  o r  w ith o u t 1[ ] Y e s 1 [ 1 Y e s 1 [ 3 Ye
m e d ic a t io n 2 [ ] N o 2  [ ] N o 2  [ 3 Nc
3 .  Rapid Opiate withdrawal using Naltrexone 1 [ ] Y e s 1 [ ] Y e s 1 [ 1 Y e
2  [ ] N o 2  [ ] N o 2  [ 3 Nc
4. Cold Turkey (u n a s s is te d  w ith d r a w a l)  w ith  o r 1 [ ] Y e s 1 I 1 Y e s 1 [ 3 Y e
w ith o u t  m e d ic a t io n 2  [ ] N o 2  [ ] N o 2  [ 3 Nc
5. Methadone Maintenance 1[ ] Y e s 1 [ ] Y e s 1 [ 3 Y e
2  [ ] N o 2  [ ] N o 2  [ 3 Nc
6. Naltrexone Maintenance treatment 1[ ] Y e s 1 [ ] Y e s 1 [ 3 Y e
2  [ ] N o 2  [ ] N o 2  [ 3 Nc
7. Maintenance Treatment with other 1 [ ] Y e s 1 [ 3 Y e s 1 [ 3 Y e
substitution pharmacotherapy (e g .  
B u p r e n o r p h in e ,  L A A M )
2  [ ] No 2  [ 3 N o 2  [ 3 No
8. Outpatient counselling n o t  a s  p a r t  o f  o th e r 1 [ ] Y e s 1 [ 3 Y e s 1 [ 3 Y e
lis te d  t r e a t m e n t 2  [ ] N o 2  [ 1 N o 2  [ 3 No
9. Residential Rehabilitation (e g .  T h e r a p e u t ic 1 [ ] Y e s 1 [ 3 Y e s 1 [ 3 Y e
C o m m u n i t y ) 2  [ ] N o 2  [ 3 N o 2  [ 1 No
10.Other 1 [ ] Y e s 1 [ 3 Y e s 1 [ 3 Y e
( P le a s e  s p e c i fy
)
2  [ ] No 2  [ 3 N o 2  [ 3 No
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Outpatient Heroin Withdrawal Using 
Buprenorphine
Randomised Control Trial
Termination From Study 
(Day 1 - 35)
• Summary of Adverse Events
• Termination From the Study
1999
SUMMARY OF ADVERSE EVENTS
(BASED ON VA / N1DA FORM)
Research Use Only
Research No. |_ I I I _J Date L_ [ i . r  f i . i 1  1 1
Study Code L_ I I I I Site Code I 1 t
,
Client Initials 1 J  Staff Initials L_ 1 1
A. PERIOD OF REVIEW :
From Date |___ |___ | . I l l . |___l l I___ | To Date I___|___ | . |___ i___ | . [___)___ |___ i
B. WHAT TREATMENT MEDICATION DID THE CLIENT RECEIVE?
(please tick S)
BUPRENORPHINE [ ]
CLONIDINE [ ]
C. ADVERSE EVENTS
Date of 
Onset
Nature of Illness, Event or Abnormal Lab 
Value
1.
Type
of
Report
IL
Relatedness
IB.
Level of 
severity
IV.
Action
Taken
V.
Outcome Daft
Resoh
1.
2.
3.
4.
5.
6.
7.
8.
1. tl. IL IV. V.
Type of report Relatedness Severity Action Taken Outcome
1 =  Antic ipated adverse f =  D efin ite ly  s tudy drug 1 = M 0 d 1 =  None required 1 = Resolved
event re la ted 2  -  Moderate 2 -  Prescription drug therapy 2 -  Unresolved
2 -  Unanticipated adverse 2  -  P robably study drug 3 =  S e v e re " 3  = In-patient hospitalisation 3  = Resulted in chronic
event re la ted 4 -  Prescription drug therapy & condition o r severe  /
3  = Concomitant Hlness 3  = P ossib ly  study drug hospitalisation permanent
4 =  Developm ent o f  clin ically re la ted 5 = Medical specialty disability**
significant abnorm al lab 4 ~ Unre lated to study consultation required 4  =  Deceased**
value d ru g 7 -  Randomisation code broken 5  = Unknown
5 = Serious adverse event 8  = Other (please specify)
* *  Complete Serious Adverse Events Form (F10SAdv.Doc)
Continued Next Page ....
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C. Is a Serious Adverse Events form required? 1[ ]Yes 0[ ] No
Adverse Event 
Number (from table 
overleaf)
Date Serious Adverse Event form completed.
-V v - - ' 1.  - j - ' ■ '
I I l / l  I I/I I I I I
I I l / l  I l/l I I I I
I I l / l  I l / l  I I I I
I I l / l  I l / l  I I I I
INFORM PRINCIPLE INVESTIGATOR WITHIN 12 HOURS OF SERIOUS ADVERSE EVENT
D. Comments:
*  PLEASE FORWARD THIS FORM TO THE PRINCIPLE INVESTIGATOR A T  TURNING POINT A.S.A.P.
Principle Investigator’s Signature and Date
_____________________________________________  I I l / l___ I___J/ L___I___ I___I__J
Principle Investigator’s Comments : ______________________________________________
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HEROIN WITHDRAWAL USING BUPRENORPHINE (RCT)
TERMINATION FROM THE STUDY
■ : £££:  " " V ; ;  f  I :  : ■ f
Research Use Only
Research No. | { | f | Date I i I . t  I l . l  1 1 i
Study Code | I I I I Site Code I \ f Client Initials | | } Staff Initials 1 1 1
A. DURATION OF TREATMENT EPISODE
D a te  enro lled  in the study (d ay  1) I I I /  I I | /
day month
D a te  T erm in a ted  from  study I I I / I  I I /
day month
T o ta l N o. o f days in study I____ I____ I
D id th e  clien t co m p le te  w ithdraw al treatm ent (8 d ays)? i [ ] yes 2  [ ]  no
D id the client en ter post-w ithdraw al treatm ent? i [ ] yes 2  [ ]  no
Did th e  clien t co m p le te  post-w ithdraw al treatm ent (3 5  days)? i [ ] yes 2  [ ] no
B. REASONS FOR TERMINATION OF TREATMENT
1. C O M P L E T E D  T R E A T M E N T  ( 3 5  D A Y S )
Please tick appropriate box 
1 [ ] Yes 0[ ] No
2 . V O L U N T A R Y  D IS C H A R G E 1C 1 Yes 0[ ] No
(a )  c lient choosing to  resum e heroin use 1[ ] Yes 0[ ] No
(b ) s ide effects  to m edication 1[ I Yes 0[ ] No
(c ) m ed ication  not holding
(s e v e re  w ithdraw al discom fort experienced) 1[ ] Yes 0[ 3 No
(d ) in co n ven ien ce  o f a ttend an ce requirem ents 1[ ] Yes 0[ ] No
(e ) en te red  o ther trea tm en t
(p le a s e  s p e c ify ............................................................ ) 1[ ] Yes 0[ 3 No
( f ) o th e r .......................................................................................... 1[ ] Yes 0[ 3 No
3 . M E D IC A L  D IS C H A R G E 1[ ] Yes 0[ 3 No
(a ) d ue to a d v e rs e  / severe  / intolerable side effects 1[ ] Yes 0[ 3 No
(a ) c lient non -respo n s ive  to m edication 1[ ] Yes 0[ 3 No
4. A D M IN IS T R A T IV E  D IS C H A R G E 1[ ] Yes 0[ 3 No
(a ) due to non -co m p lian ce  with conditions of the 
Clinical S erv ices 1[ ] Yes 0[ 3 No
(b ) n o n -a tten d an ce  a t clinic (w here  appropriate) 1[ ] Yes 0 [ 3 No
(d ) m issed  > 2 consecutive  days for dosing 1[ ] Yes 0 [ 3 No
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HEROIN WITHDRAWAL USING BUPRENORPHINE
DISCHARGE FROM THE STUDY
3. POST-WITHDRAWAL LINKAGES / REFERRALS
Please indicate post treatment linkages /  referrals. (Including provision o f continuing care for clients at comph 
o f study - Naltrexone /  Buprenorphine /  Methadone clients)
4. OTHER RELEVANT ISSUES
Please describe any other issues relating to the use o f the study medications with this client (include aspects 
regarding safety, convenience, extent to which medication alleviated withdrawal discomfort, client satisfaction
Staff Name & signature
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A p p e n d ix  2
Cost of Clinical Services Associated the Randomised Controlled Trial 
of Outpatient Heroin Withdrawal
Trial related staffing costs
Position Hourly salary Hourly salary + 
On-costs @ 16%
T u rn in g  P o in t A lc o h o l  & D ru g  C entre
C lin ic a l N u rse $ 2 0 .2 6 $23 .5 0
M e d ic a l p ra c titio n e r $ 3 2 .7 7 $38.01
P h a rm a c is t $ 2 2 .6 9 $26 .3 2
A & D  w o rk e r $ 2 0 .62 $23 .9 2
A llie d  H e a lth $ 1 9 .9 7 $23 .17
T h e L a n g to n  C e n tre
C lin ic a l N u rse $ 2 1 .00 $ 2 4 .36
M e d ic a l p ra c titio n e r $45 . 00 $ 52 .20
P h a rm a c is t $ 2 6 .7 0 $ 30 .97
Medication Costs (trial and non-trial related)
Cost per tablet / unit (SAUS)1
Trial medications
Clonidine 100 mcgm 0.184
Clonidine 150 mcgm 0.2948
Diazepam 5 mg tabs 0.165
Temazepam 10 mg 0.12
Nitrazepam 5 mg 0.08
Metoclopramide 10 mg 0.0664
Ibuprofen 400 mg 0.0774
Quinine sulphate 300 mg 0.1064
Hyoscine butylromide (Buscopan®) 10 mg 0.174
Lomotil 0.083
Imodium 0.1375
Buprenorphine (Subutex®)2 2 mg 1.54
Buprenorphine (Subutex®) 8 mg 4.62
Non -  trial medications
Fluoxetine 20 mg tabs 0.964
Moclobomide 300 mg tabs 0.416
Venlafaxine 30 mg 0.628
Oxazepam 30 mg tabs 0.056
Modecate 12.5mg (IM ampoule) 11.00
Benztropine (Cogentin®) 1mg (IM ampoule) 12.66
Sodium valproate (Epilim®) 500mg tablets 0.298
Codeine 30 mg tabs 0.134
Difflam® oral lozenges 0.284
Cipramil® 30 mg 0.964
Augmentin duoforte® (875 mg) 1.21
Daivonex® topical cream (psoriasis) 17.25 for 30g
Monofeme® oral contraceptive 0.333
Paracetamol 500 mg tabs 0.029
1 Prices refer to wholesale pharmacy prices. Subsidised prices are included for medications listed 
under the Pharmaceutical Benefits Scheme.
2 Subutex® prices are based upon Australian wholesale pharmacy price (from Reckitt Benckiser)
Non-trial related health services3
Item Cost / service Rationale / reference
Outpatient hospital
attendance
(no admission)
$141.48 Victorian Ambulatoy Costs S3 
Outpatient Mean (1998-1999)
General Practitioner $25.85 Medical Benefits Scheme Item 23, Level 
B; (November 1999). Assume 100% of 
consultation charged to Medicare
Dentist $106.38 Victorian Ambulatory Cost 
(Department of Human Services 1999- 
2000)
Naturopath / masseuse 
Clairvoyant
$45 Naturopath Practitioners Association
Individual counselling 
provided by psychologist / 
social worker
$85 National schedule of recommended fees 
(Australian Psychologist Association)
3 Fee schedules provided by the Centre for Economic Health Evaluation, Monash University
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Introduction
Buprenorphine, in sublingual tablet form (Subutex®), has recently been registered in Australia for the management of 
opioid dependence including maintenance and detoxification, within a framework of medical, social and psychological 
treatment. This preparation is effective both in the long-term, as a maintenance treatment program, and in the short-term 
as part of a heroin withdrawal program. To assist in the safe and effective implementation of buprenorphine treatment in 
Australia, the following national guidelines have been commissioned by the Commonwealth Department of Health and 
Aged Care under the auspices of the National Expert Advisory Committee on Illicit Drugs (NEACID).
These guidelines cover both the maintenance and withdrawal programs using buprenorphine. Section 1 explains the 
clinical pharmacology of the preparation; Section 2 covers the commencement of buprenorphine treatment; Section 5, 
complications and adverse events; and Section 6 discusses prescribing and dispensing issues. In all of these sections, both 
maintenance and withdrawal programs are covered. In Sections 3 and 4, however, guidelines and procedures are set out 
separately for each program: for maintenance treatment in Section 3, and withdrawal programs in Section 4.
This set of guidelines has been developed through a consensus process by a working party of senior Australian clinicians 
and researchers who have experience in the use of buprenorphine in a variety of jurisdictions. The original draft of the 
maintenance guidelines for this project was developed as part of the Buprenorphine Implementation Trial by the Turning 
Point Alcohol and Drug Centre. The Clinical Guidelines for the Buprenorphine Implementation Trial were piloted by over 20 
medical practitioners (both specialists and general practitioners) and 30 pharmacies involved in delivering buprenorphine 
maintenance treatment. In addition to the participants (patients, doctors, pharmacists and researchers) of the 
Buprenorphine Implementation Trial, the following individuals have contributed to the development of these clinical 
guidelines:
In the USA: Paul Fudala, Alice Huber, Ed Johnson, Surita Lao, Walter Ling, Laura McNicholas, Boris Meandzija, Charles 
O'Brien, Richard Rawson, Richard Schottenfeld, George Woody. In France: Marc Auricombe In the UK: Fergus Law, 
Judith Myles, David Nutt, Chris Chapleo, Don Walter. And in Australia: Louise Rushworth, Reckitt Benkizer; Gabriele 
Bammer, National Centre for Population Health and Epidemiology; Adrian Dunlop, Nadine Ezard, Alan Gisbjers, Sandra 
Hocking, Jozica Kutin, Paul Murray, and Greg Whelan.
The guidelines have been endorsed by the Royal Australian College of General Practitioners, the Royal Australian College 
of Physicians and the Australian Professional Society on Alcohol and other Drugs.
The contribution of Ms Elizabeth Vorrath, Medical Editor, in ensuring that the guidelines are clear and easy to read is 
gratefully acknowledged.
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SECTION 1. CLINICAL PHARMACOLOGY
General Information
What is Buprenorphine?
Buprenorphine is a derivative of the morphine alkaloid, thebaine, and is a portal opioid agonist at the pi opioid receptors 
in the nervous system. It is also a k (kappa) opioid receptor antagonist. It has low intrinsic agonist activity, only partially 
activating pi opioid receptors, thus producing a milder, less euphoric and less sedating effect than full opioid agonists such 
as heroin, morphine and methadone. Nevertheless, its activity is usually sufficient to diminish cravings for heroin, and 
prevent or alleviate opioid withdrawal in dependent heroin users. Buprenorphine also has a high affinity for pi opioid 
receptors, binding more tightly to these receptors than full opioid agonists. It therefore reduces the impact of additional 
heroin (or other opioid) use, by preventing heroin from occupying these receptors. By its dual effects of producing opioid 
responses while blocking the effects of additional heroin use, buprenorphine reduces the self-administration of heroin.
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What form does if  come In?
The buprenorphine product registered in Australia for treating opioid dependence is Subutex®, a sublingual tablet 
preparation of buprenorphine hydrochloride in 0.4, 2, and 8 mg strengths. Buprenorphine is also registered in Australia for 
the management of short term (not more than one week) relief of moderate to severe pain, including post-operative 
and terminal and chronic pain as Temgesic® sublingual tablets and ampoules for intramuscular or subcutaneous 
injection. Sublingual buprenorphine tablets have approximately 30-35% of the bioavailability of intravenous 
buprenorphine preparations1. Buprenorphine undergoes extensive first pass metabolism when taken orally.
How is if  mefabolised?
Peak plasma concentrations are achieved 1 - 2 hours after sublingual administration. Buprenorphine has a distribution 
half-life of 2 - 5 hours. If is principally metabolised by two hepatic pathways: conjugation with glucuronic acid and 
N-de-alkylation. The metabolites are excreted in the biliary system, with enterohepatic cycling of buprenorphine and its 
metabolites. Most of the drug is excreted in the faeces and urine.
Buprenorphine has an elimination half-life of 24 - 37 hours. It is long-acting, relative to the dose administered. Peak 
clinical effects occur 1 - 4 hours after sublingual administration, with continued effects for up to 12 hours at low doses 
(2 mg), but as long as 48 - 72 hours at higher doses (16 or 32 mg). The extended duration of action of buprenorphine 
is thought to relate to three factors:
• its very high affinity for opioid pi receptors (once bound to these receptors it is dislodged only slowly);
• its high lipophilicity (low levels of buprenorphine are released slowly from fat stores, particularly with chronic 
dosing).
• Reabsorption of buprenorphine after intestinal hydrolysis of the conjugated metabolite.
The prolonged duration of effect at high doses enables alternate-day, and even 3-days*o-week 
dispensing regimes.
’ The majority of early studies using sublingual buprenorphine used a liquid solution of buprenorphine in 30% aqueous ethanol, with a 
bioavailability of approximately 40% of subcutaneous preparations. The commercial sublingual tablet preparation of buprenorphine (Subutex®) 
is reported as having 50  - 80% of the bioavailability of the ethanol solution (Shuh and Johansen 1999; Ajir et al 2 0 0 0 ). In practice, sublingual 
tablet doses should be approximately 50% greater than sublingual solution doses referred to in earlier research studies (for example, 8 mg 
sublingual solution corresponds approximately to a 12 mg sublingual tablet dose).
TABLE 1
ONSET AND DURATION OF RESPONSE TO BUPRENORPHINE
Onset of effects 30 - 60 minutes
Peak clinical effects 1 - 4 hours
Duration of effects 8 - 1 2  hours at low dose (e.g. < 4 mg)
24 - 72 hours at high dose (e.g. >16 mg)
Buprenorphine olso exhibits antagonist effects at the k opioid receptor. The role of these receptors in humans is still 
poorly understood, but excess endogenous k  agonist activity appears to be implicated in both affective and psychotic 
conditions. Buprenorphine's antagonist effects at the k receptor are thought to produce anti-depressant and anti-psychotic 
effects in some people. However, as further research is needed into these effects, buprenorphine is not currently indicated 
for these conditions.
Withdrawal syndrome from buprenorphine
Its partial agonist properties, along with its slow dissociation from opioid receptors, are thought to explain why opioid 
withdrawal syndrome is milder with the cessation of buprenorphine treatment, than with heroin, morphine or methadone. 
Typically, the withdrawal syndrome following the abrupt cessation of long-term buprenorphine treatment emerges within 3 
-  5 days of the last dose, and mild withdrawal features continue for up to several weeks. Treatment with opioid 
antagonists (eg naltrexone) can be commenced within days of the cessation of low-dose buprenorphine treatment without 
precipitating severe opioid withdrawal. This enables patients to transfer promptly to naltrexone treatment, and avoid 
relapse and treatment drop-out. By contrast, naltrexone is not usually started until 1 0 - 1 4  days after the cessation of 
methadone (Bell et a i I 9 9 9 :  In te rn  National Naltrexone Guidelines).
Withdrawal is milder and transfers to alternate treatments are more rapid
f a ' s -  ■
Safety and side effects
High doses: Dose response studies show that, because of its ceiling effects, high doses (16 mg daily or more) do not 
result in substantially greater peak opioid effects than lower doses (8 or 12 mg). Doses many times greater than normal 
therapeutic doses appear to be well-tolerated, and rarely result in dinically-significant respiratory depression, even in non- 
opioid-tolerant individuals.
Buprenorphine is safer in high doses than full opioid agonists
Combined with other drugs: The safety of buprenorphine mixed with high doses of other sedative drugs, such as alcohol 
or benzodiazepines, is still unclear, with several deaths having been reported. Naloxone is of limited use in resuscitating 
individuals who have overdosed on high doses of buprenorphine (See section 5.2 on Management of Overdose).
Precaution should be exercised when buprenorphine is administered concomitantly with GYP 3A4 inhibitors (eg protease 
inhibitors, some drugs in the class of azole antimycotics such as ketoconazole, calcium channel antagonists such as 
nifedipine, and mocrolide antibiotics) as this may lead to increased plasma concentrations of buprenorphine.
Not safe mixed with high doses of other sedatives
Side effects: The side effects of buprenorphine are similar to those of other opioids, the most common being:
•  constipation
•  disturbed sleep
•  drowsiness
•  sweating
•  headaches
•  nausea.
Many patients report less sedation on buprenorphine than on methadone. Like all opioid medications, buprenorphine may 
affect the capacity of patients to drive or operate machinery during the early stages of treatment or following dose 
increases. It appears to have minimal impact on hepatic function, although its effects in very high doses remain unclear.
Under certain circumstances, buprenorphine may precipitate opioid withdrawal symptoms 1 - 4 hours after the first dose.
It has a higher affinity and lower intrinsic activity than agonists such as methadone, morphine or heroin. Consequently, 
buprenorphine displaces agonists from opioid receptors and, in the short term, may not produce sufficient agonist effects 
to compensate for the displaced methadone or heroin, producing opioid withdrawal as the buprenorphine reaches its peak 
effects (approx. 1 - 4 hours after initial administration). The phenomenon of precipitated withdrawal has particular clinical 
relevance during the induction of heroin users and methadone patients (see Section 3.2).
May Induce rapid opioid withdrawal
Drug Interactions
The principal drug interactions of buprenorphine relate to its opioid activity.
*  other sedatives. Buprenorphine exerts additive sedative effects when used in conjunction with other sedating 
medications. These include other opioids, benzodiazepines, alcohol, tricyclic antidepressants, sedating anti-histamines, 
and major tranquillisers. A nu m b e r of deaths hove been reported involving the combination of 
buprenorphine with benzodiazepines and other sedatives.
•  opioid antagonists (naloxone and naltrexone). Buprenorphine has higher affinity for m opioid receptors than the 
opioid antagonists. In the event of overdose of buprenorphine, very high doses of naloxone are required to reverse its 
effects (10-35 mg have been reported). Naltrexone can precipitate a delayed withdrawal reaction in patients on 
buprenorphine.
*  opioid agonists. Buprenorphine exerts a degree of blockade to the effects of full agonist opioids, which may 
complicate the use of additional opioids for analgesia. The initial dose of buprenorphine can precipitate opioid 
withdrawal in patients with high levels of neuroadaptation to full opioid agonists.
•  hepatic enzyme inducers and inhibitors. Buprenorphine is metabolized by the hepatic microsomal enzyme system 
(CYP 3A4). While current evidence is inconclusive, it is thought that the concurrent use of medications which induce 
or inhibit microsomal enzyme activity will have minimal clinical impact on buprenorphine dosing requirements.
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TABLE 2
SUMMARY OF THE PHARMACOLOGICAL AND CLINICAL PROPERTIES OF 
BUPRENORPHINE
P r o p e r t y C l in ic a l  im p l ic a t io n
Produces opioid effects Reduces cravings for heroin and enhances tre a tm e n t re ten tio n .
Less sedating than fu ll agonists (h ero in , m o rp h in e  or m e th a d o n e ).
P revents or a llev ia tes  heroin w ith d ra w a l 
s y m p to m s
Can be used for m ain ten an ce  or w ith d ra w a l tre a tm e n t.
D im in ishes th e  effects o f additional 
opioid use (e .g . hero in)
Dim inishes psychological re in fo rcem en t o f continued heroin use. 
M a y  com plicate a ttem p ts  a t  an algesia  w ith  other opioids  
(e .g . m o rp h in e ).
Long dura tio n  of action Allow s fo r once-a-day to th re e -tim e s -a -w e e k  dosing schedules.
Ceiling on dose response e ffec t H igher doses (e .g . > 1 6  m g ) m a y  no t increase th e  opioid agonist 
effects , w h ile  prolonging th e  duration  of action . S a fe r in overdose, 
as high doses in isolation rarely result in fa ta l respiratory  
depression.
S ub lin g u a l p reparation S afer in accidental overdose (e .g . in ch ild ren ) as poorly absorbed  
orally. M o re  tim e  involved in supervised dispensing.
N o severe  w ith d ra w a l precip itated  by 
opio id  an tag o n is ts .
T rea tm en t w ith  n altrexone can be com m en ced  w ith in  days of 
buprenorphine. M a y  com plicate  m a n a g e m e n t o f heroin overdose  
requiring high naloxone doses.
S ide e ffe c t profile  s im ilar to  other opioids G enera lly  w e ll to le ra te d , w ith  m o st side e ffects  tran s ien t.
SECTION 2. ENTRY INTO BUPRENORPHINE 
T R E A T M E N T
2.1 Suitability for treatment w ith Buprenorphine
The following guidelines should be token into account when considering a person's suitability for treatment with 
buprenorphine in either the maintenance or the withdrawal program.
Indications
1 . Buprenorphine treatment is only indicated for those who are opioid-dependent.
W hat is opioid dependence?
Diagnostic Definition of Opioid Dependence (DSM IV)
"A maladaptive pattern of substance use leading to clinically significant impairment or distress as 
manifested by three or more of the following, occurring at any time in the same 12 month period."
*  Tolerance as defined by either of the following:
*  A need for markedly increased amounts of opioids to achieve intoxication or desired effect;
*  Markedly diminished effect with continued use of the same amount of opioids.
*  Withdrawal as manifested by either of the following:
*  The characteristic withdrawal syndrome for opioids;
*  Opioids, or a closely related substance, being taken to relieve or avoid withdrawal symptoms.
*  Impaired control over use: Opioids often token in larger amounts or over longer period than intended.
*  Wish to quit: A persistent desire or unsuccessful attempts to cut down or control opioid use.
*  Time factor: A great deal of time regularly spent in activities necessary to obtain opioids, use opioids, or recover from 
their effects.
*  life-style changes: Important social, occupational, or recreational activities given up or reduced because of opioid use.
*  Consciousness o f  damage being out o f control: The opioid use continued, despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been caused or exacerbated by opioids.
NEUROADAPTATION TO OPIOIDS
Evidence of neuroadaptation (or physical dependence):
*  tolerance of the opioid;
*  onset of withdrawal syndrome on stopping or decreasing use.
N o te :  Neuroadaptation is not a prerequisite for the diagnosis of drug-dependence. However, in the absence of 
neuroadaptation, the prescribing medical practitioner must clearly demonstrate potential benefits to the individual's health 
and well-being that outweigh the potential disadvantages of buprenorphine treatment, and alternative treatment options 
should be carefully considered.
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2 .  T h e  p a t ie n t  m u s t be  a t  le a s t  1 8  y e a rs  o f a g e . The prescribing doctor should seek o second or specialist 
opinion before treating anyone under 18 years of age. (Note: While buprenorphine has been registered for 
administration to people aged 16 and over caution should be exercised in prescribing a drug of dependence for 
anyone in the 16-17 age group.)
3 .  T h e  p a t ie n t  m u s t be  a b le  to  p ro v id e  p ro o f o f id e n t ity  -  a  re q u ire m e n t fo r  t r e a tm e n t  w i t h  a n y  
S 8  m e d ic a tio n .
4 .  T h e  p a t ie n t  m u s t be  c ap a b le  o f g iv in g  in fo rm e d  consent to  t r e a tm e n t  w i t h  b u p re n o rp h in e .
Suitability for Buprenorphine Treatment 
opioid-dependent 
18 years or older 
proof of identity 
capable of informed consent
Contraindications
1 . Anyone with known hypersensitivity and/or severe side-effects from previous exposure to buprenorphine is ineligible 
for buprenorphine treatment.
2 .  Pregnant women and nursing mothers are also ineligible at this stage, as there is insufficient evidence that it is safe 
for either the developing fetus or the breast-fed neonate, and there is evidence in other species of harms. 
Developmental toxicity studies of buprenorphine in pregnant rats and rabbits have shown fetotoxicity, including post­
implantation loss, and decreased post-natal survival with no evidence of teratogenicity. The described effects occurred 
at systemic exposures similar to the maximum anticipated human dose of 32  m g/day.. In addition, maternal oral 
administration at high doses (8 0  m g /k g /d a y ) during gestation and lactation resulted in a slight delay in the 
development of some neurological functions (surface righting reflex and startle response) in neonatal rats.ln humans, 
there is currently not sufficient data to evaluate potential teratogenic or fetotoxic effects of buprenorphine in 
pregnancy. However, high doses, even for short durations, may induce respiratory depression in neonates. During the 
last three months of pregnancy, chronic use of buprenorphine may be responsible for a withdrawal syndrome in 
neonates.
3 .  Animal studies indicate buprenorphine has the potential to inhibit lactation. Buprenorphine passes into the mother's 
milk, therefore breast-feeding while using buprenorphine is contra-indicated until its safety has been fully established.
4 .  Severe respiratory or hepatic insufficiency.
Precautions
Particular caution should be exercised when assessing the suitability of buprenorphine treatment for anyone with any of
the following clinical conditions.
1 . High-risk polydrug use. All opioid substitution treatments should be approached with caution in individuals using other 
drugs, particularly sedative drugs such as alcohol, benzodiazepines or antidepressants. Particular emphasis should be 
given to assessing the level of neuroadaptation to opioids, the likelihood of continued use of other sedative drugs, 
and overdose risk.
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2 . Concomitant medical conditions. Buprenorphine is an opioid medication and caution should be exercised in 
using it in the following situations:
*  Recent head injury or increased intracranial pressure.
*  Compromised respiratory function. Buprenorphine, like other opioids, should be used with caution in patients 
with chronic obstructive airways disease or cor pulmonale, and in individuals with a substantially decreased 
respiratory reserve, pre-existing respiratory depression, hypoxia, or hypercapnea. In such p a tie n ts , even 
no rm a lly  safe  therapeu tic  doses o f opioids m ay decrease re s p ira to ry  d rive  w h ils t  
s im u ltaneous ly  increasing a irw a y s  resistance to  the  p o in t o f apnoea.
*  Acute abdominal conditions.
*  Severe hepatic disease. Caution needs to be taken in considering buprenorphine treatment for people with 
clinically significant hepatic failure. Severe hepatic disease may alter the hepatic metabolism of the medication. 
However, the presence of elevated enzyme levels on liver function testing, in the absence of clinical evidence of 
liver failure, does not exclude someone from treatment with buprenorphine.
*  Special risk patients. Opioids should only be given with caution, and at a reduced initial dose, to patients with 
any o f the following conditions:
advanced age or debilitation;
prostatic hypertrophy or urethral stricture;
pre-existing diabetes mellitus or a pre-disposition to it, with the possibility of increases in serum glucose 
on buprenorphine;
severe renal disease. (Pharmacokinetic studies have not been conducted on this group, so methadone 
should be the first option.)
3 . Concomitant psychiatric condition. Opioid substitution treatment should not be initiated in anyone with acute 
psychosis, severe depression, or other psychiatric conditions which severely compromise the capacity to give informed 
consent. The first priority should be an attempt to manage and stabilise the psychiatric condition. People at moderate 
or high risk of suicide should not be commenced on buprenorphine without adequate supervision, and specialist advice 
should be sought.
4 . Chronic Pain. Buprenorphine can be used as an analgesic in the management of acute and chronic pain conditions 
(although it is not registered for this purpose), but at much lower doses than for heroin dependence. Ideally, chronic 
pain is best managed under the supervision of a specialist multidisciplinary team, and appropriate referral or 
consultation should be considered.
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S. transfer from methadone maintenance. Buprenorphine may cause difficulties in transferring from methadone by 
precipitating withdrawal (see Section 3.2). This is most likely to occur in patients on high doses of methadone, and 
attempts to reduce the methadone dose to below 60 mg (and preferably below 40 mg) should be made before 
initiating buprenorphine. Methadone patients who relapse into regular heroin use following the 
reduction of their methadone dose are likely to find transition to buprenorphine difficult, if 
not unachievable.
EXERCISE CAUTION
W ith  p a t ie n ts  in  a n y  o f  th e  fo llo w in g  c a te g o rie s  
h ig h -r is k  p o ly d ru g  use
c o n c o m ita n t m ed ica l con d itio n s  (s e e  lis t  a b o v e )  
c o n c o m ita n t p s y c h ia tr ic  con d itio n s  
s u ffe rin g  chronic pain  
t r a n s fe r  fro m  m e th a d o n e  m a in te n a n c e
2*2 Assessment procedures
A careful assessment should be conducted at the outset of buprenorphine treatment. The following issues should be 
addressed:
History
*  Heroin and other opioid use:
- quantity and frequency (amount, cost, number of times used per day);
- duration;
- route of administration (injected/non-injected);
- when last used;
- features and severity of dependence.
*  Use of other drugs (including benzodiazepines, alcohol, cannabis, psychostimulants) and assessment of degree of 
dependence to each drug class.
*  Participation in high-risk drug behaviours, particularly overdoses, self-injury, or polydrug intoxication.
*  History of prior attempts at withdrawal, maintenance and other treatment - what has worked and not worked before.
*  Social circumstances, including home environment, social supports, employment, and barriers to change.
*  Medical and psychiatric history, with particular attention to unstable or active conditions which might potentially 
complicate treatment.
*  Pregnancy and contraception.
*  Motivations and goals for treatment. Finding the right approach requires an understanding of the re a s o n s  fo r  
s e e k in g  t r e a t m e n t  and of p a t ie n t  go afs  and  e x p e c ta tio n s .
Examination
*  Vital signs (blood pressure, pulse, respiratory rate);
*  Evidence of intoxication or withdrawal from heroin or other drugs;
*  Evidence of complications of injecting drug use, including injection site problems, hepatic disease, lymphadenopathy, 
systemic infections.
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Investigations
*  Urinary drug screens can be helpful in clarifying or confirming an unclear drug use history. However, delays in getting 
the results of routine urine tests often limits their usefulness at initial assessment.
*  Liver function tests and  viral serology (HIV, Hepatitis B and C) should be considered at some stage with 
appropriate pre- and post-test counselling. (This is advisable after stabilisation, when the patient is better able to 
understand the significance and consequences of testing).
A comprehensive assessment for buprenorphine treatment can rarely be completed at the initial appointment, and 
generally needs to be conducted over several sessions. Initially, clinicians should target key issues important in the 
selection and initiation of treatment, and assess indications, contraindications and precautions. Referral or consultation 
with a specialist is recommended for patients with complex presentations.
2.3 Informed Consent and Patient Literature
The participation of an informed patient in the clinical decision-making process is important in the 
treatment of all opioid dependence. It is particularly important when incorporating opioid medications - such as 
buprenorphine or methadone - as part of the treatment plan. In considering the commencement of buprenorphine for 
maintenance or withdrawal treatment, the service provider should also explore alternative treatment options with the 
patient (including alternative approaches to withdrawal or substitution maintenance treatment, self-help, residential 
rehabilitation programs, counselling, and naltrexone).
All patients commencing treatment with buprenorphine must give their informed consent to 
treatment. This process requires fully informed patients and their opportunity to discuss with the service provider the 
following topics:
*  what is buprenorphine, how does it work, and what are its advantages & disadvantages?
*  what is the duration of treatment; its cost; its associated 'routines', including urine-testing, "take-aways", transfers?
*  what are the known side-effects?
*  what about pregnancy and contraception issues?
*  what are the dangers of additional drug use, overdose?
*  what is the potential impact on driving, and on employment?
*  what are the conditions of involuntary discharge?
Specific patient literature should be provided prior to the commencement of treatment. It is recommended that consent be 
documented and that patients be given their own copies of the documents they have signed.
Section 2
Buprenorphine may affect the capacity of patients to drive or operate machinery 
during the early stages of treatment, after an increase in dose, or when patients 
are also taking other drugs. Warn patients about this effect before entry into 
treatment, when the dose of buprenorphine is increased, or when the use of other 
drugs is suspected.
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2.4 Permits and Registration of Patients
Buprenorphine is registered as a Schedule 8 medication. Each jurisdiction is responsible for a system of authorising 
medical practitioners to prescribe buprenorphine to a paricular patient. (See Appendix 3)
SECTION 3. GUIDELINES FOR MAINTENANCE 
TREATMENT
3.1 Selecting maintenance pharmacotherapies
Current evidence suggests that key treatment outcomes for maintenance buprenorphine and methadone treatment are
comparable under optimal treatment conditions. Whilst there is no evidence of the greater efficacy of one treatment over
the other, patients or clinicians may develop personal preferences. These might reflect:
•  Response to treatment. Ultimately, the continued use of a medication should depend on its ability to 
meet the aims and objectives of treatment. This requires the identification of treatment goals by the patient 
and the individual service provider, and decisions about how the treatment outcomes will be assessed.
Where these goals are not being met, a review of treatment strategies should occur, including:
- the role of psychosocial interventions,
- levels of supervision, monitoring and review,
- dose of a substitution opioid,
- the role of adjuvant interventions, and -  ultimately -
• a review of alternative opioid pharmacotherapies. For example, patients who cannot stabilise their continued 
use of heroin, even on high doses of buprenorphine, may be better suited to high doses of an agonist 
treatment (methadone).
•  Individual variation in absorption, metabolism and clearance. There may be considerable 
pharmacokinetic and pharmacodynamic differences between individuals in their response to different opioid 
substitution pharmacotherapies.
•  Adverse events. Individuals experiencing significant side-effects from one opioid medication may benefit from 
treatment with an alternative medication. In particular, buprenorphine may be preferred by individuals complaining of 
continued sedation under methadone.
•  Logistics of participating in treatment, including issues such as ease of access for participants, frequency of 
dispensing, convenient location of treatment services and the costs to patients, service providers and funding bodies. 
Once stabilised on a daily dosing regime, the majority of patients on buprenorphine will be able to switch to an 
alternate-day, or three-times-a-week dosing regime. This should be more convenient for patients and reduce the need 
for regular take-away doses. Not all patients will be comfortable on alternate-day buprenorphine dosing, and may 
require daily doses.
•  Ease of withdrawal from maintenance buprenorphine treatment. A limiting factor for many patients 
considering maintenance treatment is the problem of dependence on the maintenance opioid. As it is only a partial 
agonist and dissociates slowly from receptors, buprenorphine appears to have a milder withdrawal syndrome than 
methadone. Nevertheless, current research indicates that relapse rates to heroin use are comparable for patients 
discontinuing maintenance treatment from either opioid.
•  Patient (and clinician) expectancy. Expectations of any medication may impact seriously on its perceived 
outcomes. The introduction of new pharmacotherapies for heroin dependence may give rise to unrealistic expectations 
in patients, their families, and even service providers.
•  Capacity for transfer from methadone maintenance. Some patients require high doses of methadone to 
stabilise their heroin use, and a marked reduction can cause a relapse to regular heroin use. For patients who cannot 
reduce below high doses of methadone (i.e. 60 mg) without becoming destabilised, transfer to buprenorphine should 
not be recommended unless it is part of a broader plan of gradual withdrawal from maintenance substitution 
treatment.
Section 3
3.2 Induction to buprenorphine treatment
Commencing buprenorphine from heroin use
The in itia l dose of buprenorphine should be between 2 and 8 mg.I r q
The initial dose should not be greater than 8mg.
The following factors must be taken into consideration when considering the initial dose of buprenorphine:
•  Degree of neuroadaptation to opioids. Patients with a low degree of neuroadaptation to opioids (low opioid 
tolerance) should be commenced on a dose of 2 or 4 mg. In instances where the doctor is uncertain of the degree of 
neuroadaptation, the patient should be commenced on a dose of 4 mg. Patients with high levels of neuroadaptation 
should commence on 6 or 8 mg.
•  Extent of heroin withdrawal at the time of first buprenorphine dose. Patients experiencing 
considerable opioid withdrawal at the time of the first dose require higher doses of buprenorphine to alleviate 
withdrawal symptoms. Patients with little or no indication of opioid withdrawal at the time of the first dose should be 
prescribed a lower dose, or be asked to re-present at a later time (see rationale below).
•  The perceived likelihood o f con cu rre n t drug abuse, including alcohol consumption, unauthorised use of 
prescription sedative drugs (particularly benzodiazepines), or illicit drug use. In such instances, lower doses of 
buprenorphine should be prescribed, with frequent reviews.
•  Concurrent medical conditions (particularly impaired hepatic function and interactions with other medications) 
warrant the use of lower initial doses of buprenorphine with regular monitoring
(see Section I "Clinical pharmacology" and Section 2.1 "Precautions").
The firs t dose of buprenorphine should be odministered ot least 6 hours after last
heroin useii .
________________________________________________________________________
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Care should be taken by prescribing doctors, pharmacists and nursing staff, not to administer the first dose to a patient 
within 6 hours of heroin use, and especially not to patients intoxicated on opioids. If they do, the patient may experience 
opioid withdrawal, as the buprenorphine displaces heroin from the opioid receptors. Buprenorphine-precipitated withdrawal 
typically begins 1- 4 hours after the first buprenorphine dose, is generally mild to moderate in severity, and lasts for up to 
12 hours. If this happens, patients may require symptomatic withdrawal medication, and should be directed to see their 
doctor.
Subsequent doses of buprenorphine (taken the following day) should result in light or minimal withdrawal discomfort if 
the patient has not used heroin during the intervening period. Patients who continue to use heroin between their first and 
second doses of buprenorphine may have difficulty stabilising on the treatment, with ongoing features of opioid 
withdrawal. They should be advised to cease heroin use at least 6 hours prior to the next dose of buprenorphine.
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Transferring from methadone maintenance treatment
Buprenorphine has a higher affinity for m opioid receptors than methadone, but a weaker action (lower intrinsic activity) 
at these receptors. When methadone patients take a dose of buprenorphine, the methadone is displaced from the \x 
opioid receptors by buprenorphine. Patients on low doses of methadone (e.g. less than 30 mg) generally tolerate this 
transition with minimal discomfort. H ow ever, patients on higher doses of methadone may find the 
replacement of methadone w ith  buprenorphine precipitates transient opioid withdrawal.
This has a number of clinical implications. Wherever possible, patients in methadone treatment should have their 
methadone dose reduced and should be stabilised on this low dose prior to transferring to buprenorphine, in order to 
minimise any opioid withdrawal features. The following table describes key factors in the development of precipitated 
withdrawal.
TABLE 3
KEY FACTORS AFFECTING PRECIPITATED WITHDRAWAL
F a c t o r D is c u s s io n R e c o m m e n d e d  s t r a t e g y
Dose o f m e th a d o n e Doses grea ter than  3 0  m g o f m e th a d o n e  
are m ore o ften  associated w ith  
precip ita ted  w ith d ra w a l. In g e n era l, 
th e  higher th e  m e th a d o n e  dose, th e  
m ore severe th e  w ith d ra w a l experienced .
A tte m p t transfer fro m  lo w  dose o f  
<  4 0  m g w h e re  
possib le). Patients on >  6 0  m g  
m e th a d o n e  should n o t a tte m p t  
transfer.
T im e  b e tw e e n  la s t m e th a d o n e  
dose and firs t buprenorphine  
dose
Buprenorphine should n o t be  ta k e n  
w ith in  2 4  hours o f last m e th a d o n e  dose. 
Increasing th e  in terval b e tw e e n  last dose  
of m e th a d o n e  and firs t dose of 
buprenorphine reduces th e  incidence  
and severity  o f precip itated  w ith d ra w a l.
Cease m e th a d o n e  and  d e la y  firs t dose  
of buprenorphine until p a tie n t is 
experiencing fe a tu res  o f m e th a d o n e  
w ith d ra w a l
D ose o f buprenorph ine V ery lo w  doses o f buprenorphine  
(e .g . 2  m g ) are gen era lly  in a d eq u ate  to  
substitute fo r m e th a d o n e  (unless the  
m e th a d o n e  dose is very  lo w ) .
High first doses o f buprenorphine  
(e .g . 8  m g or m o re ) are m ore like ly  to  
prec ip ita te  w ith d ra w a l, os th e re  is g reater 
d isp lacem ent of m e th a d o n e  fro m  th e  
receptors. Ib is  is a  co m m o n  m is ta k e  b y  
in e xp erien ced  p rescrib es .
First dose o f buprenorphine should  
genera lly  be 4  m g , w ith  re v ie w  of 
th e  p a tie n t 2  - 4  hours la ter 
(o r early  th e  fo llo w in g  d a y )
P a tie n t exp ectan cy P atients w h o  are no t p repared fo r the  
possibility o f precip itated  w ith d ra w a l are  
m ore lik e ly  to be distressed and confused  
by its onset, w ith  po ten tia l negative  
consequences (e .g . tre a tm e n t drop-out, 
abuse o f o th er m e d ic a tio n s ).
In fo rm  patien ts  fu lly  (and  carers  
w h e re  re le v a n t). Provide w ritte n  
in fo rm a tio n . Prepare a contingency  
m a n a g e m e n t plan fo r severe  
sym ptom s.
Use o f o th er m ed ications S y m p to m a tic  m ed ication  (e g  clonid ine) 
can be useful in relieving a n y  precip itated  
w ith d ra w a l.
Prescribe and dispense in accordance  
w ith  a m a n a g e m e n t plan
Transferring to buprenorphine from doses of methadone of 40 mg or less:
Wherever possible, patients should be on a methadone dose of less than 40 mg (and preferably 30 mg or less) for at 
least one week prior to receiving their first dose of buprenorphine. Indeed, it is preferable for patients to be experiencing 
a mild degree of methadone withdrawal prior to converting to buprenorphine. For many patients, the optimal methadone 
dose prior to transferring to buprenorphine may be below 30 mg of methadone.
The following conversion rates should be used when converting from low-dose methadone to buprenorphine.
Lost Oral M e thadone  Dose 
(m g)
In itia l Buprenorphine Dose 
(m g ) ( S / l .  tab le t)
Day 2 Buprenorphine Dose 
(m g ) ( S /L  tab le t)
2 0  - 40  mg 4 mg 6 to 8 mg
1 0 - 2 0  mg 4 mg 4 to 8 mg
1 - 1 0  mg 2 mg 2 to 4 mg
dose of buprenorphine should be administered at least 24 hours after the 
done dose, and at least 6 hours after last heroin use.
The likelihood of precipitating withdrawal on commencing buprenorphine is reduced as the time interval between the last 
methadone dose and the first buprenorphine dose increases. A precipitated withdrawal may be avoided by ensuring the 
last dose of methadone is taken early in the morning, and the first dose of buprenorphine is taken late the following day.
Features of a precipitated withdrawal following the first dose of buprenorphine are typically mild to moderate in severity, 
which can distress the unprepared patient. Symptoms commence 1 - 4 hours after the first buprenorphine dose and last 
for up to 12 hours before subsiding. Patients experiencing discomfort may re-present to the prescribing doctor later in the 
day and require symptomatic withdrawal medication (eg donidine 100  meg 3 - 4 hourly). Subsequent doses of 
buprenorphine (the following day) are less likely to precipitate withdrawal symptoms.
Transferring to buprenorphine from doses of methadone greater than 40 mg (ie 
where there is a risk of relapse to heroin on lower dose)
Most patients in methadone treatment require maintenance doses of greater than 40  mg of methadone to achieve 
abstinence from heroin, and are unable to reduce their dose of methadone to 40  mg or less without considerable 
withdrawal discomfort or relapse to heroin use. As it may be difficult to get these patients' doses of methadone below 40  
mg, transfer to buprenorphine may need to be considered at higher methadone doses, with the inherent risks associated 
with such a procedure explained fully to the patient.
It is possible to transfer to buprenorphine from methadone doses of 40  - 60  mg for those patients who choose to do so.
The general principle is to cease methadone closing, and delay the initiation o f buprenorphine treatment until the patient 
experiences significant, observable features of opioid withdrawal. This generally means that buprenorphine is not 
commenced until 48  - 96 hours after the last dose o f methadone. Patients should be warned that the use of heroin or 
other opioids at this stage increases the likelihood of a difficult initiation to buprenorphine. Symptomatic withdrawal 
medication may be prescribed to ease the discomfort of methadone withdrawal, although the quantities of medications, 
such as benzodiazepines or donidine, should be limited. Medications containing codeine or d-propoxyphene should be 
avoided.
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Patients should have the possibility of precipitated withdrawal explained, as well as the relevant strategies for dealing 
with its symptoms. Transfer should be organised for a time when the patient has no significant work or other 
commitments, and the doctor is available for review.
Patients should be reviewed by their prescriber immediately prior to 
commencing buprenorphine, to ensure they are indeed in opioid 
withdrawal
After first dose, later the same day (approximately 3 - 4 hours after the first dose of buprenorphine): Review by 
medical practitioner.
*  If patient is experiencing no increase in withdrawn! severity, either subjectively or objectively, give another 2 or 4 mg 
of buprenorphine.
•  If patient is experiencing o worsening of withdrawal, give no further dose that day. Symptomatic withdrawal 
medication may be required for the rest of the day (eg donidine 100 meg 3 - 4 hourly).
Note: Peak withdrawal discomfort is experienced during the first day of buprenorphine treatment.
Second day: Review by the prescriber prior to dosing on the following day.
Dose con generally be increased to 6 or 8 mg.
Subsequent days: Subject to review of the patient by the prescriber, further increases.
Patients may not feel entirely comfortable during the whole first week. The recommended procedure for transferring 
patients from medium doses of methadone (e.g. 40 - 60 mg) to buprenorphine is summarised in the following table.
TABLE 4
SUMMARY OF PROPOSED PROCEDURES FOR MEDIUM DOSE 
METHADONE (40 - 60 MG! TO BUPRENORPHINE TRANSFER
1 . Prepare the patient for the transition. Provide information, organise supports, communicate with pharmacist and/or 
other staff.
2 .  Cease methadone dose and delay first buprenorphine dose until the patient experiences significant withdrawal 
discomfort (generally 48 - 96 hours after last methadone dose). Symptomatic medication (limited amounts) may be 
required.
3 .  Administer first dose of 4 mg buprenorphine in the morning or early afternoon.
4 .  Review the patient 2 ■ 4 hours after first buprenorphine dose:
*  Worsening of withdrawal following first dose ► provision of symptomatic medication for opioid 
withdrawal for remainder of the day;
•  no worsening, or an improvement, in withdrawal following the first dose ► a further 2 to 4 mg of
buprenorphine dispensed that afternoon /  evening.
5 .  Review the patient prior to dosing on the following day. Titrate the dose of buprenorphine to 6 - 1 0  mg, according to 
response on previous day.
6 .  Review frequently and titrate dose until stable. Patients may continue to describe mild withdrawal features and/or 
dysphoria for one to two weeks after transfer.
It is strongly recommended that patients on methadone doses of greater 
than 6(f mg reduce their dose to 60 mg or less prior to attempting 
transfer. Patients unable to reduce to these levels of methadone should 
not attempt transfer to buprenorphine.
3.3 Stabilisation
The optimal maintenance dose needs to be individualised according to the patient's response to buprenorphine. People's 
responses vary considerably, according to the following factors:
1 . rates of absorption or metabolism of buprenorphine;
2 .  levels of opioid neuroadaptation and dependence;
3 .  experience of side-effects;
4 .  continued use of other drugs.
These variations require the clinician to titrate the buprenorphine dose to optimise treatment objectives.
E a rly  closes can be te s t doses. Initial doses of buprenorphine can serve as 'test doses' to enable both patient and 
clinician to monitor responses to the medication. In some people they may not be adequate to prevent withdrawal over a 
24-hour period, while they may make some people feel sedated or 'drugged' (due to additional drug use, or to the initial 
dose of buprenorphine being too high).
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P ro m p t results. Equilibrium levels with buprenorphine are achieved quickly, and the effects of a dose-change should 
become apparent within 2 - 3 days. Consequently, dose levels of buprenorphine can he more rapidly titrated according to 
patient response, than can methadone.
Regular patient review
Frequent reviews by the prescriber are required in the first few weeks:
♦  to titrate the individual optimal doses of buprenorphine,
*  to make a more comprehensive overall assessment of the patient;
*  to further discuss treatment plans.
As treatment progresses, the prescribing doctor should review the patient 2-3 times a week until stabilised:
*  to establish adequacy of dose;
•  to inquire about withdrawal symptoms or side-effects;
♦  to monitor or\y additional drag use.
Maintenance buprenorphine doses should be achieved within the first one or two weeks of 
treatment subject to the patient's use of heroin, or other drugs.
The following minimal schedule o f  reviews is recommended by treating doctors or 
their nominees2:
*  The day after the first dose o f buprenorphine. This enables the prescriber to identify the onset of any precipitated 
withdrawal and the general adequacy of the first dose.
*  Every 2 - 4 days until stabilisation.
*  Every week during the following 4 ~  6 weeks.
*  Every two weeks during the following 6 - 8  weeks.
*  Monthly reviews thereafter, although the prescriber may wish to extend reviews to up to 3 months for very stable 
patients.
Individuals with continuing high-risk patterns of drug use, or concomitant medical, psychiatric or social problems, may 
require more frequent review.
2ln practice, a suitably trained nurse or pharmacist often undertakes these reviews, with reference to the prescribing doctor where necessary.
Dose increases should be made only after review of the patient by the prescribing 
doctor.
If daily reviews can be organised by the prescribe^ daily increases can be accommodated. Practically, however, most 
prescribers may not be able to review the patient more than every two or three days (eg because of sessional practice or
weekends). A period of 2 - 3 days on a specific dose allows the patient time to get a 'feel' for their current dose, and the
opportunity to modify behaviour appropriately prior to further dose changes. The buprenorphine dose may be decreased 
where there are concerns regarding the patient's safety (e.g. where there are reports of intoxication or overdose).
Changes In buprenorphine dose
The dose response curve of buprenorphine indicates that small increments have a greater impact at low doses, whereas at 
higher doses, larger changes are required for a substantial change of effect. The following increments are proposed:
*  Below 16 mg buprenorphine : dose changes of 2 ■ 4 mg
*  Above 16 mg buprenorphine : dose changes of 4 - 8 mg
Titrating the dose of buprenorphine
At each review, the buprenorphine dose should be titrated according to the following parameters:
•  features of intoxication or withdrawal over preceding 24 hours (self-report, examination);
•  cravings for heroin use;
•  additional drug use (heroin and other drugs), and reason stated by patient for using;
•  side-effects or other adverse events (including intoxicated presentations, overdoses);
•  adherence with dosing regime (attendance for dosing, route of administration);
•  patient satisfaction with buprenorphine dose and treatment.
The following should guide prescribers in determining the buprenorphine dose.
Decrease buprenorphine dose Maintain buprenorphine dose increase buprenorphine dose
Features of intoxication to No features of withdrawal or Features of withdrawal over
buprenorphine (eg sedation) intoxication preceding 24 hours,
particularly at peak effect times increasing in the period
( 1 - 4  hours after dosing) immediately prior to the next 
dose
No features of intoxication to 
buprenorphine, particularly at 
peak effect times (1 - 4 hrs 
after dosing)
Low cravings for heroin or other drugs Intense cravings for heroin in 
past 24 hrs or heroin use to 
avert withdrawal
Severe or intolerable side effects Nil /  mild and tolerable side effects Nil /  mild and tolerable side 
effects
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Regular and high risk use of heroin
Stabilisation with prescribed opioids is hard to achieve if the patient is in the habit of using additional opioids (eg heroin, 
codeine preparations), as they complicate the interpretation of withdrawal or intoxication effects. In particular, patients 
who continue to use heroin during the first few doses of buprenorphine may experience difficulties in stabilising on the 
new medication. The patient should be encouraged to make every effort to avoid heroin, or any other opioid, in the 
period prior to dosing.
Alternative regime for rapid induction onto buprenorphine
Evidence from overseas trials indicates that a faster rate of induction may be safely undertaken and that this may reduce 
the risk of early drop out from the program. The alternative regime achieves maintenance doses within 2-3 days using the 
following dose increments:
•  Day 1 8 mg
•  Day 2 16 mg
•  Day 3 24 mg
Prescribers who undertake this regime should review patients daily, looking particularly for signs and symptoms of toxicity 
(especially nausea and dizziness). If there is evidence of toxicity dose increases should be slowed.
3,4 Maintenance closing
Dose levels
Buprenorphine doses need to be individually titrated according to the patient's response to treatment. Effective 
maintenance doses, resulting in reduced heroin use and improved treatment retention, are achieved with high 
buprenorphine doses in the range of 12 - 24 mg per day. Some patients may be satisfactorily maintained on daily doses 
of 8 -1 2  mg, while doses of 4 mg or less will not be as effective in retaining patients in treatment or reducing heroin use 
(similar to, or worse than, the outcomes associated with methadone doses of 20 mg). There is little evidence to suggest 
that daily doses higher than 24 mg will result in improved outcomes or effects, and little is known regarding the nature of 
adverse events at maintenance daily doses greater than 32 mg. The maximum daily dose of buprenorphine 
routinely recommended is 32 m g.
People wishing to reduce their use of heroin, or other opioids, can do so with increases in the substitution dose of 
buprenophine, as higher doses of this substance produce more effective antagonist reactions, blocking the effects of 
additional heroin use.
However, this only succeeds up to a point. Continued heroin use despite adequate daily doses of buprenophine may 
indicate that the patient needs more intensive psychosocial interventions, and/or an alternative opioid substitution (e.g. 
methadone).
Frequency of dosing: alternate-day and three-times-a-week dosing regimes 
Buprenorphine dosing begins on a daily basis. Most clinical studies with this therapy have examined daily dosing regimes, 
but recent studies indicate that many patients who are stabilised on buprenorphine can be maintained on alternate-day 
dosing, some even on three-times-a-week dosing, without experiencing features of intoxication or withdrawal.
The convenience of reduced-frequency dosing should be considered for all patients found suitable for a trial of 
alternate-day dosing, i.e. if they meet the following conditions:
on a stable dose of buprenorphine for at least two weeks;
having no high-risk drug use (high-risk drug use refers to frequent abuse of other sedatives including alcohol, 
benzodiazepines, heroin or other opioids, intoxicated presentations to the pharmacy or medical practitioner, or 
recent history of overdose).
However, not all patients will be suited to an alternate-day, or three-times-a-week, dispensing regime, as some will 
experience increased cravings or features of withdrawal on the non-dosing days.
Estimates suggest that about 1 5 %  o f patients are more comfortable and more effectively 
maintained on daily, rather than alternate-day, dosing regimes. It is recommended that suitable patients 
initially be trialed for two weeks on an alternate-day dosing regime of buprenorphine. If this is successful, the patient can 
then be trialed on a three-times-a-week regime. If a patient cannot be stabilised on such dosing regimes due to the onset 
of withdrawal, cravings, side-effects or features of intoxication, they should be returned to a more frequent dosing regime.
Alternate-day or four-times-o-week regime. This involves attending the pharmacy for dosing on alternate days (i.e., a dose 
every 4 8  hours), or attending four times a week (with 3 x 48  hour doses and 1 x 24 hour dose each week (e.g. Mon; 
Tues; Thurs; Sat)). The advantage of the latter approach (4 times a week) is that the patient is on a regular attendance 
each week, with less likelihood of attendance errors on the patient's part and dosing errors by the pharmacist.
The dose dispensed for a 48-hour period is initially double the normal daily (24 hour) buprenorphine dose (to a 
maximum o f 32  mg dosed at a time). The patient should be reviewed following the first or second 48-hour dose, and the 
dose titrated according to the response:
•  If the patient reports features of intoxication from the buprenorphine during its peak effects (within the first 24  
hours), the 48-hour dose should be reduced.
•  If the patient reports that the dose does not prevent the onset of opioid withdrawal or cravings over a 48-hour period, 
then the 48-hour buprenorphine dose should be increased.
Three-times-a-week regime. Some patients may tolerate three-times-a-week dosing with buprenorphine, reducing the 
inconvenience and costs of treatment further. This should be attempted after a two-week trial on four-days-a-week dosing 
has been shown to be successful. The recommended regime for a three-day dose is:
3-day dose =  3  times the normal 24  hr dose i f  24 hr buprenorphine dose <  12 mg
3-day dose =  32  mg when 24 hr buprenorphine dose >  12 mg
The patient should be reviewed in the week following the first 72-hour dose, and the dose titrated accordingly. If a 
patient cannot be stabilised on a three-times-a-week dosing regime, the four-times-a-week dosing regime should be 
considered.
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TABU 5
Buprenorphine S/L dose (mg)
Daily dose (24 his) Two day dose (48 hrs) Three day dose (72 hrs)
2 4 6
4 8 12
6 12 18
8 16 24
10 20 30
12 24 32
14 28 32
16 32 32
18 32 32
20 32 32
22 32 32
24 32 32
26 32 32
28 32 32
30 32 32
32 32 32
Some patients attempting alternate-day dosing may benefit from doses greater than 32 mg, however, there is limited 
evidence regarding the safety of higher doses, and buprenorphine is registered in Australia with a maximum 
recommended dose of 32 mg. Practitioners should be aware of the medico-legal implications of off-label prescribing 
before they prescribe doses of greater than 32 mg. Frequent clinical and hepatic monitoring is recommended 
under such circumstances.
3 .5  Take-away doses
The take-away policy for buprenorphine will be determined by each jurisdiction. (See Appendix 3). "Take-away" is 
medication not administered by the dispensing clinician, but given to the patient for administration at a later time.
The benefits of take-away opioid doses:
1 . they emphasise and promote patients' responsibility for their own treatment;
2 .  they enhance the patients' integration into the community by cutting time and travel costs associated with the 
treatment;
3 . they tend to promote patient retention by minimising the inconvenience of regular attendance for doses.
(Studies show take-away policies produce better retention rates than programs which restrict take-away doses).
4 . They benefit pharmacists by reducing the inconvenience and cost of daily dispensing.
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Concerns regarding take-away doses of opioid medications:
1 . P o ss ib le  o v e rd o se  o r  a cc id e n ta l dose : Take-aways increase the risk of deliberate or accidental overdose by 
the patient or others, particularly children and other non-tolerant individuals, and by any one of these in combination 
with other sedative drugs.
2 . In je c tio n  o f  ta k e -a w a y s , resulting in overdose, damage to veins or other health consequences.
3 .  Doubtful or poor com p liance : Diversion to others of take-aways, resulting in poor outcomes for patient (poor 
compliance with treatment regime), and abuse by other individuals.
4 .  D iv e rs io n  of buprenorphine to heroin-dependent individuals or methadone maintenance patients and precipitation of 
withdrawal
5 . Bad publicity' over treatment regime - "just another drug being bought and sold".
The main issues regarding the safety of take-aways are:
a) Discerning s u ita b i l i ty .  Close monitoring by the provider is vital to decide which patients
are suitable for take-aways, and this monitoring is not always achievable in community programs.
b) Education o f  th e  patient regarding safe and responsible handling of the take-away doses.
Absence from pharmacy in patients ineligible for take-away doses 
The "one-off" supervised multiple dose. In circumstances where a patient is ineligible for buprenorphine take­
aways (eg recently commenced treatment, high-risk drug use), but is unable to attend for dosing for one or two days, it 
is possible to organise a one-off supervised multiple-dose of buprenorphine (as administered to patients engaged in 
alternate-day or three-times-a-week dispensing). In this way, the dose of buprenorphine can be doubled in circumstances 
where the patient is away from the pharmacy for one day, or increased by 3 times the daily dose (to maximum of 32 
mg) where the patient cannot attend the pharmacy for 2 consecutive days.
3.6 Ancillary interventions
People with a background of heroin dependence often have a range of social problems (e.g. financial, employment, 
parenting, legal, accommodation) and psychological difficulties (e.g. depression, anxiety). The stability afforded by long­
term substitution treatment provides an opportunity for these issues to be addressed. It is one of the key roles of treating 
clinicians to assist in this process, either as direct service providers, or as case managers referring the patient on to 
appropriate services for other areas of their lives.
There has been considerable debate over the role of counselling in maintenance substitution programs. The evidence from 
methadone treatment studies suggests that counselling should be available to all patients, and that patients should be 
positively encouraged to avail themselves of counselling services. However there is no real place for mandatory 
attendance at counselling sessions, and all ancillary services should be offered on the basis of the patient freely 
consenting to be involved.
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Counselling approaches, such as motivational interviewing, relapse prevention and social skills training, which are based 
on cognitive behavioural therapies, are frequently used and found to be effective. More intensive psychotherapy can be 
beneficial to people with concomitant affective disorders (e.g. anxiety, depression).
3 J  Continued high-risk drug use
People are said to be in continued high-risk drug use when there are frequent intoxicated 
presentations or overdoses of heroin or other substances, chaotic drug-related behaviours, or 
deteriorating medical or mental states due to drug use.
*  Attempts should be made to stabilise such patients. A review is required of their psychosocial interventions and 
supports, precipitants to continued drug use, and medication regimes.
*  An adequate dose of buprenorphine should be prescribed; and the clinician must ensure that the patient is taking the 
bupienorphine as prescribed, which may require:
x ceasing take-away doses;
x ensuring supervised consumption; and
x daily dosing regimes.
Increases in the dose of buprenorphine may assist patients to reduce their heroin use.
•  Transfer to another pharmacotherapy (e.g. methadone) may be indicated if:
(a) there is little or no response to an increase in medication;
(b) the patient is already on a high dose of medication; or
{ t )  on increase in dose is considered 'unsafe' by the prescribe!.
•  Alternatively, non-pharmacotherapeutic treatment options should be considered (e.g. therapeutic communities, 
counselling and support), and the patient withdrawn from prescribed opioid medication.
3 .8  Missed Doses
Single dose missed
Sometimes a patient who is on an alternate-day or three-times-a-week regime misses a 'dosing day', attending on the 
following ('non-dosing') day. When th is  happens, a lower dose of buprenorphine should be prescribed 
and dispensed in order to tide th e  patient over until the next scheduled dose.
The following procedures are recommended:
•  The pharmacist should contact the prescriber. The buprenorphine dose prescribed should be sufficient to last until the 
next scheduled dose (if this is 24  hours, then prescribe a 24-hour dose; if 48 hours - a 48-hr dose).
*  In circumstances where the pharmacist cannot contact the prescribing doctor, no buprenorphine can be dispensed (as 
there is no valid prescription). However, this increases the risk that the patient will drop out of treatment. To prevent 
this happening, the prescriber can issue a prescription of buprenorphine to be administered by the pharmacist as a 
one-off dose, for use if the patient on a three- or four-times-a-week regime misses the scheduled dosing day and 
presents on a non-scheduled day.
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This prescription m u st n o t be g r e a te r  th a n  th e  usua l 2 4 -h o u r  d o s e . The prescriber may wish to limit the 
maximum level of such an 'emergency dose' to o lower than usual dose in order to discourage such occurrences.
•  Patients who repeatedly miss doses under these circumstances should be reviewed by their prescribing doctor to find 
out why, and whether these issues can be addressed. Alternatively, consideration might be given to a more feasible 
dosing regime.
Multiple doses missed
Patients who have erratic attendance for dosing are unlikely to achieve optimal outcomes. Patients who have missed 
more than five consecutive days of buprenorphine must be reviewed by their prescribing doctor prior to receiving a further 
dose, to ensure their safety.
T h e  re c o m m e n d e d  re c o m m e n c e m e n t doses o f b u p ren o rp h in e  a re :
U su a l 2 4  h o u r b u p re n o rp h in e  do se R e c o m m e n c e m e n t d o se
>  8mg 8mg if <  7 days with no dose
4 mg if 7 days or more with no dose
6 - 8 mg 4 mg
2 - 4 mg 2 -  4 mg
Patients can be brought up to their usual maintenance doses over subsequent days (using dosing increments discussed 
earlier) if clinician and patient think this is appropriate.
3.9 Cessation of buprenorphine maintenance treatment
W ithdrawal from buprenorphine maintenance treatment
N a tu r e  o f  w i t h d r a w a l  fro m  b u p re n o rp h in e  m a in te n a n c e  t r e a tm e n t
There is some clinical ond anecdotal evidence that withdrawal from buprenorphine is less prolonged and less severe than 
methadone withdrawal, but the research on this is not conclusive. Withdrawal does appear to be milder during 
buprenorphine dose reductions, and the rate of buprenorphine dose-reduction is normally more rapid than with 
methadone. The symptoms and signs of withdrawal from buprenorphine are qualitatively similar to withdrawal from other 
opioids.
C o m m o n  p o lte rn  o f  lo n g -te rm  withdrawal o f b u p ren o rp h in e  t r e a tm e n t :
•  The onset of symptoms is usually around 24 - 72 hours after the last 24-hour dose.
•  Symptoms peak around days 3 - 5 following short maintenance courses of buprenorphine treatment 
(weeks /  months), or days 5 - 1 4  for longer-term treatment.
•  Duration of withdrawal from buprenorphine maintenance treatment has not been established, although mild to 
moderate withdrawal symptoms (particularly cravings, sleep and mood disturbances associated with protracted 
withdrawal) are likely to persist for weeks. One study described mild but ongoing withdrawal features 30  days after 
the last buprenorphine dose. Longer-term follow up has not been reported.
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Voluntary w ithdrawal from Buprenorphine maintenance treatment
Evidence from methadone research suggests that long-term outcomes of treatment are enhanced by:
•  L o ng e r t re a tm e n t e p iso des . Evidence from methadone research suggests that long-term outcomes are 
enhanced by longer treatment episodes (for example, more than 12 months).
•  A  m o re  s ta b le  and  s u p p o rtiv e  l i fe s ty le .  The longer treatment episode allows the opportunity for the patient 
to establish a lifestyle away from heroin and other drug use prior to withdrawing from methadone treatment. 
Premature withdrawal from methadone (before the patient has achieved a degree of stability in social circumstances 
and drug use) is more likely to be associated with a relapse into dependent heroin use.
The likelihood of premature withdrawal from maintenance treatment is reduced by:
•  A well-informed patient, w ith  a ll th e  fa c ts  a b o u t th e  maintenance program. A patient may wish to 
withdraw from maintenance treatment for a range of reasons, e.g. the need for interstate travel, concerns about 
side-effects or about remaining in treatment 'too long'. The clinician should address issues regarding the duration of 
treatment and withdrawal early in the treatment program, and provide information regarding the process of 
withdrawal. Patient literature is now available regarding withdrawal from methadone treatment (Dunlop et al 1996), 
and parallels can be made with withdrawal from buprenorphine. Despite withdrawal from buprenorphine being 
frequently described as milder than from other opioids, patients should be informed of the likely withdrawal profile.
Except in the case of involuntary withdrawal (see below), withdrawal from buprenorphine should occur only with the 
consent of the patient. Graduated reduction over weeks results in better outcomes (less relapse to heroin use) than rapid 
reductions. The following rates of dose-reduction are proposed, although reductions can occur both more rapidly and more
slowly:
TABLE 6
RATES OF DOSE RED U C TIO N
Dose of buprenorphine Reduction rate
Above 16 mg 4 mg per week or fortnight
8 -1 6  mg 2 - 4 mg per week or fortnight
Below 8 mg 2 mg per week or fortnight
An increase in heroin or other drug use, or a worsening of the patient's physical, psychological or social well-being, may 
warrant a temporary cessation or slowing-down of the reduction rate.
Supportive Core
Patients should be aware of their dose, except where an agreement has been reached between patient and service 
provider to the administration of a 'blind dose'. Increased supportive counselling, as well as information and education, 
should be available for patients withdrawing from buprenorphine. There may be a role for other medication for 
symptomatic relief. These include clonidine, NSAIDs, anti-emetics, anti-diarrhoeal agents, hypnotics, and smooth muscle 
relaxanfs (eg hyoscine) for patients experiencing severe withdrawal. However, caution should be applied regarding the 
use of potential drugs of abuse (eg benzodiazepines).
delines for Buprenorphine i.
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In v o lu n ta ry  w i th d r a w a l (without patient consen t o r  a g a in s t p a t ie n t 's  w is h e s )
The conditions for involuntary termination usually concern behaviour which the service provider finds intolerable, and will 
vary from program to program. These may include:
•  threatened or actual abuse of other patients or s ta ff;
® illegal activities, such as theft, property damage, or drug-dealing, in or near the service;
*  diversion of medications.
The rate of reductions under circumstances of involuntary treatment cessation can be faster (e.g. up to 4 - 8 mg 
reductions every 3 - 4 days). Patients who pose a considerable risk to the safety of other patients or staff may be 
abruptly terminated without a graduated dose reduction.
Transfer to other service providers should always be considered as an alternative to rapid involuntary discharge.
The use of buprenorphine to assist withdrawal from methadone maintenance pro­
grams
Many patients on long-term methadone maintenance programs experience considerable difficulties in conventional 
approaches to withdrawing from methadone, including a prolonged period of withdrawal discomfort and/or relapse to 
heroin use. Consequently, there is considerable interest in finding alternative methods of withdrawing from methadone 
maintenance programs.
Two approaches have been recently proposed:
1 . the use of opioid antagonists (rapid opioid withdrawal techniques), and
2 . transfer to buprenorphine.
The latter approach entails a reduction in the dose of methadone, transfer to buprenorphine, and subsequent withdrawal 
from buprenorphine. 4s there is limited experience or evidence to support these approaches; they cannot he generally 
recommended at this time.
Commencing naltrexone following buprenorphine maintenance treatment
There is limited experience in commencing naltrexone following the cessation of maintenance buprenorphine treatment. 
The initiation of naltrexone must be delayed until several days after the last dose of a full opioid agonist (generally 7 
days after heroin use and 10 -1 4  days after methadone use). However, naltrexone can generally be initiated within days 
of the last dose of buprenorphine. The following procedures are recommended.
In circumstances where the last dose of buprenorphine was 2mg (or less) for at least one week, naltrexone 
can be initiated 4 - 5 days after the last dose of buprenorphine (providing there has been no heroin use in the 
previous 7 days).
Where the last dose of buprenorphine was greater than 2 mg, and to reduce the likelihood of precipitating 
withdrawal symptoms, the first dose of naltrexone can be delayed until more than 7 days after the last 
buprenorphine dose.
The initial dose of naltrexone (12.5 mg orally) should be administered in the morning. The patient should be 
monitored for up to 3 hours after the first dose of naltrexone for features of opioid withdrawal.
Symptomatic withdrawal medication should be available for the patient to use in the 12 hours after the first 
dose of naltrexone, including donidine (up to 150 mg 3 - 4 hourly), benzodiazepines (eg diazepam up to 
5 -1 0  mg every 3 - 4 hours as needed), metodopramide, hyoscine butylbromide and NSAIDS.
Subsequent doses of naltrexone can be 25 mg for a further 2 - 3 days and then 50 mg per day as usually 
recommended. Clinical guidelines regarding the use of naltrexone should be consulted (Bell et al 1999).
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The high re c e p to r a f f in ity  o f buprenorph ine  com plicates th e  in te rp re ta t io n  o f a n a lo xo n e  
ch a lle n g e  te s t p rio r to  com m encing n a ltre x o n e  in p a tien ts  tra n s fe rr in g  fro m  b u p ren o rp h in e:
*  a negative naloxone challenge test does not preclude the onset of withdrawal on commencing naltrexone;
•  a positive naloxone challenge test is likely to reflect recent use of other opioids, and indicates that naltrexone 
induction should be delayed.
Given the potential for patients to use heroin or other opioids following the cessation of buprenorphine and prior to the 
commencement of naltrexone, some objective test should be conducted prior to commencing naltrexone in order to 
exclude recent opioid use. The n a lo x o n e  challenge te s t or a p p ro p ria te  u rin e  d rug screening a re  
rec o m m e n d e d .
Transferring to methadone
Consideration should be given to transferring a patient from buprenorphine to methadone under the following 
circumstances:
1 . In to le ra b le  side e ffe c ts  to  b u p ren o rp h in e .
2 .  in a d e q u a te  response  w ith  b uprenorph ine  tre a tm e n t. Treatment with buprenorphine should be considered 
unsuccessful if it has not resulted in marked improvements in the patient's drug use, injecting risk practices or other 
outcomes identified by the patient and clinician as treatment goals. In such instances, treatment with an alternative 
substitution pharmacotherapy should be considered
3 .  W h e re  b u p ren o rp h in e  is no t a v a ila b le . As buprenorphine is a relatively new drug, it may not be available in 
certain jurisdictions, when the patient is overseas, during periods of incarceration and in some hospitals. Patients 
should be transferred to methodone in such circumstances. To facilitate the subsequent return to buprenorphine 
treatment (if planned), the lowest effective methadone dose should be used.
4 .  C om plica tions  w ith  an ta g o n is ts  and analgesics. In patients who have frequent overdoses, the use of 
buprenorphine may complicate resuscitation efforts with naloxone. Such patients should be taken off substitution 
pharmacotherapies or transferred to methadone. Patients requiring frequent additional analgesia for recurrent acute or 
chronic pain conditions moy be better stabilised on full agonists, such as methadone.
Transferring from buprenorphine to methodone treatment is less complicoted than from methadone to buprenorphine.
Methadone can be commenced 24 hours after the last dose of 
buprenorphine, at an initial maximum daily dose of up to 40mg.
Patients transferring from low doses of buprenorphine (e.g. 4 mg or less) should be commenced on lower doses of 
methadone (e.g. 20 mg methadone or less). The methadone dose can then be titrated accordingly. Care should be taken 
not to increase the dose of methadone too quickly, as buprenorphine can diminish the effects of methadone for several 
days (blockade effect), and there should be adequate time to allow "wash out" of buprenorphine prior to marked 
increases in methadone dose.
SECTION 4. GUIDELINES FOR THE 
MANAGEMENT OF HEROIN WITHDRAWAL
4.1 Heroin w ithdrawal in context
Heroin withdrawal defined
Drug withdrawal is a substance-specific syndrome due to the cessation or reduction of heavy and prolonged drug use. This 
syndrome causes clinically significant distress and impairment in social, occupational, or other important areas of 
functioning (DSM IV, 1994). The characteristic features of heroin withdrawal are shown in the following table.
TABLE 7
CLINICAL FEATURES OF THE HEROIN WITHDRAWAL SYNDROME
increased sweating, lacrimation, rhinorrhoea, urinary frequency. 
Diarrhoea, abdominal cramps, nausea, vomiting.
Muscle spasm leading to headaches, back aches, leg cramps, twitching, arthralgia 
piioerection, pupillary dilatation, elevated blood pressure, tachycardia. 
Anxiety, irritability, dysphoria, disturbed sleep, increased cravings for opioids
Physical symptoms generally commence 6 - 2 4  hours after last use, peak in severity during days two to four, and 
generally subside by day seven, while the psychological features of dysphoria, anxiety, sleep disturbances and increased 
cravings may continue for weeks or even months. Heroin withdrawal is unpleasant, though rarely, if ever, life-threatening. 
It can, however, significantly complicate concomitant medical or psychiatric conditions.
Objectives of withdrawal services
Heroin users present for withdrawal services for a range of reasons and motivations, and the goals of individual patients 
may vary considerably. Withdrawal services should not be seen as a stand-alone treatment resulting in prolonged periods 
of abstinence. Indeed, research suggests that withdrawal treatment alone has little, if any, long-term impact on levels of 
drug usel - 4. Unfortunately, many patients, families, friends, and health and welfare professionals hold unrealistic 
expectations regarding the outcomes of withdrawal services. Many are disappointed when people in these programs either 
cannot give up their heroin use in the first place, or recommence regular heroin use soon after a withdrawal attempt.
1 4 Maffick, R,P.( & Hall, W. (1 9 9 6 ) . Are detoxification programmes effective?. Lancet 1996; 3 4 7 :9 7 -1 0 0 .
Hubbard, R.L., Marsden, M .E., Rachal, J.V., Harwood, H.J., Cavonough, E.R., & Ginzburg, H.M. (1 9 8 9 ) .  Drug abuse treatment a national study of 
effectiveness. University of North Carolina Press: North Carolina.
Vaillont, G.E. (1 9 8 8 ) .  What does long term follow up teach us about relapse and prevention of relapse in addiction. British Journo! oiAddiction, 83, 
1143-57 .
Simpson, D.D. & Sells, S.B. (1 9 8 2 ). Effectiveness of treatment for drug abuse: An overview of the DARF research program. Advances in Alcohol and 
Substance Abuse, 2 ,7 -2 9 .
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Ä realistic set of objectives for withdrawal services would be:
1 . To alleviate distress. Palliation of the discomfort of heroin withdrawal symptoms is an important reason for patients 
presenting for treatment, and one of the primary aims of withdrawal services.
2 .  To prevent severe withdrawal sequelae. Although heroin withdrawal on its own is almost never life-threatening, 
withdrawal can present various serious problems:
•  Complication of concomitant medical or psychiatric conditions, e.g. precipitation of an acute psychotic episode in 
a patient with schizophrenia in remission, or dehydration in an individual with poor baseline nutritional status.
*  Increased risk of overdose following withdrawal. This can occur with resumption of heroin use following the 
reduction in opioid tolerance that accompanies withdrawal, and due to the combined sedative effects of heroin 
use and medications used for the management of heroin withdrawal (e.g. benzodiazepines).
3 .  Jo break a pattern o f heavy and regular drug use. Many patients want treatment to end their heroin use completely 
during the withdrawal episode, intending to stay off it for a set period of time afterwards. However, giving up entirely 
is not the goal of every patient. Many see withdrawal as a means of reducing levels of heroin use, the severity of 
their dependence and some of its associated harms. So, although the cessation of heroin use is an optimal outcome, 
a reduction in heroin use during a withdrawal attempt may still represent a very positive outcome for patients.
4 .  Jo get patients help with any other problems. Withdrawal services are essentially acute services with short-term 
outcomes, whereas heroin dependence is a chronic relapsing condition, and positive long-term outcomes are more 
often associated with longer participation in treatment. Consequently, an important role of withdrawal services is to 
provide links with post-withdrawal services for those with other physical problems, or psychological or social needs. 
Optimally, they should have automatic access to drug treatment services, such as 'drug-free' counselling; naltrexone 
treatment; residential therapeutic communities; self-help programs; or substitution maintenance programs with 
methadone or buprenorphine. But while some people will be unwilling or unable to continue in ongoing drug 
treatment programs, they may need - and be grateful for - contacts with welfare services (e.g. accommodation); 
general support and cose management services (e.g. outreach workers); or primary or specialist health services.
4.2 Non-pharmacological aspects in managing heroin withdrawal
As well as the use of medications (pharmacotherapy) the delivery of withdrawal services entails:
•  assessment,
•  treatment-matching,
•  planning for withdrawal, and
•  supportive care.
The assessment of patients presenting for treatment was discussed in Section 2.3.
Treatment selection
Range o f Treatments
Treatment selection is a synthesis of:
- assessment of the patient;
- examination of the available treatment options and likely outcomes; and
- negotiation with the patient around a suitable treatment pathway.
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In considering possible modalities, it is important to remember that many people come for treatment with misconceptions 
and/or inadequate information about the two major options available. These treatment pathways for dependent heroin 
users are set out in Figure 1. O O
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FIGURE 1
TREATMENT PATHWAYS FOR DEPENDENT HEROIN USERS
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In general, withdrawal treatment (such as naltrexone, residential rehabilitation programs, counselling or 12-step 
programs), is appropriate for those who are considering abstinence-oriented, post-withdrawal treatment, or for those who 
are not interested in longer-term treatment, and merely want a 'break' from dependent heroin use.
However, maintenance substitution treatment (with methadone or buprenorphine) may be more appropriate for those 
with significant heroin dependence who will not accept residential rehabilitation or naltrexone treatment, but nevertheless 
want to stop or permanently reduce their heroin use and all the damage it is causing them. Clinical decision-making 
should have an evidentiary basis, and patients should be presented with the relative evidence, i.e. the merits and the 
limitations of treatment outcomes associated with each approach. Within such a framework, there is widespread evidence 
suggesting that maintenance substitution remains the 'gold standard' treatment for most people with chronic heroin 
dependence, by virtue of its success in keeping patients in treatment, and reducing drug-related harms.
Once it is established that withdrawal is to be attempted, consideration must be given to the services needed to achieve 
the best outcome. An optimal setting and adequate supports should be found for each patient, and monitoring arranged 
for their personal requirements and medication needs.
Ihe optimal setting lot withdrawal
Withdrawal can occur in a continuum of settings, ranging from intensive residential (e.g. inpatient withdrawal unit or 
hospital) to outpatient (e.g. ambulatory or home-based withdrawal services). Most heroin withdrawal attempts can occur 
in outpatient settings, usually with the assistance of a general practitioner, alcohol and drug worker, or other health 
professional. However, there are circumstances where a residential setting is indicated (see Table 2 ).
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Some patients may wish to persevere with an outpatient withdrawal, despite unsuitable home environments or having 
repeatedly 'failed' as outpatients before. Such attempts at outpatient withdrawal may still be the way to go, if it's what 
the patient really wants. However, clinicians should first negotiate with their patient some mutually agreed criterion of 
failure (e.g. no significant progress within a week) at which point a switch will be made to an alternative treatment 
pathway.
TABLE 8
COMPLEX PRESENTATIONS REQUIRING RESIDENTIAL WITHDRAWAL 
SERVICES
Getting organised for withdrawal
Residential withdrawal settings generally provide the full range of services needed for a withdrawal episode. They set out 
to be drug-free, with support available from staff and fellow patients, and the capacity for continuous monitoring. They 
usually have access to medical staff and medications. Unfortunately, such inpatient services often have waiting-lists of 
days or weeks, and the patient may need short-term support in the interim.
Commencing an outpatient withdrawal requires planning, and the mobilisation of the necessary supports and services. 
Patients should prepare themselves and their environment in advance, to maximise their chance of 'success'.
For example, it is very hard to get through withdrawal in the company of others still using heroin.
A ‘safe1 place is one where there won't be any drugs easily accessible, and where patients will not be confronted by 
other drug users. It is important to have caring people to support a patient during withdrawal, and these support people 
themselves need guidance and information about the process, and suggestions as to what they can reasonably do to 
help.
Supportive care
Provision of information and strategies for coping.
Patients need information regarding:
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*  the nature and duration of withdrawal symptoms;
*  strategies for coping with symptoms and cravings;
♦  strategies to remove high-risk situations;
*  the role of medication.
Patients often have limited concentration during withdrawal, and information may have to be repeated, perhaps 
even re-phrased, to be fully understood and absorbed. Written information is valuable in these circumstances, and is also 
recommended for support people (contact the local drug and alcohol authority for relevant literature).
Counselling during the withdrawal episode should be aimed specifically at supporting the patient through problems 
associated with withdrawal and in facilitating post-withdrawal links.
Many patients will want to deal with a range of personal, emotional or relationship problems during the withdrawal 
episode, but they should be persuaded to defer all this until later. Attempting to work through such issues will almost 
certainly be emotionally painful and anxiety-provoking, which just intensifies cravings and puts the whole withdrawal 
program in jeopardy. Furthermore, patients in withdrawal tend to be irritable, agitated, tired and run-down; they can 
suffer from mood swings and poor sleep patterns, as well as difficulty in concentrating. This is definitely not the optimal 
frame of mind in which to try to solve significant, long-standing life problems. Assure your patients that you understand 
that they have many important issues to work through to get their lives together again, but it is best to take one step at 
a time. There will be opportunities for these wider problems to be addressed as part of their ongoing rehabilitation after 
they get through withdrawal. On the other hand, crisis intervention may be required during a withdrawal episode to 
ensure adequate accommodation, food or other urgent welfare issues.
In addition to supportive counselling from health professionals and the support of family, friends and peer workers, heroin 
users may also benefit from 24-hour telephone counselling services for help when others are unavailable. Each state in 
Australia has telephone alcohoi and drug services (see Appendix 3 ).
Monitoring
An important part of withdrawal service is regular and frequent monitoring, to check:
*  general progress;
•  drug use;
•  response to the medication (s);
•  severity of withdrawal symptoms (which can be facilitated by the use of withdrawal scales);
•  complications or difficulties;
•  ongoing motivation levels.
Doses of medication can then be adjusted according to the patient's progress. It is recommended that patients undergoing 
outpatient withdrawal be reviewed by a health professional (eg alcohol and drug worker, general practitioner, or 
experienced pharmacist) at least daily during the first few days of treatment.
Objective and Subjective Withdrawal Scales
There are various opioid withdrawal scales available to refer to. Subjective scales are far more sensitive to changes in 
withdrawal severity, and are better predictors of patient outcomes. Objective scales are not only less sensitive, but usually 
need to be administered by a health professional. They may nevertheless be useful in corroborating subjective ratings, 
particularly in individuals who are thought to be over- or under- rating their withdrawal severity. Copies of the Subjective 
Opioid Withdrawal Scale and Objective Opioid Withdrawal Scale are provided in Appendix 2.
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4 .3  O verv iew  o f buprenorphine in the 
management of heroin w ithdraw al
Efficacy of buprenorphine compared to other withdrawal medication regimes (liter­
ature review)
The efficacy of buprenorphine in the monagement of heroin withdrawal has been compared to other withdrawal 
approaches in several randomised controlled trials conducted in inpatient ° '1 *3) and outpatient settingsw 6!
In general, these studies have demonstrated buprenorphine to be:
•  more effective than symptomatic medications in reducing withdrawal symptoms'11 1 5' 6>,
•  more effective in retaining patients through the withdrawal episode and in post-withdrawal treatment'6’; and
•  more effective in reducing heroin use in outpatient settings'6’.
Readers are referred to the Cochrane Review on Buprenorphine for Opiate Withdrawal.
In the medically ill. Controlled trials comparing buprenorphine with other withdrawal medications for the management 
of heroin withdrawal in medically-ill patients have not been conducted. Nevertheless, uncontrolled studies have reported 
favourably on the use of buprenorphine in these circumstances. Furthermore, the sublingual preparation is well suited to 
individuals who cannot tolerate oral medications. Caution should be used in using buprenorphine or other opioids in 
individuals with certain medical conditions (see Section 2.1).
The role of buprenorphine in withdrawal
The aim of medication in withdrawal is the reduction of withdrawal symptoms and cravings; it is 
not the complete removal of all symptoms or the intoxication of the patient.
The dinicion should discuss patients' expectations of the medication with them, and address any misconceptions.
In particular, the following principles regarding doses should be understood by the patient:
•  Buprenorphine doses that are too high can result in increased rebound withdrawal, prolonged duration of symptoms, 
increased side-effects, and increased cost of the medication.
•  Alternatively, use of doses that are too low can result in unnecessary withdrawal discomfort, continued heroin use and 
treatment drop-out.
•  Continued heroin use or cravings may not be due to inadequate doses of medication. For example, patients who 
continue to associate with other heroin users, and are present when others are acquiring or using heroin, can expect 
to have cravings regardless of their dose of buprenorphine.
1 Cheskin U , Fudola PJ, & Johnson RE (1 9 9 4 ). A controlled comparison of buprenorphine and donidine for acute detoxification from opioids.
Drug and Alcohol Dependence, 36(2), 115-21;
Nigam AK, Ray R, & Tripathi M. (1 9 9 3 ). Buprenorphine in opiate withdrawal: A comparison with donidine. Journal of Substance Abuse 
treatment, 1 0 ,3 9 1 -3 9 4 ;
3 O'Connor PG, Carroll KM, Shi J, Schottenfeld RS, et al (1 9 9 7 ). Three methods of opioid detoxification in a primary care setting. Annals of 
Internal Medicine 127(7) 526-530;
• Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, et al (1 9 8 8 ). A clinical trial of buprenorphine: Comparison with methadone in the 
detoxification of heroin aadicts. CUnicoi Pharmacology 8, therapeutics, 247, 47-53;
s Schneider U, et al. Buprenorphine and carbanazepine as a treatment for detoxification of opioid addicts with multiple drug misuse: a pilot 
study. Addiction Biology 2000, 5 (1 ) 65-69; and
* Lintzeris N, Bell J, Bammer G, Rushworth L et al (2 0 0 0 ) A randomised controlled trial of buprenorphine for the management of outpatient 
heroin withdrawal, paper presented at the November 2 00 0  National Methadone Conference, Melbourne, Australia.
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Buprenorphine dosing in withdrawal 
Over-dosing doesn't help 
Under-dosing doesn't help
Problems encountered may not be the fault of the medication dose
_________________________________________________________________
Preventing precipitated withdrawal on commencing buprenorphine
Buprenorphine can precipitate opioid withdrawal in someone who has recently used heroin (within the past 6 hours) or 
methadone (See Section 3.2). Buprenorphine-precipitated withdrawal typically commences 1- 4 hours after the first 
buprenorphine dose, is generally mild to moderate in severity, and lasts for up to 12 hours. Patients experiencing severe 
discomfort may benefit from symptomatic withdrawal medication (eg clonidine 100 meg 3 - 4 hourly as required), and 
should be directed to see their prescribing doctor.
Patients should not receive the first dose of buprenorphine if they are experiencing heroin 
effects. In practice, it is recommended that patients wait at least 6 hours after their last use of heroin prior to receiving 
their first buprenorphine dose. It is preferable to withhold the first dose until the patient is beginning to experience the 
early features of withdrawal. If there are doubts or concerns, the patient should be asked to come back for dosing later in 
the day, or alternatively, a lower initial dose can be dispensed (e.g. 2 or 4 mg) as it is less likely to precipitate 
withdrawal than a high initial dose.
Preventing precipitated withdrawal on commencing buprenorphine
Ho Heroin for ot feast 6 Hours: severe discomfort may need palliation.
No methadone for at least 24 hours.
No buprenorphine if there are obvious heroin effects: wait for withdrawal signs, or send away to return next day.
Use of ancillary medications in conjunction with buprenorphine
Buprenorphine provides general relief of withdrawal symptoms, so that other symptomatic medications for opioid 
withdrawal are not routinely required. An exception to this rule is when patients experience difficulty sleeping during 
withdrawal, and may benefit from the limited use of benzodiazepines as a hypnotic. However, benzodiazepines should 
not be used routinely from the outset of the withdrawal episode, but rather should be added, as required, following 
clinical review of the patient. Low doses of a hypnotic (eg temazepam 10-20 mg nocte, oxazepam 15-30 mg nocte or 
nitrazepam 5-10 mg nocte) are recommended, with daily dispensing from the pharmacy (or supervised by a responsible 
adult). Under normal circumstances, benzodiazepines should not be continued beyond several days, with non- 
pharmacological approaches being encouraged (sleep hygiene strategies).
Continued use of heroin a n d  other drugs
Patients who keep on using heroin during buprenorphine treatment may have difficulty stabilising on the medication, and 
may continue to experience features of precipitated withdrawal after each dose.
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It Is very important for patients to abstain from heroin use 
until they are stabilised on buprenorphine.
Persistent features of precipitated withdrawal discomfort may be grounds for transfer to methadone, or other withdrawal 
medications.
'
buprenorphine, can be extremely dangerous, resulting in respiratory 
depression, coma and death.
All patients should be informed verbally and in writing of these risks. Intoxicated patients should not be dosed with 
buprenorphine or sedative medications.
Gateway model of treatment with buprenorphine
Buprenorphine is particularly useful in managing heroin withdrawal, in that it is not only effective during the withdrawal 
period, but also facilitates links to post-withdrawal treatment. Many patients entering withdrawal treatment do so without 
necessarily having considered all their treatment options, simply 'hoping' that an attempt at withdrawal will be sufficient 
to stop heroin use.
The use of buprenorphine for several days generally alleviates withdrawal symptoms without significant sedation, thereby 
allowing patients and clinicians to examine post-withdrawal issues relatively early on in the withdrawal episode. (On 
many other withdrawal medications, such as benzodiazepines or donidine, patients are either so psychologically 
distressed or so heavily sedated that this would not be possible.) A formal review of treatment plans should be structured 
several days into the withdrawal episode, at which time treatment can be tailored accordingly. For those patients who 
have successfully refrained from heroin use during withdrawal, and who are considering longer-term naltrexone treatment, 
naltrexone can be initiated either during buprenorphine administration or after a short course is ceased. Patients who are 
not interested in ongoing pharmacotherapy treatment can cease a short course of buprenorphine with minimal rebound 
discomfort. Alternatively, those patients who want to extend the duration of their withdrawal program, or have 
reconsidered the role of a maintenance treatment program, can continue buprenorphine treatment over a longer period of 
time. Care should be exercised in transferring patients with short histories of heroin dependence from short-term 
withdrawal programs on to long-term substitution maintenance programs.
These treatment pathways are shown in Figure 2.
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FIGURE 2
GATEWAY MODEL OF TREATMENT WITH BUPRENORPHINE
Dependent herein
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Withdrawal episode
Buprenorphine regime for 4 - 8 
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for relapse prevention
Commenced during or soon after 
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Buprenorphine or methadone
No ongoing pharmacotherapy
Psychosocial interventions
4.4 Buprenorphine regimens in outpatient withdrawal settings
Buprenorphine is long-acting, and so is well suited to outpatient withdrawal settings, allowing for once-a-day supervised 
dosing.
Patients unable to attend an authorised pharmacy daily for supervised dispensing should consider alternative withdrawal 
medications.
The recommended duration of tre a tm e n t with buprenorphine for the management of heroin 
withdrawal is 4 - 8 days. This short regime ensures the treatment covers the time when heroin withdrawal 
symptoms are most severe (typically up to 4 or 5 days), and then is promptly discontinued, thereby minimising rebound 
withdrawal phenomena and limiting the duration of withdrawal discomfort.
There is no conclusive evidence of an optimal buprenorphine dosing regime for heroin withdrawal. In general, daily 
buprenorphine doses of 4 -1 6  mg appear to be most effective in reducing withdrawal severity and heroin use. The reader 
is referred to the Cochrane Review, for an analysis of relevant studies. The following short-term outpatient withdrawal 
regime is recommended:
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TABLE 9
RECOMMENDED SHORT OUTPATIENT REGIMES
P ro p o s e d  re g im e R e c o m m e n d e d  io w e r  
and  u p p e r lim its
Day 1 6 mg 4 to 8 mg
Day 2 8 mg 4 to 12 mg
Day 3 10 mg 4 to 16 mg
Day 4 8 m 2 to 12 mg
Day 5 4 mg 0 to 8 mg
Day 6 0 to 4 mg
Day 7 0 to  2 mg
Day 8 0 to  1 mg
Total dose 36  mg
Some flexibility is allowable in doses to accommodate a range of factors, such as amount of heroin use and psychological 
condition, impacting on each patient's individual dosing requirements and withdrawal severity.
Review by a trained health professional is recommended on a daily basis during the first few  
days of the withdrawal regime. This is important so that doses coo be adjusted, if accessory, ood ooy difficulties 
being experienced on the medication can be addressed. It is also needed to ensure provision of appropriate support care 
and monitoring.
ill
Titration: Buprenorphine doses should be titrated against 
severity of withdrawal features and cravings for heroin use, 
actual use of heroin or other drugs, and 
occurrence of side-effects.
F le x ib le  d o s a g e s  Doctors may choose to prescribe a fixed daily dose (e.g. Day 1 :6  mg, Day 2 : 8  mg, Day 3 : 1 0  mg 
etc) or, alternatively, prescribe a flexible regime with upper and lower limits on any particular day and instructions for the 
pharmacist or withdrawal worker regarding dose titration (e.g. Day 1 :6  mg, Day 2 :6 -1 0  mg; Day 3 :8 -1 2  mg etc).
It is a good idea to attempt a short-term regime, and schedule a formal review of progress within a few days. At this 
review, the clinician and patient can together consider the available post-withdrawal treatment options (see Section 4 .6 ) .
Those patients who remain ambivalent about long-term post-withdrawal treatment, and have not been able to cease their 
heroin use, may need referral to an inpatient supervised withdrawal program. Alternatively, an extension of the 
withdrawal regime over several weeks may be warranted.
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However, there are good reasons for not prolonging buprenorphlne treatment:
•  Intake for more than several days commonly produces rebound withdrawal when ceased, typically starting 1 - 3 days 
after the last dose of buprenorphine, peaking 2 - 5 days after the last dose, and with some symptoms persisting 
several weeks.
•  Prolonged, probably unsuccessful, attempts at withdrawal can be demoralising for the patient, resulting in lowered 
capability, self-esteem, and/or confidence in the treatment provider. For this reason, a limit on the time spent on a 
gradual reduction regime should be discussed with the patient early in the program.
Longer-term maintenance substitution treatment (with buprenorphine or methadone) should be recommended to patients
who:
•  cannot stop, or markedly reduce, their heroin use during the withdrawal episode;
•  relapse into regular heroin use as the dose of buprenorphine is reduced or ceased;
•  do not feel confident about maintaining abstinence but do not want to relapse to dependent heroin use and the 
associated harms.
It is recommended that such patients stabilise on a maintenance substitution medication for a longer period of time before
coming off their maintenance treatment, to give them the opportunity to first distance themselves from heroin use and
possibly to address any problematic psychological and social issues which may be distressing them.
4.5 Buprenorphine for heroin withdrawal in residential settings
Buprenorphine is weii suited to use in inpatient withdrawal settings, given its ability to alleviate 
the discomfort of withdrawal symptoms without significantly prolonging their duration.
It is recommended that on interval o f at least 2 - 3 days be available from the time of the last buprenorphine dose to the 
time of planned discharge.
Duration of dosing will be determined by the length of admission available, e.g. in a 7-day admission, treatment will be 
limited to the first 4 - 5 days.
Approaches to dispensing in inpatient settings will depend on the level of supervision and staffing available. Titration 
regimes generally require nursing staff who can administer withdrawal scales and S8 medications, so places with limited 
access to nursing staff may be better suited to fixed regimes with the option of additional 'rescue' doses as required.
The additional rescue doses should only be administered:
•  at least 4 hours after the earlier dose; and
*  if the patient is experiencing moderate or severe withdrawal discomfort.
Buprenorphine doses in inpatient settings can generally be lower:
*  outpatient regimes must accommodate higher cravings and exert blockade effects;
•  outpatient regimes are generally limited to once-a-day dosing.
An evening dose (between 5 PM and 1Ö PM) is recommended, to allow relief of withdrawal symptoms 
until the morning. N.B Buprenorphine should not be administered if  there are any features of intoxication or sedation.
kjimccri (jh 3$ for Buprenorphine use
The following regime is recommended for on admission time of approximately one week, and can be tailored accordingly:
TABLE 10
PROPOSED INPATIENT WITHDRAWAL REGIME
Day Buprenorphine S /L  tablet regime Total daily dose
Day 1 4 mg at onset of withdrawal, i  additional 2 to 4 mg evening dose pm 4 to 8 mg
Day 2 4 mg mane, with additional 2 to 4 mg evening dose prn 4 to 8 mg
Day 3 4 mg mane, with additional 2 mg evening dose prn 4 to 6 mg
Day 4 2 mg mane prn; 2 mg evening pm 0 to 4 mg
Day 5 2 mg prn 0 to 2 mg
Day 6 no dose
Day 7 no dose
Total proposed dose =  12 to 28 mg
This regime serves as a guide only, and considerable individual variation in withdrawal severity and medication 
requirements should be expected.
Post-withdrawal options should be explored prior to discharge (see next section).
*  Naltrexone: Patients commencing naltrexone treatment should do so during their admission.
*  Buprenorphine: Patients wishing to commence buprenorphine maintenance treatment should continue their 
buprenorphine as inpatients until transfer to a community-based provider can be organised.
4.6 Transition to post-withdrawal treatment
Transition to maintenance treatment
Buprenorphine maintenance treatment
Transition to a buprenorphine maintenance treatment program simply requires the continuation of treatment, often with 
upward titration of the dose to achieve optimal maintenance dose levels (eg. 12 - 24 mg per day). The reader is referred 
to Section 3.
Methadone maintenance treatment
The transition to methadone maintenance treatment requires the cessation of buprenorphine, with the first dose of 
methadone given at least 24  hours later. The reader is referred to Section 3 .9  of these guidelines.
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Commencing naltrexone treatment after short duration Buprenorphine withdrawal
S e v e n -d a y  ab stinence: One of the difficulties for many heroin users in commencing naltrexone treatment is staying 
off heroin for a whole week before the first dose, to avoid the precipitation of withdrawal. The recommended 7-day 
opioid-free period (Bell et al 1999) also limits the use of opioids (such as methadone, codeine or d-propoxyphene) as 
withdrawal medications, as they delay even further the initiation of naltrexone treatment.
The pharmacology of buprenorphine allows the commencement of naltrexone without major delays. This is thought to be 
because buprenorphine has a higher affinity for opioid receptors than naltrexone, so the naltrexone does not significantly 
displace buprenorphine or cause the precipitation of severe opioid withdrawal.
F rom  b u p ren o rp h in e  to  n a ltre x o n e : Researchers are yet to determine the optimal method of inducting on to 
naltrexone from buprenorphine treatment, but two general procedures have been used:
1 . commencing low doses of naltrexone whilst continuing buprenorphine;
2 .  ceasing buprenorphine and commencing naltrexone several days later.
Sample dosing regimes for the two approaches are shown in the following table.
TABLE 11
NALTREXONE INDUCTION REGIMES
D ay S am ple  
b u p renorph ine  
reg im e  ( S /L  ta b le ts )
E arly  N T X  induction  
reg im e  (o ra l)
D e la y e d  N T X  induction  
re g im e  (o ra l)
1 6 mg 0 0
2 10 mg 0 0
3 8 mg 12.5 mg 0
4 6 mg 12.5 mg 0
5 4 mg 25 mg 0
6 50 mg 0
7 50 mg 0
8 50 mg 0 or 12.5 mg
9 50 mg 12.5 mg
10 50 mg 25 mg
11 50 mg 50 mg
v a n ta g e s  and d isa d v a n ta g e s  o f each approach a re  e x p lo re d  in Table 1 2  b e lo w .
Which procedure is best?
Both procedures result in on increased severity of opioid withdrawal following the first dose of naltrexone. This typically 
commences 90 minutes to 4 hours after the first naltrexone dose, peaks around 3 - 6  hours after the naltrexone dose, 
and generally subsides in severity within 1 2 - 2 4  hours. The withdrawal is frequently experienced as moderate to severe 
at its peak. Subsequent doses of naltrexone produce considerably less severe withdrawal discomfort.
Most patients undergoing this procedure request symptomatic medication, and donidine ( 1 0 0 -  150 meg every 3 - 4  
hours as required) and a benzodiazepine (eg diazepam 5 mg 3 -  4 hourly, maximum of 30  mg in a day, as required) 
should be prescribed.
Most patients find either procedure tolerable.
M  patients need supervision and access to the prescribing doctor.
Outpatient setting is suitable only:
*  where there is a suitable and responsible person to support the patient where they live, and to supervise 
medications; and
•  if the prescribing doctor is available to address any potential complications.
PREPARE IN ADVANCE
(or the Increase in withdrawal severity the role of medications, 
and the risks of using heroin to overcome the withdrawal symptoms
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TABLE 12
COMPARISON BETWEEN EARLY AND DELAYED NALTREXONE INDUCTION
E a r ly  N T X  in d u c t io n  r e g im e D e l a y e d  N T X  i n d u c t io n  r e g i m e
Potentia l advantages Only 3 6  - 4 8  hours of abstinence  
from  heroin use is required prior 
to first dose of naltrexone; hence  
m ore patients w ill get a first N IX  dose
Allows m o re  t im e  fo r consideration  
and selection o f o p tim al p o st-w ith d raw al 
tre a tm e n t options
M o re  rapid resolution of w ith d raw al 
discom fort: NTX-precipitated w ith d raw al 
peaks early  in w ith d raw al episode, 
fo llow ing  NTX dose, w ith  resolution of 
m ost w ith d raw al sym ptom s w ith in  days.
In itia l w ith d ra w a l episode is less severe  
fo r th e  p a tie n t and less in tensive  
fo r service providers
Potentia l d isad v a n ta g e s G reater drop-out reported a fte r first NTX 
dose than in delayed induction reg im e
S o m e  p atien ts  w ill drop o u t or resum e  
heroin use prior to  d a y  8  or 9  o f 
w ith d ra w a l ep isode, and  th e re fo re  n o t 
com m ence NTX
M a y  'rush ' som e patients into NTX 
tre a tm e n t, w h ereas other post 
w ith d raw al tre a tm e n t (eg  m ain tenance  
substitution tre a tm e n t) m a y  be preferred .
NTX-precip itated  w ith d ra w a l occurs la te r  
in th e  w ith d ra w a l ep isode (o n  d a y  of 
first NTX dose)
SECTION 5 . COMPLICATIONS OR ADVERSE 
EVENTS WITH BUPRENORPHINE TREATMENT
5.1 Side Effects
Similar to those of other opioids
The reported side-effects of buprenorphine ore qualitatively similar to those of other opioids used in maintenance 
treatments (methadone, morphine, LAAM). An adverse drug reaction is any undesired or unintended effect of drug 
treatment. Adverse drug reactions may be predictable (on the basis of the drug's known actions) or unpredictable (eg 
allergic drug responses, idiosyncratic drug reactions).
Most common is opioid withdrawal
In large, multicentre trials of buprenorphine maintenance treatment, the most common adverse event (reported in over 
30% of patients) has been opioid withdrawal symptoms, and these reports have been most common in patients on low 
doses of buprenorphine (eg 1 mg daily). Other commonly reported adverse events reported by the manufacturer are 
shown in the following table.
TABLE 13
COMMONLY REPORTED SIDE EFFECTS TO BUPRENORPHINE
A d v e rs e  e v e n t P ro p o rtio n  o f p a tie n ts  re p o rtin g  
a d v e rs e  e v e n t
R e la tio n  to  dose
H eadache 8 . 7 % A ppea rs u n re la te d  to  dose
C o n s tip a tio n 7 .5 % M o re  c o m m o n  on h ig h e r doses
In so m n ia 7 . 3 % Appea rs u n re la te d  to  dose
A s th e n ia 6 .1 % A ppea rs u n re la te d  to  dose
S o m n o le n ce 4 .3  % A ppea rs u n re la te d  to  dose
N ausea 3 .5  % M o re  c o m m o n  on doses >  8  m g
D izz ine ss 2 . 7 % M o re  c o m m o n  on  h ig h e r doses
S w e a tin g 2 . 7 % Appea rs u n re la te d  to  dose
Most are mild
In general, most adverse events to buprenorphine are mild, well tolerated, and typically occurring early in treatment with 
symptoms subsiding over time.
M a n a g e m e n t o f th e  s id e -e ffe c ts , w h ich  w ill  depend on th e ir  n a tu re  and s e v e r ity , should be  
n e g o tia te d  b e tw e e n  p a tie n t and clinician. Conventional strategies should be adopted to manage opioid-related 
side effects (eg constipation) (see Table next page).
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TABLE 14
COMMON SIDE EFFECTS WITH OPIOID MAINTENANCE DRUGS
Not oil o f these may occur with Buprenorphine
Side effect C o m m o n  c a u s e s Things tha t you can do
F ee lin g  d ro w s y  a fte r  ta k in g  dose *  D ose too  high L o w er th e  m a in te n a n c e  dose  
an d  re v ie w  o th e r m e d ic a tio n s  
th e  p a t ie n t  m a y  be ta k in g
•  O th e r drug use ( le g a l or ille g a l) R e v ie w  use o f s e d a tiv e  a n d  o th e r  
drugs a ffe c tin g  co g n ition
W ith d ra w a l sy m p to m s  m a x im a l *  Dose too low Raise m a in te n a n c e  d ose or re v ie w
b e fo re  n e x t  dose
*  C han g es in legal or illeg a l drugs th a t  p a tie n t  
m a y  be using.
o th e r d rugs p a t ie n t  is ta k in g
W ith d ra w a l p rec ip ita ted  by *  Occurs ea rly  in tre a tm e n t (o r a fte r  ab se nc e T ran sien t e ffe c t. A im  to  p re v e n t
b u p re n o rp h in e  dose fro m  tre a tm e n t) w h e n  b u p re no rp h in e dose b y p a t ie n t  e d u c a tio n . D e la y
a d m in is te re d  soon a fte r  opio id  use (e g  h ero in b u p re n o rp h in e  d ose until p a tie n t
m e th a d o n e , m o rp h in e ) ex p e rie n c in g  o p io id  w ith d ra w a l
H e a d a c h e *  C o m m o n  in first w e e k  o f b up reno rp h in e S id e  e ffe c t  is t ra n s ie n t an d
p articu larly  if b up reno rp h in e dose to o  h ig h . g e n e ra lly  t re a tm e n t,  m ild . 
C onsider asp irin  o r p a ra c e ta m o l.
♦  O th e r causes o f h ead ac h e E xclude o th e r causes
N a u s ea •  C o m m o n  ea rly  in tre a tm e n t, S id e -e ffe c t u su a lly  t ra n s ie n t (d a y s ) .  
A void  rapid  d ose inc rea se s.
*  U s ua lly  m ild  and  tra n s ie n t. C onsider d os e-re du ctio n  if  p e rs is ten t
C o n stip a tio n *  All opio ids do  th is . W ill be m a d e  w o rse  by E n co urag e fib re  in ta k e  ( fru it ,
lack  o f d ie ta ry  f ib re , flu id  in ta k e  or exerc ise ce re a ls , v e g e ta b le s ) ,  flu id s , an d  
re g u la r e x erc ise .
W e ig h t  g a in , p articu la rly  fo r w o m e n *  Fluid re ten tio n  caused by opioids  
- m o re  like ly  on high doses
L ow er dose
♦  E atin g  m o re  w h ile  in tre a tm e n t; h igh R edu ce f a t  a n d  sa lt in d ie t, exerc ise
s a lt in ta k e re g im e
Poor s le e p •  Dose too  lo w  an d  causing w ith d ra w a l a t R e v ie w  m a in te n a n c e  d ose an d
n ig h t; or re v ie w  o th e r m e d ic a tio n s
*  Dose to o  la te  a t  n ig h t, causing s tim u la tio n  a t F o llo w  s lee p  h y g ie n e
tim e  o f  p e a k  effects
♦  O th e r drugs (p articu la rly  s tim u lan ts  in th e  
e v e n in g , such as co ffe e , n ico tin e , 
a m p h e ta m in e s )
*  G en era l a n x ie ty  o r irregu lar s lee p  p a tte rn
re c o m m e n d a tio n s .
National Clinical Guidelines for Buprenorphine use
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A m e n o rrh o e a  or 
o lig o m e n o rrh o e a
*  All opio ids can do this
♦  M a y  be re la ted  to life s ty le  stressors, 
poor d ie t, an d  g en era l poor h ea lth
Periods m a y  re turn  a f te r  cessation  
o f h ero in  u se , or fo llo w in g  
w ith d ra w a l fro m  opio id s .
Address o th e r causes
L o w ered  sex drive *  M o re  c o m m o n  w ith  a  high dose
*  C an b e  m a n y  o the r psychologica l factors  
(such as a n x ie ty , poor re la tio n sh ip
w ith  p artn er e tc .. . )
R e v ie w  d ose
D e n ta l p ro b lem s •  All opio ids reduce sa liva f lo w
*  Poor d ie t, d en ta l h yg ie n e
E n co urag e te e th  h y g ie n e , d e n ta l 
floss a n d  use o f su g ar fre e  g u m . 
D e n ta l ch ec k -u p . R edu ce in ta k e  o f  
s u g a ry  drinks a n d  s w e e t  fo od
oo
CDr~̂
U n
Modified from Dunlop ef ol (1996) Getting Through Methodone Withdrawal. Turning Point ADC: Fitzroy
5.2 Overdose
Less risk of iethal overdose: The risk of lethal overdose on buprenorphine in an opioid-tolerant individual is less 
than that associated with the use of other opioid medications, such as methadone. This is due to the ceiling dose 
response effects of buprenorphine.
Risk present with the opioid-naiVe: An opioid-naive individual may overdose with a high dose of buprenorphine, 
All patients should be commenced on low doses (2 - 8mg), and even lower doses (2  or 4 mg) should be considered 
where there is some doubt regarding the degree of neuroadaptation prior to commencing treatment.
Safer around children: The poor bioavailability of buprenorphine when taken orally reduces the risk of accidental 
overdose by children.
Risk increases when mixed with other sedatives: While overdose on buprenorphine is relatively uncommon, 
there is a greater risk when it is combined with other sedative drugs, such as alcohol, benzodiazepines, barbiturates, 
tricyclic antidepressants and major tranquillisers. Several such deaths have been reported.
High doses of antagonist needed for overdose reversal: Buprenorphine has a high affinity for f i  opioid
receptors, and is not easily displaced by the antagonist, naloxone. Doses o f 1 0 - 3 0  times the normal naloxone doses 
used to reverse heroin overdose (up to 1 0 - 3 5  m g /7 0  kg) may be required to reverse the effects o f buprenorphine 
toxicity.
5.3 Intoxicated presentations
Intoxicated patients should not be dosed with Buprenorphine, and patients should be made 
aware of this prior to the commencement of treatment. They may re-present later in the day (or the 
following day) for dosing. The prescribing medical officer must be notified prior to the next dose being administered.
Patients with a history of repeated intoxicated presentations should be reviewed by the treating doctor and the treatment 
plan re-considered.
5.4 Incorrect dose administered
The risks associated are not as severe with an incorrect dose of buprenorphine as with other 
opioid medications. In the event of an incorrect dose being administered:
1) the dispensing pharmacist (or nursing staff) should immediately notify the patient and medical officer of the 
error;
2 ) the patient should be warned of the likely consequences (increased sedation /  drowsiness may occur for 
several hours afterwards), and warned against any additional drug use, and driving or operating machinery, for 
the rest of the day;
3 } the patient should be monitored for at least 6 hours after an incorrect dose by trained health professionals or in 
the Accident & Emergency Department of a hospital, if any of the following circumstances apply:
a) the patient is sedated following the dose (for any reason);
b) the patient is new to substitution treatment (within the first 2 weeks of maintenance treatment);
c) the regular daily buprenorphine dose is <  4 mg, and the patient was incorrectly administered a dose of >  
16 mg.
i) a buprenorphine dose of >  64 mg ms incorrectly administered (regardless of routine doily dose)
The patient should be reviewed by the prescribing medical officer prior to the next dose of 
buprenorphine. It may be that a lower dose is required the following day (in effect, a two-day dose has been 
administered), or no dose.
5.5 Diversion of buprenorphine
Easily diverted. As buprenorphine is a sublingual tablet, it can easily be diverted by patients. They may try to avoid 
taking their buprenorphine as directed, at the pharmacy, for the following reasons:
*  to take sublingually at a later time;
*  to inject (or snort) the medication instead of the sublingual route of administration;
*  to give or sell to another person.
There are potential risks associated with these practices.
1. Patients not taking their full dose of buprenorphine may be more likely to use heroin.
2 . Injection of buprenorphine is associated with risks of venous thrombosis, thrombophlebitis and other local infections; 
and of systemic fungal or bacterial infections (particularly in circumstances where patients inject buprenorphine that 
has already been in their mouth).
3 . Diversion of the medication to other people can result in overdose (through combination with other sedating drugs) or 
precipitation of withdrawal (e.g. when taken by a patient on a high dose of methadone).
To minimise the risks of diversion, the following safeguards are recommended:
*  Pharmacists should note carefully whether the full number of buprenorphine tablets have been taken sublingually by 
the patient, who should not be allowed to handle the tablets prior to dosing.
*  Pharmacists (or their assistants) should supervise the patient closely until the tablets have dissolved (about 3 - 7 
minutes). However, inevitably there will be times when this is just not possible.
In circumstances where diversion of buprenorphine is a possibility (for example, where there is
inadequate time for supervision), the following strategies are recommended.
*  The pharmacist and medical practitioner should warn the patient of the potential health risks associated with misuse 
of the medication.
*  The pharmacist should crush the tablets, administering a fine powder sublingually to reduce the time required for 
absorption and the potential for medication to be removed from the patient's mouth. While the effect of crushing 
tablets on the bioavailability of the sublingual preparation has not been examined, it is thought to have little clinical 
impact.
Where there is ongoing misuse of the medication, patients should be warned that they may have
to be transferred from buprenorphine treatment to methadone, which is easier to supervise.
5.6 Investigations
Urine testing: Urine tests reveal someone's drug use in the preceding 48 • 72 hour period. This is an expensive 
investigation and should be conducted only if the results ore likely to be important.
At the time of writing, Australian pathology laboratories do not routinely test for buprenorphine in the urine, and it will 
not be detected as an opioid.
The only possible indications for buprenorphine urine screening ore:
*  to confirm whether a patient has taken the take-away doses;
*  to see if a patient (not in treatment) is abusing buprenorphine;
5.7 Analgesia requirements for patients on buprenorphine
Patients maintained on buprenorphine will have a diminished response to opioids prescribed for analgesia. This is because 
of the 'blocking' effect of the buprenorphine on full opioid agonists. Consequently, patients on buprenorphine who suffer 
severe or chronic pain will require considerably higher doses of opioid analgesia than individuals not in buprenorphine 
treatment.
The principles of analgesic m a n a g e m e n t are:
1. Use non-opioid analgesics where possible (such as aspirin, NSAIDS, paracetamol).
2. Maintain buprenorphine dose i f  acute or subacute analgesia is required. A temporary increase in
buprenorphine dose may provide additional analgesic cover. Patients who develop chronic pain which is not 
responding to buprenorphine, and who require ongoing additional analgesia, may require transfer to methadone 
treatment.
3 . W h e re  additional opioid a n a lg e s ia  is  re q u ire d , the dose of opioid (eg morphine) should be clinically 
titrated according to clinical response. The dose of analgesic should be closely monitored if buprenorphine is reduced 
or stopped. The concern is that high morphine doses will be required while buprenorphine is exerting 'blockade'
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effects, but gs the buprenorphine levels reduce (with a corresponding reduction in the 'blocking' effects of 
buprenorphine), there is the potential for over-sedotion - or even overdose - from the high morphine doses. If 
buprenorphine treatment stops completely (eg due to the hospital pharmacy not having the drug, doctor ignorance or 
patient non-cooperation), the dose of morphine needs to be closely monitored every day for at least 4 - 5 days after 
the last buprenorphine dose. It will probably have to be reduced over time, to avoid an overdose.
5.8 Pregnancy and lactation
Inadequate research has been conducted on the effects of buprenorphine during pregnancy and lactation in humans. For 
this reason, and because of certain adverse effects reported in animal trials, buprenorphine is contra-indicated for both 
pregnant and lactating women.
Buprenorphine is a Category C drug, which has implications for pregnancy.
ADEC states that this group of drugs "has caused, or may be suspected of causing, harmful effects on the human fetus or 
neonate without causing malformations. These effects may be reversible." Opioid analgesics are capable of causing 
respiratory depression in the neonate, and withdrawal symptoms have been reported in cases of prolonged use.
Any woman patient seeking maintenance treatment who might become pregnant should be counselled on the potential 
risks of buprenorphine during pregnancy, with this information being reinforced and presented to them in writing.
Any woman patient seeking maintenance treatment who might become pregnant should be counselled on the potential 
risks of buprenorphine during pregnancy, with this information being reinforced and presented to them in writing.
Women wanting to become pregnant are better advised to consider methadone 
maintenance, or alternative forms of treatment for the management of their heroin I
dependence.
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Reliable forms of contraception should be recommended to women not wishing to become pregnant.
The pregnant heroin user not in treatment
Heroin-dependent women who become pregnant should be advised to commence maintenance substitution treatment, 
with methadone the preferred option.
The patient who becomes pregnant while in buprenorphine treatment.
If this happens, advice should be sought from a specialist multi-disciplinary unit providing obstetric and paediatric services 
for chemically-dependent women and their babies. Counselling should be provided regarding treatment options, and 
support offered when a choice of action is made.
•  The continuation of pregnancy and transfer to methadone maintenance treatment. This is the 
preferred option for the woman who wishes to continue with her pregnancy. She should be admitted to hospital for 
transfer to methadone, allowing for close observation of both her and the fetus, for evidence of withdrawal or 
distress.
Natio I meal gu id e lin e s  for
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*  The continuation o f pregnancy and continuation of Buprenorphine treatment. In rare circumstances, 
discontinuation of buprenorphine treatment may pose a greater risk to mother and baby than continuing. In particular, 
the woman who refuses to transfer to methadone should be given the option of continuing her buprenorphine 
treatment after the risks to the foetus and baby and the concerns about breast-feeding whilst in buprenorphine 
treatment (see below), have been explained to her. The woman must be capable of giving informed consent.
* Termination of pregnancy. Women wishing to terminate the pregnancy should be referred to appropriate 
services.
Neonatal monitoring
Neonates of women exposed to buprenorphine should be monitored for neonatal abstinence syndrome or any other 
adverse events. This group of children should be followed up by paediatricians with experience in caring for children 
exposed in utero to drugs of dependence. Long-term follow-up will be required to monitor for developmental 
abnormalities.
Breast-feeding
The effects of buprenorphine on infants of nursing mothers have not been well studied. For this reason, at this stage, 
buprenorphine treatment is contra-indicated for breast-feeding mothers.
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SECTION 6 . W R IT IN G  PRESCRIPTIONS &  
D I S P E N S I N G  B U P R E N O R P H I N E
Buprenorphine is on opioid ond is registered as on S8 medication. Special precautions should be taken by clinicians in the 
prescribing, handling, dispensing and storage of the medication.
6.1 Writing Prescriptions
Prescriptions for buprenorphine may be on a standard prescription form. A valid prescription must specify the following:
*  the name and address of the prescribing doctor who has been issued with the permit to prescribe;
*  the patient's name and address;
*  the date of the prescription;
*  the preparation to be dispensed (buprenorphine sublingual tablets);
*  the dose of buprenorphine to be dispensed in mg (words and numbers);
*  different dose schedules must be written separately (ie 24-hour doses, 2-day or 3-day doses), specifying the days of 
the week the patient is to be dosed;
*  the beginning and end dates of the prescription.
It is strongly recommended that the name of the pharmacy be included on the prescription.
6.2 Protocols for administering buprenorphine
Procedures prior to dosing
Staff authorised to administer buprenorphine include a pharmacist, a medical practitioner or two 
registered nurses.
Prior to administering the medication, staff must:-
*  Establish the identity of the patient;
*  Confirm that the patient is not intoxicated;
*  Check currency and amount of prescription. A patient cannot be dosed if a prescription is not current;
*  Check that the current day is a dose day on the patient's regime;
*  Confirm the dose for the current day if it is an alternate-day or three-times-a-week regime;
*  Record the dose in the Drug of Addiction recording system.
Administering buprenorphine
After recording dose details in the necessary Drug of Addiction recording system, the following procedures should be 
observed.
1. Count and check the buprenorphine tablets into a dry dosing cup. Double check number and strength.
2. For patients unfamiliar with buprenorphine dosing, issue the following instructions:
-  do not chew the tablets;
-  do not swallow saliva until tablets have dissolved (3 - 5 minutes on average);
-  do not swallow the tablets (buprenorphine tablets have approximately half the bioavailability when taken orally 
compared to sublingually);
-  once the tablets are given to you they are your responsibility and will not be replaced.
3. Give the cup to the patient and ask the patient to tip the contents under the tongue. Discourage patients from 
handling tablets.
4 .  Observe the patient until you are satisfied tablets are not divertable (usually > 2 minutes). Ask to see "how the 
tablets are dissolving" enough times for this to become an acceptable part of the patient's pick up routine.
5. Patients should sign that they have received their dose. Offer cordial or water to rinse taste out of mouth.
6 . The prescriber should be notified if the pharmacist has concerns that patients may be attempting to divert their 
medication (see Section 5.5).
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CLINICAL GUIDELINES FOR THE USE OF 
BUPRENORPHINE IN  THE TREATMENT OF 
HEROIN DEPENDENCE
Abbreviated Version
These guidelines have been prepared to aid medical practitioners in the selection and management of patients seeking 
treatment with buprenorphine for heroin dependence.
These guidelines were prepared under the auspices of the National Expert Advisory Committee on Illicit Drugs (NEACID) in 
collaboration with the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) project, the Royal 
Australian College of General Practitioners (RACGP) and the Australian Professional Society on Alcohol and Other Drugs 
(APSAD), and are funded by the Commonwealth Department of Health and Aged Care.
These guidelines are based on international research literature and clinical experience with the use of buprenorphine in 
Australia. These guidelines have undergone a rigorous process of review and have been formally endorsed by the RACGP
and APSAD.
The contribution of various individuals and organisations in the drafting and review process is gratefully acknowledged.
The sublingual buprenorphine preparation, Subutex®, is registered for treating heroin dependence in Australia. Subutex® 
contains buprenorphine hydrochloride, is available in 0 .4 ,2 , and 8 mg strength tablets; and is registered for maintenance 
and withdrawal treatment.
1. Clinical Pharmacology
Buprenorphine is a synthetic opioid derived from the morphine alkaloid thebaine. It is a partial opioid agonist with low 
intrinsic activity and high affinity at j i  opioid receptors.
It is effective in the treatment o f heroin dependence because
*  it substitutes for heroin, preventing the emergence of opioid withdrawal symptoms and reducing cravings;
*  it diminishes the effects o f additional opioids (e.g. heroin) due to a high affinity for m receptors;
*  it is long-acting, allowing daily (or less than daily) dosing. The duration of action is related to the buprenorphine 
dose administered: low doses (e.g. 2 mg) exert effects for up to 12 hours; higher doses (eg 16 - 32 mg) exert 
effects for as long as 48 - 72 hours.
Other relevant properties:
*  Peak clinical effects are achieved 1 - 4 hours after sublingual administration.
*  Elimination half-life is between 24 and 37 hours.
*  Metabolised principally in the liver by glucuronide conjugation and N-dealkylation.
*  Excreted principally in the faeces and urine.
Withdrawal syndrome from buprenorphine.
Withdrawal on stopping treatment is milder than with other opioids (e.g. morphine). Typically, withdrawal from 
maintenance buprenorphine emerges 2 - 5  days after the last dose, with some features lasting up to several weeks.
Side effects:
*  Similar to other opioids, the most common being constipation, disturbed sleep, drowsiness, sweating, headaches and 
nausea.
*  Most prevalent in the initial treatment period.
*  High doses well-tolerated - rarely induce dinically-significant respiratory depression, even in individuals with low 
tolerance to opioids.
Drug Interactions:
*  Other sedatives. Buprenorphine in combination with other sedative drugs (e.g. alcohol, benzodiazepines) can 
result in respiratory sedation, coma and death.
*  Opioid antagonists. Naltrexone can precipitate opioid withdrawal in patients on buprenorphine. Very high doses 
of naloxone (e.g. 1 0 - 3 5  mg) are required to reverse buprenorphine effects. As buprenorphine is not readily reversed 
by naloxone, in cases where buprenorphine is contributing to respiratory depression, ventilatory support will often be 
required.
*  Opioid agonists. Buprenorphine exerts a degree of blockade on the effects of full agonist opioids, potentially 
complicating the use of opioids for analgesia. The initial dose of buprenorphine can precipitate opioid withdrawal in 
patients with high levels of opioid use (e.g. recent and heavy heroin use, methadone transfers).
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2. Regulatory requirements
Buprenorphine is an S8 medication.
•  A medical practitioner must be authorised by the relevant jurisdictional body to 
prescribe it.
*  A prescribing doctor must be authorised by the relevant jurisdictional health authority 
for each client being treated.
See the national buprenorphine policy and your state policy for further information.
3. Indications, contra-indications, 
precautions
A comprehensive assessment by an authorised prescribing doctor is 
essential.
Indications: Buprenorphine treatment is indicated for individuals only when the following criteria have been 
established:
•  opioid-dependent;
•  18 years of age or more, (a second or specialist opinion should be sought for individuals under 18);
•  able to provide proof of identity (required for treatment with all S8 medications);
» able to give informed consent to treatment.
Precautions: Particular caution should be exercised in prescribing for clients in the following circumstances:
•  in high-risk polydrug use;
•  with chronic pain;
•  with concomitant severe psychiatric condition;
•  in methadone maintenance on high doses (>30 mg);
•  with sensitivity to buprenorphine;
•  with concomitant medical conditions.
(As with all opioids, caution should be used in the case of recent head injury; acute abdominal conditions 
and severe respiratory, hepatic or renal disease).
Contraindications:
Those who showed severe side-effects to buprenorphine from previous exposure;
Pregnant women and breast-feeding mothers.
Severe respiratory or hepatic insufficiency
National Clinical Guidelines for Buprenorphine use
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4. Prescribing guidelines for maintenance 
treatment
Initial buprenorphine dose: inducting heroin users
Jhe first dose o f buprenorphine should be administered a t least 6 hours after the last heroin use to reduce the risk 
of precipitated opioid withdrawal.
Jhe initial dose should be between 2  and 8 mg.
The following must be taken into consideration when considering the initial dose:
*  the degree of neuroadaptation (or tolerance) to opioids:
•  low or uncertain tolerance to opioids: 2 or 4 mg.
•  high levels of tolerance: 6 or 8 mg.
*  extent of opioid withdrawal experienced by client at time of first buprenorphine dose:
•  moderate to severe opioid withdrawal: 6 to 8 mg.
•  little or no opioid withdrawal: 2 or 4 mg, or delay initial dose.
*  perceived likelihood of continued alcohol, sedative drug (particularly benzodiazepines), or illicit heroin use warrants 
low initial buprenorphine doses, with frequent reviews.
*  concurrent medical conditions may warrant the use of lower initial doses (see Precautions).
Initial buprenorphine dose: transferring from methadone 
treatment
maintenance
Clients transferring from methadone programs may experience precipitated withdrawal on commencing 
buprenorphine, and a proportion will continue to describe mild withdrawal features or dysphoria for 1 - 2 weeks after 
the transition. The key factors impacting upon precipitated withdrawal are described below.
Factor D iscussion R ecom m ended s tra te g y
Dose of methadone Methadone doses higher than 30 mg are 
more often associated with precipitated 
withdrawal. In general the higher the 
methadone dose, the more severe the 
withdrawal experienced.
Attempt transfer from low dose of 
methadone (e.g. <  40  mg where possible). 
Clients on >  60  mg methadone should not 
attempt transfer
Time between Buprenorphine should not be dispensed Cease methadone and delay first dose of
last methadone dose within 24 hrs of last methadone dose. buprenorphine until client experiencing
and 1st dose 
buprenorphine
Increasing the interval between last 
methadone and 1st buprenorphine 
dose reduces the incidence & severity 
of precipitated withdrawal
features of methadone withdrawal
continued ori page 60
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continued from poge 59
Dose of buprenorphine Very low doses of buprenorphine 
(e.g. 2 mg) are generally inadequate to 
substitute for methadone (unless very low 
methadone dose). High first doses of 
buprenorphine (e.g. 8 mg or more) are 
more likely to precipitate withdrawal.
First dose of buprenorphine should generally 
be 4 mg; review client 2 - 4 hours 
later (or early the following day if 
evening dose)
Client expectancy Clients who are not prepared for 
precipitated withdrawal are more 
likely to be distressed and confused by 
its onset, with potential negative 
consequences (e.g. treatment drop-out, 
drug abuse).
Inform clients fully (and carers 
where relevant). Provide written 
information. Have contingency 
plan in place for severe 
symptoms.
Use of other medications Symptomatic medication
(e.g. donidine) can be useful to relieve 
any precipitated withdrawal.
Prescribe and dispense in accordance 
to management plan
Transferring clients from low methadone doses (<40m g)
Methadone dose should be ceased abruptly, and the first buprenorphine dose given at least 24  hours after the last 
methadone dose. The following conversion rates should be used when converting from low-dose methadone to 
buprenorphine.
Lost methadone dose (mg) Initial buprenorphine dose (mg) Day 2 buprenorphine dose (mg)
2 0 - 4 0  mg 4 mg 6 - 8  m
1 0 - 2 0  mg 4 mg 4 - 8  mg
1 - 1 0  mg 2 mg 4 mg
Transferring from medium dose methadone (40 - 60  mg) to 
buprenorphine
Clients who are unable to reduce their methadone dose to below 40  mg without becoming 'unstable' may attempt a 
transfer from methadone doses between 40  and 60 mg. The following procedures should be followed:
1 . Prepare client, pharmacist and other staff. Provide information and organise supports.
2 .  Cease methadone dose and delay first buprenorphine dose until the client experiences significant withdrawal 
discomfort (generally 48  - 96  hours after last methadone dose). Symptomatic medication (limited amounts) may be 
required.
3 .  Give the first dose of 4 mg buprenorphine in the morning or early afternoon.
4 .  Review the client 2 - 4 hours after first buprenorphine dose. If client describes:
•  worsening of withdrawal following first buprenorphine dose - provide symptomatic medication for opioid 
withdrawal for remainder of the day.
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•  no worsening of withdrawal, or an improvement in withdrawal symptoms following the first buprenorphine dose
• a further 2 to 4 mg of buorenorphine can be dispensed that afternoon /  evening.
S . Review the client prior to dosing the following day. Titrate the dose to between 6 - 1 0  mg, according to the response 
on the previous day. Continue frequent reviews and dose titration.
Stabilisation
The key principles to stabilising clients are:
•  frequent review of the client by the prescribing doctor and other members of the treatment team;
•  increases in buprenorphine dose only after review by the prescribing doctor;
•  titration of the buprenorphine dose according to:
•  features of intoxication, withdrawal and cravings over preceding 24 hours;
•  additional drug-use (eg heroin), including the reason stated by the client for using;
•  side-effects or other adverse events (including intoxicated presentations, overdoses);
•  adherence to dosing regime (attendance for dosing, route of administration);
•  client satisfaction with buprenorphine dose.
•  dose changes:
•  increases should be by increments of 2 - 4 mg at a time;
•  allow at least 2 - 3 days between dose increases, although daily increases are possible.
Clients should generally be able to achieve maintenance buprenorphine dose levels within 1 to 2 weeks of commencing 
buprenorphine. Doily dosing is recommended during the stabilisation period.
Alternative regime for rapid induction onto buprenorphine
•  a faster rate of induction may be safely undertaken and may reduce the risk of early drop out from the program.
•  achieves maintenance doses within 2-3 days
•  dose increments:
•  Day 1 8 mg
•  Day 2 16 mg
•  Day 3 24  mg
•  Prescribers who undertake this regime should review clients daily, looking particularly for signs and symptoms of 
toxicity (especially nausea and dizziness).
•  If there is evidence of toxicity dose increases should be slowed.
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Maintenance treatment
Evidence suggests that most people achieve optimal outcomes on daily doses of 12 - 24 mg. The maximum 
recommended dose of buprenorphine is 32 mg daily.
Frequency of closing
Most clients can be maintained on doses of buprenorphine administered every 2 or 3 days. The following conversion is 
recommended:
2- day buprenorphine dose = 2 x daily dose of buprenorphine (to a maximum of 32 mg)
3- day buprenorphine dose =  3 x daily dose of buprenorphine (to a maximum of 32 mg)
This conversion serves as a guide only, and the dose should be titrated according to clinical response. A proportion of 
clients (10-20% ) do not tolerate alternate or three-day dosing.
Ancillary services /  interventions
Psychosocial services:
All clients should be encouraged to join a comprehensive treatment program that includes psychosocial services such as 
counselling. However, attending counselling should be voluntary.
Take-away doses:
The take-away policy for buprenorphine is determined by each Australian jurisdiction. There are both benefits and 
problems associated with take-aways, and particular care should be exercised by prescribers in authorising them.
Urine-testing:
Buprenorphine is not detected in routine urine tests for opioids.
Addressing continued high-risk drug use:
Attempts should be made to stabilise clients who continue high-risk heroin or other drug-use (as evidenced by frequent 
intoxicated presentations, overdoses, chaotic drug-related behaviours, or drug-related deterioration of medical or mental 
health).
This requires a review of:
(a) psychosocial interventions and supports;
(b )  precipitants to continued drug use; and
(c ) medication regimes.
Ensure an adequate dose of buprenorphine is prescribed and that the client is taking it as prescribed (which may require 
stopping take-away doses, supervising consumption, and imposing daily dosing regimes).
Clients who cannot stabilise on buprenorphine should consider transferring to an alternative pharmacotherapy 
(e.g. methadone); or consider non-pharmacological treatment options (e.g. therapeutic communities, counselling and
Cessation of buprenorphine maintenance treatment
W ithdrawal from buprenorphine treatment
Most clients do not experience significant withdrawal discomfort until they reduce to low doses of buprenorphine, or even 
until after doses have stopped (see pharmacology for description). A gradual dose reduction is proposed at the following 
rate:
D a ily  b u p re n o rp h in e  dose R eduction  ra te
Above 16 mg 4 mg every 1 -  2 weeks
8 -1 6  mg 2 to 4 mg every 1 -  2 weeks
Below 8 mg 2 mg per week or fortnight
Some clients will request doses of less than 2 mg. An increase in heroin or other drug-use, or a worsening of the client's 
physical, psychological or social well-being, may warrant a temporary cessation or slowing-down of the reduction rate.
Induction on to naltrexone
Some clients may wish to commence naltrexone as a relapse-prevention agent following buprenorphine maintenance 
treatment. Induction on to naltrexone at least 5 - 7 days after the last buprenorphine dose is generally possible with 
minimal discomfort. Naltrexone can be commenced more quickly (within several days of ceasing buprenorphine), but this 
has attendant risks, and the reader is referred to the more comprehensive guidelines for recommendations.
Transfer to methadone maintenance treatment
Clients should be stabilised on daily doses of buprenorphine prior to transferring to methadone. Methadone can be 
commenced 24 hours after the last dose of buprenorphine, at an initial maximum daily dose o f up to 40mq. Clients 
transferring from low doses of buprenorphine (eg 4 mg or less) should be commenced on lower methadone doses 
(e.g. <20 mg). The client should be reviewed frequently, and the methadone dose titrated accordingly.
5. Guidelines for the management of heroin
w ith d ra w a l
The non-pharmacological management of heroin w ithdrawal should include:
•  Assessment and treatment selection;
•  Environment and support management: involving family, friends, alcohol & drug workers, self-help and peer 
groups;
•  Supportive core (including provision of information and supportive counselling);
•  Monitoring (use of withdrawal scales and daily review is recommended);
•  links to post withdrawal services.
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Prescribing and administering Buprenorphine for withdrawal
*  Delay first dose until at least 6 hours after last heroin use, and preferably until the client is experiencing early 
features of opioid withdrawal.
*  Dispense daily, with daily clinical review.
*  Titrate doses against the client's experience of withdrawal severity, cravings, side-effects and other drug use.
Outpatient withdrawal regimes
The following 4 - 8 day dosing regime is proposed for outpatient withdrawal services:
Day Proposed regime Recommended upper and lower 
limits
Day 1 6 mg 4 - 8  mg
Day 2 8 mg 4 - 1 2  mg
Day 3 10 mg 4 - 1 6  mg
Day 4 8 mg 2 - 1 2  mg
Day 5 4 mg 0 -  8 mg
Day 6 - 0 - 4  mg
Day 7 - 0 -  2 mg
Day 8 - 0 -  1 mg
Clients who do not stop their heroin use during their outpatient withdrawal episode may benefit from:
( i)  an extension of the outpatient buprenorphine withdrawal regime over several weeks;
( i i )  transfer to inpatient withdrawal services; or 
( I i i )  transfer to longer-term maintenance programs.
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Inpatient withdrawal regimes 
Modify inpatient regimes according to:
•  the duration of the withdrawal episode, and
*  degree of monitoring and supervision available. 
Regime proposed for a 7 - 8 day admission.
Day Proposed reg im e Total d a ily  dose
Day 1 4 mg at onset of withdrawal, & additional 2 to 4 mg evening dose prn 4 - 8 mg
Day 2 4 mg mane, with additional 2 to 4 mg evening dose prn 4 - 8  mg
Day 3 4 mg mane, with additional 2 mg evening dose prn 4 - 6 mg
Day 4 2 mg mane prn; 2 mg evening prn 0 - 4  mg
Day 5 2 mg prn 0 - 2  mg
Day 6 no dose
Day 7 no dose
Total proposed dose =  1 2 - 2 8  mg
Ancillary medications: Because buprenorphine is effective in reducing most withdrawal spptom s, other withdrawal 
medications are not routinely required. Some clients may complain of sleep disturbance, but only limited amounts of 
benzodiazepines should be prescribed (e.g. temazepam 1 0 - 2 0  mg nocte for two nights), with supervised dispensing. 
The use of high doses of benzodiazepines in combination with buprenorphine can result in overdose.
Post-withdrawal treatment options: Withdrawal alone has limited long-term benefits, and all clients attempting 
withdrawal should be encouraged to pursue ongoing drug treatment.
Options open to them include:
•  counselling services,
•  substitution maintenance treatment (with methadone or buprenorphine),
•  naltrexone treatment,
•  self-help groups (e.g. Narcotics Anonymous), or
•  residential rehabilitation programs.
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THE SUBJECTIVE OPIOID WITHDRAWAL 
SCALE (SOWS)
Date
Time
PLEASE SCORE EACH OF THE 16 ITEMS BELOW ACCORDING TO HOW YOU FEEL
t | A U fNOW
(CIRCLE ONE NUMBER)
SYMPTOM NOT AT ALL A LITTLE MODERATELY QUITE A BIT EXTREMELY
1 fe e l anxious 0 1 2 3 4
1 fe e l like  yaw n in g 0 1 2 3 4
1 om  perspiring 0 1 2 3 4
M y  eyes are te a ry 0 1 2 3 4
M y  nose is running 0 1 2 3 4
1 h ave goosebum ps 0 1 2 3 4
1 a m  shaking 0 1 2 3 4
1 h ave h o t flushes 0 1 2 3 4
1 h ave cold flushes 0 1 2 3 4
M y bones and musdes ache 0 1 2 3 4
«■Hi 1 fe e l restless 0 1 2 3 4
1 fe e l nauseous 0 1 2 3 4
1 fe e l like  vom iting 0 1 2 3 4
M y  m uscles tw itch 0 1 2 3 4
1 h ave stom ach cram ps 0 1 2 3 4
1 fe e l like  using now 0 1 2 3 4
Range 0-64. Handelsman, L, Cochrane, K. J., Aronson, M. J. et al. 0987)
Two New Rating Scales for Opiate Withdrawal, American Journal of Alcohol Abuse, 13,293-308.
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THE OBJECTIVE OPIO ID WITHDRAWAL SCALE
(OOWS)
Date
Time
;
:
5
S IG N M EASURES SCORE
Yawning 0 =  no yawns 1 =  >  1 yawn
Rhinonhoeo 0 =  <  3 sniffs \ =  >  3 sniffs
Piloerection (observe arm) 0 = absent 1 = present
Perspiration 0 =  absent 1 =  present
Lacrimation 0 =  absent 1 =  present
Tremor (hands) 0 =  absent 1 = present
Mydriasis 0 = absent 1 = >  3 mm
Hot and Cold flushes 0 = absent 1 = shivering /  huddling for warmth
Restlessness 0 =  absent 1 = frequent shifts of position
Vomiting 0 =  absent 1 = present
Muscle twitches 0 =  absent 1 = present
Abdominal cromps 0 = absent 1 = Holding stomach
Anxiety 0 =  absent 1 = mild - severe
TOTAL SCORE
Rouge 0-13 Handelsmon, L , Cochrane, K. J., Aronson, M. i.  et ol. (1 9 8 7 ) Two New Rating Scales for Opiate Withdrawal, American Journal of 
Alcohol Abuse, 1 3 ,2 9 3 -3 0 8 .
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CONSULTANCY AND SUPPORT 
MECHANISMS
AUSTRALIAN CAPITAL TERRITORY
ACT Deportment of Health, Housing and Community Care
GPO Box 825  
Canberra ACT 2601
Alcohol and Drug Program
Acting Director
Management & Administration
Telephone: (02) 6205 0947
Facsimile: (02) 6205 1180
ACT Community Care Alcohol and Drug Program
Senior Medical Officer
Telephone: (02) 6205 4545
Facsimile: (02) 6205 0951
Chief Health Officer
Telephone:
Facsimile:
Chief Pharmacists
Telephone:
Facscimile:
Policy Information
Manager
Alcohol and Drug Priorities 
Telephone:
Facsimile:
(02) 6205 0883  
(02) 6205 1884
(02) 6205 9061 
(02) 6205 0997
(02) 6205 0909  
(02) 6205 2037
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NEW SOUTH WALES
Alcohol and Drug Information Service
Telephone: (02) 9361 2111
Toll Free: 1800 023 599
NSW Drug and Alcohol Specialist Advisory Service
■ I  Telephone: (02) 9557 2905
1  Toll Free: 1800 023 687
NSW Health Drug Programs Bureau
Telephone: (02) 9391 9244
NORTHERN TERRITORY
Alcohol and Other Drug Services
PO Box 40596  
CASUARINA NT 0811
Building 9 North, Royal Darwin Hospital Campus 
Rocklands Drive, TIWI, NT
Telephone:
Facsimile:
(08) 8922 8399 
(08) 8922 8403
QUEENSLAND
I Alcohol, Tobacco and Other Drug Services
I  Medical Advisor
1 Telephone: (07) 389 63900
Policy and Specific State Information
Senior Advisor
Alcohol, Tobacco and Other Drug Services 
Telephone: (07) 3234 1700
Üü
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TASMANIA
Alcohol and Drug Service State Office
State Manager
Telephone: (03) 6233 3860
Coordinator illicit Drugs
Telephone: (03) 6233 2269
Deputy Chief Pharmacist
Telephone: (03) 6233 3906
Alcohol and Drug Service 
Southern Regional Office 
Manager
Telephone: (03) 6222 751 1
Opiate Treatment Medical Officer
Telephone: (03) 6222 7511
Pharmacist
Telephone: (03) 6233 3906
Alcohol and Drug Service
North/North West Regional Office 
Manager
Telephone: (03) 6336 5577
Opiate Treatment Medical Officer
Telephone: (03) 6233 5577
■I
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SOUTH AUSTRALIA
ADIS (Alcohol end Drug Information Service)
Toll Free: 1300 13 13 40
Drug & Alcohol Clinical Advisory Service
Toll Free: 130013 13 40
Warinilla Clinic 
92 Osmond Terrace 
Norwood SA 5067
Telephone: (08) 8130 7500
Northern Methadone Service 
22 Langford Drive 
Elizabeth SA 5112
Telephone: (08) 8252 4040
Southern Clinic
82 Beach Road 
Christies Beach SA 5165
Telephone: (08) 8326 6644
VICTORIA
Victorian Drug and Alcohol Clinical Advisory Service
Exclusively for health and welfare professionals. Provides advice and information on clinical 
management of patients with drug and or alcohol problems, including:
*  advice on recognition and management of withdrawal syndromes
*  drug use complications
*  drug information
*  prescribing information
*  assistance with cases of acute intoxication
Metropolitan: (03) 9416 361 1
country areas (toll free): 1800 81 2804
I \ |< im cai v^uiaennes to r D uprenorpm ne useR : Ski
Drugs and Poisons Unit, Department of Human Services
The Unit issues permits for approved practitioners to prescribe methadone. It also approves individual medical practitioners 
and pharmacists to respectively prescribe or dispense methadone.
Address: PO Box 1670N, Melbourne, 3001
Telephone: 1300 364 545
Fax: 1300 360 830
Direct Line
For the general public and health and welfare professionals. Provides counselling, information and referral, including:
♦  needle syringe exchange and bin location
•  drug and aicohol agencies and drug withdrawal beds
*  methadone program contact details
*  HIV/AIDS information and referral
•  drink/drive education and assessment referral
Metropolitan: (03 ) 9416 1818
Country areas: (toll free):l 800 13 6385
Youth Substance Abuse Service
YSAS provides information, outreach and residential services for young people aged between 12 and 21 experiencing 
significant problems related to their use of drugs and/or alcohol.
14-18 Brunswick Street Fitzroy 3065
Telephone: (03) 9415 8881
Fax: (03 ) 9415  8882
Website: http://www.ysas.org.au
YSASLine
YSASline provides 24 hour access to information, telephone counseling, and referral to YSAS outreach teams. The service 
is open to young people, their families, health and welfare workers, police and ambulance officers. Call YSASline to 
contact an outreach team. Access to the YSAS residential service is made by contacting your local outreach team via 
YSASline.
Metro: (03) 9244  2450
Country freecall: 1800 014  446
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VIVÄIDS: the Victorian Users Group
VIVAIDS provides information on anything and everything to do with drugs. They also provide peer support, peer 
education, referrals, needle exchange and advocacy to drug users, while promoting harm reduction to users and the 
community.
765a Nicholson Street
North Carlton 3054
Telephone: (03) 9381 2211
Specialist Methadone Services
Specialist Methadone Services provide a consultative service to methadone prescribers seeking expert opinion about the 
management of patients with special problems, such as psychiatric, social, medical or treatment problems. Patients may 
be referred by arrangement, or advice sought by contacting the service.
Turning Point Drug and Alcohol Centre
54 Gertrude St., FITZROY 3065
Administration
Telephone: (03) 9254 8061
Fax: (03 ) 9416  342
Clinicai Services
Telephone: (03 ) 9254  8050
Fax: (03 ) 9486  9766
South Eastern Methadone Consultancy Clinic
61-69 Brighton Rd„ ELW 00D3184  
Telephone: (03 ) 9525  7399
Fax: (03 ) 9525 7369
Western Hospital Drug and Alcohol Service
Gordon St., F00TSCRAY 3011
Telephone: (03 ) 9317  2217
Fax: (03) 9319  6027
Austin and Repatriation Medical Centre Specialist Methadone Service
Studley Rd„ HEIDELBERG 3084
Administration
Telephone: (03) 9496  5000
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Pharmacy
Telephone:
Fax:
(03) 9496 4999  
(03) 9459 4546
Eastern Region Specialist Methadone Service 
Whithorse Community Health Service 
65Carrington Street, BOX HILL, 3128
Telephone: (03) 9890  2220
Royal Women's Hospital Chemical Dependency Unit
For women who are pregnant and use drugs. The unit provides a direct service for women who live within a 25 km 
radius, and secondary consultation for other women. Midwives and social workers are available for consultation.
264  Cardigan Street Carlton 3053
Health Insurance Commission.
The HIC provides information about medical consultations and pharmaceutical benefits obtained through its Doctor 
Shopper Hotline. It is also able to provide this information if the patient signs a privacy release form authorising the HIC 
to provide this information. Forms and explanatory letters are available from the HIC.
Health Insurance Commission
134 Reed Street Tuggeranong ACT 2900
Doctor shopper hotline (free call): phone 1800 631 181
Hepatitis C information
Hepatitis C Support Line 
Hepatitis C Council
The Hepatitis C Council has produced a booklet "Hepatitis C Contact" which provides information, and answers frequently 
asked questions.
Carlow House
Level 9
289 Flinders Lane 
Melbourne 3000
Telephone: (03 ) 9639  3200
Country Calls: 1800  703 003
Telephone: (03) 9344 2363
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Hepatitis C Helpline
Telephone: (03) 9349 1 111
Country Calls: 
TTY:
Vietnamese Line:
1800 800 241 
1800 032 665 
1800 456 007
Department of Human Services.
DHS pamphlet "Hepatitis: the Facts"available from the Department of Human Services, or on the internet at: 
http://www.dhs.vic.gov.au/phd/9904043/index.htm
The Department of Human Services has produced a booklet"Management; Control and Prevention of 
Hepatitis C: Guidelines for Medical Practitioners". It is available from the Department.
Health care providers can obtain information and assistance with counselling from the Hepatitis C Educator (03 9288 
4127). Advice on notification of hepatitis C can be obtained from the Infectious Diseases Unit.
AIDS information
AIDSLINE 
Telephone: 
Country Calls: 
TTY:
(03) 9347 6099 
1800 133 392 
1800 032 665
Melbourne Sexual Health Centre
580 Swanston Street
Carlton 3053 
Telephone: 
Country Calls:
(03) 9347 0244 
1800 032 017
Needle and Syringe Exchange Programs (NSEPs).
Contact details of Victorian NSEPs is available:
On the internet at: http://hna.ffh.vic.gov.au/phb/9808109/index.htm 
or by calling Direct Line (see above).
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WESTERN AUSTRALIA
A lto h o l a n d  D rug In fo rm a tio n  S erv ice  
Telephone: (08) 9442 5000
Country Calls: 1800 198 024
Clinical Advisory Service 
Next Step 
32 Moore Street 
EAST PERTH WA 6004
Phone: (08) 9442 5042
Country Calls: 1800 688 8 4 /
Pharmaceutical Services (Doctors and Pharmacists)
Health Department of Western Australia 
Telephone: (08) 9388 4985
